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ABSTRACT 
 
Functional vitamin B12 (cobalamin) deficiency is a subtle, progressive clinical 
disorder affecting 6-23% of elderly adults. Its symptoms, including fatigue, mood 
disturbances, and decreased strength, are vague and erroneously attributed to aging. 
Detection of cobalamin deficiency in elderly adults is confounded by clinical 
heterogeneity and lack of standardization in metabolic tests. Whereas some patients are 
asymptomatic with slightly altered metabolite profiles, others develop severe clinical 
outcomes. Better understanding of biologic factors contributing to cobalamin deficiency 
heterogeneity in older adults is needed.  
This is a candidate gene association study evaluating the relationship between 
genetic variation in the cobalamin-transport molecules (transcobalamin II and its 
receptor) with cobalamin-related outcome parameters in 795 research participants of the 
Women’s Health and Aging 1 and 2 Studies. Research participant DNA was whole 
genome amplified and genotyped using the iPLEX Sequenom mass spectroscopy 
platform. Relationships between genotypes and clinical parameters were assessed using 
two-way analysis of variance and two-way analysis of covariance, on the fixed factors, 
race and Single Nucleotide Polymorphism genotype.  
Results of the dissertation research generated several genetic associations that are 
useful for further hypothesis testing and clinical validation research. In the 
transcobalamin II gene, two missense variants were associated with homocysteine 
and methylmalonic acid levels (rs9621049, rs35838082), two intronic variants were 
associated with serum cobalamin and homocysteine levels (rs4820888, rs4820887), and 
one missense variant was associated with mean corpuscular volume (rs11801198). A 
cluster of SNPs in the promoter region of the transcobalamin II gene was associated with 
the physical performance parameters, hand grip strength, and walking speed. In the 
transcobalamin II-receptor gene, a missense coding SNP (rs2336573) was associated with 
mean serum cobalamin concentrations.   
 Scientific advances responsible for the technology used in this dissertation are 
being incorporated into healthcare. The tailoring of treatment to an individual’s genetic 
make-up is termed Personalized Medicine. To assist nursing professionals in 
understanding and preparing for use of these technologies, four elements of Personalized 
Medicine are reviewed, including 1) discovery of novel biology that guides clinical 
translation mechanisms, 2) genetic risk assessment, 3) molecular diagnostic technology, 
and 4) pharmacogenetics and pharmacogenomics. Opportunities for nursing profession 
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“If we’re serious about preventive medicine, and using personalized genomics 
to inform that, we’re not going to change the genome.  
It’s the environment we’re going to want to change.” 
 
 
-Francis S. Collins, MD, PhD 
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CHAPTER 1
OVERVIEW OF DISSERTATION RESEARCH
Statement of Clinical Research Problem
Prevalence of metabolically confirmed cobalamin (vitamin B12) deficiency 
among community-dwelling elderly is between 6% and 23%, and depending upon 
definition criteria used—as high as 40.5% (Allen, 2009; Baik & Russell, 1999; Johnson 
et al., 2003; Lindenbaum, Rosenberg, Wilson, Stabler, & Allen, 1994; Pennypacker et al., 
1992). Classic hematological and neurological manifestations include megaloblastic 
anemia, psycho-cognitive decline, and functional impairment. Less recognized is sub-
clinical deficiency, involving subtle biochemical and clinical changes, resulting in 
unrecognized or misattributed diagnosis.
Manifestations of cobalamin deficiency are vague and include fatigue, decreased 
cognition, malaise, peripheral insensitivity, decreased strength, sleep, and mood 
disturbances, which present prior to grossly elevated metabolite profiles and hallmark 
presence of megaloblastic anemia. Long-term consequences of cobalamin deficiency in 
older adult individuals may increase the disability trajectory, resulting in increased 
frequency of hospital admissions, lengthier and more severe hospitalizations, and greater 
degrees of chronic disablement that significantly effect mobility and quality of life 
(Bartali et al., 2006).
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Numerous challenges in detection, diagnosis, and treatment of cobalamin
deficiencies in older adults exist secondary to lack of accurate laboratory assays and vast 
clinical heterogeneity. While some individuals are asymptomatic with low-normal 
cobalamin levels and slightly altered metabolite screening panels, others with similar 
profiles develop severe, permanent clinical outcomes (Carmel & Sarrai, 2006). For these 
reasons, relatively little progress has been made in the identification of cobalamin
deficient individuals who would benefit most from pre-emptive supplementation of the 
nutrient.
Better understanding of the genetic factors contributing to clinical heterogeneity 
surrounding cobalamin deficiency, subclinical deficiency states, and treatment responses 
could enhance clinical care of elderly individuals. To identify possible factors 
contributing to the clinical heterogeneity in cobalamin deficiency, this study used a 
candidate gene approach to perform a secondary analysis of data and banked biologic 
samples from the Women’s Health and Aging Studies. Because of their roles in 
cobalamin physiology and metabolism, the candidate genes for the dissertation research 
included the cobalamin carrier protein (transcobalamin II) and the cobalamin carrier 
protein receptor (transcobalamin II-receptor). There are different forms of cobalamin; for 
the purposes of this work, the terms cobalamin and vitamin B12 will be used 
interchangeably to denote all chemical forms of the nutrient unless otherwise specified 
through more exact terminology (methyl-, 5’ deoxyadenosyl-, cyano-, etc.).
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Dissertation Project Scientific Aims and Research Questions
The goal of this project was to determine if genetic variants, Single Nucleotide 
Polymorphisms (SNPs), in two candidate cobalamin metabolic genes were associated 
with clinical and biochemical parameters in a cohort of community-dwelling elderly 
women. Secondary scholarly aims were to orient the scientific data within a broader 
translation framework for the field of professional nursing, and thus relatable to the 
context of Personalized Medicine.
Aim 1
Accounting for folate status, Aim 1 was to determine if there are differences in 
the hematological vitamin B12 indicators, hemoglobin concentration and mean 
corpuscular volume (MCV) level, by race and SNP genetic variation in the 
transcobalamin II (vitamin B12 carrier molecule) and transcobalamin II-receptor (vitamin 
B12 carrier molecule receptor) genes. 
Research Question 1.1 
Do hemoglobin concentrations differ by race and SNPs in the transcobalamin II 
and transcobalamin II-receptor genes?
Research Question 1.2




Accounting for renal function (questions 2.1-2.3), folate (question 2.2), and 
cobalamin status (questions 2.2-2.3), Aim 2 was to determine if there are concentration 
differences in the biochemical vitamin B12 indicators, serum cobalamin, homocysteine, 
and serum methylmalonic acid, by race and SNP genetic variation in the transcobalamin 
II and transcobalamin II-receptor genes.
Research Question 2.1  
Accounting for renal function, are there differences in serum cobalamin 
concentrations by race and SNPs in the transcobalamin II and transcobalamin II-receptor
genes?
Research Question 2.2 
Accounting for renal function, folate, and cobalamin status, are there differences 
in homocysteine levels by race and SNPs in the transcobalamin II and transcobalamin II-
receptor genes?
Research Question 2.3 
Accounting for renal function and cobalamin status, are there differences in serum 




Aim 3 was to determine if there are differences in the neurologic vitamin B12 
indicators, depression score and peripheral vibration sensitivity, by race and genetic 
variation within the transcobalamin II and transcobalamin II-receptor genes.
Research Question 3.1 
Do depression scores differ by race and SNPs in the transcobalamin II and 
transcobalamin II-receptor genes?
Research Question 3.2
Do peripheral extremity vibratory sensation scores differ by race and SNPs in the 
transcobalamin II and transcobalamin II-receptor genes?
Aim 4
Aim 4 was to determine if there are differences in the functional performance 
vitamin B12 indicators, hand grip strength, and walking speed, by race and genetic 
variation within the transcobalamin II and transcobalamin II-receptor genes. 
Research Question 4.1 




Accounting for standing height, does walking speed differ by race and SNPs in 
the transcobalamin II and transcobalamin II-receptor genes?
Aim 5
Aim 5 was to identify opportunities for the field of professional nursing in the 
area of genetics and genomics, or Personalized Medicine.
Research Question 5.1 
What is the current state of genetic/genomic science as relevant for professional 
nurses in research, education, and practice settings?
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CHAPTER 2
THE MOLECULAR, PHYSIOLOGIC, GENETIC, AND CLINICAL 
BASIS OF VITAMIN B12 METABOLISM 
IN AGING INDIVIDUALS
History and Origins
The critical importance of vitamin B12 to human physiology has a rich history 
steeped in vigilant patient observation. The initial discovery of what is now known to be 
pernicious anemia can be traced to 1824 when James Scarfe Combe, a civil practice 
physician, described an anecdotal account of an individual whose symptoms included 
severe pallor, thirst, diarrhea, and excessive urination (Combe, 1824). The patient, Mr. 
Alexander Haynes, initially presented to Combe in July of 1821 at which point the 
symptoms progressively became worse until his death in February 1822. 
Dr. Combe’s report did not gain recognition as being significant until 1849, when 
English physician Thomas Addison submitted a description of anemia “commencing 
insidiously, and proceeding very slowly, so as to occupy a period of several weeks, or 
even months, before any serious alarm is taken by either the patient or by the patient’s 
friends” (Addison, 1849). Addison’s clinical observations outlined physiological 
characteristics unlike any other previous classification of anemia, most striking of which 
was the subtle and progressive clinical course of symptom development. A historical
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account cites that in 1872, a German physician from Zurich, Dr. Biermer, noted the 
severe intractable progressive characteristics of the Addisonian anemia in 15 subjects and 
issued the title “pernicious anemia” (Sinclair, 2008).
Patients suffered over decades from pernicious anemia and its unsuccessful 
treatment; common therapeutic interventions for the condition included dietary 
modifications, exposure to sunlight, and even use of an arsenic supplementation known 
as “Fowler’s Solution” (Sinclair, 2008). Things would not change until 1925 when a team 
of three physicians, Drs. Whipple, Hooper, and Robscheit, researched hematopoeisis 
associated with chronic blood loss. Among the treatment interventions studied was the 
administration of beef liver to canines and significant findings were obtained; dogs who 
were bled and fed the uncooked liver were noted to experience rapid resolution of anemic 
symptoms (Whipple, 1925). Two prominent Boston-area physicians in the United States 
who learned of the work developed a protocol for human patients with pernicious anemia, 
and fed 45 patients a high protein daily diet incorporating 120-240 grams of raw liver 
(Minot, 1926). Within days of starting treatment, patients’ jaundice began to resolve, 
reticulocyte counts increased, and hemoglobin values normalized.
This discovery went on to be confirmed by many practicing physicians and in 
1934, Drs. Whipple, Minot, and Murphy were the first Americans to receive the Nobel 
Prize in Medicine and Physiology. In 1948, the fraction responsible for this physiologic, 
dubbed vitamin B12, was purified from liver and kidney and shortly after, daily dietary 
intake requirements were established (Rickes, Brink, Koniuszy, Wood, & Folkers, 1948; 
E. Smith, 1948). As researchers identified cobalt as a key component of vitamin B12, its 
name was changed from vitamin B12 to cobalamin, and in 1955-1956, a scientific team 
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led by Dorothy Hodgkin used x-ray crystallography to identify and elucidate its 
crystalline 3-dimensional structure. Using electron density measurements, Hodgkin’s 
landmark effort identified atomic positions of elements surrounding the central cobalt 
atom (Hodgkin et al., 1956; Hodgkin, Pickworth, Robertson, Trueblood, & Prosen, 
1955). The discovery led to another Nobel Prize, this time in Chemistry, and was issued 
to Dr. Hodgkin in 1964.
Scientific progress from the late 1950s through the 1960s was notable for the 
identification of variable chemical isoforms of cobalamin and the key enzymes directing 
molecular rearrangements in metabolic reduction/oxidation reactions. In 1958, Barker, 
Weissbach, and colleagues discovered a key biologic role for vitamin B12 in the bacterial 
model system Clostridium tetanomorphum; the conversion of L-methylmalonyl-
Coenzyme A required adenosylcobalamin to formulate succinyl-Coenzyme A (Barker, 
Smyth, Wawszkiewicz, Lee, & Wilson, 1958; Barker, Smyth, Wilson, & Weissbach, 
1959; Barker, Weissbach, & Smyth, 1958). In 1962, Smith and colleagues created 
carbon-enriched methylcobalamin and found that it could serve as a cofactor for 
methionine synthase (Guest, Friedman, Woods, & Smith, 1962). Shortly after, Weissbach 
deducted the chemical reaction responsible for methionine synthesis, and proved 
methylcobalamin serves as the necessary cofactor for conversion of homocysteine to 
methionine (Weissbach & Taylor, 1966).
In the 1970s, scientists produced the total chemical synthesis of cobalamin, a 
monumental achievement. The effort was notable for 11 years’ worth of chemical 
reaction calculations and required the skills of over 100 collaborating scientists 
(Woodward, 1973). Heading the project at Harvard University’s Department of 
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Chemistry was Dr. Robert Woodward, who, in 1965, also received the Nobel Prize for 
Chemistry. 
In the 1980s-1990s, scientists identified the stereochemistry and functional 
mechanisms responsible for cobalamin-dependent reduction/oxidation rearrangements. 
The piecing together of all the intricate steps of aerobic microbial cobalamin biosynthesis 
in 1993 was a capstone achievement spanning over 25 years of scientific research 
(Battersby, 1994). Elucidation of three-dimensional structures of the methionine synthase 
and methylmalonyl CoA enzymes provided understanding of how vitamin B12 reactions 
occur in both mammalian and microbial species (Dixon, Huang, Matthews, & Ludwig, 
1996; Drennan, Huang, Drummond, Matthews, & Lidwig, 1994; Mancia et al., 1996).
Recently, techniques and knowledge derived from fields such as genetics, molecular 
biology, and recombinant engineering are permitting not just discovery, but purposeful 
manipulation of both the aerobic and anaerobic cobalamin pathways to understand 
intermediate steps and biosynthetic processes across all life forms (Battersby, 1994; 
Warren, Raux, Schubert, & Escalante-Semerena, 2002).
Chemical Properties
The chemical activities of vitamin B12 vary temporally, spatially, and across 
numerous life forms. Their overall function can be broken down into three distinct 
categories where they can serve as 1) mutases, facilitating electron exchange between 
hydrogen and other atoms nested between two carbon atoms; 2) ribonucleotide 
reductases, reducing ribonucleotide triphosphate to 2’-deoxyribonucleotide phosphate via 
adenosylcobalamin; and 3) intermolecular methyl group transfers, shuttling of methyl 
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groups across chemical bonds and intermediaries as catalyzed by methylcobalamin 
(Green & Miller, 2007; Martens, Barg, Warren, & Jahn, 2002). In the animal kingdom, 
cobalamin is used for only two enzymatic reactions, which will be discussed in a later 
section.
Structure
The organometallic cobalamin molecule (chemical formula C83H88O14N14PCo; 
molecular weight 1355 daltons) is among the most structurally complex found in all of 
nature. There are two primary features in addition to its central cobalt atom, including (1) 
a planar corrin ring and (2) a nucleotide that lies perpendicular to the planar group. 
Comprising the nucleotide is a base, 5,6-dimethylbenzimidazole, and a phosphorylated 
sugar, ribose-3-phosphate. The 5,6-dimethylbenzimidazole base is exclusive to the 
cobalamin molecule in nature, and the ribose is unusually phosphorylated at carbon 
position 3.
The corrin ring contains a group of four pyrroles (5-member rings of C4H4NCH3)
with each N atom affixed and coordinated to the central cobalt atom. A fifth ligand 
extends from the central cobalt atom, where various functional (R) groups may attach and 
yield various biologic forms of cobalamin. The four primary groups in mammals include 
a 5’-deoxyadenosyl group (adenosylcobalamin), a hydroxyl group (hydroxocobalamin), a 
methyl group (methylcobalamin), and a glutathione group (glutathionylcobalamin). The 
two co-enzyme forms of cobalamin directly relevant to humans are adenosylcobalamin, 
found in mitochondrial membranes, and methylcobalamin in the cytosol, which is 
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clinically measurable in human plasma. Other forms of cobalamin exist in plants and 
bacteria.
Variable oxidation and reduction states of the cobalt atom yields greater 
complexity, where arrangement of electrons can result in varying forms of hydroxo-,
adenosyl-, and methylcobalamin. For example, trivalent cob(III)alamin represents full 
oxidation capacity in the hydroxocobalamin form, but adenosylcobalamin and 
methylcobalamin contain divalent cob(II)alamin and monovalent cob(I)alamin states of 
the cobalt atom. 
As the C-Co chemical bonds in cobalamin are extremely sensitive to degradation, 
in the presence of light and a cyanide source, all cobalamin forms are converted to 
cyanocobalamin. This is cobalamin’s most stable form, and subsequently is the 
commercial preparation used for the majority of pharmaceutical and therapeutic 
applications in the U.S. (National Academy of Sciences, 1998). Regardless of the form, 
the cobalamin that is delivered to mammalian cells is enzymatically activated to either 
methylcobalamin or 5’-deoxyadenosylcobalamin (Scott, 1999).
Synthesis
Vitamin B12 is the most chemically complex vitamin; in biologic systems that 
produce it, the coordinated and functional integration of over 30 genes is required. 
Although cobalamin is required by humans and mammals, synthesis of vitamin B12 is 
exclusive to microorganisms, and even then—limited to members of the Archea and 
Eubacteria families (Raux, Schubert, & Warren, 2000). Plants and fungi are understood 
not to produce or use cobalamin (Benner, Ellington, & Tauer, 1989).
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Microbial synthesis of vitamin B12 can be either aerobic or anaerobic, and begins 
along a complex branched pathway starting with uroporphyrinogen III. The formation of 
adenosylcobalamin from uroporphyrinogen III has three distinct steps including 1) 
synthesis of the corrin ring, 2) construction of the nucleotide base (right-angle) ligand, 
and 3) the piecing together of the corrin ring with the base ligand to produce the final 
coenzyme (Roth, Lawrence, Rubenfield, Kieffer-Higgins, & Church, 1993). Both aerobic 
and anaerobic pathways begin with uroporphyrinogen III, with precorrin biosynthetic 
intermediates of cobalamin successively carrying methyl groups across varying 
numbered carbon units (i.e., precorrin 1, precorrin 2, precorrin 3A, etc.) (Battersby, 
1994). However, the most significant difference between the two biosynthetic pathways 
is the point of cobalt insertion; aerobic production features a late insertion whereas 
anaerobic production is characterized by early incorporation (Warren et al., 2002).
Metabolism of cobalamin in mammalian cells will be discussed later in this chapter.
Food Sources and Daily Requirements
As cobalamin is produced exclusively by certain bacteria, natural sources of its 
production are found in microorganisms from soil, sewage, water, human and other 
mammalian intestines, and animal rumens (first stomach of plant-eating mammals such 
as cattle, sheep, and goats). Thus, human dependency on cobalamin is rooted in dietary 
intake of the animals ingesting microbially synthesized vitamin B12. Human food 
sources rich in vitamin B12 are animal-based protein, including liver, meat, seafood, 
shellfish, eggs, and dairy products.
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Vitamin B12 content for standard Western diets varies between 5-30 micrograms 
per day and fulfills average daily intake requirements of 7-8 micrograms per day for men, 
4-5 micrograms per day for women, and 3-4 micrograms per day for children under age 
five (Beck, 2001). For adolescents, the recommended daily intake requirement for 
cobalamin is approximately 2 micrograms per day (The Standing Committee on the 
Scientific Evaluation of Dietary Reference Intakes, Subcomittee on Upper Reference 
Levels of Nutrients, Food and Nutrition Board, 1998). Intestinal microbes represent an 
additional nondietary source of vitamin B12 for humans, and account for absorption of 1-
5 micrograms per day (Heyssel, Bozian, Darby, & Bell, 1966). Obligatory losses of the 
nutrient have been established at a rate of 0.1% of the body’s circulatory cobalamin pool 
per day, and occurs independently from other factors such as total body storage amounts 
in tissues and the liver (Heyssel et al., 1966).
Physiologic Properties
Absorption
The normal absorption of vitamin B12 in mammals demonstrates both passive 
and active mechanisms (Rosenblatt & Fenton, 2001). Passive absorption accounts for 1-
2% of oral intake, occurs rapidly throughout the entire gastrointestinal tract, and is 
extremely inefficient (Green & Miller, 2007). Active absorption is dependent upon the 
coordinated actions of binding proteins that attach to ingested dietary protein in the 
stomach and intestine, and facilitate its entry into the plasma (Herrmann, Obeid, Schorr, 
& Geisel, 2003; Rosenblatt & Fenton, 2001). Age-related changes in humans related to 
these processes are discussed in a later section in this chapter.
 16 
Intrinsic Factor
After food containing vitamin B12 enters the stomach, gastric parietal cells in the 
fundus and body of the stomach release pepsin and intrinsic factor (IF). In the acidic 
environment of the stomach, pepsin breaks down food/protein particles to release vitamin 
B12, which attaches to salivary R-binder proteins (haptocorrin family). Salivary R-
binder/B12 complexes then pass through the duodenum, where the pancreatic enzyme 
trypsin splits them apart. This frees vitamin B12 to bind to IF. Binding of vitamin B12 to 
IF is dependent on specific folding interactions with the 5,6-dimethylbenzimidazole base 
and the corrin ring, after which the complex shrinks to close around the cobalamin 
molecule (Lien, Ellenbogen, Law, & Wood, 1974). This binding process protects both IF 
and vitamin B12; free IF is particularly susceptible to rapid degradation by pancreatic 
enzymes, and similarly in acid, free vitamin B12 is susceptible to side chain 
modifications of the corrin ring and removal of axial ligands (Kondo et al., 1982). In 
mammals, all forms of vitamin B12 (methylcobalamin, adenosylcobalamin, 
cyanacobalamin) are absorbed by the IF-dependent mechanism.
Cubulin and Megalin 
IF/B12 complexes travel the small intestine until they come into contact with IF 
receptors embedded on the outer surface of the terminal ileum, and are endocytosed. Ileal 
mucosal receptors preferentially accept IF/B12 over free IF, and binding takes place in 
villous cells as opposed to crypts (Kapadia & Essandoh, 1988; Mathan, Babior, & 
Donaldson, 1974). There are two structural subcomponents to the IF receptors—cubulin 
and megalin. Cubulin is a peripherally attached glycoprotein on the intestinal brush 
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border, and megalin is a large, endocytotic transmembrane glycoprotein (Alpers, 2005; 
Birn et al., 1997; Christensen & Birn, 2002). On the external border of the enterocyte, 
cubulin uses calcium ions to recognize and bind the IF/B12 complex (Barth & Argraves, 
2001; Birn, 2006). Upon cubulin recognition and ligand binding of the IF/B12 complex, 
megalin facilitates entry of IF/B12 into the ileal enterocyte via receptor-mediated 
endocytosis (Green & Miller, 2007).
Cubulin and megalin have broader physiologic functions than just the binding of 
IF/B12 complexes in the small intestine. Located in the plasma membranes and 
endocytoplasmic surfaces of cells across various types of epithelial tissue, cubulin and 
megalin colocalize for ligand binding in renal epithelium, visceral yolk sacs, and in the 
placental cytotrophoblast (Birn et al., 1997; Moestrup et al., 1998). Other ligands bound 
by the cubulin and megalin dual-receptor complex include albumin, vitamin-D binding 
protein, and hemoglobin (Birn et al., 2000; Cui, Verroust, Moestrup, & Christensen, 
1996; Gburek et al., 2002; Nykjaer et al., 1999; Nykjaer et al., 2001). Categorized as part 
of the low-density lipoprotein family, megalin also binds ligands singularly (without 
cubulin) in a wider array of epithelial tissues. Present in lung alveoli, epididymis, 
endometrium, oviduct, inner ear, thryocytes, eye cilia, choroid plexus in cerebral 
ventricles, kidney, and parathyroid, megalin binds ligands, including retinol binding 
protein, lactoferrin, apolipoproteins (B, E, J, H), hormones, drugs, toxins, enzymes, 
immune, stress-response-related proteins, and B12 transcobalamin II complex during 




After an ileal enterocyte absorbs the IF/B12 complex, vitamin B12 is dissociated 
from IF in lysosomal compartments. It is then paired with the cobalamin transport protein 
transcobalamin II, released into the portal circulation, and carried to cells in target tissues 
throughout the body. After ingestion of food, the time required for absorption and 
binding to transcobalamin II is approximately 3-4 hours (Carkeet et al., 2006). Under 
normal physiologic conditions, transcobalamin II is 20-30% saturated, and represents 10-
20% of the total circulatory cobalamin pool (Refsum, Johnston, Guttormsen, & Nexo, 
2006). Also called holotranscobalamin (holoTC), it is the biologically active form of 
vitamin B12 in the body and has a half-life of approximately 2 hours (Lindgren, Kilander, 
Bagge, & Nexo, 1999). Upon arrival at target cells, the B12/transcobalamin II binds to 
the transcobalamin II-receptor embedded in a cell’s plasma membrane, and vitamin B12 
is endocytosed into an intracellular lysosome (Christensen & Birn, 2002).
Transcobalamin I (Haptocorrin) 
In contrast to transcobalamin II-mediated transport of cobalamin (10-20%), the 
remaining 80-90% of circulating B12 in blood is bound to plasma transcobalamin I 
(Carmel, 1985). Transcobalamin I has a second isoform known as transcobalamin III. 
Both are encoded by a single gene. Transcobalamin III contains the same protein core as 
transcobalamin I but is glycosylated differently. These sugar moieties change the 
biophysical properties of the molecule but do not significantly alter vitamin B12 binding. 
For the purposes of this work, transcobalamin I will be used to denote both isoforms. 
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Part of the haptocorrin family, transcobalamin I belongs to a group of cobalamin-
binding glyoproteins that are also found in saliva and gastric mucosa (R-binders), 
(Russell-Jones & Alpers, 1999). In the blood, transcobalamin I does not facilitate direct 
B12 uptake from a receptor-mediated mechanism; it binds to an asialoglycoprotein 
receptor in the liver and transports released hepatic cobalamin stores, recycling some into 
bile. Hypothesized functions of transcobalamin I include the removal of cobalamin 
analogs from the bloodstream (Burger, Schneider, Mehlman, & Allen, 1975; Hardlei & 
Nexo, 2009). Vitamin B12 analogs bound to the transcobalamin I protein turn over 
extremely slowly and demonstrate a half-life of approximately 10 days (Finkler & Hall, 
1967). There is significant unsaturated binding capacity and up to 47.1% of 
transcobalamin I in plasma can be free of cobalamin analogs (Beck, 2001).
Transcobalamin I receptors are not ubiquitously expressed in tissues; thus, in the blood, 
transcobalamin I’s role as an effective transport protein is unclear. 
Metabolism:  Vitamin B12 Biochemistry
Vitamin B12 is required in all mammalian cells for one-carbon metabolism and 
cellular mitosis (Refsum et al., 2006). It plays important roles in two essential reactions, 
one mitochondrial and the other cytoplasmic (Figure 1). In the mitochondria, vitamin B12 
(5’-deoxyadenosylcobalamin) is required for the enzyme methylmalonyl CoA mutase, 
which catalyzes conversion of methylmalonyl CoA to succinyl CoA. This conversion is 
critical for odd-chain fatty acid oxidation and ketogenic amino acid catabolism (Green & 
Miller, 2007).
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In the cytoplasm, vitamin B12 (methylcobalamin) is used in the conversion of 
homocysteine to methionine, and simultaneously overlaps with folate-dependent 
methylation and carbon exchange (Allen, Stabler, Savage, & Lindenbaum, 1993).
Methionine is necessary for methylation, proper protein synthesis, and DNA formation. 
Methylcobalamin catalyzes a two-substrate two-product reaction. The conversion of 
homocysteine to methionine and folate-dependent reactions co-occur, the latter being the 
conversion of 5-methylenetetrahydrofolate (5-methyl THF) to tetrahydrofolate (THF). 
The end result of cobalamin-folate one-carbon metabolism mechanism is DNA precursor 
formation, deoxythymidine monophosphate (dTMP) (Beck, 2001).
Recycling Mechanisms
Storage 
Half of ingested B12 is delivered immediately to tissues by transcobalamin II 
while the other half is taken up by the liver (National Academy of Sciences, 1998). In 
healthy adults, total body cobalamin stores are between 2 and 4 milligrams, with total 
hepatic content between 1 and 1.5 milligrams (Grasbeck, 1959). The large majority of 
hepatic cobalamin stores (up to 70%) are comprised of adenosylcobalamin. Mobilization 
and liberation of vitamin B12 stores is hypothesized to occur via hepatic cell haptocorrin 
surface receptors (Burger et al., 1975).
Reabsorption 
B12 undergoes enterohepatic recycling and between 0.5-9.0 micrograms per day 
is released into the gastrointestinal tract from biliary content (Grasbeck, 1959; Grasbeck, 
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Nyberg, & Reizenstein, 1958). Of the 0.5-9.0 micrograms, 65-70% is intestinally 
reabsorbed through the actions of intrinsic factor (Booth & Spray, 1960). Also classified 
as part of the enterohepatic circulatory process, vitamin B12 from sloughed intestinal 
epithelial cells is absorbed. It has been hypothesized that presence of bile may enhance 
cobalamin absorption from the intestine (Green, Jacobsen, Van Tonder, Kew, & Metz, 
1982).
Excretion 
Vitamin B12 bound to carrier proteins filters through renal glomeruli with tubular 
reabsorption to prevent excessive losses. In the renal tubular epithelium, colocalized 
cubulin and megalin absorb cobalamin/transcobalamin II via receptor-mediated 
endocytosis (Birn, 2006). Normal renal filtration uptake of the cobalamin/transcobalamin 
II complex is estimated at 1.5 micrograms (Lindemans, van Kapel, & Abels, 1986).
Because very small amounts of vitamin B12 binding proteins are measurable in human 
urine, it is recognized that tubular reabsorption is very effective (Hall, 1964; Wahlstedt & 
Grasbeck, 1985). When circulating levels of the vitamin B12/transcobalamin II complex 
exceeds the rate-limited binding ability of megalin and cubulin, the excess is excreted 
into urine. 
Cobalamin Transport Genetics and Molecular Biology
Individual Genes in Transport
The cobalamin transport system is categorized into three main groups of ligands 
and receptors and includes intrinsic factor (IF) and the IF receptor, transcobalamin II and 
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the transcobalamin II-receptor, and haptocorrin and the haptocorrin receptor (Seetharam 
& Yammani, 2003). This section provides an overview of key genetic and molecular 
biology principles of the genes studied in this dissertation, transcobalamin II and the 
transcobalamin II-receptor. Also highlighted is the significance of the biologic overlap of 
transcobalamin II with the other cobalamin transporters, as demonstrated by shared 
exonic sequences, interspecies conservation, and amino-acid homology (Russell-Jones & 
Alpers, 1999).
Transcobalamin II Gene 
The transcobalamin II gene, located at 22q12.2, has nine exons, eight introns, and 
a total length of 19,887 base pairs. The final protein product is non-glycosylated, 
comprises 427 amino acid residues, and yields a molecular mass of 43 kDa (Seetharam & 
Li, 2000). In humans, expression occurs across many different tissue types, but at varying 
levels. Li and associates (1994) reported a single 1.9kb 32P-labelled cDNA band present 
across heart, brain, placenta, lung, liver, muscle, kidney, pancreas, spleen, thymus, 
prostate, testis, ovary, small intestine, colon, and leukocyte tissue samples using Northern 
blot analysis (Li, Seetharam, Rosenblatt, & Seetharam, 1994). Quadros and associates 
(1989) identified a similar band, but analyses identified amino acid differences at three 
codon positions, leading to the hypothesis that there are multiple isoforms of 
transcobalamin II (Quadros, Rothenberg, & Jaffe, 1989). Kidney tissue expresses highest 
levels of transcobalamin II mRNA and compared to this kidney baseline (100%), heart 
and pancreas tissues were at 15%, placenta, lung, liver, muscle, prostate, and ovary 
tissues at 7-9%, and all remaining tissues were at between 2-5% of kidney mRNA 
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expression. Regulation of gene expression occurs through a promoter demonstrating 
features including a 1kb 5’-flanking region that is GC-rich, absence of a TATA start-
transcription motif, and presence of multiple transcription start sites such as Sp1, CF1, 
HIP1, Ets-1, and MED-1 elements (Li, Seetharam, & Seetharam, 1995, 1998).
Transcobalamin II expression occurs through binding to a TGGTCC (5’-3’) hexameric 
sequence that is located 121bp upstream from the transcription start site (Regec, Quadros, 
& Rothenberg, 2002).
Transcobalamin II-Receptor Gene
The transcobalamin II-receptor gene, located at 19p13.3, has five exons, four 
introns, and is 6,229 base pairs in length. The final protein product is heavily 
glycosylated with a molecular mass of 58,000 atomic mass units (Quadros, Sai, & 
Rothenberg, 1994).
Expression of the transcobalamin II-receptor gene has been identified in many 
human tissues. Bose and associates (1995) used immunoblotting experiments to ascertain 
presence of a noncovalent homodimerized 124 kDa protein band (Bose, Seetharam, & 
Seetharam, 1995). Quantitative evaluation showed expression in human kidney was the 
greatest (100%) followed by placenta at 28%, intestine at 18%, and liver at 2%. 
Subsequent monomeric purification of the 124 kDa fragment yielded a 62 kDa band 
bound to a phospholipid bilayer. Study of the purified 62 kDa fragment identified a single 
polypeptide with 27% carbohydrate content and four intermolecular disulfide bonds; 
these characteristics were thought to indicate that transcobalamin II-receptor’s functional 
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importance extended beyond ligand binding to include Golgi-trafficking across plasma 
membranes (Bose & Seetharam, 1997).
Despite these novel purification findings, they proved incomplete and 
irreproducible until 2005, when the binding and functional properties of transcobalamin 
II were described by Quadros and associates (Quadros, Nakayama, & Sequeira, 2005).
Results differed significantly from previously published work, where a 58 kDa band was 
observed and demonstrated binding specificity lacking in previous reports. Full 
purification and definitive identification of transcobalamin II-receptor’s primary structure 
and gene sequence was published in 2009 (Quadros, Nakayama, & Sequeira, 2009).
Because transcobalamin II-receptor is highly glycosylated, the true size and the 
conformations of the attached sugars were difficult to identify and likely contributed to 
ambiguous results between various laboratory efforts. Quadros and associates (2009) 
used sodium dodecyl sulfate-polyacrylamide gel electrophoresis to separate a single 
homogenous band of 58-60 kDa that was 252 amino acid residues in length. Comprising 
the 252-amino acid sequence is an extracellular domain of 199 residues, a transmembrane 
domain of 21 residues, and a cytoplasmic domain of 32 residues. Within the molecule are 
18 residues that comprise two low-density lipoprotein receptor-class A domains, 
indicating that disulfide bonding is likely. 
Relationships Between Cobalamin Transport Genes
Since cobalamin is a highly polar and complex molecule, it cannot easily cross 
plasma membranes in physiologically significant amounts. All higher animals, including 
humans, use hydrophobic cobalamin transport proteins to bind dietary vitamin B12, and 
 25 
facilitate its movement from the stomach and intestine (haptocorrin R-binders and 
intrinsic factor) into the plasma and cells (transcobalamin II), and across circulatory 
storage pools (transcobalamin I in the haptocorrin family).
Sequence Alignment  
Although proteins across the three groups are distinct and function through 
specific receptors, they share biologic similarity in their capacity to bind cobalamin with 
high affinity (Seetharam, 1999). This insight was first appreciated when Hoedemaker and 
associates described presence of IF in the stomachs of multiple species (Hoedemaeker, 
Abels, Wachters, Arends, & Nieweg, 1966). Several decades later, molecular biologic 
approaches significantly advanced this understanding. Through techniques such as 
cloning, genetic sequence from multiple organisms was compared in genes across the 
three groups.
A 1988 analysis of genetic sequence (cDNA) for rat IF determined primary 
structural domains for cobalamin binding and outlined preliminary homologies to other 
biochemical proteins (Dieckgraefe, Seetharam, Banaszak, Leykam, & Alpers, 1988).
Comparison of these genetic rat IF features to human transcobalamin II and 
transcobalamin I (haptocorrin) sequences yielded identification of homologous regions 
across the groups; transcobalamin II had 20% amino acid identity with both human 
transcobalamin I and rat IF (Platica et al., 1991). Simultaneous progress in porcine model 
systems produced additional alignments between rat IF, porcine haptocorrin, and human 
transcobalamin I (Hewitt, Seetharam, Leykam, & Alpers, 1990; Johnston, Bollekens, 
Allen, & Berliner, 1989). Collectively from these studies, overall protein alignment was 
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at 33% and found within them were six regions of high structural sharing, at 60-90% 
similarity in amino acid sequence. The most highly conserved of these six regions 
extends across 15 residues, from position 174 to 188 (174SVDTAAMAGLAFTCL188).
Ancestral Origins 
The overlap across species for the cobalamin binding protein genes is significant 
because it indicated a likely common ancestral gene of evolutionary origin. Recent 
mammalian (rat, mouse, porcine, bovine, human) phylogenetic analysis of the highly 
conserved 15-amino acid residue showed an evolutionary relationship suggesting that 
transcobalamin II evolved earlier than other cobalamin binding proteins (Kalra, Li, 
Yammani, Seetharam, & Seetharam, 2004). The radial tree that was generated from this 
work pictured a relationship where transcobalamin II evolved independently and earlier 
than that of IF and haptocorrin, which co-evolved in a more dependent manner. The 
analysis was also significant for the convergence of mouse and rat transcobalamin II, 
with 95-98% sequence homology compared to 71-74% for human and bovine 
counterparts.
Pathophysiology of Cobalamin Deficiency
Since total-body stores of cobalamin are between 2 and 5 milligrams and daily 
requirements are at several micrograms per day, abrupt cessation of cobalamin dietary 
intake does not yield immediately clinically observable effects. It can take many years for 
classical cobalamin deficiency clinical symptoms to appear as tissues slowly release 
needed minute daily requirements. There are numerous causes of clinical cobalamin 
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deficiency that result from 1) insufficient intake from poor diet or mal-absorptive 
pathology, 2) increased metabolic needs (i.e., pregnancy), and 3) impaired use or vitamin 
activation in tissues such as that which occurs in genetic inborn errors of metabolism. 
The majority of documented clinical deficiencies arise from the first category stemming 
from varying states of impaired gastrointestinal absorption.
Traditional and common clinical definitions of the cobalamin deficiency include 
1) presence of megaloblastic anemia and/or neuropsychiatric alterations that respond to 
supplemental cobalamin therapy, or 2) decreased total serum cobalamin with or without 
altered biochemical metabolites (Miller et al., 2006; Savage, Lindenbaum, Stabler, & 
Allen, 1994).
Megaloblastic Anemia
When there is decreased availability of dTMP coming from conversion of 
homocysteine to methionine, deoxyuridine monophosphate (dUMP) is erroneously 
incorporated into DNA. DNA repair enzymes subsequently recognize this 
misincorporated uracil and cleave out the base. Incomplete DNA repair leads to frequent 
gaps and breaks in DNA sequence (Goulian, Bleile, & Tseng, 1980). Improper DNA 
synthesis results in cellular derangement and premature cell death. Although required in 
all cells, vitamin B12 is needed most by dividing cells, such as those in the bone marrow. 
In absence of adequate dTMP, all hematopoietic precursors undergo abnormal DNA 
synthesis and yield delayed or halted cell division events observable via variable cell 
morphologies (Aster, 2005). As a result, up to 90% of an affected patient’s red blood cell 
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precursors may be destroyed prior to their release into the blood, compared to 10-15% 
under normal circumstances (Babior & Franklin Bunn, 2005).
Destruction of red blood cell precursors on this scale will result in decreased 
hemoglobin concentration and elevated mean corpuscular volume (MCV); presence of 
both are classic hallmark hematologic indicators of megaloblastic changes (Andres et al., 
2006). Normal hemoglobin values in adult women according to the World Health 
Organization are 12-16 g/dL, and levels under 12 g/dL are considered indicative of 
anemia (Aster, 2005; Chaves, Ashar, Guralnik, & Fried, 2002). MCV is used in anemia 
classification discerning microcytic (MCV below 83 fL), normocytic (MCV 83 to 103 
fL), and macrocytic (MCV greater than 103 fL) categories (Williamson et al., 1995).
Thus, macrocytic anemia is characterized by a low red blood cell count, decreased 
hemoglobin concentration, and abnormally large (macrocytic) red blood cells, and 
indicates presence of cobalamin or folate deficiency (Aster, 2005). Cobalamin’s overlap 
with folate will be discussed later in this section. 
In cobalamin deficiency, rapidly dividing granulocytic precursors demonstrate 
nuclear immaturity while protein assembly continues normally. Although cytoplasmic 
features are intact, nuclei demonstrate visible chromatin clumping, become abnormally 
large for the cell’s size, and develop numerous, hyper-segmented granules (Chui et al., 
2001). Malformed platelets, thrombocytopenia, hypercellular bone marrow, and 
decreased white blood cell counts can also occur (Allen et al., 1993).
Accompanying these cellular changes, symptoms commonly reported by patients 
include vertigo, light-headedness, palpitations, and chest pain. Physical examination may 
yield pallor, jaundice (secondary to red blood cell destruction), rapid heart rate, evidence 
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of cardiomegaly, and a holosystolic murmur. Insidiously, anemia impacts a person’s 
perception and understanding of their own health, resulting in feelings of fatigue, 
decreased strength, and a poor sense of well-being (Eisenstaedt, Penninx, & Woodman, 
2006; Guralnik, Eisenstaedt, Ferrucci, Klein, & Woodman, 2004; Penninx et al., 2004; 
Woodman, Ferrucci, & Guralnik, 2005). Life threatening hematological changes can also 
occur, including symptomatic pancytopenia, pseudo-thrombotic microangiopathy, and 
hemolytic anemia (Andres et al., 2006).
Neurologic Changes
Although anemic symptoms usually occur first in cobalamin deficiency, 
neurological symptoms can present prior to, in concordance with, or separately from 
hematological alterations (Carmel, 2000; Carmel, Green, Rosenblatt, & Watkins, 2003; 
Lindenbaum et al., 1988). The central nervous system and neural cells are dependent 
upon continuous supply of nutrients (Selhub, Bagley, Miller, & Rosenberg, 2000). For 
example, myelin sheaths experience frequent turnover and are dependent upon 
methylations of precursor proteins and essential fatty acid oxidations (Scott, 1999). When 
altered, the primary feature of neurologic pathology resulting from decreased cobalamin 
is demyelination that affects both central and peripheral neurons (Green & Kinsella, 
1995).
There are two hypotheses on the pathophysiology that leads to demyelination: 1) 
in the absence of cobalamin, there is decreased synthesis of the methyl group donor S-
adenosylmethionine, which prevents precursor myelin basic protein from being formed, 
(the S-adenosylmethionine hypothesis); and 2) in the absence of cobalamin, 
 30 
mitochondrial precursor methylmalonyl CoA accumulates, becomes toxic, and disrupts 
odd-chain fatty acid metabolism in neurons, (the adenosylcobalamin hypothesis). The 
first of these hypotheses, the S-adenosylmethionine hypothesis, is favored to the second, 
adenosylcobalamin hypothesis. 
The S-Adenosylmethionine Hypothesis 
In the cytoplasm, methylcobalamin serves as a cofactor for the conversion of 
homocysteine to methionine. This enzymatic conversion feeds two cycles, the 
methylation cycle and the DNA replication cycle (Figure 2), (Scott, 1999). The universal 
methyl donor S-adenosylmethionine donates a methyl group to S-adenosylhomocysteine 
for which to use in methylation of proteins, DNA, lipids, and other needed substrates 
(Dinn et al., 1980). Without proper methylation, required substrates are not produced 
properly, including neurotransmitters, membrane phospholipids, and precursor proteins 
used in nerve conduction, such as myelin basic protein (Metz, 1992). Multiple nervous 
system components become affected by these derangements, including long tracts of 
white matter in the posterior and lateral columns of the spinal cord, sensory fibers 
responsible for vibration sensitivity and position sense, and motor fibers controlling 
movement.  
The Adenosylcobalamin Hypothesis 
The alternative hypothesis to neurodegenerative changes observed in cobalamin 
deficiency postulates that neurologic symptoms arise from insufficient conversion of 
methylmalonyl CoA to succinyl CoA in the mitochondria. There is evidence that suggests 
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that accumulated methylmalonic acid disrupts odd-chain fatty acid metabolism, leading 
to neurological damage (Frenkel, 1973). Although there are numerous studies that 
identify quantitative abnormalities of odd-chain and branched-chain fatty acids in vitamin 
B12-deficient spinal cord and peripheral nerve tissue, there is not a clear relationship 
between these measurements and clinical development of cobalamin neuropathy 
(Kishimoto, Williams, Moser, Hignite, & Biermann, 1973; Levy, Mudd, Schulman, 
Dreyfus, & Abeles, 1970; Ramsey, Scott, & Banik, 1977). Further evidence against the 
adenosylcobalamin hypothesis comes from children with inherited disorders yielding 
high methylmalonic acid levels; despite having extraordinarily high levels, the patients’ 
neurologic features are inclusive of mental retardation and muscular hypotonia and not 
those of cobalamin deficiency neuropathy (Rosenblatt & Cooper, 1987).
Clinical Progression and Effects
When there is insufficient methylation for normal neurologic homeostasis, small 
vacuoles in the myelin sheath result in focal swelling of individual neuronal fibers (Pant, 
Asbury, & Richardson, 1968). The focal swellings expand in scope to develop larger foci; 
beginning at the cervicothoracic junction of the spinal cord, posterior columns are usually 
the first to be affected before spreading up and down the cord and into anterior segments. 
On magnetic resonant imaging, increased T2-weighted signal, decreased T1-weighted 
signal, and contrast enhancement of the posterior and lateral spinal cord columns in 
cervical and upper thoracic segments are observed (Locatelli, Laureno, Ballard, & Mark, 
1999).
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Clinical presentation of the focal neuronal swelling is initially mild and 
measurable only by electrophysiological methods (Carmel & Sarrai, 2006).
Neuropsychiatric symptoms, including parasthesias, ataxia, memory loss, mood 
alterations, and extremity weakness, are common initial presentations. If untreated, these 
symptoms become more severe and progress to numbness and tingling of extremities, 
clonus, weakness, spasticity of extremities, ataxia, abnormal reflexes, and gait and visual 
disturbances (Babior & Franklin Bunn, 2005). Underlying these worsening symptoms is 
progressive demyelination that affects peripheral nerves, posterior and lateral columns of 
the spinal cord, and the cerebrum (Allen et al., 1993).
If continuing uncorrected, permanent pathology such as axonal degeneration and 
neuronal death occur (Babior & Franklin Bunn, 2005). Cerebellar involvement is 
inclusive of urinary and/or fecal incontinence, and cranial nerve decompensation, 
including visual disturbances and optic neuritis (Allen et al., 1993). Decreases in 
cognitive function, development of dementia, personality changes, and occurrence of 
depression and Parkinsonian symptoms have all been documented as part of the clinical 
neurologic vitamin B12 deficiency profile (Carmel, 2000; Carmel & Sarrai, 2006; Clarke 
et al., 2003).
Metabolite Abnormalities
Prior to development of hallmark anemic or neurologic symptoms, metabolite 
assays are a valuable tool in providing an indication of a patient’s vitamin B12 status. In 
deficiency states, the cobalamin metabolic reaction precursors methylmalonic acid 
(mitochondrial indicator) and homocysteine (cytosolic indicator) are not metabolized and 
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accumulate in cells and tissues (Lindgren et al., 1999). Increased serum methylmalonic 
acid and total homocysteine correlate with hematological and neurologic symptoms of 
clinical vitamin B12 deficiency and decrease responsively with supplemental cobalamin 
therapy (Henning, Tepel, Riezler, & Naurath, 2001; Naurath et al., 1995; Rajan et al., 
2002).
In clinical practice, normal vitamin B12 metabolic profiles include serum 
cobalamin at >258 pmol/liter, total homocysteine at 5.4-	
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nmol/liter. Less restrictive parameters are used for ascertaining presence of subclinical 
vitamin B12 deficiency, which is present when serum cobalamin is 185-258 pmol/liter, 
total homocysteine is 15-#	
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#-999 nmol/liter. Altered 
metabolite levels in subclinical deficiency can be present even if hemoglobin 
concentration and MCV are normal. In addition to reflecting altered vitamin B12 status, 
abnormal metabolite concentrations have been hypothesized to affect risk for 
development of comorbid pathology, such as homocysteine and cardiac disease. For 
some time, elevated serum homocysteine was recognized as a risk factor for the 
occurrence of cardiovascular disease and thrombosis (Refsum, Ueland, Nygard, & 
Vollset, 1998). However this role is no longer clear, as a recent randomized evaluation of 
folic acid and vitamin B12 versus placebo on blood homocysteine failed to demonstrate 
beneficial effects in preventing myocardial infarction (Study of the Effectiveness of 
Additional Reductions in Cholesterol and Homocysteine Collaborative Group, 2010). 
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Elevated methylmalonic acid and homocysteine concentrations occur in over 90% 
of patients with vitamin B12 deficiency, are increased prior to development of overt 
clinical symptoms, and often accompany normal serum cobalamin levels (Herrmann et 
al., 2003; Stabler, Allen, Savage, & Lindenbaum, 1990). Both methylmalonic acid and 
homocysteine concentrations can be altered in other disease states, such as inborn errors 
of metabolism, folate deficiency, and renal insufficiency (Allen, Lindenbaum, & Stabler, 
1996; Bostom & Lathrop, 1997; Herrmann et al., 2000; Manns et al., 1999; Metz et al., 
1996; D. S. Rosenblatt & Cooper, 1987). Serum homocysteine can be elevated in folic 
acid deficiencies, but methylmalonic acid elevations are specific to cobalamin deficiency 
(Stabler, Lindenbaum, & Allen, 1997).
To better define subtle features of early clinical development of cobalamin 
deficiency, four stages of progressive metabolite alterations and clinical characteristics 
have been suggested: (1 and 2) depletion of plasma and cell stores; (3) incidence of 
functional imbalances as measured by decreased biologically active cobalamin in serum, 
increased homocysteine and/or methylmalonic acid; and (4) appearance of megaloblastic 
and neuropsychiatric clinical symptoms (Herrmann et al., 2003).
Measurement Challenges
Even in individuals with known cobalamin deficiency, normal circulating levels 
of vitamin B12 can be maintained at the cost of tissues for several years (Lindenbaum, 
Savage, Stabler, & Allen, 1990). Total serum cobalamin demonstrates poor sensitivity 
and specificity for ascertainment of when the body is “low” in cobalamin from a tissue 
perspective (Miller et al., 2006). Serum holotranscobalamin, the biologically active 
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cobalamin in serum that is bound to transcobalamin II, is recognized for providing 
improved detection of cobalamin status in individuals (Green, 2008; Lindgren et al., 
1999). Although more precise measurement alternatives such as holotranscobalamin can 
provide clinicians better proof of deficiency, it is generally accepted that interpreting 
multiple testing analytes with clinical presentation symptoms yields accurate detection 
(Green & Miller, 2007; Herrmann et al., 2003; Herrmann et al., 2000; Obeid, Schorr, 
Eckert, & Herrmann, 2004).
Measurement of cobalamin metabolites can be challenging, as sophisticated 
techniques require specialized equipment and training. This is primarily because 
methylmalonic acid and homocysteine levels accumulating in cobalamin deficiency states 
are typically in the nanomolar to micromolar range, and accurately detected by gas 
chromatography-mass spectrometry (GC-MS) and high-pressure liquid chromatography 
(HPLC) in both serum and urine (Green, 1995; Miller et al., 2006). Due to their cost, 
many laboratories cannot afford the technology required for these specialized assays. For 
laboratories that do perform them, accurate interpretation can be affected by absence of 
standardized laboratory procedures, assay reagents, and testing approaches. For serum 
cobalamin, concentrations reported by laboratories often vary from those used in 
international measurement standards, contributing to clinician misinterpretation. Coupled 
with absence of consensus on what is considered ‘elevated’ or ‘decreased’ due to poor 
correlation with actual tissue level—clinicians can erroneously underestimate the 
complexity of commonly used cobalamin laboratory tests (Carmel et al., 2003).
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Cobalamin Overlap with Folate and the Methyl-Folate Trap
As mentioned, megaloblastic anemia and elevated homocysteine clinical features 
can also be caused by decreased folate. This is because cobalamin metabolism overlaps 
with folate metabolism in the conversion of homocysteine to methionine (Figure 3). In 
the absence of adequate cobalamin, an intracellular backlog of 5-
methylenetetrahydrofolate occurs. Since the 5,10-methylenetetrahydrofolate enzyme 
strongly favors one direction, it does not go backwards in the pathway; thus, the cell has 
plenty of folate but it is “trapped” in an unusable form for DNA synthesis (Scott & Weir, 
1981; Scott & Weir, 1994). The resulting clinical presentation is identical to that of 
megaloblastic anemia caused by true deficiency of folate. 
Synthetic folate (folic acid) enters downstream of the methionine synthase 
conversion, and as it is converted to tetrahydrofolate from dihydrofolate, can rescue DNA 
synthesis in cobalamin deficiency. However, it does not resolve elevated homocysteine 
levels, as cobalamin is required for conversion of homocysteine to methionine. If a well-
meaning health care provider aims to treat megaloblastic anemia with folic acid without 
fully reviewing metabolic parameters, the patient experiences resolution of megaloblastic 
anemia as cobalamin deficiency continues, masked by this treatment (Pfeiffer, Caudill, 
Gunter, Osterloh, & Sampson, 2005). In such cases, it is not until progression of 
neurologic symptoms becomes significantly severe that cobalamin deficiency is 
suspected and more detailed metabolite profiles are checked. In the advent of widespread 
folate fortification, research into vitamin B12 and folate status has identified that low-
cobalamin levels exist with high folate levels, and can compound risk of neurologic 




Nutritional deficiencies in the elderly population are well characterized as 
functions of expected age-related physiological changes (Saltzman & Russell, 1998). At 
worst, 20-50% of the aging population experience some form of vitamin B12 deficit 
(Lindenbaum, Rosenberg, Wilson, Stabler, & Allen, 1994; Selhub et al., 2000; Stabler et 
al., 1997). Pernicious anemia (Type A atrophic gastritis) is the end-stage presentation of 
autoimmune gastritis and is the primary cause of frankly overt clinical vitamin B12 
deficiency in North American populations (Baik & Russell, 1999). For every elderly 
adult female diagnosed with pernicious anemia, approximately five males are affected, 
and Caucasian and African American elderly adults shoulder increased prevalence of 
pernicious anemia compared to other racial demographic groups (Baik & Russell, 1999).
Antibodies that attack H+/K+ ATPase pumps progressively destroy parietal cells, causing 
continued decline of vitamin B12 absorption and extraction from protein (Morris, 
Jacques, Rosenberg, & Selhub, 2007).
In contrast, Type B atrophic gastritis is a naturally occurring phenomenon of 
aging, stemming from decreased secretion of stomach acid, pepsin, and intrinsic factor 
(Saltzman & Russell, 1998). Concomitant with achlorydia stemming from all forms of 
gastric atrophy, microorganism overgrowth fostered by decreased gastric acid production 
can competitively consume ingested vitamin B12 in aging individuals (Suter, Golner, 
Goldin, Morrow, & Russell, 1991). Although more rare in elderly populations, poor diet, 
decreased dietary intake of foods containing vitamin B12, and strict vegetarianism can 
also result in dietary deficiency for aging adults.
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Additional causative factors include side effects from medications and comorbid 
conditions that increase nutritional need for vitamin B12. Medications interfering with 
vitamin B12 absorption commonly prescribed in elderly individuals include antiepileptic 
agents, proton pump inhibitors, histamine receptor antagonists, the antidiabetic drug 
metformin, antibiotics, and cholestyramine (Wolters, Strohle, & Hahn, 2004). Comorbid 
conditions contributing to malabsorption or increasing nutritional requirements include 
intestinal diseases (Crohn’s), gastric or ileal resections, alcohol intake, smoking, renal 
insufficiency, diabetes mellitus, and lymphoma (Wolters et al., 2004).
Subclinical Cobalamin Deficiency
Subclinical B12 deficiency is a burden largely shouldered by older adults because 
symptoms indicating its presence are often interpreted by clinicians to be associated with 
other disease states or nonspecific effects of aging (Andres et al., 2004). The subtle 
nature of weakness, fatigue, headache, depression, shortness of breath, malaise, vertigo, 
early dementia, and sensory parasthesias is common in aging patients and often 
improperly attributed to other causative mechanisms (Baik & Russell, 1999; Clarke et al., 
2003). Unrecognized deficiency or misattribution of symptoms to folate increases chance 
of progression to irreversible neurological changes. For elderly adults, permanent 
neurological changes commonly experienced by the elderly stemming from unrecognized 
cobalamin deficiencies include taste alterations, memory loss, parasthesias, spinal cord 
subacute degeneration, neuropathy, gait ataxia, dementia, anosmia, incontinence, 
impotence, decreased visual acuity, and psychosis (Baik & Russell, 1999; Carmel, 2000).
For elderly individuals, the best primary defense against permanent neuropsychiatric 
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injury is maintaining a healthy awareness for subclinical cobalamin deficiency in the 
event of nonspecific symptom presentations.
Although measuring cobalamin metabolite levels helps greatly in ascertaining 
presence of deficiency in older adults, several clinical factors are known to affect 
accurate detection. Similar to trends in other age groups, erroneous attribution of 
megaloblastic anemia to folate in the absence of a full metabolic workup can obscure 
diagnosis (Allen & Casterline, 1994; Pfeiffer et al., 2005). Common in elderly 
individuals, renal insufficiency is known to cause increases in both homocysteine and 
methylmalonic acid (Herrmann, Obeid, Schorr, & Geisel, 2005; Herrmann, Schorr, 
Geisel, & Riegel, 2001; Obeid, Kuhlmann, Kirsch, & Herrmann, 2005). Molecular 
etiology for accumulations of homocysteine and methylmalonic acid stemming from 
renal dysfunction are largely unknown. However, elevations in either serum 
homocysteine or methylmalonic acid from renal insufficiency are modest compared to 
those that occur in true cobalamin deficiency states (Savage et al., 1994; Stabler, 
Lindenbaum, & Allen, 1996).
Renal Function Assessment
In clinical practice, serum creatinine is a common measure of renal function and 
is the most widely used method of assessing an individual’s renal status. However, it is 
recognized that relying on serum creatinine measurement alone is limiting, as it does not 
correlate with actual physiologic glomerular filtration rates (Shemesh, Golbetz, Kriss, & 
Myers, 1985; Stevens, Coresh, Greene, & Levey, 2006). In older adults, renal function 
slowly declines and tubular secretion of creatinine increases; thus, elevations in serum 
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creatinine are not seen until more than half of total glomerular filtration is lost (Giannelli  
et al., 2007). In addition, decreased muscle mass in older adults is associated with 
decreased creatinine production. If kidney problems in older adults are not diagnosed, 
renal disease can progress and result in additional costly comorbidities, clinical 
complications, and drug toxicities. In a recent study of 660 elderly adults with normal 
serum creatinine values, alternative renal-estimation equations identified that up to 39% 
of them could be classified as having renal impairment (Giannelli et al., 2007).
A common measure of renal-function estimation used in elderly individuals that 
employs age, weight, and serum creatinine, is the Cockcroft-Gault estimation equation 
(Cockcroft & Gault, 1976). For females, the Cockcroft-Gault formula incorporates a 
constant of 0.85 to account for 15% less muscle mass as compared to males. The 
Cockcroft-Gault has been used in many studies of older adults, and although reported to 
underestimate creatinine clearance, is considered by many experts a more valid and 
reliable method than if using serum creatinine alone (Froissart, Rossert, Jacquot, Paillard, 
& Houillier, 2005; Lamb et al., 2005).
Role of Cobalamin in Cognition
There is a significant and storied history of the suspected role of cobalamin in 
cognition, with much clinician speculation focused on delineating cause and effect 
between altered homocysteine levels and dementia in Alzheimer’s disease (McCaddon, 
2006). However, the concept that deficits in nutritional status would precipitate 
neuropsychiatric decline was not fully acknowledged until 1990, when it was reported 
that low-normal concentrations of cobalamin were associated with cognitive impairment 
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(Bell et al., 1990). The chart review by Bell et al. of 102 geriatric inpatients found that 
the 3.7% of patients who were vitamin B12 deficient were more likely to have 
significantly lower Mini-Mental State Examination scores. Shortly later, Rosenberg and 
Miller’s review of dietary factors and neuro-cognitive health concluded that elderly 
individuals were extremely susceptible to cognitive decline from subtle and progressive 
forms of subclinical nutritive deficiencies (Rosenberg & Miller, 1992). An unintended 
consequence of this position was the assumption that vitamin B12 indeed contributed to 
pathologic progression of cognitive decline in elderly patients, without there being 
presence of strong prospective controlled clinical evidence to confirm it.
Since that time, numerous research studies have reported variable efficacy of 
vitamin B12 on the protection and maintenance of cognitive function (Smith & Refsum, 
2009). Total homocysteine and cognitive measures were inversely related in 2,096 
elderly adult dementia and stroke-free participants (>60 years) of the Framingham 
Offspring Study (Elias et al., 2005). A 3-year prospective evaluation of the association 
between dietary B-vitamin intake and cognitive decline in a subset of 321 men in the 
Veterans Affairs Normative Aging Study revealed that the association of poor cognitive 
status with low vitamin B12 and high homocysteine was only applicable to performance 
on a construction praxis spatial copying score (Tucker, Qiao, Scott, Rosenberg, & Spiro, 
2005). A 6-year prospective observational study of 3,718 community-dwelling elderly 
individuals over 65 indicated that high dietary B12 intake was associated with slower 
cognitive decline, but only in the oldest individuals (Morris et al., 2005). Authors of a 
recent Cochrane Collaboration meta-analysis concluded that there is no evidence that 
folic acid with or without vitamin B12 improves cognitive function of elderly individuals 
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with or without dementia; however, long-term supplementation may be protective for 
healthy elders with high homocysteine levels (Malouf & Grimley Evans, 2008). This is 
likely due to the great clinical and research heterogeneity across studies in the literature. 
Variability in cognitive assessment tools, clinical outcome parameters, quasi-
experimental study designs, laboratory metabolite measurements, and deficiency 
threshold cutoffs contribute to poor-quality evidence from which to draw clinical 
conclusions (Raman et al., 2007).
The Dissertation’s Clinical Measurements of 
Altered Cobalamin Status
The dissertation research uses multiple measures of cobalamin status for elderly 
adult women subjects. Measures previously discussed as related to pathophysiology, 
diagnosis, and clinical management of vitamin B12 deficiency include hemoglobin, mean 
corpuscular volume, serum cobalamin, and the biochemical metabolites homocysteine 
and methylmalonic acid. However, the dissertation also explores relationships to other 
clinical outcomes, including depression, peripheral neuropathy, and functional decreases 
in strength and speed of ambulation.  
Depression
Patients experiencing alterations in mood, primarily depression, are commonly 
reported to also have abnormal cobalamin and folate laboratory values (Bell et al., 1990; 
Carney et al., 1990; Lindenbaum et al., 1988; Savage & Lindenbaum, 1995). Previous 
work in the Women’s Health and Aging Study found a twofold increase in risk of severe 
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depression in patients who experienced clinical cobalamin deficiency as measured by 
serum cobalamin, homocysteine, and methylmalonic acid levels (Penninx et al., 2000). A 
longitudinal association study of depressive symptoms in 3,503 older adults over 7 years 
identified that for each 10 additional micrograms of vitamin B12 intake, there was a 2% 
lower odds of depressive symptoms per year (Skarupski, Tangeny, Li, Ouyang, Evans & 
Morris, 2010). 
Although the association between vitamin B12 intake and depression in older 
adults is reported in multiple observation studies, causation of its presence has not been 
able to be determined. Hypothesized molecular origins of the connection may stem from 
insufficient cobalamin and folate to drive the conversion of homocysteine to methionine, 
preventing methylation of key neurotransmitters in the brain, including the monoamines 
dopamine and serotonin (Bottiglieri et al., 2000; Weir & Scott, 1999). However, many 
behavioral factors that accompany depressive symptomology in aging individuals, such 
as decreased appetite and socioeconomic status, likely contribute to this association as 
well (Donini, Savina, & Cannella, 2003). 
Depression is a challenging phenomenon to measure; it displays lack of 
agreement between clinicians and researchers on the concepts that comprise it, and 
classification mechanisms across numerous settings and groups vary widely according to 
patient subpopulation and clinical care specialty (Pasacreta, 2004). Depression contains 
both affective and somatic components, which results in significant overlap with 
comorbid symptomology (i.e., fatigue, decreased appetite) obscuring accurate research 
measurement. Common to elderly populations, dementia is a common confounder where 
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psychomotor retardation and passive responses to examiner questions are misinterpreted 
as depressive pathology. 
The Geriatric Depression Scale (GDS) was derived for use in geriatric 
populations so that somatic depression manifestations and dementia presence do not 
threaten validity of accurate detection (Feher, Larrabee, & Crook, 1992; Yesavage et al., 
1982). Comprised of 30 items requiring a yes/no answer, higher GDS scores indicate 
depression severity. Generally accepted cutoffs are no depression (scores less than or 
equal to 9), mild depression (scores 10-13), and severe depression (scores greater than or 
equal to 14) (Ferrucci, Kittner, Corti, & Guralnik, 1995; Lyness et al., 1997; Norris, 
Gallagher, Wilson, & Winograd, 1987). Criterion validity using psychiatric evaluation of 
DSM III diagnostic standards for mild depression on GDS was 89%, and for severe 
symptoms was 78%. Specificity values were similar at 73% for mild depression and 86% 
for severe depression (Norris et al., 1987). Although GDS measurements are reliable and 
valid in older persons with respect to research diagnostic criteria and DSM-IV criteria, 
presence of mild or severe depression using the screening scale is not necessarily 
indicative of a clinical diagnosis.
Peripheral Neuropathy
Abnormal sensation is a widely reported indicator of presence or development of 
vitamin B12 deficiency pathology (Carmel et al., 2003). Abnormal sensation is also 
considered a key subtle clinical manifestation indicative of subclinical vitamin B12 
deficiency (Carmel & Sarrai, 2006). As discussed in previous pathophysiology sections, 
aberrated methylation for myelin basic protein precursors from altered conversion of 
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homocysteine to methionine disrupts neuronal signaling. The neurologic syndrome of 
cobalamin deficiency commonly starts with peripheral paresthesias in the feet before 
progressing to more severe pathology (Beck, 2001; Green & Miller, 2007). In a study of 
neurologic aspects of cobalamin deficiency in 369 cobalamin deficient patients, it was 
found that paresthesia was the most common neurologic finding at the time of diagnosis 
on physical examination (Healton, Savage, Brust, Garrett, & Lindenbaum, 1991).
Comprising 87.7% of the paresthesia symptom profiles, the most common abnormality 
was found to be significant diminishment of vibration sensitivity in the feet, or feet and 
legs up to the knees. Less commonly, diminished abnormality also extended up from the 
feet to include the iliac crest, lower thoracic area, midthoracic area, hands and elbows, 
and shoulders. 
Alterations in vibration sensitivity stemming from large-fiber peripheral nerve 
function provide an objective measurement for declining nerve function (Ferrucci, 
Kittner, et al., 1995). Vibratory perception sensory thresholds in older adults are 
reproducible and reliable indicators of polyneuropathy (de Neeling, Beks, Bertelsmann, 
Heine, & Bouter, 1994). Vibration perception testing (VPT) protocols involve serial 
application of quantified vibration and assessing if subjects are able to feel it or not. 
Depending upon a patient’s response, the strength of stimulus is incrementally adjusted 
until an individual can no longer sense vibration. VPT can be administered via electronic 
or mechanical clinical measurement tools, such as vibrometers and tuning forks. 
Although reliability is well established for varying measurement modalities individually, 
measurement methods are not interchangeable due to slight physiological differences in 
how sensory neurons transmit mechanical stimuli (tuning fork) as compared to energy-
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based stimuli (voltage or current) (Temlett, 2009). Key advantages to using voltage- and 
current-based modalities include the removal of variability coming from inconsistent 
techniques of generating and applying the tuning fork’s blade intensity. 
VPT in the Women’s Health and Aging Studies (WHAS) 1 and 2 were assessed 
using different techniques, WHAS 1 with a vibrometer modality and WHAS 2 with a 
tuning fork. In WHAS 1, the VPT used was modeled after a diabetic neuropathy protocol, 
where vibration measures are considered valid if 18 or less stimulation attempts are 
made, and not more than one error occurs in the first eight attempts (Ferrucci, Kittner, et 
al., 1995; Maser et al., 1989). The amplitude of vibration stimulus is converted to a 
micron unit measurement, with higher values indicating that a stronger stimulus was 
required to elicit a correct sensory response from the patient (Resnick et al., 2000; 
Volpato et al., 2003). Accepted neuropathic functional micron unit cutoffs include normal 
function at less than 3.43 units, mild dysfunction at 3.44-4.87 units, moderate dysfunction 
at 4.88-6.31 units, and severe dysfunction at over 6.31 units (Resnick, Vinik, Heimovitz, 
Brancati, & Guralnik, 2001; Volpato, Leveille, Blaum, Fried, & Guralnik, 2005).
Functional Indicators
As reviewed in earlier sections, 5’ adenosylcobalamin serves as the coenzyme for 
methylmalonyl-coenzyme A mutase, which facilitates conversion of methylmalonyl-
coenzyme A to succinyl-coenzyme A in the mitochondria. This conversion is necessary 
for catabolism of odd-chain fatty acids and some amino acids, and results in maintenance 
of normal energy metabolism. 
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In the absence of this conversion, methylmalonyl-coenzyme A and its precursor, 
propionic acid, accumulates and diffuses out of the mitochondria into the cytoplasm and 
disrupts normal metabolism (Brass, Tahiliani, Allen, & Stabler, 1990). The cellular 
accumulation of propionic acid and methylmalonic acid (acyl-coenzyme A thioesters) has 
been shown to inhibit gluconeogenesis from pyruvate, pyruvate oxidation, fatty acid 
oxidation, and ureogenesis (Brass, 1986; Glasgow & Chase, 1976; Walajtys-Rode, Coll, 
& Williamson, 1979; Walajtys-Rode & Williamson, 1980). In cobalamin deficiency, the 
combined effects of deranged energy production processes in addition to accumulated 
methylmalonic, propionic acids, disrupts energy homeostasis and impairs the action of 
multiple critical enzymes (Depeint, Bruce, Shangari, Mehta, & O'Brien, 2006; Kolker & 
Okun, 2005). The clinical effects of these metabolic impairments can be severe, such as 
that which is demonstrated by individuals diagnosed with methylmalonic acidurias. 
As a diagnostic class, methylmalonic acidurias are a group of autosomal recessive 
genetic disorders that offer valuable biologic insight to the broader mechanisms of 
cobalamin deficiency. Methylmalonic acidurias are caused by autosomal recessive 
mutations in genes that code for methylmalonyl-coenzyme A mutase or the cobalamin 
complementation groups, which synthesize 5’ adenosylcobalamin for use in the 
mitochondria (Chandler et al., 2007; Coelho et al., 2008; Rosenblatt & Fenton, 2001).
Inherited methylmalonic acidurias produce severe clinical symptoms that are often fatal. 
Because of their severity, clinical study of organ-system derangements from drastically 
excessive methylmalonic acid levels is limited to animal studies, observations of affected 
newborn infants, postmortem analyses, and children with less severe defects who have 
matured into adolescence and young adulthood. Common symptoms experienced by 
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individuals with methylmalonic acidurias include lactic acidosis, decreased muscle 
strength, muscular hypotonia, lethargy, and failure to thrive (Coelho et al., 2008; 
Rosenblatt & Cooper, 1987; Tanpaiboon, 2005). In a recent characterization of the 
methylmalonic aciduria phenotype, investigators examined correlations of murine and 
human disease characteristics and found that altered metabolism in skeletal muscle was a 
significant source of pathology (Chandler et al., 2007).
Although the autosomal recessive methylmalonic acidurias do not present in older 
adults and thus cannot be generalized to the geriatric population, they may offer biologic 
insight into concomitant metabolic processes when methylmalonic acid concentrations 
are significantly elevated. For example, methylmalonic acidurias in neonates and children 
produce drastically elevated methylmalonic acid levels at approximately 1000 nmol/L, a 
level which is similar to that of severe cobalamin deficiency in older adults. Although 
these metabolic concentrations may be similar, a key limitation in understanding the 
relationship between elevated methylmalonic acid concentration and poor functional 
status in elderly individuals is that it is relatively unexplored in the area of cobalamin 
metabolism. 
Available data is limited to several separate investigations of neuromuscular 
effects of cobalamin deficiency and its possible genetic influences. In a focused 
observational study of 153 cases of cobalamin deficiency in older adults, 16 individuals 
experienced weakness in limbs and 28 individuals experienced difficulties walking 
(Healton et al., 1991). Descriptive data on the neurophysiologic profiles of older 
individuals with cobalamin deficiency identify ataxia as a common clinical presentation, 
with confirmatory decreases in motor neuron action potentials (Fine, Soria, Paroski, 
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Petryk, & Thomasula, 1990). Recent investigations of the Women’s Health and Aging 
Study cohorts have identified that genetic variation in cobalamin metabolism genes 
influences methylmalonic acid concentrations and functional status (Matteini et al., 2008; 
Matteini et al., 2010). The dissertation study more fully explored these relationships by 
examining the functional performance measures hand grip strength and 4-meter walking 
speed.  
Hand Grip Strength
Hand grip strength measurements are an indication of basic upper extremity 
function and measure total force of upper limb muscles (Rantanen, Era, & Heikkinen, 
1994). Although it is a measurement of isometric strength in the upper body, hand grip 
strength has been found to also correlate with other skeletal muscle groups in the body 
(Rantanen, Pertti, Kauppinen, & Heikkinen, 1994). For this reason, hand grip strength is 
commonly used as an estimate of overall body strength.
Hand grip strength has consistently demonstrated value in clinical and research 
settings as a reliable and valid measurement technique. It is a sensitive predictor of 
progressive disability, and morbidity, mortality in elderly adults (Blake et al., 1988; Kerr 
et al., 2006; Phillips, 1986; Rantanen, Era et al., 1994; Rantanen et al., 1999).
Additionally, it has been found to be a useful clinical assessment parameter in screening 
individuals for nutritional deficiencies (Klidjian, Archer, Foster, & Karran, 1982; Matos, 
Tavares, & Amaral, 2007). Crucial for work with elderly patient populations, the hand 
dynamometers that measure grip strength force are portable, inexpensive, rapid, simple to 
use, and ideal for clinical assessments in home and community health settings.
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Various studies identify use of grip strength as a valuable measurement technique, 
since it demonstrates both low intra- and interobserver variability and high clinical 
reproducibility (Bohannon, 2006; Schaubert & Bohannon, 2005; Windsor & Hill, 1988).
However, it is recommended that use of dynamometers in research and clinical settings is 
consistent with respect to device manufacturer (Guerra & Amaral, 2009). A recent 
comparison report identified that although accuracy of dynamometers is high in elderly 
adults, measurements do not correlate well across manufacturers.  
Walking Speed
An indication of strength, mobility, coordination, proprioception, reflex control, 
and balance, the ability to walk provides significant information about a patient across 
numerous functional parameters (Ferrucci, Guralnik, et al., 1995). One of these 
parameters, lower extremity muscle strength, is determined by the speed at which an 
individual is able to walk (Holloszy, 1995; Schwartz, 1997). Walking speed, or gait 
velocity, in combination with other key lower extremity functional health assessments 
can predict disability, mortality, and nursing home admission across diverse elderly 
populations (Fried, Bandeen-Roche, Chaves, & Johnson, 2000; Guralnik, Ferrucci, 
Simonsick, Salive, & Wallace, 1995; Guralnik et al., 1994; Ostir, Markides, Black, & 
Goodwin, 1998; Seeman et al., 1994). When used singularly, gait speed is a relatively 
accurate proxy for full lower extremity performance battery examination, and predicts 
incident disability up to 6 years (Guralnik et al., 2000). Furthermore, longitudinal 
evaluations identify that changes in lower extremity strength over time are linearly 
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associated with meaningful changes in gait speed for sedentary older adults (Purser, 
Pieper, Poole, & Morey, 2003).
In addition to their predictive capacity for adverse outcomes, walking speed 
measurements are simple, reliable, and inexpensive to obtain. Commonly identified 
factors known to affect their accurate measurement include height and gender (Samson et 
al., 2001). Presence of dual tasking, simultaneously performing another task while an 
individual is walking, has also been recognized to affect gait measurement and its 
interference correlates to the difficulty of the concurrent task (Ble et al., 2005; Springer et 
al., 2006). Environmental and contextual factors, such as familiarity with surroundings, 
lighting, smooth walking surface, and use of assistive medical equipment, are also 
recognized to modify walking speed assessments (Hoenig et al., 2006; Richardson, Thies, 
DeMott, & Ashton-Miller, 2004a, 2004b).
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Figure 1. The Biochemical Role of Cobalamin (Vitamin B12) in the Cell.
Vitamin B12 participates in 2 essential reactions: (1) methylcobalamin in folate-
dependent conversion of homocysteine to methionine (cytoplasm) for DNA synthesis and 
methylation, (2) adenosylcobalamin in conversion of methylmalonyl coenzyme-A to 
succinyl coenzyme-A (mitochondrial).  Abbreviations: TCN2 (Transcobalamin II), 



























Figure 2. The Metabolic Pathway Overlap of Cobalamin and Folate in the Cell. 
The metabolic pathways that involve cobalamin and folate are shown. Their point of 
overlap encompasses the vitamin B12-dependent conversion of homocysteine to 
methionine, which drives 1) methylation (lipids, myelin basic protein, DNA, others) and 
2) the 5-methyl-THF conversion to THF that produces DNA precursors. 
For methylation to occur, S-adenosylmethionine donates a methyl group to S-
adenosylhomocysteine. In the absence of sufficient vitamin B12, this transfer stops. Folic 
acid supplementation bypasses this path. 
Abbreviations: 5,10-MTHFR (5,10-methylene-tetrahydrofolate reductase), 5-MTHF (5-
methyl-tetrahydrofolate), THF (tetrahydrofolate), DHFR (dihydrofolate reductase), 10-
FTHF (10-formyl-tetrahydrofolate), dUMP (deoxyuridine monophosphate), dTMP 

























   
CHAPTER 3
STUDY DESIGN, MEASUREMENT, METHODS, AND ANALYSIS
Introduction
The Women’s Health and Aging Study (WHAS) 1 and 2 cohorts offer a unique 
and valuable research opportunity to evaluate cobalamin metabolism through the lens of a 
population-based approach. The WHAS study methods were designed to capture 
functional health heterogeneity existing in the community-dwelling elderly, including 
presence of disability and its complex modifiers (Kasper, Shapiro, Guralnik, Bandeen-
Roche, & Fried, 1999). The WHAS 1 and 2 initiatives are a rich data source, cataloguing 
numerous clinical, psychosocial, and demographic measures over several years in order 
to assess trajectories of aging and disability. For example, several hundred peer-reviewed 
publications stem from WHAS 1 and 2 data. 
Study Design
This dissertation project is a candidate-gene association study using previously 
collected data from the National Institute on Aging’s WHAS 1 and 2 research initiatives. 
WHAS 1 and 2 were cross-sectional research cohorts of low-, mid-, and high-functioning 
community-dwelling elderly women. Primary objectives of both WHAS initiatives were 
to better understand the causes and trajectories of physical disability in elderly women
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(Chaves et al., 2006; Ferrucci et al., 1995; Guralnik, Fried, Simonsick, Bandeen-Roche, 
& Kasper, 1995). Subjects in WHAS 1 were active study participants from 1992-1995
and for WHAS 2 from 1994-1996.
Sampling and Recruitment, Data Collection
Sampling for both WHAS cohorts was conducted by randomly selecting subjects 
from 32,538 Health Care Financing Administration Medicare eligibility lists in 12 
contiguous Baltimore zip codes (Fried, Bandeen-Roche, Chaves, & Johnson, 2000;  
Guralnik, Fried, Simonsick, Kasper, & Lafferty, 1995). Patients who were unable to 
speak English, physically unable to complete the screening, or who were too cognitively 
impaired to respond to questions were excluded from participation in both cohorts. 
Participants in WHAS 2 had to be well functioning enough to participate in a 1-day clinic 
evaluation.
Sampling and Recruitment:  WHAS 1, 1992-1995
From the 32,538 Health Care Financing Administration (HCFA) Medicare 
records, 6,521 age stratified elderly women (65-74, 75-84, and over 85) were randomly 
selected for screening and possible enrollment (Ferrucci et al., 1995). An introductory 
letter describing the WHAS 1 study was sent to the 6,521 potential participants, which 
was followed 2 weeks later by a second letter inviting participation from Dr. Linda Fried. 
A study interviewer contacted women and administered a screening instrument in each 
patient’s home. Women who lived in nursing homes or were not able to be contacted by 
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study personnel were not eligible for screening, resulting in the final total of 3,841 
participants screened.
The objectives of WHAS 1 recruitment were to select the community-dwelling 
elderly adult women who were most disabled. To do this, population-based disability 
screening was used to select WHAS subjects that were the one-third most disabled in the 
Baltimore area. Each screened research participant was evaluated on 15 tasks across four
physical disability domains: 1) mobility and exercise tolerance, 2) upper extremity 
function, 3) higher function tasks (instrumental activities of daily living), and 4) basic 
self care (high function tasks that are nonmobility dependent). Using the combination 
approach of 4 domains allowed many more women to participate in WHAS than if using 
one singular criterion (i.e., such as self care disability). Previous factor analyses and 
piloting efforts demonstrated validity in using this type of prospective population-based 
functional screening (Branch, Katz, Kniepmann, & Papsidero, 1984; Fried, Ettinger, 
Lind, Newman, & Gardin, 1994; Kasper et al., 1999).
To conduct the disability screening, trained study personnel conducted 20-30
minute home interviews to collect basic demographic information, self-reported health 
status, and medical history (Guralnik et al., 1995). Data collected for the physical 
disability screening included a participant’s ability to perform basic tasks, their 
adaptation to disability, difficulty, and/or dependency, prescription and nonprescription 
medication use, presence of medical diagnoses, physical symptoms for over 20 chronic 
medical conditions, psychological health, social networks and support, health behaviors, 
and health care utilization practices (Ferrucci et al., 1995).
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Women who reported difficulty with two, three, or four physical disability 
domains and had a Mini-Mental State Examination (MMSE) score of 18 or higher were 
invited to participate in WHAS 1 (n = 1,409) (Fried, Kasper, Guralnik, & Simonsick, 
1995; Guralnik et al., 1995). MMSE is a global measure of cognition and surveys 
multiple domains in order to comprehensively assess for presence of impairment 
(Folstein, Folstein, & McHugh, 1975). Total possible score is 30, and anything under 24 
indicates presence of cognitive impairment (Kaufman, Weinberger, Strain, & Jacobs, 
1979). The final WHAS 1 sample size eligible for WHAS and who consented to 
participation was 1,002 (Guralnik et al., 1995). A further subset of 762 elderly women 
consented to research involving phlebotomy. Missing data are discussed later in this 
chapter. 
Sampling and Recruitment:  WHAS 2, 1994-1996
Following shortly after WHAS 1 was WHAS 2, a companion study that focused 
on the higher functioning group in Baltimore’s community-dwelling elderly women 
population. Primary aims for WHAS 2 included prospective observation and analysis of 
the transition from predisability states to functional impairment (Chaves, Garrett, & 
Fried, 2000). WHAS 2 participants were the two-thirds least disabled community-
dwelling elderly women. Although using the same sampling frame as WHAS 1 (HCFA 
records in 12 Baltimore zip codes), a new random sample was selected from 3,592 age-
stratified (70-74, 75-79 years) HCFA Medicare Enrollee records. A total of 2,541 elderly 
women were randomly selected for physical disability screening, with a total of 1,630 
women undergoing initial screening (Fried et al., 2000).
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Women who were not living in extended care facilities were contacted by a 
trained study interviewer who evaluated a third of the patients directly in their home, and
the remaining two-thirds via telephone (secondary to cost). Of the same 15 tasks across 4 
domains, women who reported difficulty in zero or one domain of functioning, and 
demonstrated an MMSE score of 24 or higher were eligible for WHAS 2 (Chaves et al., 
2006; Fried et al., 2000; Fried, Young, Rubin, & Bandeen-Roche, 2001). For participants 
screened over the phone, the MMSE was abbreviated to exclude irrelevant questions (i.e., 
location of examination center) and questions requiring in-person assessment. Screened 
individuals answering at least 80% of abbreviated MMSE questions correctly via 
telephone were eligible for WHAS 2 study inclusion. A total of 1,630 patients were 
screened for eligibility, n = 880 were invited to participate, with final WHAS 2 sample 
size participation at n = 436 (Fried et al., 2000). Similar to WHAS 1, a subset of the 
consented WHAS 2 patients also consented to additional phlebotomy (n = 405). Missing 
data is discussed later in this chapter. 
Data Collection:  WHAS 1, 1992-1995
Approximately 2 weeks after eligibility screening, a trained nurse conducted a 
standardized 4-5 hour examination in the homes of each study participant (Ferrucci et al., 
1995). Reported medical conditions were validated and their severities ascertained. A 
comprehensive examination was completed and included: physical assessments, vital 
signs, anthropomorphic data, electrocardiography, joint photographs, audiometry, 
pulmonary function, and various other strength, agility, and endurance performance 
measures. Medical records underwent ongoing surveillance and participants’ primary 
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care physicians provided confirmation of self-reported information. Phlebotomy was 
performed on 762 of the 1,002 participants who signed a secondary consent. Prospective 
data collection occurred in the form of in-home follow up visits that were conducted 
every 6 months for a total of 3 years (Volpato, Leveille, Blaum, Fried, & Guralnik, 
2005). Updated information on participants’ health status was collected, including new 
diagnoses of any major illnesses, medication changes, surgeries, hospitalizations, and 
acute decompensations stemming from chronic conditions. After the 3-year prospective 
follow-up was completed, two more phone interviews were done to perform vital status 
assessment, yielding a total follow-up time span of 5 years (Chaves et al., 2004).
Data Collection:  WHAS 2, 1994-1996
After screening, eligible participants were scheduled for a 5-6 hour baseline 
examination at the John’s Hopkins Functional Laboratory (Fried et al., 2000).
Participants completed the same standardized questionnaires as WHAS 1 subjects. 
Detailed demographic information, information on functional capacity, and self-report of 
medical diagnoses for 11 chronic diseases were among data collected. Many tests of 
functional capacity were administered, and phlebotomy was performed on 369 of the 436 
participants who signed a secondary consent. A 4-5 hour follow-up examination (also at 
the John’s Hopkins Functional Laboratory) was performed for each participant 18 months 
after baseline to ascertain change in functional status. For the majority of laboratory and 
clinical measurements, WHAS 2 methods of data collection were standardized to WHAS 
1 instrumentation and techniques (Semba, Garrett, Johnson, Guralnik, & Fried, 2000).
Exceptions to this rule were due to time and cost constraints. 
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Data Collection Differences Between WHAS 1 and 2
For the dissertation study’s laboratory, clinical outcome, and covariate 
measurements, all data collection and measurement methods used the same laboratory 
services, clinical instrumentation, and data collection protocols except for the peripheral 
extremity vibration sensitivity testing. WHAS 1 employed a vibrometer (voltage/current 
stimuli) measurement protocol while WHAS 2 used a tuning fork measurement protocol. 
For several reasons, dissertation analysis of peripheral sensitivity scoring was restricted 
to include only WHAS 1 vibrometer data (n = 498). 
Reasons for restricting analyses to WHAS 1 included the following: 1) reliability 
of results would be threatened if using measurements from both instruments since the 
protocols were not interchangeable; 2) there was potential for variability coming from 
tuning fork stimulus application that could not be adjusted for (i.e., could not ensure 
clinician hit the tuning fork the same way in the same location for all WHAS 2 subjects); 
and 3) there was a much smaller sample size for WHAS 2 subjects with tuning fork data, 
which did not meet power analysis estimate requirements.  
Subject Demographics
Numerous investigations have pooled WHAS 1 and 2 subject data for a 
strengthened approach representative of the community-dwelling elderly (Bandeen-
Roche et al., 2006; Chaves, Ashar, Guralnik, & Fried, 2002; Chaves et al., 2005; Leng, 
Xue, Tian, Walston, & Fried, 2007; Semba et al., 2000; Semba et al., 2005; Walston et 
al., 2005). Key differences in the two WHAS studies include an increased proportion of 
 84 
individuals with higher education in WHAS 2, and greater representation of African-
Americans in WHAS 1. Both cohorts have minimal inclusions for other racial minorities. 
Outcome Variable Measurement
Hematological measurements used in the dissertation include hemoglobin 
concentration and mean corpuscular volume (MCV). Cobalamin-related biochemical 
measurements used in the dissertation include serum cobalamin and the metabolites 
homocysteine and methylmalonic acid. Neurologic measurements used in the dissertation 
include depression scores (Geriatric Depression Scale) and vibratory sensitivity.
Functional performance measurements include grip strength and 4-meter walking speed. 
Phlebotomy and WHAS Sample Processing, Storage
The dissertation research includes measurements from WHAS 1 and 2 
participants who consented to phlebotomy. WHAS 1 venipuncture was performed in 
subjects’ homes by a certified phlebotomist who followed a standardized study protocol. 
The blood samples were nonfasting and after venipuncture, taken for processing and 
aliquoting at the Core Genetics Laboratory in Johns Hopkins University School of 
Medicine. WHAS 2 venipuncture was performed during clinic visits by a certified 
phlebotomist following the same standardized protocol as used in WHAS 1. The blood 
samples were also nonfasting and processed at the Johns Hopkins University School of 
Medicine. Frozen aliquots were sent on dry ice to Quest Diagnostics (formerly Corning 
Clinical Laboratories and MetPath) in Teterboro, NJ for analysis that included complete 
blood count, and biochemical, hormonal serum measurements. Remaining aliquots were 
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stored at -80 degrees Celsius in the Core Genetics Laboratory at the Johns Hopkins 
University School of Medicine.
Hematologic Measures
Hemoglobin 
WHAS 1 and 2 blood samples were collected for hemoglobin assessment in 
sterile, vacuum, ethylenediaminetetraacetic acid (EDTA) tubes.  At Quest Diagnostics, 
hemoglobin levels were measured via the standard cyanmethemoglobin method, a 
calorimetric approach that determines hemoglobin concentration through 
spectrophotometry (Chaves et al., 2006; Williamson et al., 1995).
Mean Corpuscular Volume (MCV) 
The MCV is a calculated value of the hematocrit percentage (proportion of 
erythrocyte volume to whole blood volume in a sample) divided by the red blood cell 
count number, and is reported in femtoliters (fL), (Williamson et al., 1995). Performed as 
part of the complete blood count for WHAS subjects, the MCV levels were collected at 
the same time and in the same tubes as blood drawn for hemoglobin.
Biochemical Metabolites
Serum Cobalamin
At Quest Diagnostics (Teterboro, NJ), serum cobalamin concentrations were 
determined using a competitive intrinsic factor protein-binding assay according to the 
method of Ciba-Corning Diagnostics Corporation in Medfield, MA (Stabler et al., 1999).
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Homocysteine and Methylmalonic Acid
A subset of WHAS 1 and 2 sample aliquots were shipped on dry ice from the 
Core Genetics Laboratory at John’s Hopkins University School of Medicine to the 
University of Colorado Health Sciences Center (UCHSC) for measurement by WHAS 
collaborator, Dr. Sally Stabler (Penninx et al., 2000; Stabler et al., 1999). Both total 
homocysteine and methylmalonic acid levels were obtained using stable-isotope dilution 
and capillary gas chromatography-mass spectrometry with selected ion monitoring 
(Stabler, Marcell, Podell, Allen, & Lindenbaum, 1986; Stabler et al., 1988).
Neurologic Measures
Geriatric Depression Scale (GDS)
WHAS 1 and 2 subjects were administered the GDS. It is a straightforward 
depressive examination scale consisting of 30 items requiring approximately 10 minutes 
to administer (Yesavage et al., 1982). Questions require a yes/no answer from 
participants; of 30 items, only one concerns presence of somatic (physical) 
symptomology, which was of special interest for WHAS applications where on average 
participants had at least one chronic condition (Kasper et al., 1999).
Questions in many generalized depression screening tools involve assessing 
presence of symptoms that are also present in other disease states, such as “do you have 
low energy”? A false positive can easily result in elderly individuals suffering from a 
chronic condition such as chronic obstructive pulmonary disease, as they would 
experience low energy due to difficulty breathing and not depression. The GDS was 
specifically designed to assess depression symptoms in the elderly to reduce the 
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occurrence of these false positives from the aging process or other common comorbid 
conditions, by removing focus from physical symptoms (Norris, Gallagher, Wilson, & 
Winograd, 1987). GDS scores under 10 indicate absence of depression, 10-13 mild 
depression, and scores over 14 indicating moderate and severe depression (Norris et al, 
1987). 
Vibratory Sensitivity  
As indicated in Chapter 2 and earlier in this chapter, vibration sensitivity was not 
measured similarly between WHAS 1 and WHAS 2 subjects due to cost and time 
limitations. Because the measurement methods did not use the same instruments and 
protocols, only WHAS 1 subjects’ vibration sensitivity data were analyzed in the 
dissertation study. 
In WHAS 1, vibration perception testing (VPT) was conducted using a 
vibrometer. Thresholds were measured and established by applying voltage/current based 
stimuli called ‘vibration units’ to participants’ lower extremities with the Vibratron II 
(Physitemp Instrument, Inc., Clifton, NJ). Women were asked to indicate when vibration 
was felt after stimulation of the lower surface of their right big toe (yes/no), using a two-
alternative forced choice procedure. Progressive stimulation intensity decreases in 10% 
increments were performed until subjects could no longer detect vibration. Upon error, 
the intensity was increased by 10%, with progressive incremental decreases continued 
until a total of five errors were made. After conversion of vibration units to microns, 
mean thresholds were identified by taking the five errors and five lowest correct scores, 
 88 




Grip strength was measured for study subjects using a JAMAR hand 
dynamometer (Model #BK-7498; Fred Sammons Inc, Burr Ridge, IL). WHAS 1 and 2 
subjects were asked to grasp the dynamometer and squeeze as hard as possible three 
times on each hand. The best measure in the stronger hand was recorded and reported in 
kilograms. 
Four-Meter Timed Walk
WHAS 1 and 2 participants were asked to walk over a 4-meter course, two times 
at their usual speed and once, as fast as possible. For some participants, 4 meters was not 
available in their homes and a distance of 3 meters was used instead. Beginning at a
starting line, walking and timing of the walk did not begin until the command to start was 
given by the interviewer. Using the faster of the two usual-pace walks, average walking 
speed was calculated by dividing the length of the walk (in meters) by the time in seconds 
required to complete it. Subjects were permitted to use a cane, walker, or walking aid, but 




The dissertation research analyzes biochemical metabolite data that is adjusted for 
a participant’s renal function. An essential component of several renal-estimation 
calculations, serum creatinine levels were obtained for WHAS 1 and 2 subjects who 
participated in venipuncture. Performed by Quest Diagnostics in Teterboro, NJ, serum 
creatinine concentrations were analyzed via the conventional Jaffe method (Semba et al., 
2009). Incorporating serum creatinine, age, weight, and a female muscle mass constant, 
the Cockcroft-Gault formula used in the dissertation research to estimate WHAS 1 and 2 
subjects renal function (mL/min) is: 
Creatinine Clearance = (140-age in years) x (mass in kg) x 0.85 
72 x serum creatinine (mg/dL)
Folate
In addition to serum cobalamin levels, the central laboratory of Corning Clinical 
Laboratories in Teterboro, NJ also determined serum folate concentrations for WHAS 1 
and 2 subjects. Serum folate concentrations were determined using a competitive folate-
binding protein assay according to the method of Ciba-Corning Diagnostics Corporation 
in Medfield, MA (Penninx et al., 2000).
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Standing Height
During in-home screenings for WHAS 1 subjects and clinic visits for WHAS 2 
subjects, standing height (in centimeters) was measured by trained study staff accordant 
with study protocol.
Genotyping Methods
Isolation and Preparation of WHAS Subject DNA
Blood Processing
At the Core Genetics Laboratory in Johns Hopkins School of Medicine, WHAS 1 
and 2 subject DNA was extracted from whole blood using the Puregene DNA 
Purification Kit from GentraSystems, Inc. DNA samples were then stored in a -80
(Celsius) freezer at the Johns Hopkins University. Approximately 50 nanograms of 
genomic DNA was provided for genotyping the 794 WHAS 1 and 2 subjects. It was not 
known how many freeze/thaw cycles WHAS subject DNA underwent prior to their 
receipt for this project; however, genetic research using WHAS material dates from 
published reports in 2005. 
Whole Genome Amplification
Large-scale genotyping methods, such as that used in this dissertation research, 
require several micrograms of DNA. The small amount of available starting material (50 
nanograms) would be quickly consumed, severely limiting investigative capacity. In the 
case of limited starting DNA, a method that can be used to provide ample supply of 
genomic material is Whole Genome Amplification (WGA). Relatively new, WGA 
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reproduction of small amounts of DNA is becoming a widely utilized technique in 
conducting high-throughput SNP genotyping (Berthier-Schaad et al., 2007; Dean et al., 
2002).
There are several WGA methodologies and they are categorized into polymerase 
chain reaction (PCR)-based, and non-PCR-based approaches. A non-PCR-based method, 
multiple displacement amplification, is the WGA technique that was used in this 
dissertation research to amplify the limited starting quantity of WHAS DNA into more 
substantiative working material for genotyping. Multiple displacement amplification is 
based on the rolling circle amplification mechanisms used by plasmids and viral vectors 
during DNA replication—but is adapted to use genomic DNA instead (Dean et al., 2002).
In multiple displacement amplification, a highly processive bacteriophage enzyme *@#
DNA polymerase) displaces DNA strands, replicates copies, and proofreads their 
assembly. Compared to Taq Polymerase@#\^"	
	
significantly lower error rate and faithfully amplifies DNA across the entire genome 
(Lovmar & Syvanen, 2006). Accuracy and fidelity of multiple displacement amplification 
is dependent upon the amount and quality of genomic DNA that is used as starting 
material in the reaction; at least 10 nanograms of genomic DNA input is required for SNP 
genotyping (Bergen, Qi, Haque, Welch, & Chanock, 2005).
The dissertation research used Qiagen’s 100-reaction REPLI-g Midi Kit. The 
protocol required 10 nanograms of starting genomic material to yield over 40 micrograms 
of final high-molecular weight material in 10-100kb stretches (Appendix A). Although 
use of multiple displacement amplification prod
@#\^"
polymerase can randomly amplify one of the patient’s alleles and drop out the remaining 
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counterpart (Bergen et al., 2005). As a result, heterozygotes are susceptible to “allele 
drop-out,” often causing heterozygotes to be erroneously interpreted as homozygotes. To 
correct for incidence of heterozygote dropouts, the dissertation research performed two 
separate and independent rounds of multiple displacement amplification, which were 
pooled together into a common solution for genotyping.   
Candidate Gene SNP Selection
The Haplotype Map, or HapMap, was a research initiative completed in 2003 that 
provides public access to a catalogue of human genetic variation for racial subgroups:  
Caucasian, African American, Chinese, and Japanese (The International HapMap 
Consortium, 2003). Following successful dissertation proposal defense in May 2008, the 
most current version of HapMap (2.0) was used to select SNPs for the dissertation 
research (The International HapMap Consortium, 2007). Within HapMap 2.0, Haploview 
and Tagger were used to visualize population SNP alleles, genomic regions, and overall 
SNP selection. Conceptualized and released by Broad Institute, Haploview is a freely 
accessible public program that can be used to visualize linkage disequilibrium plots. A 
function that exists as part of the Haploview program, Tagger identifies similarity among 
SNPs as a function of their proximity to one another. SNPs closest together offer the 
same information as that contained by its neighbors (linkage disequilibrium), (Ardlie, 
Kruglyak, & Seielstad, 2002). The population statistic that is used to discern similarity 
among SNPs is r2 and for the dissertation research, a conservative threshold (r2 = 0.9) was 
used to eliminate redundancies (Wall & Pritchard, 2003).
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In addition to HapMap SNPs, other variants that were likely to have functional 
implications were explored and included. Searched for in the public catalogue of SNPs 
(dbSNP), additional selected candidates included variants within exons, promoters, 
conserved sequences across species, and those reported in literature that were associated 
with clinical characteristics and biochemical parameters being explored in this research. 
In sum, a total of 51 SNPs incorporating both Caucasian and African American ethnic 
ancestries were selected for the dissertation study—29 SNPs in the transcobalamin II 
gene and 22 SNPs in the transcobalamin II-receptor gene (Tables 1 and 2).
SNP Genotyping for Whole Genome Amplified WHAS Material
There are many high-throughput SNP genotyping systems available for laboratory 
use, and they vary according to throughput capacity, accuracy, cost, and scale. The 
Sequenom MassARRAY iPLEX Platform is well known for its ability to incorporate 
high-throughput features for reasonable multistep system/reagent use and costs (Gabriel, 
Ziaugra, & Tabbaa, 2009).
The Sequenom MassARRAY platform allows for accurate custom SNP 
genotyping by using a homogeneous reaction format with two progressive phases of
specificity comprising: 1) a locus-specific PCR reaction to obtain a 100-base pair region 
where a SNP is located, and 2) a locus-specific primer extension reaction that produces 
the SNP genotype. A single extension primer can generate allele-specific results with 
unique masses, and multiplexed SNP extension reactions can be performed with a single 
termination mix (iPLEX) and universal reaction conditions. Following extension, 
samples are analyzed by MALDI-TOF mass spectroscopy.  
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A singular Sequenom system is capable of generating over 100,000 genotypes per 
day (Gabriel et al., 2009). There are multiple preparatory phases and reaction steps that 
were required to obtain genotypes for plates of whole genome amplified WHAS DNA,
including pre-PCR sample and assay preparation, PCR amplification, post-PCR cleanup, 
iPLEX primer extension, primer extension cleanup, and spotting extension products onto 
SpectroChips. 
Pre-PCR: WHAS Sample and Assay Preparation 
After WHAS DNA was whole genome amplified and the amplification rounds 
were pooled in 96-well plates, samples were diluted to create working stocks at a 
concentration of 10ng/ul. Four groups of 96-well plates were concatenated onto a single 
384-well plate and stored in desiccators. In sum, there were nine unique master 384-well 
WHAS plates for the dissertation research, from which small volumes of sample were 
aliquoted and stamped into genotyping stockpiles using automated liquid transfer 
machinery (BeckmanCoulter’s Biomek; Tomtec’s Quadra tower). Labeled genotyping 
plates (384 wells) had approximately 5-20 ng of whole genome amplified DNA placed 
into each well. Negative blank and water control wells were created prior to automated 
transfer and were spatially unique to each master WHAS plate.  
An automated approach was used to design PCR assays and to select 
oligonucleotide primers. Using sequence in publicly available bioinformatics databases, 
DNA sequence (~100 base pairs 3’-5’) surrounding each selected SNP was copied and 
pasted into an Excel Spreadsheet and brackets were inserted around SNP sites. The final 
Excel spreadsheet was converted into a text file and run through Sequenom’s 
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MassARRAY Designer software. The software automatically designed forward and 
reverse PCR primers, and extension iPLEX primers, and grouped all the assays into 
chemically optimized assay pools. Through this pooling, many different individual SNP 
loci can be analyzed simultaneously within the same sample well. The WHAS 
dissertation project had a total of 5 pools (also called “plexes”) and were broken down 
according to the following: Plex 1 with 19 SNP assays, Plex 2 with 18 SNP assays, Plex 
3 with 28 SNP assays, Plex 4 with 23 SNP assays, and Plex 5 with 17 SNP assays. Thus, 
when prepping a 384-well plate, reactants and primers would be mixed and aliquoted into 
each of the wells according to which Plex was being run. 
PCR Amplification of Target Loci 
PCR primers from Sequenom’s MassARRAY Designer software output file were 
ordered from Integrated DNA Technologies (IDT) and were unmodified with standard 
purification at 25 nanomolar concentration. The following reactants were mixed and 
added to the 384-well plates of WHAS whole genome amplified DNA (1X reaction): 
2.85 ul water, 0.625 ul of 10X PCR Buffer, .325 ul of 25 mM MgCl2, 0.1 ul of 25mM 
dNTPs, 1 ul of 500 nM F/R PCR Primer Mix, and 0.1 ul of 0.5U/ul HotStart Taq 
Polymerase. Automated fluid transfer from a dispenser holding the PCR reaction mix into 
each of the 384 wells was performed through the automated Biomek (Beckman Coulter) 
in a pre-PCR area of the laboratory. PCR thermocycler conditions for the 384-well plates 
were as follows: initial denaturation at 94 degrees C for 15 minutes; 45 cycles of 
denaturing at 94 degrees C for 20 seconds, annealing at 56 degrees C for 30 seconds, and 
extension at 72 degrees C for 60 seconds; followed by final extension at 72 degrees C for 
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3 minutes; and held at 4 degrees C for infinity until removed from the thermocycler 
block.
Post-PCR Cleanup Using SAP
Following the PCR reaction, there are many remaining nonincorporated dNTPs 
from amplification products in each well of the 384-well plate. If allowed to remain in the 
wells, functional dNTPs can extend in the primer extension reactions, causing erroneous 
contaminant peaks to occur, which greatly detriments data analysis and interpretation. 
Treatment with the enzyme shrimp alkaline phosphatase (SAP) is performed to remove 
any remaining and unincorporated dNTPs from the PCR amplification products. SAP acts 
by dephosphorylating the unincorporated dNTPs and cleaves available phosphate groups 
from the 5’ termini. The following reactants were mixed and added to the 384-well plates 
of WHAS whole genome amplified DNA following PCR (1X reaction): 1.53 ul water, 
0.17 ul SAP buffer, and 0.30 ul SAP.  Automated fluid transfer from a dispenser holding 
the SAP reaction mix into each of the 384 wells was performed through the automated 
Multimek in a post-PCR area of the laboratory. SAP thermocycler conditions for the 384-
well plates included SAP activation treatment at 37 degrees C for 20 minutes, SAP 
deactivation at 85 degrees C for 5 minutes, and held at 4 degrees C for infinity until 
removed from the thermocycler block.
Primer Extension Using iPLEX Chemistry
In comparison to previous Sequenom genotyping technologies, the use of iPLEX 
extension assays is what allows for routine multiplexing of up to 30-36 SNPs in one 
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sample well. In the iPLEX extension assay, primers and amplified target DNA are 
incubated with dideoxynucleotide terminators that are mass modified. The extension into 
the SNP site proceeds according to the sequence at the variant loci, and is a single and 
complementary terminator base. Before iPLEX, the masses of the A, C, G, T terminators 
that were incorporated at the SNP site were very close together and difficult for the mass 
spectrometer to discern between; only several assays could be run simultaneously (i.e., 1-
6 SNP assays). Sequenom’s development of mass-modified dideoxynucleotide 
terminators provides clearer allele signals, reducing allele-bias and providing for easy 
discernment by the mass spectrometer (Table 3) (Oeth et al., 2006).
For the dissertation’s iPLEX reaction in the lab, unmodified extension primers 
from Sequenom’s MassARRAY Designer software output file were ordered from 
Integrated DNA Technologies (IDT) featuring standard purification at 250 nanomolar 
concentration. Because there is an inverse relationship between mass spectrometer peak 
intensity and the mass of the SNP analyte, all extension primers were optimized so that 
they were as equal in intensity as possible. After optimization, the following reactants 
were mixed and added to the 384-well plates of WHAS whole genome amplified DNA 
(1X reaction): 0.619 ul water, 0.2 ul 10X iPLEX buffer, 0.2 ul iPLEX terminator, 0.94 ul 
of extension primer mix, and 0.041 ul of 0.655U/ul iPLEX extension enzyme. Automated 
fluid transfer from a dispenser holding the iPLEX extension reaction mix into each of the 
384 wells was performed through the automated Multimek in a post-PCR area of the 
laboratory. Extension thermocycler conditions for the 384-well plates included initial 
denaturation of 94 degrees C for 30 seconds, 40 cycles of denaturing at 94 degrees C for 
5 seconds, annealing at 52 degrees C for 5 seconds, and extension at 80 degrees. 
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Embedded in each of the 40 cycles are 5 repeat cycles between annealing at 52 degrees C 
for 5 seconds and extension at 80 degrees for 5 seconds. Following the 30 cycles, a final 
extension at 72 degrees for 3 minutes occurs before being held at 4 degrees C for infinity 
(until taken out of thermocycler block).
Post-iPLEX Resin Cleanup
Following primer extension, there are many salts left over from the iPLEX 
extension reaction products. If left in the sample wells untreated, salts including Na+, K+,
and Mg2+ ions can cause a great deal of background noise in the spectra, preventing the 
mass spectrometer from making genotype calls. Sequenom’s SpectroCLEAN is a sand-
like resin that is pretreated with acid reagents, and is added directly to the primer 
extension products in each of the 384 wells. To make the slurry, 80ul of water is added to 
12 mg of resin in a 96-well PCR plate; the Multimek transfers 16 ul of the resin/water 
slurry to each of the 384 wells. After automated addition of the slurry, the 384-well plate 
is slowly rotated for 10-30 minutes to ensure that samples are thoroughly mixed with 
cation removal resin.  
Spotting of iPLEX Products on SpectroChips
After rotation of the 384-well plates, the plates were centrifuged. Clear fluid on 
top of the settled resin contained the extended/desalted SNP genotype analyte products. 
After the plate was laid flat in an automated spotting machine, a pinned robotic spotting 
head transferred ~25 nL of the sample analyte solution onto a silica chip (SpectroChips). 
Each of the 384 spots on the SpectroChips was comprised of 3-hydroxypicolinic acid, the 
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appropriate matrix for MALDI TOF mass spectroscopy. In addition to the 384 sample 
matrix spots, 10 additional reference matrix spots were reserved for application of 
Sequenom’s MassARRAY mass spectrometry calibrant solution.   
Calling the Genotypes
Mass Spectrometry Detection of SNP Genotype 
Matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass 
spectrometry can differentiate SNP densities and ascertain a patient’s genotype at a SNP 
locus for one of three combinations: heterozygous alleles (A/T) or homozygous alleles 
(A/A and T/T). The laser is measuring the time-of-flight that genotype analyte fragments 
on the SpectroChip’s matrix take to travel from one end of the mass spectrometer to the 
other. Each allele or allelic combination has an expected time-of-flight, which correlates 
to a specific weight in daltons. Longer times indicate heavier products and shorter times 
indicate lighter products.
A total of 80 SpectroChips were analyzed for the dissertation research. After 
spotting, each chip was placed into the mass spectrometer (Sequenom; Bruker 
Instruments), placed under vacuum pressure, and the spots were sequentially shot with a 
laser. The 3-hydroxypicolinic acid matrix comprising each spot played an important role 
in the MALDI-TOF; it absorbed the laser light energy and caused part of the illuminated 
analyte substrate to vaporize. The vaporized matrix plume expanded after the laser fired, 
and as it passed into the vacuum, became ionized. After vaporization and ionization, the 
genotype analyte fragments were electrostatically transferred into the time-of-flight 
chamber and separated from matrix ions. The genotypes were then detected (or “called”) 
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based on this mass-to-charge characteristic; ion detection at the end of the flight chamber 
was directly proportional to the square root of the postvapor plume mass-to-charge ratio.
MassARRAY Typer 4.0 and Manual Calling  
After spectra and calls for each chip were generated, Typer 4.0 Software was used 
to visualize plate results and the spectral curves. The Typer 4.0 system allowed 
visualization of an assay’s performance for the chip, and inspection of automated calls by 
the software. MassARRAY had difficulties in automatically calling genotypes of WHAS 
material due to the whole genome amplification process. For example, heterozygote calls 
for many assays were scattered widely from the x-axis to the y-axis, as opposed to the 
typical tight cluster formation at the 45-degree demarcation area between the axes. 
MassARRAY often erroneously called these spread-out heterozygotes as homozygotes, 
since heterozygotes demonstrated a greater range than would normally be expected due to 
the whole genome amplified process. Subsequently, all genotype calls in the dissertation 
research were inspected manually, and approximately 40-50% of all WHAS genotypes 
were issued manually following the creation of a validated calling algorithm (Appendix 
B). To ensure manual calling did not introduce unacceptable levels of variability, all 
plexes (1 through 5) of WHAS DNA underwent three to five independent rounds of 
genotyping and calling, and irreconcilable discordant genotypes were discarded from 
analyses. 
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Protection of Human Subjects
For both WHAS 1 and 2, protection of human subjects was obtained through 
Institutional Review Board approval at the John’s Hopkins University and the National 
Institutes of Health’s National Institute on Aging. To obtain human subjects approval for 
the genotyping phase of this research, I submitted an application to the University of 
Utah IRB. A review panel concluded that the genotyping in my dissertation research did 
not meet the definitions of Human Subjects Research according to Federal regulations. 
Therefore, IRB oversight was not required (Appendix C).  
To ensure maximum confidentiality, WHAS samples were anonymized and 
clinical phenotype data were not linkable to patients without a master code file, which 
was available only to approved study staff at Johns Hopkins University and at the 
National Institute on Aging. For the dissertation research, I catalogued WHAS subject 
DNA samples by anonymous ID numbers in an Excel spreadsheet on a heavily fire-
walled NIH intramural network. Each record had a unique identification number that was 
not connected to any traceable personally identifiable information such as date of birth, 
social security number, address, etc. Presently, many of the WHAS 1 and 2 participants 
are deceased.
Analysis
The independent variable in this study across all aims and research questions was 
the transcobalamin II and transcobalamin II-receptor SNP genotype, according to three 
ordered categories: homozygous minor allele (AA), heterozygous (AB), and homozygous 
major allele (BB). The dependent outcome variables are continuous, and include 
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hemoglobin concentration, MCV, serum cobalamin and cobalamin metabolites, 
depression scores, vibration sensitivity, grip strength, and walking speed measurements. 
Genetic data was analyzed using Haploview 4.0 and linkage disequilibrium plots were 
constructed for the transcobalamin II and transcobalamin II-receptor genes for 
Caucasians and African American subjects.  
Using SPSS v12.0, missing clinical phenotype data and descriptive statistics were 
analyzed, with summary statistics (means, medians, standard deviations, ranges, 
quartiles) reported for each outcome measure. Histograms and trend plots were evaluated 
to assess data normality, and Kolmogorov-Smirnoff tests were conducted to assess degree 
of normality violation. Extreme outliers that were greater than 3 standard deviations away 
from the mean were identified, evaluated, and removed from analyses if they 
inappropriately skewed sample population means or greatly affected normality tests. 
Pearson correlations between the dependent variables were evaluated for collinearity. 
Genotype and allele frequencies were counted for each SNP in both Caucasian and 
African American cohorts, and Hardy-Weinberg statistics were calculated. Hardy-
_`{2 test (Pearson goodness-of-fit) to ascertain presence of equilibrium and 
	{2 probability distribution under the null hypothesis (Balding, 2006). A 




Cohen’s small effect size (.25), two-tailed significance of .05, and desired power of 
0.90, the minimum sample size necessary for adequate strength was n = 171. Overall 
differences in socio-demographic, clinical, and biochemical variables between African 
Americans and Caucasians, and between WHAS 1 and WHAS 2 cohorts, were assessed 
using independent t-tests.  
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To assess differences in outcome variable means across race and SNP genotype, 
an analysis of variance or covariance was performed for each outcome measure. 
Homogeneity of variance was assessed through the Levene’s test of equality of error 
variances. For all analysis of covariance tests, linearity was assessed between the 
covariates and the dependent variable, covariate reliability was ensured, and homogeneity 
of regression was evaluated by exploring slope inequality between the dependent variable 
and the covariate. 
Significant interaction (race) and main (genetic) effect F tests from the analysis of 
variance or covariance were explored further with traditional post-hoc comparison tests. 
Statistical interactions between Caucasian and African American subjects across 
genotype groups were assessed by evaluating plotted graphs in SPSS. Post-hoc testing for 
significant main effects was conducted with the Tukey procedure to identify where mean 
differences between groups existed. Post-hoc testing for simple main effects following 
significant interactions was conducted with the Least Significant Difference procedure. In 
the presence of extreme normality violations or a violated Levene’s test, nonparametric 
post-hoc comparison tests were used. The Bonferroni adjustment was used to reduce 
alpha inflation stemming from performing multiple statistical tests. At nine outcome 
measures and 27-29 SNPs per measure, the Bonferroni adjustment was designated at
p=(0.05/243)=0.0002. Linkage disequilibrium plots to assess tagging success were 




Hemoglobin concentrations were continuous data. Differences in means were 
analyzed using a 2-way analysis of covariance (ANCOVA) on the fixed factors, race 
(African American, Caucasian) and SNP genotype, and accounted for serum folate 
variance. Post-hoc analyses for significant F tests were conducted by using simple tests 
of pairwise comparison for main effects and evaluating graphical interactions on profile 
plots.
Research Question 1.2 
Mean corpuscular volume (MCV) concentrations were continuous data and 
differences in means were analyzed using a 2-way ANCOVA on the fixed factors, race 
(African American, Caucasian) and SNP genotype, and adjusted for serum folate 
variance. Post-hoc analyses for significant F tests were conducted by using simple tests 
of pairwise comparison for main effects and evaluating graphical interactions on profile 
plots.
Aim 2
Research Question 2.1 
Serum cobalamin concentrations were continuous data. To account for the effects 
of a subject’s renal function (creatinine clearance estimation per Cockcroft-Gault), 
differences in mean cobalamin concentration were analyzed using a 2-way ANCOVA on 
the fixed factors, race (African American, Caucasian) and SNP genotype. Post-hoc 
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analyses for significant F tests were conducted by using simple tests of pairwise 
comparison for main effects and evaluating graphical interactions on profile plots.
Research Question 2.2 
Serum homocysteine concentrations were continuous data. To account for the 
effects of a subject’s renal function (creatinine clearance estimation per Cockcroft-Gault), 
serum folate, and serum cobalamin, a 2-way ANCOVA was used to ascertain presence of 
association between homocysteine concentration and the fixed factors, race (African 
American, Caucasian) and SNP genotype. Post-hoc analyses for significant F tests were 
conducted by using simple tests of pairwise comparison for main effects and evaluating 
graphical interactions on profile plots.
Research Question 2.3 
Serum methylmalonic acid concentrations were continuous data. Accounting for 
renal function (creatinine clearance estimation per Cockcroft-Gault) and serum 
cobalamin, a 2-way ANCOVA was used to ascertain presence of association between 
methylmalonic acid concentration and the fixed factors, race (African American, 
Caucasian) and SNP genotype. Post-hoc analyses for significant F tests were conducted 
by using simple tests of pairwise comparison for main effects and evaluating graphical 




Geriatric Depression Scores (GDS) scores were continuous, interval-level data. 
Differences in GDS means were analyzed using a 2-way ANOVA on the fixed factors, 
race (Caucasian or African American) and SNP genotype. Post-hoc analyses for 
significant F tests were conducted by using the Tukey test and evaluating graphical 
interactions on profile plots. 
Research Question 3.2 
Vibrometer sensitivity measurements were continuous data. Differences in means 
were analyzed using a 2-way ANOVA on the fixed factors, race (African American,
Caucasian) and SNP genotype. Post-hoc analyses for significant F tests were conducted 
by using the Tukey test and evaluating graphical interactions on profile plots. 
Aim 4
Research Question 4.1 
Hand grip strength dynamometer measurements were continuous data. 
Differences in hand grip strength means were analyzed using a 2-way ANOVA on the 
fixed factors, race (African American, Caucasian) and SNP genotype. Post-hoc analyses 
for significant F tests were conducted by using the Tukey test and evaluating graphical 
interactions on profile plots. 
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Research Question 4.2
Three and 4-meter walking speed were continuous data. Differences in mean 
walking speeds were analyzed using a 2-way ANCOVA on the fixed factors, race 
(African American, Caucasian) and SNP genotype, adjusted for an individual’s standing 
height. Post-hoc analyses for significant F tests were conducted by using simple tests of 
pairwise comparison for main effects and evaluating graphical interactions on profile 
plots.
Missing Data
Data Availability, Transfer Procedures, and File Merging
Although a total sample of 1,167 women consented to phlebotomy in WHAS 1 
and 2, blood was no longer available for all subjects at the onset of the dissertation study 
in 2008. DNA availability for WHAS 1 was n = 536 and for WHAS 2 was n = 253, 
yielding a total available patient sample of n = 789 for the dissertation’s genetic analysis. 
A file provided by Johns Hopkins University study staff (Dr. Amy Matteini) in 
November 2009 contained selected health, clinical, and socio-demographic 
measurements for the total documented 1,438 WHAS 1 and 2 participants and included 
data on subjects who did not provide blood samples. 
In December 2009, a combined data file was generated that restricted content to 
include only the WHAS 1 and 2 research subjects with corresponding genotype data 
generated in the laboratory (n = 789). Missing data within this pool of 789 subjects were 
analyzed (genotype field entries plus social and clinical characteristics) for nonrandom 
patterns through the SPSS ‘Missing Data’ function and cleaned. No outstanding patterns 
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of nonrandom missing data were identified; however, restricting analyses to WHAS 1 
and 2 subjects with available genomic DNA likely affected result generalizability, in that 
it represented 54.7% (789/1,438) of the original sampling study frame. The 789 available 
DNA samples represented 67.6% of WHAS 1 and 2 subjects consenting to phlebotomy 
(789/1,167).
Collectively, missing data for the dissertation research in the n = 789 sample 
population were observed across two categories: genotyping failures (including 
noninformative monomorphic alleles) and unavailable clinical data in the WHAS 1 and 2 
dataset. 
Missing Genetic Data
Genotyping failures included 6 noninformative SNPs that were monomorphic in 
both African American and Caucasian subjects. A total of 16 of the 51 total SNPs did not 
meet quality control thresholds in the laboratory and were removed from analysis. For the 
remaining 29 SNPs, missing genotype data ranged from n = 11 to n=63 depending on the 
assay. On average each SNP was missing 40 genotypes, which corresponded to 5% of the 
dissertation study sample, which met the National Human Genome Research Institute’s 
standard laboratory threshold metrics for minimally required data. 
Missing Laboratory and Clinical Data
For each of the dissertation study’s biochemical and clinical outcome variables, 
there were varying degrees of missing data. For example, not all laboratory tests were 
successful for each study participant and not all clinical parameters (depression, walking 
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speeds, vibration testing) were successfully measured in patient homes or during clinic 
appointments. Missing data for each of the dissertation study’s outcomes for the 789 
WHAS subjects include the following: n = 37 hemoglobin, n = 38 mean corpuscular 
volume, n = 12 cobalamin, n = 25 homocysteine, n = 25 methylmalonic acid, n = 0 
depression score, n = 39 peripheral sensitivity score, n = 70 hand grip strength, and n =
21 walking speed. Missing data for each of the dissertation study’s covariates for the 789 
WHAS subjects include the following: n = 9 folate, n = 53 estimated creatinine 
clearance, and n = 41 standing height. 
Outliers
For many of the laboratory traits, there were severe outliers that were either zero 
(representing an error in laboratory reporting) or greater than 3 standard deviations away 
from the mean. These values were coded as missing data and removed from analysis to 
mitigate their skewing effect on outcome variable sample means, distributions, and
normality tests (n = 6 cobalamin, n = 6 total homocysteine, n = 10 serum methylmalonic 
acid, and n = 7 MCV). Final exact sample sizes for each genetic marker that was 
genotyped, and mean values for each WHAS outcome analyzed in this study, are listed 
for reader reference in Appendix D. 
Impact of Missing Data
To meet the stated objectives of the dissertation’s research aims and questions, 
research subjects had to have laboratory values and clinical parameter measurements in 
addition to a SNP genotype result to be included in the analyses of variance and 
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covariance statistical evaluation. Chapters 4 and 5 report F statistics and post-hoc test 
analyses incorporating this requirement. However, the generalized assessments of means 
and standard deviations for the WHAS subjects’ biochemical and clinical traits in 
Chapters 4 and 5 (delineated by race and cohort) were conducted separately from this 
requirement in order to assess the impact of missing data. 
Outcome means and clinical mean parameter profiles obtained from the 
dissertation sample were compared with previously published WHAS 1 and 2 data using 
the full sample population. Across all clinical outcome and covariate parameters, the 
means and standard deviations in the n =789 WHAS dissertation sample corresponded 
closely with previously published results for both the combined and separated WHAS 
cohort literature (Chaves et al., 2006; Fried et al., 2000; Guralnik, Fried, Simonsick, 
Kasper et al., 1995; Resnick et al., 2000; Resnick, Vinik, Heimovitz, Brancati, & 
Guralnik, 2001; Penninx et al., 2000; Rantanen et al., 1998; Stabler et al., 1999).
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Table 1
Transcobalamin II Gene SNPs
Reference Sequence #      Gene Position     Target Population       Identified From
rs12159600 intron 3 AA HapMap
rs16988838 intron 1 AA HapMap
rs11912238                intron 5        AA HapMap
rs7286107 intron 1                 CEPH HapMap
rs4820021 intron 6                 CEPH HapMap
rs3178000 exon 8 CEPH HapMap
rs2301955 intron 7 both HapMap
rs2267163 intron 5 both HapMap
rs2072194 intron 8 both HapMap
rs740234 intron 2 both HapMap
rs4820889 exon 8 both HapMap
rs4820886 intron 7 both HapMap
rs2301958 intron 7 both HapMap
rs7289549 intron 1 both HapMap
rs11703570 intron 3 both HapMap
rs16988828 intron 1 both HapMap
rs4820887 intron 7 both HapMap
rs4820888 intron 7 both HapMap
rs9606756 exon 2 both HapMap
rs35915865 exon 3 CEPH dbSNP
rs35838082 exon 5 both dbSNP
rs1801198 exon 6 both dbSNP
rs9621049 exon 7 both dbSNP
rs1131603 exon 8 CEPH dbSNP
rs11557600 exon 3 AA literature
rs17849434 exon 5 n/a literature
rs2301956* intron 7 CEPH HapMap
rs2267162* intron 4 both HapMap
rs740233* intron 2 both HapMap
Note. Dropped assays marked by asterisk (*), AA=African American, CEPH=Caucasian. 
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Table 2
Transcobalamin II-Receptor Gene SNPs
Reference Sequence #           Gene Position        Target Population Identified From
rs3760680 3’ near gene AA HapMap
rs250510 exon 5 (3’ UTR) AA HapMap
rs36263 3’ near gene AA HapMap
rs2232772 5’ UTR AA HapMap
rs2232779 intron 1 AA HapMap
rs2232788 exon 5 (3’ UTR) AA HapMap
rs2232768 5’ near gene CEPH HapMap
rs2927707 intron 1 both HapMap
rs2227288 intron 4 both HapMap
rs2232775 exon 1 AA dbSNP
rs2232787 exon 5 no data dbSNP
rs2336573 exon 4 both dbSNP
rs2232786 exon 5 AA dbSNP
rs173665 3’ near gene both Brody lab hit
rs12461677* intron 1 AA HapMap
rs2232766* near gene AA HapMap
rs2227266* 5’ near gene AA HapMap
rs250511* intron 4 both HapMap
rs2232765* near gene both HapMap
rs2232774* exon 1 no data dbSNP
rs5719548* exon 2 no data dbSNP
Note. Dropped assays marked by asterisk (*), AA=African American, CEPH=Caucasian. 
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Table 3
Dalton Differences in iPLEX Dideoxynucleotide Mass-Modified Terminators
Terminator A C G T
A 0.0 -24.0 16.0 55.9
C 24.0 0.0 40.0 79.9
G -16.0 -40.0 0.0 39.9
T -55.9 -79.9 -39.9 0.0
Note. Chemically modified dNTPs for iPLEX extension reaction (Oeth et al., 2006).
   
CHAPTER 4
ASSOCIATION OF TRANSCOBALAMIN II AND TRANSCOBALAMIN II-
RECEPTOR GENETIC VARIATION WITH COBALAMIN 
METABOLITE LEVELS IN ELDERLY WOMEN
Abstract
Functional cobalamin deficiency, a subtle progressive clinical disorder, affects 6-
23% of individuals >60 years old. This deficiency arises due to age-related decreases in 
the ability of the GI tract to extract and absorb cobalamin. Better understanding of 
biologic and genetic factors that contribute to the high prevalence of cobalamin 
deficiency observed in older adults would allow for targeted care and improved 
functional quality of life in advanced age. This candidate gene association study 
examined the association of genetic variation in the transcobalamin II and transcobalamin 
II-receptor genes on the concentration of cobalamin, homocysteine, and methylmalonic 
acid in the blood of 789 participants of the Women’s Health and Aging Studies. A total 
of four SNPs were identified for additional hypothesis testing. In the transcobalamin II 
gene, a missense coding SNP (rs9621049) was associated with mean homocysteine 
concentrations, a missense coding SNP (rs35838082) was associated with mean 
homocysteine and methylmalonic acid levels, and two SNPs in intron 7 were associated 
with serum cobalamin (rs4820888) and homocysteine (rs4820887) concentrations. A
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final SNP in the transcobalamin II-receptor gene, a missense coding SNP (rs2336573), 
was associated with mean serum cobalamin concentrations. 
Introduction
Cobalamin, commonly known as vitamin B12, is a critical nutrient. Humans are 
dependent upon adequate dietary intake or supplementation of cobalamin for survival, 
since it is only synthesized by microorganisms. In the human body, cobalamin is used as 
enzymatic cofactors for only two biochemical reactions. The first is in the cytoplasm, 
where methylcobalamin serves as a cofactor for methionine synthase. This enzyme uses 
folate to convert homocysteine to methionine, which is necessary for one-carbon 
metabolism that fuels essential cell processes, including methylation and DNA synthesis. 
The second is in the mitochondrion where 5’-deoxyadenosylcobalamin catalyzes 
conversion of methylmalonyl coenzyme-A to succinyl coenzyme-A, which is essential 
for odd-chain fatty acid and amino acid catabolism (Beck, 2001). In the event of 
decreased cobalamin availability, the metabolites homocysteine and methylmalonyl 
coenzyme-A (methylmalonic acid) accumulate. Additionally, deficit of one-carbon 
intermediates produces a range of clinical disorders, including megaloblastic anemia and 
neurologic impairment (Lindenbaum et al., 1988). Because clinical symptoms can exist 
and progress in individuals with normal serum cobalamin concentrations, homocysteine 
and methylmalonic acid are commonly used as deficiency indicators in the assessment of 
an individual’s cobalamin nutrition status (Green, 2008).
Prevalence of cobalamin deficiency in elderly adults is reported to range from 6% 
to 23%, and depending on diagnostic criteria used—even as high as 40.5% (Allen, 2009;  
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Baik & Russell, 1999; Johnson et al., 2003; Lindenbaum, Rosenberg, Wilson, Stabler, & 
Allen, 1994; Pennypacker et al., 1992). Elder adults are especially susceptible to 
cobalamin deficiency due to a combination of factors, including decreased dietary intake, 
age-related decline in gastric absorption, use of interfering medications, and presence of 
comorbid conditions (Baik & Russell, 1999; Wolters, Strohle, & Hahn, 2004).
Unrecognized cobalamin deficiency in older adults may result in an exaggerated 
disability trajectory involving higher frequency of hospital admissions, lengthier and 
more severe hospitalizations, or greater degrees of chronic disablement significantly 
affecting mobility and quality of life (Bartali et al., 2006).
To assist in the development of strategies to prevent or delay the disablement 
process, better understanding of the biologic factors contributing to altered cobalamin 
status is needed. For example, low cobalamin concentrations inside cells can also result 
from disturbances in transport and cellular uptake processes. Following intestinal 
absorption, cobalamin is bound to the carrier molecule transcobalamin II in the plasma 
for nutrient delivery to target cells. From the circulation, the cobalamin-transcobalamin II 
complex is endocytosed into lysosomal compartments via the transcobalamin II-receptor 
(Quadros, Nakayama, & Sequeira, 2009; Seetharam & Li, 2000). Structural variations in 
the transcobalamin II carrier molecule and its receptor can affect binding efficiency 
characteristics, resulting in decreased cellular availability for essential metabolic
reactions and influencing susceptibility to deficiency (Miller, Ramos, Garrod, Flynn, & 
Green, 2002; Quadros et al., 2010). To explore these factors more broadly, this study 
examined if transcobalamin II and transcobalamin II-receptor genetic variation was 
associated with biochemical cobalamin parameters in elderly participants of the Women’s 
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Health and Aging Study 1 and 2 cohorts. Parameters of interest included serum 
cobalamin, homocysteine, and methylmalonic acid concentrations.  
Methods
Study Design and Population
This project is a candidate gene association study using genetic material from 
research subjects who participated in the Women’s Health and Aging Study (WHAS) 1 
and 2 cohorts. WHAS 1 (1992-1995) and WHAS 2 (1994-1996) were prospective, 
observational research initiatives that examined the trajectories and sources of physical 
disability in community-dwelling elderly women in 12 Baltimore, MD area zip codes. 
WHAS 1 was designed to sample the one-third most disabled women in the Baltimore 
community, and as a complementary companion study, WHAS 2 was designed to sample
the two-thirds least disabled women. Numerous investigations have pooled WHAS 1 and 
2 subject data for a strengthened approach representative of the community-dwelling 
elderly (Bandeen-Roche et al., 2006; Chaves, Ashar, Guralnik, & Fried, 2002; Chaves et 
al., 2005; Leng, Xue, Tian, Walston, & Fried, 2007; Semba, Garrett, Johnson, Guralnik, 
& Fried, 2000; Semba et al., 2005; Walston et al., 2005). Although summarized briefly in 
this report, detailed descriptions of the sampling, screening, recruitment, and data 
collection procedures employed in WHAS 1 and 2 are fully described elsewhere (Fried, 
Bandeen-Roche, Chaves, & Johnson, 2000; J. Guralnik, Fried, Simonsick, Kasper, & 
Lafferty, 1995). The data collection protocols utilized in WHAS 1 and 2 were approved 
by the Johns Hopkins Medical Institutions institutional review board. The genotyping 
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portion of this research was approved by the Office of Human Subjects Research at the
National Institutes of Health and the University of Utah’s institutional review board. 
WHAS 1 (1992-1995) 
From 32,538 Health Care Financing Administration (HCFA) Medicare enrollee 
records in Baltimore, MD, 6,521 age-stratified elderly women (65-74, 75-84, and >85) 
were randomly selected for screening and possible enrollment (Ferrucci et al., 1995). A
total of 3,841 individuals were evaluated for physical disability across four domains: 1) 
mobility and exercise tolerance, 2) upper extremity function, 3) high function tasks 
(activities of daily living), and 4) basic self care. Women who reported difficulty with 
two, three, or four physical disability domains and had a Mini-Mental State Examination 
(MMSE) score of 18 or higher were invited to participate in WHAS 1 (n = 1,409), (Fried, 
Kasper, Guralnik, & Simonsick, 1995; Guralnik, Fried, Simonsick, Bandeen-Roche, & 
Kasper, 1995). Of the 1,409 individuals eligible, 1,002 consented to participate in WHAS 
1. Trained interviewers administered several health questionnaires and conducted 
physical performance measures and a standardized physical examination in homes of 
consented subjects. Part of a secondary consent, 762 of the 1,002 total WHAS 1 
participants agreed to phlebotomy and provided blood samples for research. DNA that 
was still available for genetic analysis used in this study was for 536 WHAS 1 research 
participants.  
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WHAS 2 (1994-1996) 
From the same 32,538 Health Care Financing Administration (HCFA) Medicare 
enrollee records in Baltimore, MD, another sample of elderly women (ages 70-79) was 
randomly selected for screening and possible enrollment. A total of 1,630 individuals
were evaluated for physical disability across the same four functional disability domains. 
Women who reported difficulty with zero or one disability domains and had a Mini-
Mental State Examination (MMSE) score of 24 or higher were invited to participate in 
WHAS 2 (n = 880). In WHAS 2, some subjects were screened by telephone, and an 
abbreviated MMSE was used; individuals who correctly answered at least 80% of 
questions were eligible for study inclusion. Of the 880 eligible individuals, 436 consented 
to WHAS 2 participation. The consented subjects participated in a clinic examination 
visit where trained study personnel administered the same standardized questionnaires, 
physical performance measures, and standardized physical examination as WHAS 1 
subjects. Also part of a secondary consent, 405 of the 436 total WHAS 2 participants 
agreed to phlebotomy and provided blood samples. The DNA that was still available for 
genetic analysis used in this study was for 253 WHAS 2 research participants.  
Blood Assay Measurement
Nonfasting blood samples from WHAS 1 and 2 subjects were processed, 
aliquoted, and frozen (-80 degrees Celsius) at the Core Genetics Laboratory in the Johns 
Hopkins University School of Medicine. 
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Serum Cobalamin, Folate, Creatinine
For determination of serum cobalamin, folate, and creatinine concentrations, 
frozen aliquots were sent from Johns Hopkins University School of Medicine to Quest 
Diagnostics (formerly Corning Clinical Laboratories and MetPath) in Teterboro, NJ. At 
Quest Diagnostics, serum cobalamin and folate concentrations were determined using 
competitive intrinsic factor protein-binding and folate-binding protein assays, according 
to the methods of Ciba-Corning Diagnostics Corporation in Medfield, MA. The normal 
range of serum cobalamin and folate was reported at 148-664 pmol/L and 6.8-36.0
nmol/L. Also at Quest Diagnostics, serum creatinine concentrations were analyzed via 
the conventional Jaffe method with normal ranges reported at 0.6-1.1 mg/dL for females. 
Cobalamin, folate, and creatinine laboratory values were available for the WHAS 
participants, including n = 772 cobalamin concentrations, n = 780 folate concentrations, 
and n = 769 creatinine concentrations.  
Homocysteine and Methylmalonic Acid
A subset of WHAS 1 and 2 sample aliquots were shipped on dry ice from the 
Core Genetics Laboratory at John’s Hopkins University School of Medicine to the 
University of Colorado Health Sciences Center for measurement. Homocysteine and 
methylmalonic acid levels were obtained using stable-isotope dilution and capillary gas 
chromatography-mass spectrometry with selected ion monitoring (Penninx et al., 2000; 
Stabler et al., 1999). Normal homocysteine and methylmalonic acid concentrations are 
5.4-13.9 	
-271 nmol/L per previous WHAS 1 and 2 research reports 
(Penninx et al., 2000; Stabler et al., 1999). Homocysteine and methylmalonic acid 
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laboratory assay values were available for the WHAS participants, including n = 758 
homocysteine concentrations and n = 754 methylmalonic acid concentrations. 
Renal Function Assessment 
Previous studies of elderly individuals demonstrate that modest elevations in 
homocysteine and methylmalonic acid can occur from renal insufficiency (Lindenbaum 
et al., 1994; Pennypacker et al., 1992; Stabler, Lindenbaum, & Allen, 1996). However, in 
older adults, singular use of serum creatinine as a kidney function assessment is 
recognized to significantly underascertain presence of impaired renal status (Giannelli et 
al., 2007). Thus, this study used serum creatinine to estimate creatinine clearance for 
WHAS 1 and 2 subjects through the Cockcroft-Gault formula: creatinine clearance 
(mL/s) = weight (kg) x [140 – age (years)] / [72 x serum creatinine (mg/dL) x 0.85],
(Cockcroft & Gault, 1976). According to guidelines established by the National Kidney 
Foundation’s Kidney Disease Outcome Quality Initiative (NKF-KDOQI), a calculated 
estimated value of over 90 mL/min indicates normal glomerular filtration (Stage 1), 60-
89 mL/min indicates mild renal impairment (Stage 2), 30-59 mL/min indicates moderate 
renal impairment (Stage 3), 15-29 mL/min indicates severe kidney impairment (Stage 4), 
and under 15 mL/min indicates presence of kidney failure requiring dialysis (Stage 5) 
(National Kidney Foundation, 2002). Estimated creatinine clearance values were 




Single Nucleotide Polymorphisms (SNPs) were selected for the study’s candidate 
genes using publicly available databases HapMap (Phase 1 and 2 full dataset), dbSNP 
(build 125), and NCBI (build 35). For both Caucasian and African American ancestral 
groups, Haploview (4.0) Tagger was used to tag SNPs in the candidate genes and 
including 10kb flanks on both ends of the genes. Because both candidate genes were 
small, at 19 kilobases and 6 kilobases, and there was high likelihood of dropped assays 
due to working with whole genome amplified material, the r2 statistic threshold was set at 
0.9 and minor allele frequency set at 0.05. Additional selected candidates included 
variants within exons, promoters, conserved sequences across species, and those reported 
in literature associated with clinical characteristics and biochemical parameters of 
interest. A total of 51 SNPs were selected—29 SNPs in the transcobalamin II gene and 22 
SNPs in the transcobalamin II-receptor gene.
Whole Genome Amplification
At the Core Genetics Laboratory in Johns Hopkins School of Medicine, DNA 
from WHAS 1 and 2 subjects was extracted from whole blood using the Puregene DNA 
Purification Kit from GentraSystems, Inc. DNA samples for WHAS subjects were plated 
at Johns Hopkins University and 50 ng was sent on dry ice to the National Human 
Genome Research Institute for genotyping. Because of limited starting quantity of genetic 
material, 10 ng of each participant’s DNA was whole genome amplified using Qiagen's 






possible allele dropout, two independent reactions of whole genome amplification for 
each WHAS subject were performed and pooled for use in high-throughput genotyping. 
Hardy-Weinberg calculations in pilot genotyping analyses for whole genome amplified 
material matched that of nonamplified WHAS genomic material. All 789 WHAS 
participant genomic samples were successfully amplified. 
SNP Genotyping
Genotyping of the WHAS 1 and 2 whole genome amplified samples was 
performed at the National Human Genome Research Institute using the Sequenom 
MassArray iPLEX platform (San Diego, CA). The genotyping reaction is characterized 
by two phases: 1) a locus-specific PCR reaction to produce a 100-base pair region that 
contains the SNP of interest, and 2) a locus-specific primer extension reaction that 
produces a mass-modified product for each allele of the SNP. Following amplification 
and extension reactions, the mass-modified products are resolved using MALDI-TOF 
mass spectroscopy. Genotype data were transferred to a local database for analysis. 
Statistical Analysis
Descriptive and inferential statistics were analyzed using the SPSS program 
(version 12.0). Summary statistics, frequency distributions, and independent t-tests were 
evaluated for sociodemographic and health characteristics, and for the study’s three 
outcome variables, serum cobalamin, homocysteine, and methylmalonic acid. Missing 
data were assessed for nonrandomness and WHAS subjects missing SNP genotypes, 
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study outcome parameters, or covariate values were removed from analysis. Assessment 
of the outcome and covariate variables for linearity, homogeneity of variance, 
homogeneity of regression slopes, and measurement reliability indicated no violations of 
statistical assumptions. For the study’s three biochemical outcome parameters, extreme 
outliers that were zero or greater than 3 standard deviations away from the mean were 
removed from analysis (serum cobalamin n = 6, homocysteine n = 6, methylmalonic acid 
n = 10).  
Hardy-Weinberg statistics, allele, and genotype frequencies were calculated for 
transcobalamin II and transcobalamin II-receptor SNPs in African American and 
Caucasian WHAS subjects. To test for association between cobalamin concentration and 
the two independent variables, race and SNP, while also accounting for variability 
produced by altered renal function, a two-way analysis of covariance was conducted. To 
ascertain presence of association between mean homocysteine concentration and the 
independent variables while also accounting for variability produced from known 
physiologic mediators, a two-way analysis of covariance was conducted on the fixed 
factors, race and SNP genotype, with folate, creatinine clearance, and serum cobalamin 
designated as covariates. Similarly, a two-way analysis of covariance was performed to 
ascertain presence of association between mean methylmalonic acid and the fixed factors, 
race and SNP genotype, with creatinine clearance and serum cobalamin as covariates. 
Significant (p<0.05) interaction and SNP main effect F tests were explored further using 
the Tukey and Least Significant Difference procedures, and by assessing interaction 
graphs. The Bonferroni adjustment was used to correct for alpha inflation arising from 




Demographic and other baseline health characteristics of the 789 study 
participants are shown in Table 4. The 591 Caucasian participants in this study
represented 75% of the study sample, were slightly older than the 198 African Americans 
[t(787)= -2.90, p=0.004], and had more years of education [t(787)= -7.27, p<0.01]. There 
were 536 WHAS 1 subjects, who comprised 68% of the study sample. The remaining
WHAS 2 subjects (32%) were significantly more educated than their WHAS 1 
counterparts [t(787) = -10.9, p<0.01]. The study population was 71% Caucasian and 29% 
African American for WHAS 1 participants, and 83% Caucasian and 17% African 
American for WHAS 2 participants. 
The number of chronic diseases did not differ substantially between the African 
Americans as compared to Caucasians; however, WHAS 1 subjects had more chronic 
diseases than WHAS 2 subjects due to that cohort’s sampling focus on the more disabled 
portion of the Baltimore population [t(787)= 9.50, p<0.01]. African American elderly 
women were more likely to have elevated body mass index values [t(741)= 5.13, p<0.01], 
as were WHAS 1 cohort participants [t(741)= 3.62, p<0.01].              
Biochemical Characteristics
Descriptive summary statistics and clinical biochemical profile parameters for the 
WHAS 1 and 2 participants are presented in Tables 5 and 6. The mean serum cobalamin 
for African American subjects was 563 pmol/L compared to 461 pmol/L for Caucasian 
elderly women [t(770)= 5.24, p<0.01]. Clinically low serum cobalamin was more 
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prevalent in Caucasian subjects [t(775)= 2.83, p=0.005] with 3% of Caucasians 
demonstrating low serum cobalamin concentrations compared to 1% in African 
Americans. Although mean homocysteine concentrations were similar between African 
American and Caucasian subjects in both cohort groups, the mean values for WHAS 2 
subjects were much lower than WHAS 1 subjects [t(756)= 4.90, p<0.01]. Caucasian 
subjects had higher mean methylmalonic acid concentrations at 254 nmol/L compared to 
209 nmol/L for African Americans [t(752)= -3.78, p<0.01], and WHAS 1 Caucasian 
women had the highest mean methylmalonic acid concentration at 268 nmol/L. Moderate 
clinical elevations in methylmalonic acid levels [t(762)= 3.70, p<0.01] were more 
prevalent in Caucasian elderly women, where 29% of Caucasians experienced moderate 
to high serum methylmalonic acid concentrations compared to 15.7% in African 
Americans.
There were no differences between African American and Caucasian women or 
between participants for WHAS 1 and 2 cohorts in overall mean folate concentration. 
However, African American women were more likely to have clinically low serum folate, 
with 44.4% demonstrating concentrations less than 6.8 nmol/L compared to 28.3% for 
Caucasians [t(778)= 4.32, p=0.00]. Although the mean serum creatinine concentration for 
WHAS subjects was in the normal laboratory reference range for renal function 
assessment, mean values of creatinine clearance estimation for both groups indicated 
presence of moderately impaired renal status. Estimated glomerular filtration rates of 52 
mL/min for Caucasians and 53 mL/min for African Americans corresponded to Stage 3 
NKF-K/DOQI criteria. WHAS 2 subjects had better renal function per Cockcroft-Gault 
creatinine clearance estimation [t(734)= -2.61, p=0.009]. Both groups were comparable 
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in their distribution of renal function, and the majority of WHAS subjects experienced 
mild to moderate renal insufficiency (NKF-KDOQI Stage 2 and 3). 
Genetic Data 
Of the total 51 SNPs selected for genotyping in the transcobalamin II and 
transcobalamin II-receptor genes, 29 SNPs were successfully genotyped, resulting in 
incomplete tagging coverage for both genes. SNPs were dropped if they were 
monomorphic (n = 6) or if they did not meet genotyping quality control thresholds (n =
16). Genotype and allele frequencies for the 29 successfully genotyped SNPs are 
presented in Table 7. For two-way between-groups analysis of covariance statistical 
association tests, WHAS subjects were divided into one of the three genetic categories 
(AA, AB, BB) according to their genotypes and stratified by race. Bonferroni adjustment 
for multiple testing of the 29 SNPs across the three biochemical outcomes in this study 
yields a corrected alpha significance threshold of 0.0006 (0.05/87). Table 8 provides a 
summary of the F values obtained in this research, including interaction effect, SNP main 
effects, and race main effects. No result reached the stringent level of significance 
according to the Bonferroni-adjusted threshold. However, several results were significant 
at the p=0.01 level and p=0.05 level. These findings may be true associations that fail to 
survive correction. Due to the exploratory nature of this research and the value of 
hypothesis generating information, several of these are highlighted below. 
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Cobalamin
For the two-way analysis of covariance evaluating mean cobalamin 
concentrations across race and genetic factors adjusted for estimated creatinine clearance, 
there were two significant SNPs—rs4820888  in the transcobalamin II gene and 
rs2336573 in the transcobalamin II-receptor gene. 
The rs4820888 G|A SNP is located in intron 7 of the transcobalamin II gene, and 
although there was no significant interaction (race) effect, there was a statistically 
significant main (genetic) effect [F(2, 692)= 3.17, p=0.04, partial eta squared = 0.01]. 
Pairwise comparison of main effects across the genotype groups indicated that mean 
cobalamin concentrations of GA heterozygotes (M=474 pmol/L) were lower than the AA 
homozygotes (M=507 pmol/L) at p=0.018. Differences between AA homozygotes 
(M=507 pmol/L) and GG homozygotes (M=470 pmol/L) were not statistically significant 
at p=0.06, as was the difference between GA heterozygotes (M=474 pmol/L) and GG 
homozygotes (M=470 pmol/L) at p=0.95. A significant main race effect was found [F(1, 
692)= 22.37, p=<0.01, partial eta squared=0.032] for African American subjects’ higher 
cobalamin concentrations.
The rs2336573 C|T SNP in the transcobalamin II-receptor gene is a missense 
polymorphism located in exon 4, resulting in an arginine to glycine amino acid change at 
codon position 220. The interaction effect between race and rs2336573 genotype 
category [F(2, 684)= 0.27, p=0.76] did not reach statistical significance. However, there 
was a statistically significant main genetic effect with a small effect size [F(2, 684)= 
3.25, p=0.04, partial eta squared 0.01]. Pairwise comparison tests across the main genetic 
groups indicated that mean serum cobalamin concentrations in the TC group (M=573 
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pmol/L) were higher than the CC group (M=466 pmol/L) at p=0.02. Differences between 
CC homozygotes (M=466 pmol/L) and TT (M=576 pmol/L) were insignificant at p=0.16, 
as were differences between TT and TC groups significant at p=0.96. A significant main 
race effect was found [F(1, 684]= 6.78, p=0.009, partial eta squared=0.01] for African 
Americans’ higher cobalamin concentrations.  
Homocysteine
The two-way analysis of covariance was performed to evaluate mean 
homocysteine concentrations on the fixed factors, race and SNP genotype, after 
designating a singular mean value for WHAS subjects’ creatinine clearance, serum folate, 
and serum cobalamin concentrations. After creatinine clearance, serum folate, and serum 
cobalamin adjustment, there was no interaction effect [F(2, 673)= 2.66, p=0.071], and a 
significant main effect for the transcobalamin II SNP rs9621049 [F(2, 673)= 4.97, 
p=0.007, partial eta squared=0.015]. The rs9621049 SNP is a C|T missense 
polymorphism in exon 7 that results in an amino acid change of a phenylalanine to serine 
at codon position 348. Simple comparison testing found the mean homocysteine 










A significant main race effect was found [F(1, 673)= 6.91, p=0.009, partial eta 
squared=0.01] for African Americans’ higher homocysteine concentrations.
A second significant result from the analysis of covariance on mean homocysteine 
concentration included an interaction effect [F(2, 666)= 4.58, p=0.01, partial eta 
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squared=0.014] for the transcobalamin II A|G SNP rs4820887 in intron 7 (Figure 3). 
Simple comparison testing on the interaction effect found that African American subjects 
with an AA genotype (M}	
`
		
concentrations from both the GA group (M}	
p=0.001, and the GG group 
(M}#	
p=0.002. For this SNP, there was also a significant main effect [F(2, 
666)= 4.73, p=0.009, partial eta squared =0.014]. Simple comparison testing on the SNP 
main effect found that mean homocysteine was different between the AA (M=12.9 
	
"*M}	
`	`	p=0.002, and between the AA and 
GG (M}	
`	`	 at p=0.003. However, these relationships are not 
certain nor are the strengths of the significant associations assured; the A allele frequency 
of 0.09 in both the African Americans and Caucasian WHAS subject groups resulted in a 
small number of AA homozygotes (n=3 for African Americans and n=9 for Caucasians) 
from which wider variability may spuriously be driving significance. For this SNP, there 
was also a significant main race effect [F(1, 666)= 7.94, p=0.005, partial eta 
squared=0.012] for African Americans’ higher homocysteine concentrations.
The last SNP found to be associated with mean homocysteine concentration was 
SNP rs35838082, a C|T missense polymorphism in exon 5 of the transcobalamin II gene 
resulting in an amino acid change of tryptophan to arginine at codon position 215. There 
was no interaction effect [F(2, 676)= 0.001, p=0.98] and a significant SNP main effect 
[F(2, 676)= 3.36, p=0.035, partial eta squared=0.01]. Simple comparison testing 




There was no race main effect [F(1, 676)= 1.50, p=0.22].
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Methylmalonic Acid 
The two-way analysis of covariance evaluated mean methylmalonic acid 
concentrations on the fixed factors, race and SNP genotype, after designating a singular 
mean value for WHAS subjects’ creatinine clearance and serum cobalamin. The only 
significant SNP in this analysis for the outcome parameter methylmalonic acid was 
rs35838082—a C|T missense polymorphism in exon 5 of the transcobalamin II gene that 
was also associated with mean homocysteine concentrations. Although a highly 
significant interaction effect was found [F(2, 671)= 7.58, p=0.004, partial eta 
squared=0.011], the low frequency of the T allele in WHAS Caucasians resulted in 
absent TT and low CT cell sample sizes (TT n=0 and CT n=6); these small sample 
numbers increase the risk that the observed significance is spurious. For this SNP, there 
was also a significant main race effect [F(1, 671)= 12.62, p<0.01, partial eta 
squared=0.019] for Caucasians’ higher methylmalonic acid concentrations.
Discussion
Reported cobalamin deficiency prevalence indicates evidence of widespread 
decreases in cobalamin nutritional status for older adults. Understanding which older 
adults are susceptible to functional cobalamin deficiency could improve healthcare 
mechanisms and strategies aimed at decreasing onset or speed of disability trajectories. 
To better understand genetic factors contributing to decreased cobalamin nutrition status 
in the elderly, this study examined association of variants in the transcobalamin II and 
transcobalamin II-receptor genes with metabolic parameters in Women’s Health and 
Aging Study 1 and 2 participants. Although no genetic variants reached the stringent 
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Bonferroni-adjusted significance threshold of p=0.0006, this exploratory analysis did find 
six variants that were associated with various biochemical parameters ranging from the 
p=0.004 to p=0.04 level of significance. Concordant with HapMap reference population 
statistics, two of the six significant variants (rs35838083 and rs4820887) had low allele 
frequencies that resulted in decreased cell sizes for which to make fully adequate 
comparisons. The four remaining SNPs are discussed further.  
The primary finding from this study was the significant main effect indicating 
association of a F348S missense SNP in exon 7 (rs9621049) in the transcobalamin II 
gene with mean homocysteine concentration. After adjusting for estimated creatinine 
clearance, serum folate, and serum cobalamin, TT homozygotes experienced a 2.0 
	
`						`	




	tein as a result of the 
phenylalanine-to-serine amino acid residue change could result in variable binding 
efficacy of cobalamin in serum, preventing effective transport to cells, and affecting 
conversion of homocysteine to methionine.
Elevated homocysteine has been previously reported as a risk factor in the 
development of cardiovascular disease via a hypothesized connection to atherosclerosis 
through hypomethylation, generation of reactive oxygen species, and vascular endothelial 
dysfunction (Di Minno, Tremoli, Coppola, Di Minno, & Lupoli; Lawrence de Koning, 
Werstuck, Zhou, & Austin, 2003; Zhou & Austin, 2009). However, a recent randomized 
evaluation of folic acid and vitamin B12 supplementation versus placebo on blood 
homocysteine concentration did not demonstrate benefit in preventing myocardial 
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infarction outcomes (Study of the Effectiveness of Additional Reductions in Cholesterol 
and Homocysteine Collaborative Group, 2010). Presently, it is not known if elevated 
homocysteine is mediated by interactions between genetic factors such as rs9621049 SNP 
genotype and an individual’s cobalamin nutrition status.  
The rs9621049 SNP finding obtained in this study is not consistent with a 
previous study of transcobalamin II genetic variation on homocysteine concentrations 
(Lievers et al., 2002). The evaluation by Lievers et al. of transcobalamin II missense 
SNPs found rs1801198 (P259R) to be significantly associated with elevated 
homocysteine, whereas rs9621049 was not significant. For the WHAS participants, there 
was no rs1801198 interaction effect [F(2, 676)=1.23, p=0.29] or SNP main effect [F(2, 
676)=0.11, p=0.90]. Differences in results obtained may be due to the dissimilarity in 
patient sampling and demographics as Lievers et al. examined the influence of altered 
homocysteine levels in younger patients at risk of cardiac disease. 
A second key finding from this study was the significant association of two SNPs 
in intron 7 of the transcobalamin gene with mean serum cobalamin (rs4820888) and 
homocysteine (rs4820887) concentrations. After adjusting for estimated creatinine 
clearance, GG rs4820888 homozygotes experienced a 37 pmol/L lower mean cobalamin 
concentration than AA rs4820888 homozygotes, and the difference between mean serum 
cobalamin of the GG and GA groups was similar, at 33 pmol/L. After adjusting for 
estimated creatinine clearance, serum folate, and serum cobalamin, rs4820887’s 










rs4820887 in intron 7 is 3,495 base pairs and the relationship between these two SNPs is 
not known. 
Neither rs4820888, rs4820887, or the chromosomal region (haplotype block) on 
which they lie, are currently indicated in literature as being associated with biochemical 
parameters of cobalamin deficiency. Because the genetic distance between both intron 7 
SNPs is only 408 base pairs, it is not known if one marker is acting as a surrogate for the 
other. As this was a candidate gene association study using haplotype tagging to select 
SNPs for genotyping, it is possible that both SNPs are significant because the real signal 
is nearby in close linkage disequilibrium to rs4820888 and rs4820887, but was not 
genotyped in this study.  
The final SNP to be highlighted from this study is rs2336573 (A220G), the 
missense coding SNP in exon 4 of the transcobalamin II-receptor that was associated 
with mean serum cobalamin concentrations (Figure 4). Regardless of an individual’s 
race, individuals with a CC genotype had significantly lower mean serum cobalamin, 
demonstrating a 110 pmol/L difference from subjects with a TT genotype. This finding 
may possibly indicate that the C allele of rs2336573 exerts a functional difference 
resulting in decreased cobalamin uptake by a cell, reducing intracellular nutrient 
availability. Because rs2336573 is located in an exon, it is biologically plausible that it 
could result in functional differences in cobalamin uptake kinetics across a cell’s plasma 
membrane; however, this hypothesis has not been tested in an experimental system. As 
the transcobalamin II-receptor gene and protein were only just recently identified and 
purified, little is known about the clinical effects of genetic variation or the relevance it 
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may hold for patients in cohorts such as WHAS (Quadros et al., 2009). Nonetheless, the 
rs2336573 results obtained in this study identify an attractive candidate polymorphism 
for further research.
The work outlined in this study also mirrors recently published WHAS reports on 
the evaluation of methylmalonic acid with SNPs in the transcobalamin II gene (Matteini, 
Walston, Bandeen-Roche, Arking, Allen, Fried et al., 2008; Matteini, Walston, Bandeen-
Roche, Arking, Allen, Fried et al., 2010). In their candidate gene analysis reports on 326
Caucasian WHAS 1 and 2 subjects, no significant association between methylmalonic 
acid levels and transcobalamin II SNPs were found. 
In addition to genetic association data, this study indicated presence of variability 
in the mean outcome measures that was not due to genetics. Of the 29 SNPs, there were 
18 significant race main effects for the serum cobalamin outcome, and 8 significant race 
main effects for the homocysteine and methylmalonic acid outcomes. Factors specific to 
the social contexts of the WHAS participants such as nutrition, socio-economics, quality 
of life, and mental well-being, may explain a small portion of the variability observed in 
this study. Additionally, some of these observed findings may be coming from other 
factors that were not controlled for in this research, including use of medications and 
presence of comorbid chronic diseases. Although participants’ ages were controlled for 
through the sampling design (WHAS 1 at 65-74, 75-84, >85 and WHAS 2 at 70-74, 75-
79), the mean age of WHAS 1 participants at 77.4 years was higher than that of WHAS 2 
participants at 73.9 years. Some of the observed race main effects may also be arising 
from the age differences between the cohorts. Ultimately very little data exists on gene-
environment interactions involving social factors and their effects on the transcobalamin 
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II and the transcobalamin II-receptor genes for which to confirm these findings in the 
broader literature base.      
Strengths of this research include the use of a well-characterized and examined 
elder adult cohort to ascertain effects of genetic variation on metabolic parameters of 
cobalamin deficiency. In that there was limited quantity of genomic starting material, this 
study also demonstrates that use of whole genome amplification to generate genetic data 
is a sound technique to augment previous clinical and epidemiological research 
initiatives. Also notable is that this investigation includes examination of genetic 
variation from a recently characterized gene and protein, the transcobalamin II-receptor.
Limitations of this study are primarily notable for incomplete tagging of the 
transcobalamin II and transcobalamin II-receptor genes. This stemmed from 
implementation of stringent quality control criteria and other genotyping challenges 
associated with using whole genome amplified material of DNA that ranged from 16-18
years old. Another limitation of this research is that serum holotranscobalamin 
measurements, the amount of cobalamin bound to the transcobalamin II carrier molecule, 
were not available for WHAS 1 and 2 subjects. Using holotranscobalamin as an outcome 
variable would have permitted more direct assessment of the relationship between 
biologically active cobalamin in serum and transcobalamin II-receptor uptake. 
Another limitation to this work is that environmental factors known to affect 
susceptibility to cobalamin deficiency in older adults (such as medications and co-
morbidities), were not included in these analyses. Because many genotype frequencies 
were low in African American and Caucasian subgroups and several covariates were 
already used, further loss of power from additional covariate inclusion would have 
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removed ability to detect genetic effects. Had environmental factors been included there 
may have been less variance in the study’s outcomes attributable to genetic influence.  
Despite the limitations of this study, the findings obtained suggest that there are 
additional biologic factors that contribute to an elderly adult’s susceptibility to decreased 
cobalamin nutritional status. Further research in more highly powered and diverse patient 
cohorts is needed to replicate the transcobalamin II rs9621049 (F348S), rs4820888, 
rs4820887 findings, and the transcobalamin II-receptor rs2336573 (A220G) finding 
reported here. The information produced from this report may contribute to identification 
of valuable cobalamin-related targets for future functional studies.  
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Table 4
Selected Sociodemographic and Health Characteristics for WHAS Subjects
Characteristic Mean (SD) N Mean (SD) N Mean (SD) N
Age (Years) WHAS 1** WHAS 2 Total
African American 75.7 (7.0)   155        73.0 (2.5)    43       75.1  (6.4)  198*
Caucasian 78.1 (7.8)   381    74.1 (2.7)  210       76.7  (6.8)  591
Education (Years completed) WHAS 1** WHAS 2 Total
African American 8.6 (3.2)   155 11.0 (3.8)   43          9.1  (3.5) 198*
Caucasian 10.3 (3.7) 381 13.2 (3.2) 210        11.3  (3.8)  591
Number of Chronic Diseasesa WHAS 1** WHAS 2 Total
African American 1.4 (1.6)   155 0.6 (1.1)   43         1.3   (1.5) 198  
Caucasian 1.4 (1.4) 381 0.4 (0.9) 210         1.0   (1.3) 591
Body Mass Index (kg/m2) WHAS 1** WHAS 2 Total
African American 31.5 (16.1)  138    29.3 (6.3)   43      31.0 (14.3) 181*  
Caucasian 28.0   (6.1)  352  26.0 (0.9) 210      27.2   (5.7) 562
Note. Summary statistics including mean values, standard deviations (SD), and sample 
size. Significant differences from independent t-tests between WHAS 1 and WHAS 2 
subjects (**p<0.01) and African American and Caucasian subjects (*p<0.01) are 
indicated. 
aSelf-reported diseases include angina, myocardial infarction, coronary artery disease, 
congestive heart failure, peripheral artery disease, stroke, diabetes mellitus, and cancer. 
 149 
Table 5
Serum Metabolite and Chemistry Concentration Descriptive Summaries 
Variable
Mean (SD) N Mean (SD) N Mean (SD) N
Cobalamin (pmol/L) WHAS 1 WHAS 2 Total
African American 557   (263)   149        579   (267)     43       563 (264)  192*
Caucasian 456   (223)   372        468   (221)   208       461  (222)  580
		*	
 WHAS 1** WHAS 2 Total
African American 11.3   (4.3)   149          9.7   (3.2)    39        11.0  (4.1)  188
Caucasian 11.1   (4.3)   369          9.7   (2.6)  201        10.6  (3.8)  570
Methylmalonic acid (nmol/L)         WHAS 1** WHAS 2 Total
African American 214   (135)   150        190   (122)   39         209  (133)  189*
Caucasian 268   (135)   364        227   (149)  201        253  (141)  565
Folate (nmol/L) WHAS 1 WHAS 2 Total
African American 11.2  (23.0)  152          9.8  (8.3)    43        10.9  (20.1)  195
Caucasian 12.6  (10.5)  375  12.2  (8.1)  210   12.5   (9.7)   585
Creatinine WHAS 1 WHAS 2 Total
African American 1.2   (0.9)   152 1.1   (0.2)    42          1.2   (0.8)   194
Caucasian 1.1   (0.4)   366 0.9   (0.2)  209          1.0   (0.3)   575
Creatinine ClearanceE (mL/min)a WHAS 1** WHAS 2 Total
African American 52.3   (22.0) 136 57.2   (18.0)   42      53.4   (21.2) 178
Caucasian 50.4   (21.0) 349 54.3   (14.0) 209      51.8   (18.8) 558
Note. Significant differences from independent t-tests between WHAS 1 and WHAS 2 
subjects (**p<0.01) and African American and Caucasian subjects (*p<0.01) are 
indicated. 
aEstimated creatinine clearance by Cockcroft-Gault formula.
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Table 6
Metabolic and Clinical Profiles for WHAS Subjects by Race Category
Clinical Parameter
N % N % N %
Cobalamin (pmol/L) African American*   Caucasian              Total
Low (<148) 2      1.0 18       3.0 20     2.5
Moderate (149-258) 11     5.6            67     11.3 78     9.9
Normal (>259) 181   91.4 498   84.3 679   86.1
		*	
 African American Caucasian Total
Normal (<14) 149   75.3 486   82.2 635   80.5
Moderate (15-49) 31   15.7 68   11.5 99   12.5 
High (>50) 1     0.5 2     0.4 3 0.4
Methylmalonic acid (nmol/L) African American*    Caucasian Total
Normal (<279) 158   79.8 391   66.2 549   69.6
Moderate-High (280-999)     31   15.7 174   29.4 205   26.0
Very High (>1000) 2    1.0 8     1.4 10 1.3
Folate (nmol/L) African American* Caucasian Total
Low (<6.8) 88   44.4 167   28.3 255   32.3
Normal (>6.9) 107   54.0 418   70.7 525   66.5
Creatinine ClearanceEa African American Caucasian Total
Stage 1 (>90) 11     5.6 17    2.9 28     3.5
Stage 2 (60-89) 46   23.2 140   23.7 186   23.6 
Stage 3 (30-59) 98   49.5 325   55.0 423   53.6
Stage 4 (15-29) 20   10.1 50     8.5 70     8.9
Stage 5 (<15) 2     1.0 2     0.3 4     0.5
Note. Percentages may not add to 100% due to missing data. Significant differences in 
means of African American and Caucasian clinical parameter groups from independent t-
tests (*p<0.01) are indicated.
aNational Kidney Foundation-KDOQI Clinical Practice Guideline criteria, in mL/min.
 151 
Table 7
Genotype and Allele Frequencies for TCNII and TCNII-Receptor SNPs
African American Caucasian
SNP AA     AB    BB        Aa B AA    AB BB        A         B
TCNII
rs16988828 5 39 141 0.13 0.87 10      87    454      0.10     0.90
rs7289549 19       67     103       0.28     0.72 11      92    458      0.10     0.90
rs7286107 12       60     117       0.22     0.78 3        1    561      0.01     0.99
rs9606756    10       48     132       0.18     0.82         28 87    447      0.13     0.87
rs740234                  4       29     157       0.10     0.90 35    159    371      0.20     0.80
rs35915865 1         2     188       0.01     0.99 4      19    544      0.02     0.98
rs11703570 14 50     123       0.21     0.79 45    148    367      0.21     0.79
rs35838082              9       54 126 0.19     0.81 0        7    562      0.01     0.99
rs2267163 14       56 116 0.23 0.77 123    225    203      0.43     0.57 
rs1801198 16 65 108 0.26     0.74       133    251    183      0.46     0.54
rs4820021 0         6     187 0.02 0.98 14      92    455      0.11     0.89
rs9621049 7 51 134 0.17     0.83 14    101 448      0.11     0.89
rs4820886 4 50 135 0.15     0.85 12    102    450      0.11     0.89
rs4820887 4 27     157       0.09     0.91 9      85    465      0.09     0.91
rs4820888 38      90       62       0.44 0.56 127    235    199 0.44     0.56
rs2301955 17      71     102       0.28     0.72 120    230    220      0.41     0.59
rs2301958 11      59     121       0.21     0.79 32    172    368      0.21     0.79
rs1131603                 0        1     195       0.00     1.00           2      49    531      0.05     0.95   
rs4820889 5      31     154       0.11     0.89           2      23    547      0.02     0.98
rs2072194 4      44     136       0.14     0.86       115    238    200      0.42     0.58
TCNII-Receptor
rs173665 7      33     148       0.13     0.88 10      79    466 0.09     0.91
rs250510 3      22     157       0.08     0.92 1        6    539      0.01     0.99
rs2232787 1        3     186       0.01     0.99 1        0    547 0.00     1.00 
rs2227288 13      50     125       0.20     0.80 12      98    427      0.11     0.89
rs2336573 21      72       94       0.30     0.70 9      35    512      0.05     0.95
rs2232779 2      18 174       0.06     0.94 5        2    573      0.01     0.99
rs2927707 16     51     118       0.22     0.78         57     202   288      0.29     0.71
rs3760680 29     75       78       0.37     0.63 81     221 242      0.35     0.65
rs8100119 23     65      102      0.29     0.71 5       35   524      0.04     0.96
Note. SNP data in genomic order as occurring on the chromosome. 
aA denotes the minor allele and B denotes the major allele.
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Table 8
Two-Way ANCOVA F-Statistics for Cobalamin-Related Clinical Outcomes 
Cobalamin Homocysteine MMAa
SNP                  Int.    M(S)    M(R)        Int.    M(S)    M(R)        Int.    M(S)    M(R)  
TCNII
rs16988828  0.55     1.31     8.47**     1.13     0.86     0.04         0.39      1.60     1.29 
rs7289549      2.36     0.05   14.39** 0.12     0.18     1.67 1.86      0.85     6.87**
rs7286107      0.50     0.46     0.01         0.19     1.30 0.00 0.05      0.10     0.45
rs9606756      0.02     0.01     7.54**     1.41     0.52     3.10 0.09      0.96     1.28
rs740234        0.20     0.14     3.38         0.33     0.46     0.00 1.76      0.58     0.75
rs35915865    0.04     0.57 1.38         0.95     0.58 0.19         0.60      2.18     0.15
rs11703570    0.56     2.73   11.29**     1.61     0.92     0.60 0.39      0.29     1.56
rs35838082    0.03     0.39     3.92*       0.00     3.36*   1.50  8.21**  2.51 12.62**
rs2267163      0.86     1.69     5.90**     1.30     0.16 3.49         0.38      0.06     3.96* 
rs1801198      1.25     1.97     6.41*       1.23     0.29 6.21**     0.17      0.01     3.79
rs4820021      0.85     2.11     0.81         0.73     0.01     2.56         0.50      0.04     0.27
rs9621049      2.30     0.77     6.41**     2.66     4.97** 6.91**     0.60      0.01     2.56
rs4820886      2.07     1.24     4.37         1.72     2.89     5.17* 0.69      0.19     3.00
rs4820887      0.75     0.74     5.24*       4.58** 4.73** 7.94**     0.37      0.03     0.76
rs4820888      1.59     3.17* 22.33**     0.80     1.17     5.33*       0.26      0.33     5.58*
rs2301955      1.05     0.98   15.82**     1.17     0.66 1.86 0.57      0.73     2.31
rs2301958      1.11     2.79   10.68**     1.40     0.43     0.07 0.05      0.01     3.70
rs1131603      1.64     1.30     0.15 0.10     0.14     0.02 0.78      0.91     1.81
rs4820889      1.54     1.21     1.52 0.03     0.27     0.83 1.77      1.54     1.22 
rs2072194      0.22     0.25     4.72* 1.03     0.58 4.47*       1.13      0.24     3.42
TCNII-Receptor
rs173665        0.01     1.01     5.55* 0.77     1.04 0.02          0.81     1.23 1.89
rs250510        0.06     2.05     1.87 1.25     1.82 4.38*        0.08     1.35     0.01
rs2232787      0.32     0.98     1.47 0.17     0.03     0.01 3.55     0.32     4.85*
rs2227288      0.27     2.80     5.94* 1.29     0.00 0.85 1.28     0.07     0.09
rs2336573      0.27     3.25*   6.78** 1.86     0.35     0.00          0.29     0.41     2.29
rs2232779      0.39     0.01     3.84* 0.39     0.37     0.06 0.96     0.69     4.10*
rs2927707      2.20   1.59     7.24**     0.76     0.73     5.67* 1.07     0.08     7.75**
rs3760680      1.34     1.95   17.47** 3.51     1.22     1.19 0.40     0.16     5.37*
rs8100119      0.01     2.10     2.72 1.21     0.33 0.17          0.84 0.34     0.55
Note. 2-way ANCOVA F-statistics for Interaction Effects (Int.), SNP Genotype Main 
Effects M(S), and Race Main Effects M(R), after adjustment for covariates. (*) indicates 
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Figure 3. Race by SNP Genotype Interaction for SNP rs4820887 on Mean 
Homocysteine. 















































Figure 4. Transcobalamin II-Receptor SNP rs2336573 and Mean Serum Cobalamin. 
Box and whiskers plot serum cobalamin concentration (pmol/L) in African American and 
Caucasian WHAS subjects by rs2336573 (A220G) genotype in the transcobalamin II-
receptor. The figure also includes the distribution of outlying cases.  
   
CHAPTER 5
ASSOCIATION OF TRANSCOBALAMIN II AND TRANSCOBALAMIN II-
RECEPTOR GENETIC VARIATION WITH CLINICAL FEATURES 
OF VITAMIN B12 DEFICIENCY IN ELDERLY WOMEN
Abstract
Vitamin B12 (cobalamin) deficiency is an insidious and chronically progressive 
condition that demonstrates increased prevalence in older adult populations. Elder adults 
are particularly susceptible to its development due to age-related decreases in nutrient 
absorption, presence of comorbidities and medications that interfere with vitamin B12, 
and misattribution of vague symptoms to “older age.” Confounding accurate detection is 
clinical heterogeneity in the spectrum of symptom presentation, where clinical 
presentation spans mild fatigue and weakness to full-blown megaloblastic anemia and 
permanent neuropathic injury. This study aimed to better understand the heterogeneity 
observed in clinical cobalamin deficiency by evaluating the role of genetic variation on 
vitamin B12 deficiency symptom profiles in 795 Women’s Health and Aging Study 
elderly subjects. A candidate gene association study was performed to test for 
associations between variation in genes involved in vitamin B12 transport and 
hematologic, neurologic, and functional performance features of cobalamin deficiency. 
Two genes were studied, the primary cobalamin transport molecule and its receptor
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(transcobalamin II and transcobalamin II-receptor). An association was identified 
between a missense coding SNP (rs11801198) in the transcobalamin II gene and red 
blood cell mean corpuscular volume. A cluster of SNPs in the promoter region of the 
transcobalamin II gene were associated with the physical performance parameters, hand 
grip strength, and walking speed.  
Introduction
Vitamin B12, also referred to as cobalamin, is an essential nutrient for survival in 
human beings. Because vitamin B12 is made only by bacteria, humans are dependent on 
receiving at least 2-`	`	
	
poultry, seafood, eggs, dairy, or alternatively, through supplementation practices 
(National Academy of Sciences, 1998). In the human body, vitamin B12 has two primary 
forms, methylcobalamin and adenosylcobalamin, and is used as a cofactor for two 
enzymatic reactions: 1) in the cytoplasm, methylcobalamin overlaps with folate and 
serves as a methyl donor for the reaction catalyzed by methionine synthase. The products 
of this reaction provide the molecular precursors for DNA synthesis and cellular 
methylations, and 2) in the mitochondria, adenosylcobalamin is used as an essential 
cofactor in the metabolism of odd chain fatty acids and ketogenic amino acids for proper 
energy balance (Rosenblatt & Fenton, 2001).
Pathophysiologic responses to vitamin B12 deficiency commonly occur in cells 
that divide rapidly, such as those in the hematopoietic system, and in cells that require 
methylations for proper neurologic function, such as axons that experience frequent 
myelin sheath turnover. When methylations and DNA synthesis are disrupted, classical 
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pathology development includes macrocytic anemia, peripheral neuropathy, and subacute 
degeneration of the spinal cord (Beck, 2001). However, clinical vitamin B12 deficiency 
more often presents subtly, spanning a sizeable and heterogeneous preclinical spectrum 
with nonspecific symptom profiles, including malaise, vertigo, fatigue, mood alterations, 
sleeping, and gait disturbances (Carmel, 2000). Furthermore, neurologic symptoms may 
or may not occur before development of macrocytic anemia, and individuals receiving 
treatment may or may not experience resolution of neurologic symptoms even if using 
prescribed standardized replacement therapy (Allen, Stabler, Savage, & Lindenbaum, 
1990; Lindenbaum, Savage, Stabler, & Allen, 1990).
The challenge of accurately identifying presence of decreased vitamin B12 status 
and effectively treating it is especially difficult for older adult populations. Nonspecific 
symptoms of borderline cobalamin status are often erroneously attributed to older age. 
Presence of common medications, age-related declines in gastric function, and 
comorbidities in older adults can impair normal vitamin B12 absorption (Baik & Russell, 
1999). Estimated vitamin B12 deficiency prevalence in older adults ranges from 6 to as 
high as over 40% depending on the definition criteria used (Allen, 2009; Baik & Russell, 
1999; Johnson et al., 2003; Lindenbaum, Rosenberg, Wilson, Stabler, & Allen, 1994; 
Pennypacker et al., 1992). If unrecognized, vitamin B12 deficiency could contribute to 
increased disability trajectories in older adults (Bartali et al., 2006).
Improved understanding of the factors contributing to the heterogeneity of clinical 
features observed in vitamin B12 deficiency affecting older adults is needed. Recently, 
research has identified that genetic variation in cobalamin metabolism genes can affect 
clinical parameters such as serum metabolites (Hazra et al., 2009; Miller, Ramos, Garrod, 
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Flynn, & Green, 2002; Tanaka et al., 2009). Genes involved in the transport of all 
biologically active vitamin B12 used by the body are especially attractive candidates in 
exploring the role of genetic variation in an elder adult’s cobalamin status. 
To explore this hypothesis, a candidate gene association study was performed to 
examine if genetic variation in the primary cobalamin carrier molecule (transcobalamin 
II), and its receptor (transcobalamin II-receptor) were associated with clinical indicators 
of vitamin B12 deficiency in a population of elderly women. Research subjects were 
previous participants of the Women’s Health and Aging Studies. The clinical phenotypes 
examined in this study were traits that represented primary manifestations of clinical 
cobalamin deficiency and spanned hematological, neurologic, and functional 
performance parameters. Specifically, this study evaluated if genetic variation in the 
transcobalamin II and transcobalamin II-receptor gene was associated with hemoglobin 
concentration, mean corpuscular volume, depression scale score, peripheral neuropathy 
desensitization, hand grip strength, and walking speeds.  
Methods
Study Design and Population 
The Women’s Health and Aging Study (WHAS) 1 and 2 were prospective 
observational female cohort research initiatives conducted by the National Institute on 
Aging (NIA) in conjunction with the Johns Hopkins School of Public Health (Fried, 
Bandeen-Roche, Chaves, & Johnson, 2000; Guralnik, Fried, Simonsick, Bandeen-Roche, 
& Kasper, 1995). Designed as complementary companion studies, data from WHAS 1 
and 2 are often combined for a strengthened analytic approach representative of the 
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community-dwelling elderly (Bandeen-Roche et al., 2006; Chaves, Ashar, Guralnik, & 
Fried, 2002; Chaves et al., 2005; Leng, Xue, Tian, Walston, & Fried, 2007; Semba, 
Garrett, Johnson, Guralnik, & Fried, 2000; Semba et al., 2005; Walston et al., 2005). The 
WHAS studies represent a broad spectrum of illness and health in the Baltimore, MD 
community-dwelling female elderly population, as WHAS 1 focused on examination of 
the one-third most disabled women and WHAS 2 focused on two-thirds of the least 
disabled individuals. Although outlined briefly here, detailed reports of the sampling, 
screening, recruitment, and data collection procedures employed in WHAS 1 and 2 are 
reported elsewhere (Fried et al., 2000; Guralnik et al., 1995). The research protocols used 
by WHAS 1 and 2 investigators were approved by the Johns Hopkins Medical 
Institutions institutional review board. The genotyping portion of the WHAS research 
presented in this report was conducted at the National Human Genome Research 
Institute, and was approved by the Office of Human Subjects Research at the National 
Institutes of Health and the institutional review board at the University of Utah.   
WHAS 1 (1992-1995) 
Using Health Care Financing Administration (HCFA) Medicare enrollees from 12 
Baltimore area zip codes, 6,521 elderly women were randomly selected for WHAS 1 
screening (Fried, Kasper, Guralnik & Simonsick, 1995). Of the 6,521 age stratified 
women (65-74, 75-84, and >85) who were selected, 3,841 individuals met screening 
eligibility criteria and were assessed for physical disability across four domains: 1) 
mobility and exercise tolerance, 2) upper extremity function, 3) high function tasks 
(activities of daily living), and 4) basic self care. If participants had trouble performing 
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tasks in two, three, or four of the domains, and were moderately cognitively impaired as 
indicated by a score of at least 18 on Mini-Mental State Examination (MMSE), they were 
invited for WHAS 1 participation (n = 1,409) (Fried, Kasper, Guralnik, & Simonsick, 
1995; Guralnik et al., 1995). Following consent, trained interviewers collected data on 
1,002 WHAS 1 participants. In subjects’ homes, interviewers used standardized 
assessment protocols to administer health questionnaires, physical examinations, and 
functional performance measures. A subset of 762 WHAS 1 research subjects consented 
to phlebotomy. DNA availability from the phlebotomy performed in 1992-1993 included 
samples for 536 WHAS 1 subjects. 
WHAS 2 (1994-1996) 
Also randomly selected from the 32,538 Health Care Financing Administration 
(HCFA) Medicare enrollee records in Baltimore, MD, an age-stratified sample (70-74,
75-79) of 1,630 women was identified for health screening and enrollment. Evaluated 
across the same four physical disability domains, women with difficulties in none or one 
of the domains with a Mini-Mental State Examination (MMSE) score of 24 or higher 
were invited for study participation (n = 880). Subjects assessed over the telephone with 
an abbreviated MMSE who correctly answered at least 80% of the verbal response items 
were also eligible. A total of 436 subjects consented and were enrolled in WHAS 2, 
where they participated in a clinic examination visit conducted by trained study 
personnel. The same standardized questionnaires, physical examination criteria, and 
functional performance measures were administered to WHAS 2 subjects as in WHAS 1. 
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A subset of 405 WHAS 2 research subjects consented to phlebotomy with DNA 
availability for 253 research subjects. 
Blood Assay Measurement
Blood assay measurements used for this study included hemoglobin 
concentration, mean corpuscular volume (MCV), and serum folate. Nonfasting blood 
samples for WHAS 1 and 2 subjects were collected using venipuncture into sterile tubes 
containing ethylenediaminetetraacetic acid as an anticoagulant and processed at the Core 
Genetics Laboratory in the Johns Hopkins University School of Medicine. Frozen 
aliquots were sent to Quest Diagnostics (formerly Corning Clinical Laboratories and 
MetPath) in Teterboro, NJ. Hemoglobin concentrations were measured using the 
traditional cyanmethemoglobin method. Hemoglobin concentrations under 12.0 g/dL are 
considered to be low, indicating presence of anemia (World Health Organization, 1968).
MCV values were calculated by taking the proportion of blood volume in a subject’s 
sample comprised of erythrocytes (hematocrit) and dividing it by the total red blood cell 
count number. MCV values are reported in femtoliters (fL) and used to differentiate 
between various etiologies of anemia: microcytic (<83fL), normocytic (83-103 fL), and 
macrocytic (>103 fL). For serum folate measurement, frozen aliquots were sent from 
Johns Hopkins University School of Medicine to Quest Diagnostics (formerly Corning 
Clinical Laboratories and MetPath) in Teterboro, NJ. At Quest Diagnostics, subjects’ 
serum folate concentrations were determined using a competitive folate-binding protein 
assay, according to reported methods of the Ciba-Corning Diagnostics Corporation 
(Medfield, MA). The Quest Diagnostics laboratory’s reported normal reference range for 
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serum folate was 6.8-36.0 nmol/L. The hemoglobin, MCV, and serum folate values 
available for the WHAS participants included n = 752, hemoglobin concentrations, n =
744 MCV concentrations, and n = 780 folate concentrations. 
Neurologic Clinical Measures
Depression
Depressive symptoms in WHAS 1 and 2 subjects were evaluated through use of 
the Geriatric Depression Scale (GDS), a psychometric depression assessment in elderly 
adults designed to circumvent somatic depression symptoms and presence of dementia 
(Yesavage et al., 1982). The GDS is a validated 30-item survey of dichotomous (yes/no) 
questions requiring approximately 8 minutes to administer. Although the continuous 
scores were used for analysis in this study, generally accepted clinical scoring cutoffs 
include no depression (less than or equal to 9), mild depression (scores 10-13), and severe 
depression (greater than or equal to 14) (Ferrucci, Kittner, Corti, & Guralnik, 1995; 
Lyness et al., 1997; Norris, Gallagher, Wilson, & Winograd, 1987). Depression scores 
were available for all 789 WHAS 1 and 2 research subjects in this study. 
Peripheral Neuropathy
To assess for presence and severity of peripheral neuropathy, vibration perception 
testing (VPT) was conducted in both WHAS 1 and 2 cohorts. Unlike other laboratory 
tests and clinical measurements in WHAS, VPT data collection was not standardized 
between the two cohorts. WHAS 1 measurement protocols used a vibrometer and WHAS 
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2 measurement protocols used a tuning fork. To ensure reliability, the genetic analysis 
performed for this study was restricted to VPT continuous data for WHAS 1 subjects.
VPT testing for the WHAS 1 elderly women was performed on study participants’ 
lower extremities using the Vibratron II (Physitemp Instrument, Inc., Clifton, NJ). 
Modeled after a diabetic neuropathy protocol, subjects placed their right toe on the 
Vibratron II’s platform and reported whether or not a vibratory stimulus was felt using a 
two-alternative (yes/no) forced choice procedure (Ferrucci, Kittner, et al., 1995; Maser et 
al., 1989). Stimulation intensity was progressively decreased in 10% decrements until 
study subjects could no longer detect vibration. When a study subject provided an 
erroneous response, the vibration intensity was increased by 10% and the progressive 
decrements continued until a total of 5 errors were made. Vibration units measured by the 
Vibratron II were converted to microns, and after identifying the five errors and five 
lowest correct scores, a participant’s mean vibratory threshold was identified by 
removing the highest and lowest scores and averaging the remaining values. Although the 
continuous scores were used for analysis in this study, accepted neuropathic functional 
micron unit cutoffs include normal function (<3.43 units), mild dysfunction (3.44-4.87
units), moderate dysfunction (4.88-6.31 units), and severe dysfunction (>6.31 units) 
(Resnick, Vinik, Heimovitz, Brancati, & Guralnik, 2001; Volpato, Leveille, Blaum, 
Fried, & Guralnik, 2005). There were n = 498 continuous WHAS 1 vibration scores 




A JAMAR hand dynamometer was used to measure hand grip strength in WHAS 
elderly participants (Model #BK-7498; Fred Sammons Inc, Burr Ridge, IL). Testing was 
performed with subjects in a seated position and elbow flexure at a 90-degree angle 
(Ferrucci, Guralnik, Bandeen-Roche, Lafferty, Pahor & Fried, 1995). Subjects were 
asked to grasp the dynamometer and squeeze as hard as possible three times on each 
hand. The best measure in the stronger hand was recorded and reported in kilograms of 
force. There were n = 718 hand grip strength measurements available for this study’s 
analysis. 
Four-Meter Walking Speed 
WHAS 1 and 2 participants were asked to walk over a 4-meter course, at their 
usual speed two times and once, as fast as possible. For some participants, 4 meters was 
not available in their homes and a distance of 3 meters was used instead. Walking and 
timing of the walk beginning at a starting line did not start until the command to start was 
given by the interviewer. Using the faster of the two usual-pace walks, average walking 
speed was calculated by dividing the length of the walk (in meters) by the time in seconds 
required to complete it. Subjects were permitted to use a cane, walker, or walking aid, but 
not assistance from an additional person. There were n = 767 walking speed 




Information from publicly available databases (HapMap phase 1 and 2 full 
dataset, dbSNP build 125, and NCBI build 35) was used to select single nucleotide 
polymorphisms (SNPs) in the candidate genes, for Caucasians and African Americans. 
Haploview (4.0) Tagger was used to tag SNPs spanning both candidate genes, including 
10kb flanking regions, using an r2 threshold of 0.9 and a minor allele frequency of 0.05. 
Other candidates selected included those reported in literature to be associated with 
clinical vitamin B12 deficiency parameters, and functional variants within exons, 
promoters, or conserved sequences across species. A total of 51 SNPs were selected 
including 29 SNPs in the transcobalamin II gene and 22 SNPs in the transcobalamin II-
receptor gene.
Whole Genome Amplification 
To extract WHAS 1 and 2 subjects’ genomic DNA from whole blood samples, 
study staff at the Core Genetics Laboratory in the Johns Hopkins School of Medicine 
used the Puregene DNA Purification Kit from GentraSystems, Inc. WHAS subject 
genomic DNA was plated at Johns Hopkins University and 50ng was provided to the 
National Human Genome Research Institute for genotyping. Due to limited starting 
quantities of genetic material, 10 ng of WHAS subject DNA was whole genome 
amplified using Qiagen's REPLI-g Midi Kit (Product # 150045_100 Rx). This kit is 







one allele. To minimize random allele dropout, two independent rounds of whole genome 
amplification reactions were performed and pooled for high-throughput genotyping. In 
pilot analyses, Hardy Weinberg statistics were closely correlated between calculations of 
whole genome amplified material and those of nonamplified genomic material. All 789 
WHAS participant genomic samples were successfully amplified.
SNP Genotyping
Genotyping of the WHAS whole genome amplified material was completed at the 
National Human Genome Research Institute using the Sequenom MassArray iPLEX 
platform (San Diego, CA). Sequenom’s high-throughput genotyping platform is 
characterized by a locus-specific PCR reaction producing a 100-base pair segment with 
the SNP of interest, followed by a locus-specific primer extension reaction producing a 
mass-modified SNP genotype. Following these serial amplifications and extensions, the 
mass-modified SNP genotypes were resolved using MALDI-TOF mass spectroscopy.  
Statistical Analysis
SPSS (version 12.0) was used to compute descriptive and inferential statistics. 
Summary data, frequency distributions, normality parameters, and independent t-tests 
were evaluated for WHAS participant demographic characteristics and the study’s 
hematologic, neurologic, and functional performance outcomes. For genetic data, Hardy-
Weinberg statistics were calculated for each SNP in the transcobalamin II and 
transcobalamin II-receptor genes. Allele and genotype frequencies were obtained for 
African American and Caucasian WHAS subjects. Missing data were evaluated through 
 167 
SPSS’ missing data analysis function, and no nonrandom patterns were observed. WHAS 
subjects missing genotypes, clinical outcome measurements, or covariate measurement 
data were removed from analysis. For the outcome and covariate variables used in this 
study, assessment of linearity, homogeneity of variance, homogeneity of regression 
slopes, and covariate reliability indicated no violations of statistical assumptions. For the 
study’s laboratory parameters, extreme outliers that were zero (indicating a false 
laboratory entry) or greater than 3 standard deviations away from the mean were removed 
from analysis (hemoglobin n = 0, MCV n = 7, and serum folate n = 1).
For hematologic parameters, a two-way analysis of covariance was conducted to 
ascertain presence of differences in mean hemoglobin concentration, MCV, covaried on 
serum folate by the independent variables, race and SNP genotype. For neurologic 
parameters, a two-way analysis of variance was performed to ascertain presence of 
differences in mean depression score and peripheral vibration sensitivity outcomes by the 
independent variables, race and SNP genotype. For physical performance parameters, a 
two-way analysis of variance was performed to assess differences in hand grip strength
by race and SNP genotype. An analysis of covariance was conducted to ascertain 
differences in subjects’ 4-meter walking speed by independent variables, race and SNP 
genotype, covarying on standing height to adjust for the influence of an individual’s 
height on gait length. All analyses of variance and covariance in this study used 
continuous data. Significant interaction and main effect F tests (p=0.05) were evaluated 
using the Tukey and Least Significant Difference pairwise comparison test procedures,
and by assessing interaction graphs. To correct for alpha inflation arising from multiple 




The demographic and other baseline health characteristics for the WHAS 1 and 2 
study participants are summarized in Table 9. Caucasian participants were significantly 
older than African Americans [t(787)= -2.90, p=0.004], and WHAS 1 subjects were older 
than WHAS 2 subjects [t(787)= 7.01, p<0.01]. Caucasians had more years of education 
than African Americans [t(787)= -7.27, p<0.01] and as a cohort, WHAS 2 participants 
were more highly educated [t(787)= -10.9, p<0.01]. The number of chronic diseases was 
higher in WHAS 1 participants due to the cohort’s focus on more disabled members of 
the community [t(787)= 9.50, p<0.01]. African American participants had elevated body 
mass index (BMI) parameters compared to the Caucasian participants [t(741)= 5.13, 
p<0.01], and WHAS 1 subjects had higher average BMI compared to WHAS 2 subjects 
[t(741)= 3.62, p<0.01]. 
Clinical Characteristics 
Summary data for the WHAS subjects’ clinical outcome characteristics are shown 
in Table 10 and frequencies for the clinical diagnoses related to the study’s outcome 
parameters are indicated in Table 11. The mean hemoglobin concentration for African 
Americans at 12.4 gm/dL was lower than that for Caucasians at 13.3 gm/dL [t(750)=        
-8.58, p<0.01]. This difference was also noted for mean corpuscular volume (MCV),
where African Americans’ mean MCV was significantly lower at 90.3 fL compared to 
94.2 fL for Caucasian participants [t(742)= -8.39, p<0.01]. African Americans subjects 
had a significantly higher prevalence of anemia compared to Caucasians [t(750)= 6.04, 
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p<0.01], and microcytic anemia affected more African Americans than Caucasians 
[t(742)= -7.05, p<0.01]. Across the cohorts, WHAS 1 elderly subjects had lower mean 
hemoglobin concentrations [t(750)= -3.65, p<0.01]. Although mean depression scale 
scores were similar between African Americans and Caucasians participants, WHAS 1 
elderly women had higher scores than WHAS 2 elderly women [t(787)= 10.0, p<0.01]. 
Peripheral neuropathy measurements were only available for WHAS 1 subjects. Mean 
peripheral sensitivities did not differ between the ethnic groups and at 8.4 microns for 
African Americans and 8.3 microns for Caucasians, reflected an average of severe 
neuropathy for the sample. Given the varying and complementary selection criteria 
between the two different cohorts, these observed differences were expected and mirrored 
results of other WHAS publications.
Mean hand grip strengths indicate that African American elderly women were 
physically stronger than Caucasian elderly women [t(716)= 2.86, p=0.004], and mean 4-
meter walking speeds for Caucasian elderly women were significantly faster than the 
African Americans [t(765)=  -6.25, p<0.01]. WHAS 1 elderly women were less strong 
[t(716)= -11.4, p<0.01] and not as fast [t(765)= -20.3, p<0.01] as WHAS 2 elderly 
women. Table 12 provides functional performance percentiles for the WHAS elderly 
subjects on hand grip strength and 4-meter walking speeds. Previous characterization of 
physical performance measures in WHAS participants ascertained that individuals in the
lowest quintile of measurement meet the definition of physical weakness, and physical 
slowness (Fried et al., 2001).
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Genetic Data 
Of the 51 SNPs selected for genotyping, only 29 SNPs were genotyped 
successfully. SNPs that were monomorphic (n = 6) or did not meet genotyping quality 
control thresholds (n = 16) were dropped. This resulted in incomplete tagging coverage 
for the transcobalamin II and transcobalamin II-receptor genes. SNPs were not included 
in the analysis if they were monomorphic or did not meet strict quality-control thresholds. 
Table 13 shows the genotype (AA, AB, BB) and allele (A, B) frequencies for SNPs that 
were successfully genotyped in WHAS African American and Caucasian subjects. 
Bonferroni adjustment for multiple testing of the 29 SNPs across the six clinical 
outcomes in this study yields a corrected alpha significance threshold of 
[p=(0.05/174)=0.0003]. Tables 14-16 provide a summary of the F values for interaction 
effects, SNP main effects, and race main effects obtained from the two-way analysis of 
variance and analysis of covariance statistical testing, and no results approach the 
Bonferroni-adjusted threshold level. However, several SNP main effect results were 
significant at the unadjusted p=0.01 levels for the hematologic parameters, and p=0.05 
for the neurologic and functional performance parameters. 
Hematologic Parameters
The two-way analysis of covariance of mean hemoglobin concentrations and 
MCV across race and SNP genotype factors adjusted for serum folate identified four 
highly significant SNPs, two for hemoglobin concentration and two for MCV (Table 14). 
Although there were no gross normality violations for the hemoglobin distribution, the 
MCV distribution demonstrated a bimodal peak that corresponded to differences between 
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African American’s mean MCV of 90.3 fL and Caucasian subjects’ mean MCV of 94.2 
fL. Levene’s test for equality of variances was violated in all analyses of covariance for 
MCV, resulting in the need for cautious interpretation in SNPs that did not meet more 
stringent alpha significance levels, such as under 0.025 (Tabachnik & Fidell, 2007).
For the hemoglobin concentration outcome, an A|G SNP in intron 7 of the 
transcobalamin II gene, rs4820888, demonstrated a significant interaction effect [F(2, 
716), p=0.008, partial eta squared = 0.013] between race and genotype. Simple 
comparison testing type on the interaction effect indicated that African American GG 
homozygotes (M=12.7 gm/dL) were different from AG heterozygotes (M=12.2 gm/dL) at 
p=0.04. The SNP main effect of rs4820888 was insignificant [F(2, 716)= 0.694, p=0.5]. 
Also associated with mean hemoglobin concentration, a significant interaction effect 
[F(2, 700)= 5.57, p=0.004, partial eta squared = 0.016], and a significant SNP main effect 
[F(2, 700)= 4.10, p=0.017, partial eta squared = 0.012] was observed for the SNP 
rs2072194, an A|G polymorphism in intron 8 of the transcobalamin II gene. However, 
this association was  spurious, its strength stemming from too few cases in the African 
American GG and GA genotype group cells that contained lower hemoglobin 
concentrations, thus driving the differences detected in the SNP main effect.
For the MCV outcome trait, a missense C|G polymorphism in exon 6 of the 
transcobalamin II gene, rs1801198 (P259R), demonstrated a significant interaction effect 
[F(2, 709)= 5.37, p=0.005, partial eta squared = 0.015]. Simple pairwise comparison tests 
were performed and identified statistically significant differences between the GG and
CG groups (p=0.002) and the GG and CC groups (p=0.029) of African American elderly 
subjects. African American GG homozygotes had lower MCV (M=86.1 fL) compared to 
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CG heterozygotes (M=91.4 fL) and CC homozygotes (M=89.7 fL). There was no 
graphical interaction observed between African Americans and Caucasians for the MCV 
trait by rs1801198 genotype. Pairwise comparison tests across genotype groups in 
Caucasian elderly subjects were insignificant. Although there was a significant SNP main 
effect for rs1801198 [F(2, 709)= 3.73, p=0.025, partial eta squared = 0.011], it was likely 
driven by the strength of the association observed in African Americans. A second SNP 
associated with MCV was rs2232787, a synonymous SNP (S280S) in exon 5 of the 
transcobalamin II-receptor gene with a significant interaction effect [F(2, 690)= 4.874,
p=0.028, partial eta squared = 0.007]. However, this SNP was monomorphic in both 
African American and Caucasian elderly subjects; discrepancies in MCV of genotype 
group cell sizes with zero, one, or two research subjects were driving this signal. In 
summary, the key finding identified in the analysis of hematologic parameters that was 
not attributable to low genotype frequencies was that of rs1801198 on MCV in African 
American subjects. 
Neurologic Parameters
The two-way analysis of variance evaluating geriatric depression score and 
peripheral neuropathy measurements across race and SNP genotype factors identified no 
SNPs significantly associated with neurologic vitamin B12 deficiency parameters at the 
p=0.01 level, and three SNPs at the p=0.05 level (Table 15). The association closest to 
the 0.01 alpha threshold was a significant interaction effect [F(2, 738)= 5.64, p=0.018, 
partial eta squared 0.008] observed for the rs2232787 synonymous SNP (S280S) in exon 
5 of the transcobalamin II-receptor gene; however, this was the same monomorphic SNP 
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from the MCV results. Inadequate cell sizes for the AA homozygotes (n=1 for African 
Americans, n=1 for Caucasians) and AG heterozygotes (n=3 for African Americans, n=0 
for Caucasians) were driving wide variability in mean depression scores, resulting in 
false association.
Demonstrating weaker significance were three SNPs associated with peripheral 
neuropathy micron measurements. The first SNP, rs4820886, a G|T polymorphism in 
intron 7 of the transcobalamin II gene, demonstrated a significant SNP main effect [F(2, 
470)= 3.67, p=0.026, partial eta squared 0.016] between genotype groups. The Tukey 
post-hoc analysis test ascertained significant differences between the mean micron 
measurement levels of GT heterozygotes (M=7.3 microns) and TT homozygotes (M=8.6 
microns) at p= 0.04. The second SNP, rs2227288, a C|G polymorphism in intron 4 of the 
transcobalamin II-receptor gene on peripheral neuropathy micron measurement, 
demonstrated a significant interaction effect [F(2, 451)= 3.21, p=.041, partial eta squared 
= 0.014]. The Tukey post-hoc comparison test identified significant differences of mean 
micron measurements across genotype groups in African Americans and Caucasians. For 
Caucasian elderly women, mean micron measurements in GC heterozygotes (M=9.8) 
were significantly different from GG homozygotes (M=8.0) at p=0.024, and also 
significantly different from CC homozygotes (M=5.4) at p=0.006. However, the minor C 
allele comprised small cell sizes, at n=10 for African Americans and n=6 for Caucasians. 
The last SNP reaching significance with mean micron measurement was rs2927707, a 
T|C polymorphism located in intron 1 of the transcobalamin II-receptor gene, which 
demonstrated a weakly significant interaction effect [F(2, 448)= 3.02, p=0.05, partial eta 
squared = 0.013]. In African American elderly women, Tukey post-hoc testing 
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ascertained that African American CC homozygotes (M=10.9 microns) were significantly 
different from TT homozygotes (M=8.4 microns) at p=0.048. 
In summary, four significant SNPs were found to be associated with neurologic 
parameters, one for depression (rs2232787) that was spurious due to low genotype 
frequencies from a monomorphic SNP, and three for peripheral neuropathy (rs4820886, 
rs2227288, and rs2927707). There was a significant main effect between genotype 
groups for rs4820886 independent of race. For rs227288, small genotype frequencies in 
the minor allele group drove false association. For rs2927707, differences in peripheral 
neuropathy measurements across genotype groups were identified in African Americans. 
Functional Performance Parameters
At the p=0.05 level, the two-way analysis of variance for hand grip strength 
identified four significant SNPs, and the two-way analysis of covariance for walking 
speed, adjusted for standing height, identified three significant SNPs (Table 16). The 
majority of these observed findings were clustered in the five prime region of the 
transcobalamin II gene, including rs16988828 in intron 1, rs7289549 in intron 1, 
rs7286107 in intron 1, rs9606756 in exon 2, and rs11703570 in intron 3. The strongest of 
these significant associations is rs7286107, a C|T polymorphism in intron 1, 
demonstrating a SNP main effect in genotype groups across mean walking speeds [F(2, 
708)= 4.18, p=0.016, partial eta squared = 0.012]. Simple comparison testing to ascertain 
which genotype groups were significantly different from each other showed that CT 
heterozygotes (M=0.54 m/s) had lower mean walking speeds than TT homozygotes 
(M=0.78 m/s) at p=0.018. 
 175 
The final SNP in this analysis to be significantly associated with a functional 
performance parameter was rs2232779 in the transcobalamin II-receptor gene, an A|G 
polymorphism in intron 1 that had a significant interaction effect [F(2, 726)= 3.47, 
p=0.032, partial eta squared = 0.010] on walking speed. Pairwise comparison testing 
identified differences in mean walking speeds for Caucasians between TT homozygotes 
(M=0.67 m/s) and TC heterozygotes (M=1.3 m/s) at p=0.006, and between TT and CC 
(M=0.80 m/s) homozygotes at p=0.023, but inadequate cell frequency numbers were 
responsible for this effect (TT n = 4 and CT n =2). In summary, differences in functional 
performance not attributable to low cell frequencies were identified in a small cluster of 
six significant SNPs in the five prime region of the transcobalamin II gene. 
Discussion
A candidate gene association study was performed to ascertain if genetic variation 
in the transcobalamin II and transcobalamin II-receptor genes was associated with 
clinical phenotype parameters of B12 deficiency in a cohort of older adult women. Using 
banked samples and previously catalogued clinical measurements, genotypes were 
generated and analyzed for their association with clinical traits using a two-way analysis 
of variance and covariance. Although no genetic variant association reached the level of 
statistical significance required from the Bonferroni adjustment (p=0.0003), this 
exploratory analysis did find a transcobalamin II variant that was significant with the 
MCV trait at p=0.008, and a cluster of lower-level significant SNPs associating with 
physical performance parameters in a region of the transcobalamin II gene. 
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The first, and primary, finding from this study was a significant interaction effect 
between the transcobalamin II rs11801198 (P259R) SNP and the clinical parameter MCV 
in African American elderly women (Figure 5). African American subjects with a GG 
genotype had significantly lower MCV values compared to other genotype groups. 
Currently, there are no published reports that identify effects of rs11801198 on the MCV 
trait. However, this SNP is suspected to exert a functional biologic effect, most notably 
resulting in altered cobalamin-dependent metabolite levels in serum (Afman, Lievers, van 
der Put, Trijbels, & Blom, 2002; Lievers et al., 2002).
Current population-based studies identify that hematologic parameters including 
hemoglobin and MCV percentiles in African American individuals are slightly lower 
than in Caucasian individuals (Cheng, Chan, Cembrowski, & van Assendelft, 2004).
Although it has been proposed that differences in hemoglobin and MCV in African 
Americans may be attributable to socio-economic differences between the two 
populations, recent studies have identified alternative causes, such as genetic factors 
(Beutler & West, 2005). Ultimately, reasons for the rs11801198 finding in this study are 
unknown, and further research would be needed to validate this association in 
independent cohorts and ascertain its magnitude in a more adequately powered sample of 
elderly African American women.
A second finding from this work is the cluster of SNPs in the five prime region of 
the transcobalamin II gene associated with the cobalamin functional performance 
parameters. These SNPs span a genomic distance of approximately 5kb, extending across 
intron 1, exon 2, and intron 3, indicating that they are likely travelling together as part of 
a haplotype block. In addition to protein coding regions, this block is likely to include 
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sequences that regulate the expression of transcobalamin II messenger RNA, including 
enhancers and silencers. SNPs associated with decreased physical performance could act 
by influencing vitamin B12 availability and increase risk of functional vitamin B12 
deficiency in elderly individuals.
Two recent reports of transcobalamin II candidate gene associations with frailty 
parameters in Caucasian Women’s Health and Aging Study 1 and 2 subjects were 
published (Matteini, Walston, Bandeen-Roche, Arking, Allen, Fried et al., 2008; 
Matteini, Walston, Bandeen-Roche, Arking, Allen, Fried et al., 2010). These efforts 
identified significant associations between the frailty syndrome and transcobalamin II 
SNPs, specifically rs2267163 (and rs11801198 in linkage disequilibrium), which are 
located in the genomic region of intron 5 and exon 6. In comparison, results reported in 
this paper were slightly different in that the location of the significant SNPs was in intron 
1 through intron 3. 
Reasons for this difference may be in the varying analytic approaches used. 
Matteini and colleagues collapsed five continuous measurements of functional 
performance traits (walking speed, hand grip strength, energy level, body mass, and 
physical activity) into dichotomous outcomes according to widely accepted frailty 
parameters. Research subjects with at least three of the five frailty traits were categorized 
as being frail and entered into multivariate logistic regression models with SNP 
genotypes. In comparison, the analysis of covariance and analysis of variance approach 
outlined in this work used continuous data and conducted analysis of African American 
subjects in addition to Caucasian subjects. As both efforts identified findings in the 
transcobalamin II gene as being significant to functional performance in older adults, the 
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transcobalamin II gene remains an attractive biologic candidate for further replication and 
validation with a larger sample of older adults.
This study also assessed presence of variability in the mean outcome measures 
that was not due to genetics. For hemoglobin, MCV, and walking speed outcomes, the 
majority of SNPs had significant race main effects. There was one significant race main 
effect for depression score and peripheral neuropathy, 14 significant race main effects for 
hand grip strength, and 23 for walking speed. The variability in outcome measures in the 
race main effects was arising from factors related to the social contexts of the WHAS 
subjects, including nutrition, comorbidities, socio-economic status, or access to health 
care. For the traits hemoglobin and MCV, it is understood that social factors in addition 
to biologic differences account for clinical variability between African Americans and 
Caucasians (Beutler & West, 2005). However, there is no data on gene-environment 
interactions involving social mechanisms that is known to affect transcobalamin II and 
the transcobalamin II-receptor gene function in the broader literature base. Although this 
study indicates that social factors are present and impacting the outcome measures, this 
research does not ascertain which factors from an individual’s environment are 
generating the observed association. 
The strengths of this research include the use of a well-characterized elder adult 
research cohort such as WHAS 1 and 2 to investigate effects of genetic variation on 
clinical parameters of cobalamin deficiency. Additionally, because this study made use of 
very small amounts of genomic DNA, it demonstrates that use of whole genome 
amplification is a sound methodological technique to complement previous 
epidemiological investigations, such as WHAS 1 and 2. 
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Limitations of this work include the inability to fully tag both genes, due to the 
genotyping challenges associated with using whole genome amplified material from 
WHAS subject DNA that was between 16 and 18 years old. Because this is a candidate 
gene association study, it is important to note that although the findings identify new 
transcobalamin II and transcobalamin II-receptor genetic associations, knowledge of 
these associations cannot provide information as to their role in biologic causation of 
clinical vitamin B12 deficiency.     
Another limitation to this research is that environmental factors known to affect 
cobalamin status in older adults, such as medication use and comorbidities, were not 
included in the analyses. Since frequencies were low in many African American and 
Caucasian SNP genotype subgroups, greater loss of statistical power through additional 
covariate inclusion would have impaired ability to detect genetic effects. However, if data 
on medications and comorbidities was incorporated, there may have been less variance in 
the study’s outcomes attributable to SNP genotype. 
The MCV and physical performance genetic associations identified in this 
research support improved understanding of clinical heterogeneity of cobalamin 
deficiency parameters in older adult women. Additional research is required to replicate 
rs1801198 SNP (P259R) and the SNP cluster associations identified in the 
transcobalamin II gene, and to ascertain their biologic significance in the development 
and progression of vitamin B12 deficiency. The results obtained in this study may 
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Table 9
Selected Demographic and Health Characteristics for WHAS Subjects
Characteristic Mean (SD) N Mean (SD) N Mean (SD) N
Age (Years) WHAS 1**              WHAS 2 Total
African American 75.7 (7.0)   155        73.0 (2.5)    43  75.1  (6.4)   198*
Caucasian 78.1 (7.8)   381    74.1 (2.7)  210      76.7  (6.8)   591
Education (Years completed)         WHAS 1** WHAS 2                      Total
African American 8.6 (3.2)   155 11.0 (3.8)   43        9.1  (3.5) 198* 
Caucasian 10.3 (3.7) 381 13.2 (3.2) 210        11.3  (3.8) 591
Number of Chronic Diseasesa WHAS 1**              WHAS 2                      Total
African American 1.4 (1.6)   155 0.6 (1.1)  43         1.3   (1.5) 198
Caucasian 1.4 (1.4) 381 0.4 (0.9) 210         1.0   (1.3) 591
Body Mass Index (kg/m2)              WHAS 1** WHAS 2 Total
African American 31.5 (16.1)  138    29.3 (6.3)   43    31.0 (14.3) 181*  
Caucasian 28.0   (6.1)  352  26.0 (0.9) 210      27.2   (5.7) 562
Note. Summary statistics including mean values, standard deviations (SD), and sample 
size. Significant differences on independent t-tests between WHAS 1 and WHAS 2 
subjects (**p<0.01) and African American and Caucasian subjects (*p<0.01) are 
indicated. 
aSelf-reported diseases include angina, myocardial infarction, coronary artery disease, 
congestive heart failure, peripheral artery disease, stroke, diabetes mellitus, and cancer. 
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Table 10
Descriptive Summary of Cobalamin-Related Clinical Outcome Variables
Clinical Outcomea
Mean (SD) N Mean (SD) N Mean (SD) N
Hemoglobin (gm/dL) WHAS 1** WHAS 2 Total
African American 12.3   (1.6)  144        12.6   (1.0)    41      12.4  (1.5)   185*
Caucasian 13.2   (1.3)  367        13.4   (1.1)  200      13.3  (1.2)   580
Mean Corpuscular Volume (fL)    WHAS 1 WHAS 2 Total
African American 90.3   (6.3)  143        90.4   (6.9)    41       90.3  (6.4)  184*
Caucasian 95.1   (5.2)  361        92.7   (4.8)  199       94.2  (5.2)  560
Geriatric Depression Score            WHAS 1** WHAS 2
African American 7.2   (5.1)  155          4.2   (4.1)    43         6.6  (5.0)  198
Caucasian 8.2   (5.9)  381          3.9   (3.8)  210         6.7  (5.6)  591
Peripheral Neuropathya (microns) WHAS 1
African American 8.4  (4.6)  144                  
Caucasian 8.3  (4.4)  354
Hand Grip Strength (kg)                WHAS 1** WHAS 2 Total
African American 21.9   (5.9)  129 27.1 (5.6)    43        23.2 (6.3)  172*
Caucasian 19.8   (5.4)  341 24.8 (4.7)  205        21.7 (5.7)  546
4-Meter Walking Speed (m/s) WHAS 1** WHAS 2 Total
African American 0.5   (0.2)  145 0.9 (0.3)    43          0.6 (0.3)  188*
Caucasian 0.6   (0.3)  372        1.1 (0.3)  207          0.8 (0.4)   579 
Note. Significant differences in means from independent t-tests between WHAS 1 and 
WHAS 2 subjects (**p<0.01), and African American and Caucasian subjects (*p<0.01)  
are indicated.




Clinical Profile Descriptive Summaries for WHAS Subjects by Race Category
Clinical Parameter
N % N % N %
Hemoglobin (gm/dL) African American* Caucasian Total
Anemia (<12.0) 60     30.3 75     12.7 135     17.1
Normal (>12.0) 125     63.1 492     83.2 617     78.2
Mean Corpuscular Volume (fL) African American* Caucasian Total
Microcytic (<83) 30     15.2 9       1.5 39      4.9
Normal (83-103) 151     76.3 529     89.5 680    86.2 
Macrocytic (>103) 3       1.5 22      3.7 25 3.2
Geriatric Depression Score African American Caucasian Total
None (0-9) 148     74.7 445     75.3 593    75.2
Mild (10-13) 23     11.6 66     11.2          89 11.3
Moderate/Severe (>13)        27      13.6 80     13.5 107 13.6
Peripheral Neuropathy African American Caucasian Total
None (<3.44)                        14       7.1 41       6.9 55      7.0
Mild (3.44-4.87) 21     10.6              42       7.1 63      8.0
Moderate (4.88-6.31) 24     12.1 52 8.8          76      9.6
Severe (>6.31) 85     42.9 219      37.1       304    38.5 
Note. Percentages may not add to 100% due to missing data. Significant differences in 
means of African American and Caucasian clinical parameter groups from independent t-
tests (*p<0.01) are indicated.
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Table 12
Functional Performance Percentiles in WHAS Elderly Subjects
Clinical Parameter African American Caucasian Total
Hand Grip Strength (kg) N=188 N=546 N=718
20th percentile 18.00 17.00 17.00
40th percentile 22.00 20.00 20.00
60th percentile 24.00 23.00 24.00
80th percentile 28.00 26.00 27.00
4-Meter Walking Speed (m/s) N=172 N=579 N=767
20th percentile 0.34 0.48 0.43
40th percentile 0.51 0.67 0.63
60th percentile 0.64 0.83 0.78
80th percentile 0.85 1.08 1.03
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Table 13
Genotype and Allele Frequencies for TCNII and TCNII-Receptor SNPs
African American Caucasian
SNP AA     AB    BB        Aa B AA    AB BB        A         B
TCNII
rs16988828 5 39 141 0.13 0.87 10      87    454      0.10     0.90
rs7289549 19       67     103       0.28     0.72 11      92    458      0.10     0.90
rs7286107 12       60     117       0.22     0.78 3        1    561      0.01     0.99
rs9606756              10       48     132       0.18     0.82         28 87    447      0.13     0.87
rs740234                  4       29     157       0.10     0.90 35    159    371      0.20     0.80
rs35915865 1         2 188       0.01     0.99 4      19    544      0.02     0.98
rs11703570 14 50     123       0.21     0.79 45    148    367      0.21     0.79
rs35838082              9       54 126 0.19     0.81 0        7 562      0.01     0.99
rs2267163 14       56 116 0.23 0.77 123    225    203      0.43     0.57 
rs1801198 16 65 108 0.26     0.74       133    251    183      0.46     0.54
rs4820021 0         6     187 0.02 0.98 14      92    455      0.11     0.89
rs9621049 7 51 134 0.17     0.83 14    101 448      0.11     0.89
rs4820886 4 50 135 0.15     0.85 12    102    450      0.11 0.89
rs4820887 4 27     157       0.09     0.91 9      85    465      0.09     0.91
rs4820888 38      90       62       0.44 0.56 127    235    199 0.44     0.56
rs2301955 17      71     102       0.28     0.72 120    230    220      0.41     0.59
rs2301958 11      59     121       0.21     0.79 32    172    368      0.21     0.79
rs1131603                 0        1     195       0.00     1.00           2      49    531      0.05 0.95
rs4820889 5      31     154       0.11     0.89           2      23    547      0.02     0.98
rs2072194 4      44     136       0.14     0.86       115    238    200      0.42     0.58
TCNII-Receptor
rs173665 7 33     148       0.13     0.88 10      79    466 0.09     0.91
rs250510 3      22     157       0.08     0.92 1        6    539      0.01     0.99
rs2232787 1        3     186       0.01     0.99 1 0    547      0.00     1.00 
rs2227288 13      50     125       0.20     0.80 12      98    427      0.11     0.89
rs2336573 21      72       94       0.30     0.70 9      35    512      0.05     0.95
rs2232779 2      18     174       0.06     0.94 5        2    573      0.01     0.99
rs2927707 16     51     118       0.22     0.78         57     202   288      0.29     0.71
rs3760680 29     75       78       0.37     0.63 81     221   242      0.35     0.65
rs8100119 23     65      102      0.29     0.71 5       35   524      0.04     0.96
Note. SNP data in genomic order as occurring on the chromosome. 
aA denotes the minor allele and B the major allele.
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Table 14 
Two-Way ANCOVA F-Statistics for Hematologic Parameters
Hemoglobin Mean Corpuscular Volume
SNP                 Interaction    Main(S)     Main(R)      Interaction     Main(S)     Main(R)
TCNII 
rs16988828            0.25          0.06   8.73**            0.75          1.30             8.70**
rs7289549     0.02 0.10 26.40**            2.63          0.59 12.61**
rs7286107    0.22          1.06           1.58                0.49          1.58 5.23*
rs9606756      2.38 1.13 45.94** 0.60          0.33 17.42**
rs740234                1.48    0.86 4.74*              0.20 0.24 13.83**
rs35915865    2.41 1.97 0.09                0.56          1.06 4.10*
rs11703570   2.11 0.13 18.60**            1.13          0.02 37.87**
rs35838082    0.57 1.64 19.13** 0.26          2.65           17.46**
rs2267163              1.74 0.91         65.10**            3.67*        2.98 59.91**
rs1801198              0.84          0.28         56.92**            5.37**      3.73* 66.29**
rs4820021              0.07  0.11 14.11**            1.44          0.79 19.97**
rs9621049 1.46          0.30 19.60** 0.26          0.01 20.86**
rs4820886 1.33 0.50 19.88**            0.25          0.01 9.24**
rs4820887             1.73 0.77 19.20**            1.86          0.65 5.03*
rs4820888              4.81** 0.69 57.50**            2.92          0.86 77.88**
rs2301955 2.73 0.27 33.28**            1.21          0.02 50.60**
rs2301958            1.01 0.36 19.17** 0.53          0.66 33.81**
rs1131603              1.81 1.11 0.03** 0.40          2.29 0.59
rs4820889              0.64 0.55 6.66**            0.35 0.49 10.24**
rs2072194 5.57** 4.10** 50.29**            0.22          0.69 23.31**
TCNII-Receptor
rs173665                0.01 0.67 18.70** 0.37          0.26           20.61**
rs250510                1.01 0.77 0.94 0.44          0.15             6.92**
rs2232787 0.14 0.67 0.50 4.87**      0.19 9.89**
rs2227288              2.70 0.78 25.75** 1.43          1.62 14.69**
rs2336573 0.45 1.07 37.68** 1.52          0.73 26.95**
rs2232779 0.27 0.04 0.04 0.81          1.22 7.80**
rs2927707              0.20 0.46 48.90**            0.10          0.33           38.26**
rs3760680 0.01 0.19 67.00** 0.74          0.43 49.36**
rs8100119              0.32 0.76 14.82** 0.28          0.94 16.87**
Note. ANCOVA F-statistics covaried on serum folate, with Interaction Effect, SNP Main 
Effect (S), and Race Main Effect (R) values shown.  (*) indicates p=0.05 significance and 
(**) indicates p=0.01 significance. Data shown are before Bonferroni adjustment.
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Table 15
Two-Way ANOVA F-Statistics for Neurologic Parameters
Geriatric Depression Score Peripheral Neuropathy
SNP                Interaction    Main (S)    Main (R)        Interaction    Main (S)    Main (R)
TCNII 
rs16988828 2.08          0.41          2.41                     2.49          0.94          2.29
rs7289549     0.63          1.36 0.59 0.13          0.53 0.05
rs7286107              2.90          1.16 0.73 2.90 2.40 4.51*
rs9606756      0.05          1.95 0.00 0.13          0.94          0.24
rs740234        0.85          0.12 1.28 0.34          0.34 0.05
rs35915865    1.60          0.29 1.95 2.48          0.84          3.57
rs11703570   0.06          0.15 0.00 0.85          0.51 0.14
rs35838082    0.49          1.63 0.72 0.12          0.12          0.15
rs2267163              0.20          0.97 0.24 0.98          1.02          0.81
rs1801198              0.02          0.85 0.32 1.42          1.69          1.58
rs4820021              0.93      0.63 0.31                     0.01          0.08          0.00
rs9621049 0.55          0.16 0.20 0.78          2.57          0.14
rs4820886 0.06          0.36 0.09 1.29          3.67*        1.10
rs4820887              0.09          0.25  0.06 0.47          0.86          0.37
rs4820888              0.10          0.21 0.50 1.72          1.26          0.00
rs2301955 0.21          0.75 0.03 2.10 1.09          1.02
rs2301958              1.45          0.49 0.83 1.98          0.90          0.75
rs1131603              1.40          0.73 1.46 -- 0.11          0.13
rs4820889              1.12          0.33 0.65                     1.63          0.50          1.77 
rs2072194 1.32          0.72 1.22                     0.89          2.87          0.18
TCNII-Receptor
rs173665                1.20          0.16 0.32 1.26 0.03          0.71
rs250510                0.79          1.82 1.37 1.84          0.40 1.51
rs2232787 5.64*        2.10 5.50* 0.01          0.35          0.01
rs2227288              2.58          0.27 1.40 3.21*        2.32          0.08
rs2336573 0.14          1.13 1.13 0.30          0.40          0.43
rs2232779 0.39          4.51 0.05 0.13 2.34          0.01
rs2927707              0.49          0.80 0.04 3.02*        0.61          3.05
rs3760680 0.20          0.63 0.22 2.32          0.06          1.22
rs8100119              0.14          0.03 0.09 0.65          1.61 0.45
Note. F-statistics with Interaction Effect, SNP Main Effect (S), and Race Main Effect (R) 




Two-Way ANOVA and ANCOVA F-Statistics for Functional Performance 
Parameters 
Hand Grip Strength                           4-Meter Walking Speed
SNP               Interaction    Main (S)    Main (R)        Interaction     Main (S)     Main (R)
TCNII 
rs16988828 3.64*         1.25          7.44** 0.23          0.28          5.44*
rs7289549     3.69*         2.29        16.22**                 3.84*        0.80        29.49**
rs7286107            1.56           0.54          5.11*                   1.52          4.18*    0.54
rs9606756      0.86           3.74*        0.68                     0.19          1.04          8.60**
rs740234              0.74           1.34          4.49*                   0.33          0.77          3.81*
rs35915865    0.03 0.73          0.29 0.07          0.11          1.05
rs11703570   3.08*         1.69        10.65**                 0.39          0.13        11.67** 
rs35838082    0.26           0.19          0.62 0.65          0.12          7.48**
rs2267163            1.23           0.44          3.18                     0.07          1.59        14.29** 
rs1801198            0.23           1.22          5.23* 0.07          2.77        18.10**
rs4820021            2.15   0.27          0.00                     0.42          0.14          8.49**
rs9621049 0.04           0.07          2.53                     0.39          0.12          6.68**
rs4820886 0.14           0.10          0.89                     0.71          0.17          4.12*
rs4820887            1.42           1.75          0.48 0.41          0.05          3.81*
rs4820888            0.03           0.21          7.62**                 0.99          0.11        26.95**
rs2301955         0.26           1.06          8.25**                 1.47          0.28        14.82**
rs2301958            0.55           0.56          6.37** 1.85          0.74          5.47*
rs1131603            1.77           1.59          3.38              0.49          0.11          0.10
rs4820889            0.26           1.91          0.94                     0.66          1.53          8.25**
rs2072194 1.66           1.77          0.13                     0.84          1.30        11.72**
TCNII-Receptor
rs173665              0.38            0.47 4.13*                   0.68          2.33          3.22
rs250510              0.01            1.70 0.24 0.23          1.37          0.48
rs2232787 -- --        -- 1.33          0.35          3.48
rs2227288            0.69            0.15         4.66*                   1.50          1.52        14.80**
rs2336573 0.72            0.64 1.98 1.43          0.22           5.01*
rs2232779 1.42            1.69         4.01*                   3.47*        2.03           5.12*
rs2927707            0.19            0.12 6.16** 0.78          0.69         16.73**
rs3760680 1.89            1.06         4.91* 0.42 0.43         22.33**
rs8100119            0.10            1.81 2.26 0.01          0.72           6.69**
Note. F-statistics with Interaction, SNP (S), and Race (R) main effect values. (*) 






































Figure 5. Transcobalamin II SNP rs1801198 and Mean Corpuscular Volume. 
Box and whiskers plot mean MCV for African American and Caucasian WHAS subjects 
by genotype of rs1801198 (P259R) in the transcobalamin II gene. The distribution of 
outlying cases is included. 
   
CHAPTER 6
TRANSLATION OF GENETICS AND GENOMICS FOR NURSING—
PERSONALIZED MEDICINE
Abstract
Scientific advances in genetics and genomics will be incorporated into healthcare 
soon. The tailoring of treatment to an individual’s genetic make up has been termed 
Personalized Medicine. These advances are promising and are receiving significant 
attention; however, many nurses are caught in the gap between technologic advances and 
clinical diffusion and uptake. Four elements of Personalized Medicine are described in 
this paper, which include 1) discovery of novel biology that guides clinical translation 
mechanisms; 2) genetic risk assessment; 3) molecular diagnostic technology; and 4) 
pharmacogenetics and pharmacogenomics. Opportunities for engagement of the nursing 
profession that are presented by Personalized Medicine are addressed. Successful design 
and implementation of Personalized Medicine will hinge on the roles of nurses 




Formally completed in 2003, The Human Genome Project provided a reference 
map of human genome DNA sequence (The International Human Genome Sequencing 
Consortium, 2001, 2004). Similarly, the International Haplotype Map Project (HapMap, 
www.hapmap.org), completed in 2005, provided a map of variation in human DNA and 
how this variation was arranged in populations (The International HapMap Consortium,
2005). Fruits of these research efforts are revolutionizing biology, medicine, and 
ultimately, healthcare delivery (Collins, Green, Guttmacher, & Guyer, 2003; Collins & 
McKusick, 2001). Clinical translation of these landmark scientific achievements will 
contribute to Personalized Medicine, where an individual’s DNA can be used to finely 
tailor healthcare practices. Health advances include personalized risk assessments that 
predict disease development years before clinical appearance, use of precisely tuned 
molecular screening tests and clinical diagnostics, and safer and more effective 
pharmaceutical agents prescribed to match individuals’ genetic constitution. Further 
developing and fueling these innovative applications is the continued discovery of novel 
biology in high-tech laboratory settings across the country and throughout the world.
Scientific achievement beyond The Human Genome Project and the HapMap is 
being fueled by unprecedented technological advancement. Cost of sequencing an 
individual’s genome in 2002 was 1 billion dollars, but through Illumina, Inc., Personal 
Genome Sequencing Service can now be commercially performed for $48,000 (Illumina, 
2009). Furthermore, it is estimated that this price will drop to under $1000 per genome in 
the next 2-3 years, a magnitude and rate of cost reduction that surpasses the gains made 
by the microprocessor industry. Because the human genome is approximately 6 billion 
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data points, the sheer volume of scientific data is overwhelming, and data flowing from 
studies examining the associations between genetic sequences and disease has been 
likened to ‘drinking water from a fire hose’ (Hunter & Kraft, 2007). A PubMed search 
using the terms “genetics” and “genomics” comparing 1989-1999 and 1999-2009
demonstrates this rapid increase: 576,170 and 7,412 results, respectively, for 1989-1999,
compared to 1,169,310 and 47,297 for the past decade 
(http://www.ncbi.nlm.nih.gov/sites/entrez/ queried on 30 November 2009).
Intense mainstream media coverage of scientific progress in genetics and genomics 
has resulted in public expectation that these advances are already incorporated into 
clinical practice. Capitalizing on this environment, several companies have launched 
direct-to-consumer marketing campaigns for genomic profiling tests. Some testing 
companies provide test results and interpretations that are not supported by scientific data 
(Janssens et al., 2008). Others may include information that is difficult for the consumer 
to interpret in the absence of knowledgeable practitioner guidance (Gollust, Wilfond, & 
Hull, 2003; Kutz, 2006). Current examples include services offered by 23andMe, 
DeCode, and Navigenics, where for $300-$1500, a consumer can submit a sample of their 
DNA and obtain personalized analyses of their genetic code. Information contained in 
these companies’ reports includes a person’s lifetime risk for development of health 
conditions such as osteoporosis, cancer, diabetes, and heart disease. 
Previous scholarly papers in nursing have discussed genetics, and genomics, but 
none outline Personalized Medicine while identifying implications and opportunities for 
nurses. In this paper, I outline four conceptual Personalized Medicine elements, describe 
their healthcare implications and the current translation obstacles they face, and outline 
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implications for nurses in research, education, and practice settings. Although the 
biologic advances fueling Personalized Medicine offer sound proof of technologic 
possibility, it will likely be one or two decades until there is enough evidence concerning 
its application before nurses can use the entirety of an individual’s genome to guide 
personalized patient healthcare. During this long incubation period, health care patterns 
and practices will begin to incorporate elements of genetics. The field of nursing should 
anticipate and contribute to these developments and play an integral role in their 
translation and application. 
Clinical Application of Genetics and Genomics:  
Personalized Medicine
Personalized Medicine, in lay definition, is “using information about a person’s 
genetic makeup to tailor strategies for the detection, treatment, or prevention of disease”
(Collins, 2005). This new paradigm of healthcare rests on four key elements, the first 
driving the latter three, which contain direct clinical relevance to the nursing community 
(Figure 6): (1) discovery of novel biologic processes, which serve as the foundation for 
all clinical translation; (2) personalized risk assessments; (3) enhanced diagnostic 
accuracy through molecular profiling; and (4) pharmacogenetics and pharmacogenomics. 
Throughout the paper, refer to Table 17 for a concept glossary and Table 18 for relevant 
reference genetics and genomics websites.  
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The Foundation of Personalized Medicine—
New Biology, New Drugs
Novel biologic knowledge arising from the Human Genome Project and HapMap 
has great implications for advances in future healthcare practices. Validated Genome 
Wide Association Study (GWAS) associations identify 100 new loci for over 40 common 
health and disease traits, and are publicly searchable in an online catalogue maintained by 
the National Human Genome Research Institute at www.genome.gov/26525384
(Hindorff et al., 2009; Manolio, Brooks, & Collins, 2008). This knowledge translates to 
understandings of biologic networks not previously known as involved with common 
diseases (Figure 7). Through these new pathway connections, opportunities for improved 
clinical measurement and therapeutic manipulation will arise. A relevant example is 
illustrated by the case of age-related macular degeneration (Figure 8), one of the first 
conditions to be analyzed with the GWAS approach.
While gene/disease associations like those for age-related macular degeneration 
arose from the Human Genome Project and HapMap, several additional ongoing 
scientific initiatives are expected to yield similar biomedical impact. These include 
ENCylopedia Of DNA Elements (ENCODE), 1000 Genomes Project, Human 
Microbiome Project, and the Cancer Genome Atlas. As nurses play integral roles in 
generation of new knowledge and clinical realization of novel technologies, 




ENCODE is a public research consortium for identification of all parts of the 
human genome (within each gene) that regulate normal physiologic and biologic 
functions (National Human Genome Research Institute, 2008). Findings from ENCODE 
have shown that regions of the human genome previously thought to have no obvious or 
direct protein coding function are extremely important in gene regulation; expansive 
areas of intronic ‘junk’ DNA actually regulate protein production in distant genes and 
chromosomes (The ENCODE Project Consortium, 2007). Demonstrating enormous 
complexity, new structural categories are realized through ENCODE; instead of clear 
translation boundaries between exons and introns, there are alternative start and stop sites 
that have temporal and spatial uniqueness. When completed, ENCODE will demonstrate 
how an individual’s biologic make-up may be linked to a person’s responses in health, 
illness, and injury states. 
1000 Genomes Project
Through HapMap and GWAS efforts, common genetic variants have been 
identified that contribute to complex chronic diseases. But the effects of those identified 
variants account for very little, in terms of risk, of developing a particular trait or 
phenotype. For example, obesity GWAS research identifies two common variants in the 
FTO and MC4R (melanocortin-4 receptor) genes carried by ~20% of those of European-
descent. These variants exert physiologic effects on Body Mass Index but account for 
only 2% of adult variability of the trait (Frayling et al., 2007; Loos et al., 2008). Rare and 
difficult to find genetic variants may explain more of the variability in BMI, but are not 
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currently known. Sequencing the genomes of more individuals will allow for 
identification of rare variants with greater and more sizeable genetic effects (The 1000 
Genomes Project Analysis Group and Steering Committee, 2008). In September 2008, an 
international consortium launched the 1000 Genomes Project to generate an extensive 
catalogue of human genetic variation capable of increasing discoveries of new biology 
from a population perspective.
Human Microbiome Project
Understanding how bacterial colonies interact in our bodies is increasingly 
important (Hsiao & Fraser-Liggett, 2009). Bacteria and the colonies with which they live 
interact elegantly and intricately in contexts of greater host micro-environments. 
Recently, presence of specific types of bacteria in gut flora were found to predict 
occurrence of Type 1 Diabetes in experimental mouse models (Wen et al., 2008).
Although symbiotic bacteria outnumber human body cells by 10:1, the species living 
upon and within us have yet to be cataloged and information on how they communicate 
with each other and their human hosts is unknown (Turnbaugh et al., 2007). Using 
genomic sequencing, analyses of microbes from intestinal epithelial tissue in animals and 
individuals with obesity, intestinal disease, and cancer identified unique microbial 
profiles (Chu et al., 2004; Eckburg & Relman; Turnbaugh et al., 2006). To ascertain the 
extent that microbial communities participate in health and disease, the NIH Roadmap for 
Medical Research established the Human Microbiome Project (HMP) (The Human 
Microbiome Project, 2007). A global consortium, the HMP will provide genome 
sequence for floral communities across various human epithelial tissues. Initial data 
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identify great diversity within and across individuals dependent on tissue sampling site 
(Grice et al., 2008).
Cancer Genome Atlas 
In 2007, the National Cancer Institute and the National Human Genome Research 
Institute began large-scale genome sequencing of human tumor cells from cancer cohorts 
to provide a comprehensive catalogue of malignancy abnormalities (Collins & Barker, 
2007; The Cancer Genome Atlas, 2008). Characterization of glioblastoma, a common 
brain malignancy in adults noted for poor survival outcomes, yielded molecular profiles 
that may be used to reclassify and target clinical treatments (The Cancer Genome Atlas 
Research Network, 2008). Continued progress with other common tumor types such as 
ovarian and pancreatic cancer are revolutionizing how molecular derangements in 
malignancies are understood, and are expanding diagnostic, prognostic, and treatment 
options. 
Genetic Risk Assessment
Human genetic variation holds great promise in predicting the development of 
costly chronic and preventable diseases. For example, carriers of Single Nucleotide 
Polymorphism (SNP) risk alleles in the Transcription Factor 7-like 2 (TCF7L2) gene 
have significantly increased lifetime risk of developing diabetes (Helgason et al., 2007; 
Prokunina-Olsson et al., 2009). Using the information contained in a person’s genetic 
constitution for these purposes is increasingly attractive given that recent Genome-Wide 
Association Studies (GWAS) delineate numerous novel and quantifiable genetic risks for 
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common health conditions including heart disease, depression, colorectal cancer, and 
osteoporosis (Figure 7) (McPherson et al., 2007; Scott et al., 2007; Tomlinson et al., 
2007; Wellcome Trust Case Control Consortium, 2007).
Of particular interest is if the SNPs identified in GWAS reports can be used in 
preventive medicine, to predict illnesses. Sponsored by the Agency for Healthcare 
Research and Quality (AHRQ), the U.S. Preventive Services Task Force (USPSTF) 
evaluates health screening mechanisms for efficacy, cost, and accuracy, and includes well 
known examples of screening standards (Atkins, Fink, & Slutsky, 2005; Harris et al., 
2001; U.S. Preventive Services Task Force, 2002a, 2002b, 2003a, 2003b, 2004, 2005).
Presently, there is not enough evidence to guide a USPSTF review of using genomic SNP 
sequence for preventive screening (Burke & Psaty, 2007; Gwinn & Khoury, 2006; 
Khoury, Yang, Gwinn, Little, & Dana Flanders, 2004). For example, many gene-gene 
and gene-environment interactive effects are unknown, attributable risk over one’s 
lifetime is small to modest for many SNPs, and population SNP allele frequencies are not 
yet fully established (Janssens et al., 2007; Khoury, Little, Gwinn, & Ioannidis, 2007).
Further contributing to delays in clinical translation are inadequate experimental designs, 
biased or erroneous interpretation of scientific data, and public dissemination of results 
from less rigorous research (Little et al., 2002; Moonesinghe, Khoury, & Janssens, 2007).
In order to properly inform a USPSTF investigation, novel genetic variant associations 
must be consistently replicated across various settings (Burke & Psaty, 2007).
Knowledge gaps aside, the most heated debates involving SNP genetic testing 
concern provision of maximal benefit while limiting harm to patients (Khoury, Gwinn, 
Burke, Bowen, & Zimmern, 2007). Possible adverse unintended consequences of SNP 
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genomic profiling include increased anxiety stemming from a test that does not impact 
health outcomes and excessive financial cost for little clinical advantage (Burke & 
Zimmern, 2004). Equally important is need for scientific data demonstrating how patients 
will use personalized genetic risk information once they receive it (McBride & Brody, 
2007; Thompson, 2007).
As mentioned previously, several companies market and sell genomic “risk” 
profiles directly to consumers (Burke & Press, 2006; Janssens et al., 2008). Proposed 
advantages of direct-to-consumer genomic profiling are increased availability, privacy, 
convenience, and enhanced market translation of molecular research advances (Goddard 
et al., 2007). Test results are interpreted and communicated to customers via a report that 
is mailed to them or accessed via the Internet. Detailed test interpretations and lifestyle 
recommendations may also be provided. Regulatory protection against false health claims 
for consumers using these services is a key deficiency as genomic technologies flood 
healthcare markets (Katsanis, Javitt, & Hudson, 2008; The Secretary's Advisory 
Committee on Genetics Health and Society, 2008).
To enhance accurate clinical translation of SNP associations, numerous resources 
are available to guide how biologic information can be used (Table 18). The Centers for 
Disease Control has developed and maintained HuGENet (Human Genome 
Epidemiology Network), a research database similar to The Cochrane Collaboration 
Reviews, where results of population-based gene-environment associations can be 
searched and obtained (Higgins et al., 2007; Lin et al., 2006; Seminara et al., 2007).
Launched in 2004, The Evaluation of Genomic Applications in Practice and Prevention 
(EGAPP) is an independent and multidisciplinary panel that critically evaluates evidence 
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supporting use of genomic tests in clinical practice through assessment of analytic 
validity, clinical validity, and clinical utility (Teutsch et al., 2009). Genetic test 
recommendations are available for a variety of conditions, including venous 
thromboembolism, breast cancer, and Lynch syndrome (HNPCC). Building on the 
foundations of EGAPP, The Genomic Applications in Practice and Prevention Network 
(GAPPNet) brings together more collaborative stakeholders in order to better outline and 
disseminate current knowledge; develop an evidence-based recommendation process for 
review of newly released genetics/genomics technologies; translate research into real-
world dissemination; and develop comprehensive education, outreach, and surveillance 
programs (Khoury, Feero, et al., 2009). Professional organizations are also assuming 
positions of leadership by clarifying a clinician’s role when managing patient inquiries 
about genomic profiling. For example, The American Society for Human Genetics  
issued a position statement outlining scope of clinical services that can be safely and 
legitimately provided to consumers (Hudson, Javitt, Burke, & Byers, 2007).
Diagnostics
Nurses can expect that technology-driven increases in diagnostic capacity will 
yield dramatic advancements for Personalized Medicine. Efficient diagnosis is presently 
a benchmark standard for healthcare quality and patient safety, and improved specificity 
and sensitivity for clinical decision-making is a key feature of many programs of research 
(Bissonnette & Bergeron, 2006; Dietel & Sers, 2006; Institute of Medicine, 2001; 
Snyderman & Langheier, 2006). The ability to generate and analyze enormous amounts 
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of unique biologic data is fueling three fields of clinical application: infectious disease, 
cancer, and biomarker discovery.
Infectious Disease 
In prescribing antimicrobial agents, the inability to reach a definitive clinical 
diagnosis is a significant challenge. Diagnostic certainty in treating infectious disease 
decreases patient inflammatory responses, transmission risks, and harmful exposure to 
clinicians (Bissonnette & Bergeron, 2006; Diekema et al., 2004; McGowan & Tenover, 
2004; Raoult, Fournier, & Drancourt, 2004; Tenover, 2006; The Alliance for the Prudent 
Use of Antibiotics, 2005). However, culturing of patient specimens typically requires 1-2
days for results, and until they are obtained, incorrect use of broad-spectrum prescriptive 
agents yields high pharmaceutical costs and the formation of antibiotic-resistant bacterial 
strains. 
Genomic science is revealing why it is so challenging to effectively identify 
organisms resulting in a patient’s clinical deterioration. Microbial genome sequence 
comparison shows evidence of horizontal gene transfer, resulting in enormous differences 
across and between singular pathogenic strains, shattering standard dogma of bacterial 
classification and clinical treatment (Fraser & Rappuoli, 2005). Applying these findings 
to clinical settings, it is hoped that ultra-fast sequencing of microbial genomes from 
infectious specimens can provide agent identification in 1-2 hours, versus the traditional 
culturing standard of 24-48 hours (Bissonnette & Bergeron, 2006).
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Cancer
As a professional discipline, oncology currently experiences the most clinical 
progress in working towards Personalized Medicine, where molecular tumor profiles can 
be used to correlate targeted treatment regiments. Classic examples include breast cancers 
expressing human epidermal growth factor receptor-2 protein (HER2/neu) and chronic 
myelogenous leukaemia with positive Philadelphia chromosome status. Molecular 
understanding of both conditions has yielded extraordinarily successful response rates to 
drug therapy with the monoclonal antibody Herceptin, and tyrosine kinase inhibitor 
Gleevec. These therapeutic agents target specific and clinically measurable genetic 
changes (Fischer, Streit, Hart, & Ullrich, 2003). Further expansion of molecular cancer 
profiling beyond these examples is being driven by the Cancer Genome Atlas Project (see 
above) and high-throughput screening technologies (Ludwig & Weinstein, 2005; 
Srivastava, 2006).
As with other areas of genomic scientific advancement, translation into clinical 
treatment and screening mechanisms is proving challenging. Presently, a formidable 
challenge preventing Personalized Medicine from being realized in cancer care is 
reconciling the unexpected difference between meaningful clinical diagnostic standards 
with personalized genomic tumor profiling (Ludwig & Weinstein, 2005). For example, 
genetic and genomic molecular profiles challenge current oncologic survival and 
treatment curves, necessitating redefined scoring criteria for the Tumor, Nodes, and 
Metastasis (TNM) staging system, the widely used clinical grading system for cancer 
diagnosis stratification (Lam, Shvarts, Leppert, Figlin, & Belldegrun, 2005; Leong, 2006; 
Nguyen & Schrump, 2006; Piccaluga et al., 2008). Also contributing to the translation 
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gap is the need for improved clinical research standards when validating positive 
scientific findings or performing cross-comparison analyses across different study 
populations. Spanning both research and clinical settings—differences in tumor specimen 
collection, laboratory processing and testing procedures, and clinical phenotype 
documentation are proving to be a significant source of confounding variability when 
trying to validate high-throughput genomic screening signals (Compton, 2007; 
Srivastava, 2006).
Biomarker Discovery
Nurses are widely familiar with biomarkers, or singular proteins and molecules in 
body fluids associated with diseases, as a way to facilitate personalized approaches to 
patient health. The linking of biomarkers to clinical outcome measurements presently 
represents a fruitful area of biologic research, and efforts can be classified into genetic, 
proteomic, antigen and auto-antibody classes (Srivastava, 2006). Powerful molecular 
approaches, such as microarray platforms, are fueling biomarker discovery because of 
technological ability to simultaneously evaluate thousands of molecules within and across 
numerous samples and patients (He, 2006). In the coming years, biomarkers will 
contribute greatly to Personalized Medicine by providing increasingly precise 
mechanisms of disease detection, prognostication, and therapeutic monitoring (Rai, 
2007). Presently, the technology-driven increases in data volume and precision have yet 
to replace less accurate and widely used screening tests, such as the prostate-specific 
antigen, and ovarian cancer antigen-125 tests. A chief reason for biomarker adoption 
delay is the vast amount of time and work that is required to appropriately screen and 
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validate initial findings before reliable reproducibility is obtained (Ransohoff, 2004).
Development chronology occurs over many years with five distinct basic and clinical 
research development phases: (1) preclinical discovery, (2) assay analytical validation, 
(3) case/control cohort investigation, (4) longitudinal observation, and lastly, (5) 
prospective case/control investigation (Pepe et al., 2001). Stage progression occurs in a 
“funnel” format, where initial screens of many molecules are examined and eliminated in 
order to meet rigorous specificity and sensitivity criteria, while also demonstrating 
potential for predictive capacity (Srivastava, 2006). Poor reproducibility early on 
prohibits further application and progression to clinical translation.
Pharmacogenomics
Pharmacogenomics evolved from pharmacogenetics, a field established 50 years 
ago when it was demonstrated that a person’s genetic inheritance could effect drug 
metabolism (Alving, Carson, Flanagan, & Ickes, 1956; Evans & Relling, 2004; Meyer, 
2004). Building on the pharmacogenetic paradigm of one-gene and one-drug, 
pharmacogenomics studies how numerous genes interact with each other and the 
environment (Evans & McLeod, 2003; Goldstein, Tate, & Sisodiya, 2003; R. 
Weinshilboum, 2003; R. M. Weinshilboum & Wang, 2006). Presently, pharmacogenomic 
science understands and predicts adverse reactions to medical therapeutics based upon an 
individual’s DNA sequence (Ginsburg, Konstance, Allsbrook, & Schulman, 2005; A. D. 
Roses, 2004). Pharmacogenomics is projected to have broad clinical utility in 
multifactorial diseases in order to reduce adverse drug reactions (Phillips, Veenstra, Oren,
Lee, & Sadee, 2001).
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A recent illustrative case study for Personalized Medicine is warfarin 
(Coumadin), a frequently prescribed anticoagulant. Warfarin demonstrates costly 
challenges such as limited therapeutic windows, large dosage differences across
individuals, risk for serious bleeding sequelae, inability to estimate patient drug-
responses from medical and physical criteria, and need for frequent International 
Normalized Ratio (INR) monitoring via phlebotomy (Daly & King, 2003). Traditional 
dosing factors incorporated include diet, age, gender, dietary intake, body weight, and use 
of other medications (Wadelius et al., 2007). More recently, variation in genes encoding 
the hepatic microsomal enzyme cytochrome P450 2C9 (CYP2 C9) and the vitamin K 
epoxide reductase complex 1 (VKORC1) demonstrated influence respectively on 
warfarin pharmacokinetics and pharmacodynamics (Higashi et al., 2002; Rieder et al., 
2005). Single Nucleotide Polymorphisms (SNPs) in CYP29 and VKORC1 genes 
explained 35-50% of dosage difference variability among patients—leading to 
development of a clinical genetic test for alleles resulting in altered dose requirements 
(Aquilante et al., 2006; Gage et al., 2004; Geisen et al., 2005). On August 16, 2007, the 
Federal Drug Administration (FDA) updated the warfarin label to support combined CYP
2C9 and VKORC1 genetic testing, with up to 35% of individuals benefiting from lower 
starting doses (FDA Press Conference on Warfarin Transcript, 2007).
Though the FDA’s position incorporating genomic information prior to dosing is 
indicative of movement towards pharmacogenomics in Personalized Medicine, it is not a 
formal recommendation to conduct CYP2 C9/VKORC1 genetic testing prior to 
anticoagulation. Furthermore, warfarin is the first mainstream drug for which the FDA 
provides genomic recommendations and is not yet successful from a combination
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perspective of uptake, utility, and cost perspectives. Recent warfarin genetic testing 
studies show that CYP2 C9/VKORC1 is predictive of INR level but not bleeding or 
thrombotic sequelae, and that cost effectiveness remains a key concern (Eckman, Rosand, 
Greenberg, & Gage, 2009; Millican et al., 2007; Rieder et al., 2005). As a result, Centers 
for Medicare and Medicaid Services (CMS) could not conclude from available evidence 
that warfarin pharmacogenetic testing was better than existing care coverage, and denied 
reimbursement for CYP2/C9 testing on May 4, 2009 (Jensen et al., 2009). Opening the 
door for decision reversal if clinical trials demonstrate significant and cost-effective 
clinical utility, CMS issued the decision “pursuant to Coverage with Evidence 
Development (CED).” For widespread clinical uptake in the U.S., use of the 
CYP2C9/VKORC1 genetic test (currently priced at $300-$500) in current clinical trials 
will need to demonstrate ability to affordably improve current standards of care through 
prevention of adverse bleeding and thrombotic events for CMS coverage to be issued 
(Figure 9). 
Implications and Opportunities for Nursing 
in Personalized Medicine
Personalized Medicine, or healthcare practices tailored to a person’s genetic 
make-up, is poised to enter healthcare stemming from unprecedented technology 
advances. Implementation and uptake of Personalized Medicine is presently hampered by 
lack of clinical application evidence and could benefit greatly from nursing’s patient-
focused approach. Across the four domains outlined in this paper, nurses are uniquely 
positioned to reconcile the competing perspectives of scientific innovation with practical 
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matters of clinical adoption and dissemination. The expertise of nurses across all 
research, education, and practice roles could be harnessed to address the global nature of 
the clinical translation challenges outlined thus far.  
Research
Nurse scientists and scholars presently have limitless possibilities for which to 
become involved in the translation of Personalized Medicine from research settings to 
clinical application mechanisms. For example, academic nursing leaders can evaluate 
their current research programs and integrate any number of genetics/genomics themes 
into institutional and individual grant submissions to fill recently identified priorities of 
evidentiary need (Khoury et al., 2008; Khoury, McBride et al., 2009; NIH Consensus 
Development Program, 2009). Individually, interested nurse scientists can develop 
expertise to incorporate genetics/genomics into their current programs of research (Barr 
et al.; Ersig, Williams, Hadley, & Koehly, 2009; Meilleur et al., 2009; Voss et al., 2008).
This can be done by collaborating with knowledgeable colleagues in multidisciplinary 
settings or by obtaining supplemental training to add genetic questions, outcomes, or 
markers to current scholarly efforts. Because many nurse scientists are currently most 
familiar with research incorporating the latter three Personalized Medicine domains 
(genetic risk assessment, diagnostics, and pharmacogenetics), this section will highlight 
nursing research opportunities presented by recent biologic initiatives.    
The ENCylopedia Of DNA Elements (ENCODE), 1000 Genomes Project, Human 
Microbiome Project, and the Cancer Genome Atlas represent key opportunities for nurse 
scientists to ask clinically relevant scientific questions. As nurses have long appreciated 
 213 
the uniqueness of a patient’s biologic make-up, they can empower the scientific 
community to pair clinically observed phenotypes with generated sequence data. For 
example, nurses can link newly identified genetic elements (silencers, enhancers, and 
promoters) from ENCODE with knowledge of a patient’s environment and clinical status 
to better understand, predict, or manipulate functional health outcomes in various 
diseases. From the 1000 Genomes Project, nurses can more finely search genetic data to 
select and study effects of rare genetic variants that may be responsible for biologic traits 
in their patient populations. Nursing scientists can ensure the Human Microbiome Project 
findings are translated into clinically useful tools by cross-comparing microbial sequence 
from a wide range of patients (varying health and disease states, age groups), aligning 
clinical infection measurements with microbial sequence results, developing standards for 
clinical specimen sampling protocols, identifying what quality control mechanisms are 
needed, and developing affordable models of health care access for clinical use (Bryant, 
Venter, Robins-Browne, & Curtis, 2004; Burnett, Henchal, Schmaljohn, & Bavari, 2005; 
Call, 2005; Loy & Bodrossy, 2006; Simon, 2003; Tenover, 2007). Cancer Genome Atlas 
sequence will become most useful if nurse researchers can help oncologic scientists to 
create genomic profiles that correlate meaningfully with clinical phenotype 
characteristics, such as symptom presentation and disease progression, for each tumor 
type.
Education
Because genetics and genomics science is accelerating and its impact on health is 
growing in significance, nursing educators can prepare for Personalized Medicine by 
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nurturing development of genetic/genomic expertise at their institutions and in their 
students. Nurses have been at the fore-front of genetic education initiatives for many 
years, and efforts in designing basic genetic/genomic professional competencies, 
curriculum guidelines, and nursing faculty resources are well noted (Calzone et al., 2009; 
Greco & Salveson, 2009; Jenkins & Calzone, 2007; Lewis, Calzone, & Jenkins, 2006; 
Prows, Glass, Nicol, Skirton, & Williams, 2005; Read, Dylis, Mott, & Fairchild, 2004; 
Seibert, Edwards, & Maradiegue, 2007). Cumulatively, these efforts have been so 
effective that for 2009 credentialing, the American Association of Colleges of Nursing 
has integrated the genetic competencies into three of the nine Essentials of Baccalaureate 
Education: liberal education for baccalaureate generalist nursing practice (I), clinical 
prevention and population health (VII), and baccalaureate generalist nursing practice (IX) 
(American Association of Colleges of Nursing, 2008). Despite these tremendous 
advances, a key challenge presented by Personalized Medicine will be how to best 
prepare professional nurses to move beyond single-gene concepts to that of genomics, 
where patients will need extensive help in understanding complex and probabilistic 
health information spanning multiple genes and the environment (Guttmacher, Porteous, 
& McInerney, 2007). The difficulty of this transition faces not just nursing but all 
healthcare professionals, for which the Secretary’s Advisory Committee in Genetics 
Health and Society is preparing a detailed report for the Health and Human Services 
Secretary in its 2010 Genetics Education and Training Task Force report (Secretary's 
Advisory Committee on Genetics Health and Society, 2009).
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Practice 
No other group of professional nurses will be as heavily impacted by the science 
of Personalized Medicine as clinically practicing registered nurses and advanced practice 
registered nurses. Because health promotion interventions and lifestyle management 
needs rely on genetic components of disease development, nursing clinicians are 
expected to translate genomic risk factor information into practical language for patients, 
families, and communities. Pursuant, the Essential Nursing Competencies for Genetics 
and Genomics were established in 2005 with 50 professional nursing stakeholder 
organizations endorsing minimal genetic/genomic services every practicing nurse should 
be capable of providing (Lewis et al., 2006). A similar consensus effort is currently 
underway for advanced practice nursing competencies (Seibert, Greco, & Tinley, 2009).
When applying these competencies to recent scientific findings such as the Human 
Microbiome Project, practicing nurses can appreciate that despite their patients being 
enrolled in nutritional counseling or adhering to recommended guidelines, gene-
environment effects of microbiotic floral communities may proffer great challenges to 
best clinical management efforts.
However, the most powerful translational promoter of Personalized Medicine will 
be the collaborations between nursing scientists/researchers and practicing nurses. For 
example, upon combining symptom profiles with genomic data, collaborating nursing 
teams can submit findings to scientific initiatives such as The Pharmacogenomics 
Knowledge Base (Pharmacogenomics Knowledge Base, 2009); contributing to these 
efforts will ensure understanding how a patient’s unique biology predicts response to 
medication or adherence to prescriptive requirements (Sangkuhl, Berlin, Altman, & 
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Klein, 2008). Similarly, advanced practice nurses or registered nurses who collaborate 
with molecular scientists in tertiary care settings can help guide adaptation and feasibility 
trials of molecular diagnostic tools like the 1-2 hour ultra-fast microbial sequencing 
platforms. As such, baccalaureate-prepared nurses who are interested in research, 
genetics, and the scientific process can seek clinical genetic/genomic research studies that 
are ongoing in their practice settings. For example, a motivated intensive care nurse in an 
academic research setting can quickly and powerfully organize and promote the 
sampling, recruitment, and enrollment of patients in a genomic investigation trial. The 
benefit to science from practicing nurses who work with senior scientific mentors in these 
ways is untold, and largely an untapped resource at present. 
Concluding Remarks
This paper outlines how personalization of healthcare practices will be affected 
through continued waves of scientific knowledge about how an individual’s DNA guides 
tailored healthcare interventions. Despite the presence of these opportunities and the great 
potential for improved health across the four domains, scientific initiatives outlined in 
this paper will fall short of desired outcomes without the commitment and global 
participation of the nursing community. As these technologic efforts expand and 
accelerate, it is hoped that professional nurses of all backgrounds heed this call to 
increase their practical involvement in the realization of Personalized Medicine. The 
country’s 2.9 million Registered Nurses represent a valuable and untapped resource at the 
forefront of Personalized Medicine to translate biologic findings into practical clinical 
applications. Because nurses “hold the keys” to accurate patient observation and 
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healthcare practice dissemination, they are the foremost health discipline capable of 
bringing full investment in scientific advancement to fruition—yielding advanced health 
for patients, families, and communities. 
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Table 17
Personalized Medicine Working Glossary
Term/Acronym Definition*
Allele Varying (or variant) forms of a gene at a specific location in the 
genome.  
Analytic validity Accuracy and reliability a genetic/genomic test detects a particular 
genetic characteristic.
Biomarkers Biological molecules in blood or other body fluids whose 
parameters can be associated with disease presence and severity. 
Can be detected and measured by many different methods such as 
laboratory assays and imaging technology. 
CNV Copy Number Variation; where combinations of 2-3 nucleotides 
are continually repeated in non-coding portions of the genome, i.e.: 
CACACACACACACA.
Clinical utility Degree with which a genetic or genomic test will provide benefit 
to patients after accounting for potential harms.
Clinical validity Ability of a genetic/genomic test to detect or predict a clinical 
condition or outcome.
Deletion A mutation caused by the removal of DNA from the chromosome. 
Deletions can be of any length, from one base pair to a large 
chromosomal segment (millions of base pairs). 
Enhancer Short stretch of regulatory DNA sequence that signals where 
transcription factors should bind. Enhancers modulate rate of 
transcription and can be found great distances away from the gene 
it regulates. 
Epigenetics Study of heritable differences in gene function which occur 
without changes in DNA sequence (i.e.: methylation patterns).
Exon Region of a gene encoding for a particular portion of the complete 
protein.
Gene The functional and physical unit of heredity passed from parent to 
offspring. Genes contain information for making a specific protein.




Genetic Testing Generic term for an array of techniques that analyze DNA, RNA or 
proteins for general health or medical identification purposes. 
Currently over 1200 tests are clinically available.
Genome The entirety of an individual’s genetic code, approximately 6 
billion nucleotides comprising 23,500 genes. 
Genomics Scientific study of a genome—including any or all combinations of 
genes, their functions, and their interactions with each other and 
the surrounding environment.
Genotype An individual’s 2 alleles at a specific loci. 
Haplotype Combinations of SNP alleles located close to one another on a 
chromosome. If close together, haplotypes can be inherited as units 
or blocks. 
HapMap The Haplotype Map: a map of all inherited genetic variation 
(haplotypes) in the human genome.
Heterozygous Having two different forms of a particular gene (AB).
Homozygous Having two identical forms of a particular gene (AA).
Indel An insertion/deletion polymorphism where AA, AB, BB yield:  
insertion/insertion, insertion/deletion, deletion/deletion. 
Insertion A mutation caused by the insertion of DNA from the chromosome. 
Insertions can also be of variable length (one to many base pairs).
Intron Non-coding sequences of DNA that are removed from the RNA 
transcript prior to exportation from the nucleus. 
Locus The physical location of a gene or gene segment on a chromosome. 
Loci The plural of locus. 
Methylation Chemical reactions that place a methyl group (3 hydrogen atoms
and 1 carbon atom) on the DNA nucleotide cytosine (C); presence 




Multifactorial Dx Diseases caused by interactions of numerous genes with 
environmental factors. Examples include obesity, diabetes, heart 
disease and cancer. 
Mutation Permanent and structural alteration in DNA. Most cause little, if 
any harm. If in a critical location, such as the DNA repair genes in 
BRCA 1 and 2, can cause severe disease such as early onset 
cancer. 
Negative Predictive Probability that patients with a negative genetic/genomic test result 
will
Value not get a specific disease or condition.  
Phenotype A patient’s observable clinical and physiologic characteristics as a 
result of inherited genotype interacting with their environment.
Polymorphism The existence of multiple genotypes in a population, at one locus. 
Variants are not due to mutations in DNA because they occur at a 
frequency greater than can occur by evolutionary (slow) means. 
Polymorphisms may take several forms, including SNPs, CNVs, 
and insertion/deletion (indel’s). 
Positive Predictive
Value Probability that patients with a positive genetic/genomic test result 
will get a specific disease or condition.  
Promoter Short stretch of regulatory DNA sequence that signals where 
transcription should start in a gene (for the RNA polymerase).
Sensitivity (clinical) Percent of patients with positive genetic/genomic test result that 
are correctly identified as having the defined clinical trait.
Silencer Short stretch of regulatory DNA sequence that signals where 
chromatin should become condensed. This blocks other enzymes 
from accessing the DNA strands to prevent transcription.  
Specificity (clinical) Percent of patients with a negative genetic/genomic test result that 




SNPs Single Nucleotide Polymorphism(s). The difference of a single 
base pair at a specific position in the genome between 2 different 
individuals in a population. Most are inconsequential, but if in a 
coding region, may cause changes in gene efficiency and/or 
function. 
Variant Another word for polymorphism. There are different types of 




Genetics and Genomics Scientific and Clinical Translation Resources
Resource Title Reference Websites Locations
GENERAL INFORMATION
Centers for Disease Control www.cdc.gov
Current Drug Trials www.clinicaltrials.gov/
Database of Genotype and Phenotype www.ncbi.nlm.nih.gov/sites/entrez?Db=gap
Food and Drug Administration www.fda.gov/
Genomic Careers for Students http://www.genome.gov/27538514
Gene Tests www.genetests.org/
Human Genome Epidemiology Network www.cdc.gov/genomics/hugenet/
Illumina, Personalized Genome Service http://www.everygenome.com/
NCHPEG www.nchpeg.org/
NCI’s Early Detection Research Network edrn.nci.nih.gov/
NIH www.nih.gov
NHGRI www.genome.gov/
National Office of Public Health Genomics www.cdc.gov/genomics/






American Society for Human Genetics
www.ashg.org/pdf.dtc_statement.pdf
American College of Medical Genetics
http://www.acmg.net/AM/Template.cfm?Section=Policy_Statements&Template=/CM/H
TMLDisplay.cfm&ContentID=4157
International Society of Nurses in Genetics 
http://www.isong.org/about/ps_consumer_marketing.cfm
National Society of Genetic Counselors
http://www.nsgc.org/about/position.cfm#DTC
*Direct-to-Consumer Testing and Complex Disease Management
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Figure 7. Basic Foundation of Genome Wide Association Studies.
Shown above is the basic model for Genome Wide Association Studies, where DNA 
from diseased patients is compared to healthy individuals to detect differences. Patient 
DNA is placed on a chip and millions of SNPs can be tested at once. This approach 
permits identification of genes that cannot be predicted by selecting candidates from 
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Figure 8. Age-Related Macular Degeneration: From HapMap to Clinical Trial in <5 
Years.
Age-related Macular Degeneration (AMD) is a complex and multi-factorial disease, is 
the leading cause of blindness with 1.75 million affected Americans, and is projected 
to affect 1 in 4 individuals >75 years old (R. Klein, Peto, Bird, & Vannewkirk, 2004; 
Ting, Lee, & MacDonald, 2009). In 2004-2005, researchers using HapMap identified 
a genetic variant responsible for 50% increased risk of developing AMD in the 
Complement Factor H gene (Edwards, et al., 2005; Haines, et al., 2005; R. J. Klein, et 
al., 2005). Complement Factor H is part of the inflammatory complement cascade, and 
helped lend credibility to concurrent investigations on inflammatory pathways as 
causative mechanisms of AMD, such as those involving C-Reactive Protein (Seddon, 
Gensler, Milton, Klein, & Rifai, 2004; Seddon, George, Rosner, & Rifai, 2005). These 
research efforts permitted development of prospective assessments of the role of the
contributory SNP in patients; findings validated the role of genetics and inflammation 
in AMD (Schaumberg, et al., 2006). Follow-up investigation ascertained interactive 
effects of the Complement Factor H variant with modifiable environmental risk 
factors, including Body Mass Index, smoking, regular aspirin intake, and dietary 
habits (Schaumberg, Hankinson, Guo, Rimm, & Hunter, 2007). This culminated in the 
formation of a large, randomized, controlled clinical trial enrolling 4,757 patients from 
11 medical centers (M. L. Klein, et al., 2008). The multi-disciplinary collaborative 
effort, “The Age Related Eye Disease Study”, ascertained pharmacogenetic effects of 
treatment with zinc and antioxidant supplements according to SNP genotypes, one of 
which being in the Complement Factor H gene. 
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Figure 9. The Pharmacogenomic and Policy Implications of CYP 2C9 and VKORC1 
Genetic Testing. 
Despite strong scientific genetic evidence of efficacy, warfarin classically 
demonstrates the systematic, structural, and clinical evidentiary challenges awaiting 
pharmacogenomics in Personalized Medicine (Phillips & Van Bebber, 2006). Because 
tests must demonstrate high predictive value for adverse events, metabolically 
accurate dosing ranges and treatment effects will need to be established according to 
allele prevalence in populations (Smits et al., 2005). Study designs specific to 
population genetics do not reflect current standards for FDA drug evaluation and 
approval, where criteria are dependent upon 20th century infrastructure and 
measurements (Califf, 2004; Haga, Thummel, & Burke, 2006; Woodcock, Witter, & 
Dionne, 2007). Moving forward, a key concern is that randomized clinical trials 
cannot account for genomic variability across study participants, or clearly delineate 
patient groups per genetic responses to pharmaceutical agents. Common approaches to 
address the issue involve patient stratification according to race or ethnicity, but 
question of appropriateness is necessary as genetics research identifies serious flaws 
in these categories (Bamshad, Wooding, Salisbury, & Stephens, 2004; Doyle, 2006; 
Foster & Sharp, 2002; Lee, 2007). To better account for biotechnologic advancement, 
many proposals call for overhauled federal regulatory networks allowing improved 
focus on pharmacogenomic clinical research including: synchronized payment 
systems; genetic/genomic education for patients and healthcare providers; and clinical 
care focusing on an individual’s dynamic probability for disease development (Califf, 
2004). What may achieve this most quickly is integration across government networks 
to form clinically accurate, large-scale, prospective observational cohorts (A. Roses, 
2007).
A barrier to large-scale clinical genetic research efforts is reluctance in wholly 
embracing research efforts, stemming from public fears of genetic discrimination. To 
better address these concerns, the Genetic Information Non-discrimination Act was 
passed in 2008. This legislation guarantees basic protection for individuals receiving 
genetic testing, so that they are protected against employer and health insurance 
discrimination practices (Slaughter, 2008). Limitations of the legislation are that it 
does not protect individuals from discrimination in the military or for long term care 
coverage determinations, in addition to considerations that the legislative language is 
not specific enough regarding what is considered a “genetic test” (Baruch & Hudson, 
2008; McGuire & Majumder, 2009).
   
CHAPTER 7
CONCLUSIONS
Summary of Dissertation Research and Its Scientific Context
The overarching intent of the work performed in this dissertation research was to 
“bridge” seemingly disparate disciplines and worlds. As exemplar to this inspired path, 
the problem of clinical heterogeneity observed in cobalamin deficiency of older adults 
was investigated using genetic technology through a behavioral lifespan lens—a common 
perspective in nursing research. The theoretical underpinnings of vitamin B12 as a health 
concern extend back to the early 1800s from simple observations of confounding clinical 
trajectories that resulted in tragic loss of life. Three Nobel prizes were issued to 
individuals able to solve intricately complex puzzles of nature, permanently improving 
morbidity and mortality for all humankind. Collectively, as science continued its forward 
movement, the age of molecular genetics produced ability to clone cobalamin-related 
genes and manipulate model organisms for more sophisticated awareness of why 
cobalamin is an essential nutritional requirement. 
Despite these tremendous and storied advancements, there is still not a clear 
understanding as to why certain individuals are severely affected by small changes in 
cobalamin status, while others remain completely unaffected. Not all “low” serum 
cobalamin and metabolite test results paint the clinical picture of deficiency, and not all
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“normal” test results indicate that metabolic sufficiency is present (Carmel 2000; Carmel 
et al., 1999). Clinical signs alone cannot be the only metric, as severe metabolic crises 
can occur in their absence and may be reversible with supplemental therapy (Carmel et 
al., 1995; Carmel, Sinow, & Karnaze, 1987).
Study Context Within Broader Literature Base
The overarching hypothesis of this dissertation research was that there exists a 
genetic basis to the phenomenon of clinical heterogeneity observed in cobalamin 
deficiency affecting older adults. The use of a well-characterized and measured 
phenotype is instrumental in exploring genetic associations; otherwise, carefully 
generated genetic data are at risk of being spurious or meaningless upon combination 
with clinical data. Use of the Women’s Health and Aging Study Cohorts (WHAS) 
permitted examination of a sophisticated combination of clinical traits that either would 
not have been possible, or at the very least, quite costly to prospectively collect the 
amount and type of data used in this study. 
Although the WHAS 1 and 2 publications on physical disability trajectories are 
widely known and number into the several hundreds, linking the original WHAS data to a 
genetics focus is not nearly as common. For genetic researchers that have realized that 
carefully catalogued phenotypes are contained within these extraordinary epidemiologic 
research initiatives, genetic-focused analyses have been performed. Walston and 
colleagues examined the role of genetic variation in the interleukin-6 gene and its 
relationship with circulating inflammatory biomarkers, and muscle, weakness, and frailty 
measurements in WHAS 2 subjects (Walston et al., 2005). Seibert and colleagues 
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examined polymorphic variation in the human myostatin (GDF-8) gene and its 
relationship with various strength measures in WHAS 1 and WHAS 2 participants to 
ascertain a genetic basis of skeletal mass decline (Seibert, Xue, Fried, & Walston, 2001).
And recently, genome-wide association studies were undertaken to evaluate the effect of 
genetic variation in iron metabolism genes on serum iron concentrations in WHAS 1 and 
2 subjects (Tanaka et al., 2010).
However, the most closely relevant effort to the dissertation research has been the 
recent work by Matteini et al. in evaluating the WHAS 1 and 2 cohorts for susceptibility 
to frailty through study of genetic variation in one-carbon metabolism genes (Matteini et 
al., 2008; Matteini et al., 2010). In the 2008 and 2010 reports, SNPs from vitamin B12
candidate genes were selected, genotyped, and analyzed for their relationship with serum 
methylmalonic acid and frailty syndrome. Frailty syndrome was characterized as WHAS 
participants having at least 3 of the 5 following indicators: slow walking speed, weak 
hand grip strength, decreased energy level, decreased body mass, and low physical 
activity. Although the dissertation results corresponded to Matteini’s findings of no SNPs 
being associated with methylmalonic acid, data related to the physical performance of the 
WHAS 1 and 2 participants was somewhat divergent. For example, rs2267163 (in intron 
5) was found to have significant association with frailty syndrome according to Matteini 
and colleagues. In the dissertation study, neither rs2267163 nor the SNPs in close 
proximity to it were significantly associated with the continuous functional performance 
outcomes, hand grip strength and walking speed. Instead, a small cluster of several SNPs 
in the five prime region of the gene (intron 1-intron 3) were identified as being 
significant. 
 245 
Reasons for these differing results may lie in the varying analytic approaches used 
and the population sample differences between the research efforts. Whereas this 
dissertation study directly analyzed continuous traits of WHAS participants in analyses of 
variance and covariance, Matteini and colleagues collapsed five different continuous 
physical performance measurements (walking speed, hand grip strength, energy level, 
body mass, and physical activity) into dichotomous outcomes (slow, weak, decreased 
energy, decreased muscle density, low activity) to create a ‘frail’ profile before entering 
them into multivariate logistic regression models. 
Additionally, because Matteini’s genotyping used the Illumnia BeadArray 
genotyping technology, analysis was restricted to WHAS 1 and 2 subjects with ample 
remaining amounts of native genomic DNA for chip typing requirements (i.e., at least 
100 ng). As a result, the final sample size available for analysis was n = 326 Caucasian 
and n = 90 African American subjects, representing 35.6% of the total 1,167 WHAS 1 
and 2 subjects who consented to phlebotomy. Furthermore, results are only reported for 
Caucasian subjects since African Americans were too underpowered to detect any effects, 
yielding a final sample size that was 27.9% of the initial WHAS 1 and 2 subject pool who 
had blood samples drawn. Because the dissertation used whole genome amplification to 
augment remaining genomic material, many more WHAS 1 and 2 subjects’ DNA were 
able to be analyzed than in Matteini’s reports. Furthermore, use of two-way analysis of 
variance and covariance in the dissertation study permitted evaluation of SNP effects 
across all 789 African Americans and Caucasian WHAS subjects collectively, which 
provided greater statistical power in assessing presence and impact of genetic differences. 
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Study Rationale
The broader goals of WHAS 1 and 2 research initiatives are to identify which 
functional determinants may (or may not) contribute to physical disability, the frailty 
syndrome, and the development of comorbidities in older adults (Fried, Ferrucci, Darer, 
Williamson, & Anderson, 2004). Availability of genetic data greatly enhances the 
biologic understanding of these processes. Thus, the dissertation aims of evaluating 
genetic variation in the transcobalamin II and transcobalamin II-receptor genes on 
cobalamin deficiency parameters in WHAS subjects were selected to better understand 
factors leading to poorer health status in aging individuals. 
Ascertaining biologic correlates to functional determinant outcome measures has 
been a fruitful area of WHAS research. For example, several WHAS 1 and WHAS 2 
studies outline a variety of biologic, socio-demographic, and psychologic factors that 
affect the dissertation’s functional performance outcomes, hand grip strength and walking 
speed. Presence of reactive oxygen species in skeletal muscle, as measured by serum 
protein carbonyls, was independently associated with poor hand grip strength (Howard et 
al., 2007). Hand grip strength measurements were shown to be significant predictors of 
cardiovascular disease, respiratory disease, and total mortality for up to 5 years (Rantanen 
et al., 2003). Decreased serum insulin-like growth factor-I and elevated serum 
interleukin-6 concentrations were associated with slower walking speeds (Cappola et al., 
2003). Tobacco smoking and cognitive decline were found to affect physical decline 
trajectories, including walking speeds, independent of potential confounders (Atkinson et 
al., 2005). And lastly, although presence of pain did not predict walking difficulties for 
WHAS subjects, report of widespread musculoskeletal pain was found to be associated 
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with onset and deterioration of walking capacity (Leveille, Bean, Ngo, McMullen, & 
Guralnik, 2007). Similar to these published efforts, the dissertation study was designed to 
better identify those biologic factors contributing to functional impairment and decline of 
health status across cobalamin-related outcomes in WHAS 1 and 2 subjects.     
The Dissertation’s Candidate Genes
Transcobalamin II and the transcobalamin II-receptor were candidate genes 
selected from a careful evaluation of cobalamin pathophysiology in humans. In selecting 
both, they represented the system of serum transport and target cell uptake for all 
biologically active cobalamin in the body, and thus the “least common denominator” that 
could provide the most information about an individual’s clinical deficiency from a 
genetic perspective. The transcobalamin II-receptor gene was only recently identified, the 
protein purified and structure elucidated (Quadros, Nakayama, & Sequeira, 2009). Until 
this time, very little information on the transcobalamin II-receptor was available in public 
databases and published reports. At the time of dissertation writing, no information 
existed about the contribution of genetic variation in the transcobalamin II-receptor gene 
to clinical conditions affecting humans. Thus, the dissertation research is the first 
examination of association between transcobalamin II-receptor genetic variation and 
clinical outcomes in individuals. Knowledge obtained from the dissertation contributes to 
a better understanding of the importance of this candidate gene to human health, while 
also generating more focused targets for functional laboratory analyses. Understanding 
which part of the transcobalamin II-receptor gene yields increased cobalamin uptake for 
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certain individuals as compared to others may enhance clinical care treatments and help 
prevent deficiency from occurring. 
There were also other interesting genes considered for evaluation, had the 
dissertation study been adequately powered to investigate more genes. Other possible 
candidates included intrinsic factor (the molecule pairing with dietary cobalamin in the 
duodenum) and its receptor on ileal enterocytes. Representing a ‘class’ of targets are the 
cobalamin-cofactor synthesis groups, nicknamed “cbl.” After the transcobalamin II-
receptor endocytoses cobalamin into a lysosome, the cobalamin is shuttled through a 
series of cytoplasmic cbl compartments where chemical reactions prepare cobalamin for 
use in the mitochondria or cytoplasm (Coelho et al., 2008). There are eight cbl 
complementation groups (cblA, cblB, cblC, cblD, cblE, cblE, cblF, cblG, cblH), and 
candidate selection of cbl groups responsible for intracellular trafficking to the cytoplasm 
(cblF, cblC, or cblD) or mitochondria (cblD, cblA, or cblB) would also have been 
meaningful candidates for investigation. 
The Dissertation’s Cobalamin-Deficiency Phenotype Traits
Selection of the phenotype characteristics representative of cobalamin deficiency 
was undertaken with the intent to strike a balance between the classic “hallmarks” and the 
chronic, subtle “preclinical” symptoms. Hemoglobin concentrations, mean corpuscular 
volumes (MCV), and the biochemical assays including serum cobalamin, methylmalonic 
acid, and total homocysteine are all regularly utilized components in deriving a clinical 
diagnosis of cobalamin deficiency (Beck, 2001). However, subtle signs of cobalamin 
deficiency, such as mood and sleep alterations, gait disturbances, peripheral insensitivity, 
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and fatigue, also accompany the subclinical metabolic definitions that are yielding higher 
prevalence rates identified in older adult populations (Carmel, 2000). It was important for 
the dissertation research to include assessment of quantitative traits that included these 
subclinical aspects of the cobalamin deficiency trajectory, including depression, 
peripheral insensitivity, physical strength, and walking capacity. That being noted, these 
outcomes were objective measurements of biological and physical traits. It also would 
have been interesting to explore the genetic basis of subjective phenomena that is 
associated with cobalamin deficiency, such as fatigue symptoms and perceived quality of 
life.
Biochemical Metabolites
The first data-based paper in this dissertation ascertained if genetic variation in 
the transcobalamin II and transcobalamin II-receptor gene was associated with any of the 
biochemical parameters traditionally used in making a clinical diagnosis of cobalamin 
deficiency. Results identified two significant genetic variants that were very promising 
for future research, because they were both located in genetic positions responsible for 
amino acid changes. The first coding variant, rs2336573, in exon 4 of the transcobalamin 
II-receptor gene, encodes an arginine to glycine switch (R220G) and was associated with 
serum cobalamin after adjusting for creatinine clearance. The second coding variant, 
rs9621049, in exon 7 of the transcobalamin II gene (F348S), was associated with 
homocysteine concentrations after adjusting for creatinine clearance, serum folate, and 
serum cobalamin.
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In evaluating the transcobalamin II-receptor genotype group differences of 
rs2336573, even though none of the mean serum cobalamin values were “low,” there was 
a 112-115 pmol/L difference between the CC genotype and the other genotype groups. 
However, measurement of serum cobalamin reflects not just the biologically active B12 
in the circulation that is bound to transcobalamin II, but also includes the longer 
circulating bound forms, transcobalamin I and III (20-30 days). Since approximately 80% 
of serum cobalamin measures the cobalamin attached to transcobalamin I and III, it is not 
clear how much different forms of the transcobalamin II-receptor on cell surfaces would 
impact serum cobalamin levels. Additional research efforts should analyze the 
association of rs2336573 with measures of holotranscobalamin, the fraction of B12 that is 
only bound to transcobalamin II. In doing so, there would be a more direct biologic link 
between SNP influence, substrate availability in serum, and uptake capacity by the 
receptor on the cell surface. 
The second key biochemical finding was the association between rs9621049 in 
the transcobalamin II gene with homocysteine concentration. There were significant 
differences between the three genotype groups independent of race. Three percent of 












cobalamin deficiency in tissues, may be a risk factor for development of cardiovascular 
diseases and occurrence of thrombotic events (Arnesen et al., 1995; Boushey, Beresford, 
Omenn, & Motulsky, 1995; Selhub et al., 1995). However, this link is not well 
understood, since recent randomized evaluation of folic acid and vitamin B12 
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supplementation versus placebo on blood homocysteine concentration did not have any 
effect on preventing myocardial infarction outcomes (Study of the Effectiveness of 
Additional Reductions in Cholesterol and Homocysteine Collaborative Group, 2010).
The broader significance of the associations observed for these two genetic 
variants is not clear. The measured partial eta effect sizes, at 0.01 for rs2336573 and at 
0.015 for rs9621049, are very small—indicating that the effect on biochemical parameter 
means approaches 1%. This effect is typical compared to other phenotype 
characterizations of complex traits demonstrating both environmental and genetic 
components, and illustrates the difficulty of ascertaining meaning from genetic variability 
observed across individuals.  
Clinical Parameters
The second data-based paper in this dissertation ascertained if genetic variation in 
the transcobalamin II and transcobalamin II-receptor gene was associated with any of the 
hematologic, neurologic, and functional performance parameters that comprise some of 
the clinical assessments and symptoms indicative of cobalamin deficiency. Results 
identified one significant coding variant in the transcobalamin II gene associated with 
mean corpuscular volume (MCV), and second, a genomic region of interest in the 
transcobalamin II gene associated with hand grip strength and walking speed. 
The first finding identified was differences in MCV by rs1801198 SNP allele. 
This SNP is a coding polymorphism encoding a proline to arginine switch at position 259 
(P259R) in exon 6 of the transcobalamin II gene and demonstrated a significant 
interaction effect after adjusting for folate status. In African American WHAS elderly 
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women, GG homozygotes had the lowest mean MCV of 86.1 fL, compared to CG (91.4 
fL) and CC (90.1 fL) genotype groups. The reason for this result is not clear; there is no 
published research on the effect of transcobalamin II genetic variation on hematologic 
traits such as MCV. Although it is widely known that there is a race effect for the 
hematological traits, MCV and hemoglobin, the reasons for this difference cannot 
currently be explained by socio-economic differences, and genetic reasons for this 
possible difference are just beginning to be explored. While values for MCV are at 
physiologically lower levels for African American as compared to their Caucasian 
counterparts, the large difference found in this dissertation study suggests a biologic 
influence from rs1801198 occurring within the African American group only. 
The second finding was the identification of a cluster of significant SNPs in the 
five prime (front end) of the transcobalamin II gene with the physical performance 
measures, hand grip strength and walking speed. Singularly, none of these SNPs on their 
own were highly significant, but that they were clustered within a specific region of one 
gene and associating only with the strength-related outcome measures is intriguing. 
Because of the high assay dropout stemming from working with whole genome amplified 
material (of genomic DNA that was 16-18 years old) the analysis for this research 
conducted a series of independent association tests, and the significance obtained from 
each SNP was relatively muted. However, reperforming the analyses in blocks of SNPs 
that are inherited together could likely produce a signal for this region that is more 
intense. If the signal obtained in the dissertation research is found to be true after further 
validation, this would mean that elderly patients with specific transcobalamin II allelic 
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combinations may be predisposed to experience physical weakness and slowness 
compared to others. 
Dissertation Research Limitations and Future Research
The most significant shortcoming of this research is the inability to completely 
“tag” both the transcobalamin II and transcobalamin II-receptor genes with full genetic 
coverage. Due to the difficulty of working with whole genome amplified material from 
DNA that was 16-18 years old, there was a tremendous amount of assay loss that resulted 
in an inability to analyze SNPs in heredity blocks as they occur on the chromosome, also 
called “haplotype blocks.” 
Although the counter-measure to this was to independently analyze SNPs 
singularly, great loss of power to detect significant loci in WHAS subjects was the cost of 
running many tests. But as the clustered findings of the functional performance 
parameters indicate, the analyses are not independent, making the Bonferroni adjustment 
an especially restrictive and overly stringent corrective mechanism. Furthermore, the fact 
that many singular tests were run in linked areas of the genome, it is likely that existing 
signals found in this dissertation research would be greatly amplified upon performance 
of a haploblock analysis. Because of poorly performing assays, regenotyping WHAS 
whole genome amplified material will not be able to fill existing holes in blocks of the 
two candidate genes to produce the required coverage. Other alternatives to validating the 
signals obtained in this dissertation include 1) imputation of population-specific reference 
genotypes from HapMap, and 2) transitioning efforts to another adult cohort with similar 
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clinical measurements but with better genomic DNA quality, and genotype selected 
transcobalamin II, transcobalamin II-receptor SNPs.    
As with any candidate gene association study, positive findings (even if validated 
in independent cohorts) do not yield information about molecular mechanism or 
causality. Although knowledge of association can provide increased understanding of 
how genetics may be involved with a clinical phenotype, it cannot answer the question as 
to whether a SNP with functional effects results in a disease or health status changes. 
Additional studies involving different methodologic and laboratory approaches would be 
required to address the issue of causation. Despite the genotyping shortcomings and the 
inferential methodologic limitations, this dissertation research provides several 
hypothesis-generating genetic variants to evaluate in further cohorts of elderly adults. If 
validated, these variants may become meaningful targets for laboratory research to better 
understand their functional consequences and lay the foundations for future translation 
into clinical interventions.
A second limitation to this study is that analyses were conducted without 
adjusting for all of the environmental factors known to impact B12 nutrition in older 
adults. For example, Chapter 2 indicated numerous medications (antiepileptic agents, 
proton pump inhibitors, histamine receptor antagonists, the antidiabetic drug metformin, 
antibiotics, and cholestyramine) and comorbid conditions (intestinal diseases, gastric or 
ileal resections, alcohol intake, smoking, diabetes mellitus, and lymphoma) known to 
affect cobalamin nutritional status and deficiency parameters (Wolters, Strohle, & Hahn, 
2004).
 255 
The overarching reason that many of these factors were not incorporated into the 
dissertation analysis is that accounting for them as covariates would have consumed 
further statistical power. As frequencies in African American and Caucasian genotype 
subgroups were low for many SNPs, the genetic effects being studied accounted for a 
small percentage of variance in each outcome trait, and many outcome variables were 
already being analyzed with two and three covariates—including additional medications 
and comorbidities would have further decreased statistical power to detect changes in 
study outcomes due to genetics. Because the research advantages of their inclusion could 
not offset the decrease in statistical power that would have occurred, they were not taken 
into account. Further validation efforts should aim for a sample size that is large enough 
to fully account for environmental factors such as medication use and comorbid 
conditions.
A third concern regarding this work is that the use of WHAS, despite all the 
advantages and strengths it carries in performing genetic research, could possibly be 
limiting. WHAS and similar aging research initiatives from the National Institute on 
Aging constitute the “state of the science,” and many citations in this dissertation look to 
the precedent that was set by these landmark efforts. Unfortunately, this carries a risk of 
sampling error being built into the knowledge base, in that previous WHAS findings are 
driving further research conducted in the WHAS cohorts. 
However, the issue of clinical heterogeneity in cobalamin deficiency of older 
adults, as reported by multiple non-WHAS sources in Chapter 2, is a distinctly separate 
and significant problem. As little genetic research has been published regarding the 
WHAS participants and genetic contributors to vitamin B12 deficiency were gaining in 
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their health significance for older adults, this dissertation represented a unique research 
opportunity and a valuable learning experience.     
The final limitation of this research is that it was a secondary data analysis of pre-
existing studies (WHAS 1, 2). Although it added new information to the field through the 
generation of candidate-gene SNP genotypes, the analysis of selected outcome 
measurements and covariates in this study was limited to what data was available. 
Already mentioned is that use of serum cobalamin is not a direct measurement of 
biologically active cobalamin, the fraction of vitamin B12 that is bound to the 
transcobalamin II molecule. Serum “holotranscobalamin” measurements, cobalamin 
bound to transcobalamin II, were unavailable for WHAS subjects. This limitation made 
inference about how a genetic variant may be exerting a biologic effect (i.e., on serum 
metabolites) more difficult.      
Implications for Leadership and Policy
Using the knowledge of biologic diversity provided through resources such as the 
Human Genome Project and the Haplotype Map, genomics research is unraveling 
complexities of chronic diseases in humans (Hindorff et al., 2009; Manolio, Brooks, & 
Collins, 2008). Without the ability to translate these findings into clinically relevant and 
meaningful tools that can be practically applied to patient care settings, many of these 
technologic breakthroughs will remain limited to the halls of science where they were 
conceived. The dissertation research was undertaken with an overarching interest in 
bridging these seemingly disconnected worlds. However, simply performing the research, 
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without effort of broader education or outreach, would not help facilitate true 
understanding between the worlds of nursing research and genomic science. 
Chapter 6, the final manuscript of this dissertation, reflects an exercise in 
academic nursing leadership. The effort was undertaken to highlight the opportunities in 
genetics/genomics for nurses to advance human health through the adoption and 
utilization of Personalized Medicine. Policy, research, education, and practice 
implications were addressed in order to provide a bridge between the genetic 
technologies used in Chapters 4 and 5’s research, and what nurses from varying settings 
may expect upon seeing the same technologies in their local healthcare settings. For 
nurses who are able to incorporate and implement these incredible tools, significant 
groundwork will be laid for sound health policy derivation and widespread health benefit 
for patients, families, and communities. 
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APPENDIX A
WHOLE GENOME AMPLIFICATION FOR DISSERTATION 
Scientific Protocol for Qiagen REPLI-g Midi Kit (Product #150045_100)
Reagents:
Microcentrifuge tubes Pipetes and pipet tubes




Prepare Buffer DLB by adding 500 ul nuclease-free water to the tube. Mix 
thoroughly and centrifuge briefly. Reconstituted buffer DLB can be stored for 6 
months at -20 degrees C. Buffer DLB is pH-labile. Avoid neutralization with 
CO2. All buffers and reagents should be vortexed before use to ensure thorough 
mixing. Set heating block to 30 degrees C.
Protocol:
1. Prepare a sufficient amount of Buffer D1 (denaturation buffer) and Buffer N1 
(neutralization buffer) for the total number of whole genome amplification 
reactions.
Preparation of Buffer D1:
Reconstituted Buffer DLB 5.0 ul
Nuclease-free water 35.0 ul 
Total 40.0 ul (for 7 reactions)
Preparation of Buffer N1:
Solution B (stop solution) 8.0 ul
Nuclease-free water 72.0 ul
Total 80.0 ul (for 7 reactions)
2. Place 5.0 ul of template DNA into a microcentrifuge tube.
3. Add 5.0 ul of Buffer D1 to the DNA. Mix by vortexing and centrifuge briefly. 
4. Incubate the samples at room temperature for 3 minutes.
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Scientific Protocol for Qiagen REPLI-g Midi Kit (Product #150045_100)
1. Add 10.0 ul of Buffer N1 to the samples. Mix by vortexing and centrifuge 
briefly. 
2. Thaw REPLI-g DNA polymerase on ice. Thaw all other components at room 
temperature; vortex then centrifuge briefly.
7.  Prepare a master mix on ice. Mix and centrifuge briefly. 
Preparation of Master Mix:
REPLI-g Mini Reaction Buffer 29.0 ul
REPLI-g Mini DNA Polymerase 1.0 ul (for 1 reaction)
8. Add 30 ul of master mix to 20 ul of denatured DNA. 
9. Incubate at 30 degrees C for 10-16 hours. The maximum DNA yield is 
achieved using an incubation time of 16 hours. 
10. Inactivate REPLI-g DNA Polymerase by heating the sample for 3 minutes at 
65 degrees C.
11. Store amplified DNA at 4 degrees C for short-term storage or -20 degrees C 
for long-term storage. 
 
   
APPENDIX B
MANUAL GENOTYPE CALLING OF WHOLE
GENOME AMPLIFIED MATERIAL 
Parameters for Manual Calling in Typer 4.0
1. No signals under log/height arc threshold of .25 are called. 
2. No use of “lasso” function to manually change multiple calls simultaneously; 
spectra of each call must be individually inspected for accuracy. If inaccurate, 
change to No Call, save file, and issue recall.  
3. Spectral peaks of all “aggressive” calls at bleed-border edge of 
heterozygote/homozygote cluster overlap regions are inspected to ensure they are 
accurately heterozygous or homozygous.
4. Low-probability calls can be made manually if they are not located in red or 
yellow wells.
5. Peaks in yellow and red wells can be called as long as using parameter guidelines.  
6. Inspect spectral peak and log/height scatter plot to assess the following:
a. On the spectra, where is the Unexpected Primer (UEP) in relation to the 
expected SNP allele? 
i. If UEP difficult to visualize and separate from allele peak = No 
Call
ii. If UEP is distinctly separate and visible = Call
b. On the spectra, where does the midline of the call’s peak lie in relation to 
the expected allele mass?
i. If midline of peak is not present at expected allele mass = No Call
ii. If midline of peak is present at expected allele mass = Call
c. On the spectra, what is the amplitude of a candidate peak in relation to the 
underlying baseline? 
i. If difficult or impossible to distinguish from baseline = No Call
ii. If candidate peak can be is noticeably higher or distinguishable 
from baseline = Call
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Parameters for Manual Calling in Typer 4.0
a. On the log/height plot, how far away is the candidate call from the closest 
cluster of calls? 
i. If far away from cluster = No Call; or conservatively follow 
parameter 6a through c.  
ii. If within or close to existing cluster = Call
b. On the log/height plot, is the candidate call within a region of cluster bleed 
border overlap?
i. If yes = No Call; or conservatively follow parameter 6a through c.
ii. If no = Call according to 6d.
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Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs16988828 M SD N
African American GG 12.60 0.84 4
GA 12.34 1.26 35
AA 12.33 1.52 132
Total 12.34 1.45 171
Caucasian GG 13.05 1.60 10
GA 13.22 1.27 84
AA 13.32 1.24 431
Total 13.30 1.25 525
Total GG 12.92 1.41 14
GA 12.96 1.33 119
AA 13.09 1.37 563
Total 13.06 1.36 696
TCN2_rs7289549 M SD N
African American CC 12.29 1.39 18
CG 12.27 1.66 60
GG 12.35 1.33 98
Total 12.32 1.45 176
Caucasian CC 13.19 1.44 11
CG 13.28 1.15 88
GG 13.30 1.26 436
Total 13.29 1.25 535
Total CC 12.63 1.46 29
CG 12.87 1.46 148
GG 13.12 1.32 534




Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs7286107 M SD N
African American CC 12.85 1.07 11
CT 12.10 1.64 54
TT 12.37 1.35 110
Total 12.32 1.44 175
Caucasian CC 13.73 0.93 3
CT 12.10 . 1
TT 13.30 1.25 535
Total 13.30 1.24 539
Total CC 13.04 1.08 14
CT 12.10 1.62 55
TT 13.14 1.31 645
Total 13.06 1.36 714
TCN2_rs9606756 M SD N
African American GG 12.22 0.97 9
GA 12.32 1.20 44
AA 12.34 1.55 123
Total 12.33 1.44 176
Caucasian GG 13.87 1.21 26
GA 13.58 1.05 80
AA 13.19 1.26 430
Total 13.28 1.25 536
Total GG 13.45 1.36 35
GA 13.13 1.26 124
AA 13.00 1.38 553




Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs740234 M SD N
African American CC 13.17 0.67 3
TC 12.59 1.18 29
TT 12.25 1.50 144
Total 12.32 1.45 176
Caucasian CC 13.15 1.17 34
TC 13.28 1.27 150
TT 13.31 1.26 355
Total 13.30 1.25 539
Total CC 13.15 1.13 37
TC 13.17 1.27 179
TT 13.01 1.42 499
Total 13.06 1.37 715
TCN2_rs35915865 M SD N
African American CC 13.80 . 1
CT 14.15 1.20 2
TT 12.31 1.44 174
Total 12.34 1.45 177
Caucasian CC 13.02 0.56 4
CT 13.28 0.98 19
TT 13.29 1.26 518
Total 13.29 1.25 541
Total CC 13.18 0.60 5
CT 13.36 1.00 21
TT 13.04 1.38 692
Total 13.05 1.36 718
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs11703570 M SD N
African American AA 12.77 1.02 12
AT 12.40 1.26 46
TT 12.29 1.55 115
Total 12.35 1.45 173
Caucasian AA 12.98 1.51 42
AT 13.16 1.21 143
TT 13.37 1.22 349
Total 13.28 1.25 534
Total AA 12.93 1.41 54
AT 12.98 1.27 189
TT 13.10 1.39 464
Total 13.05 1.36 707
TCN2_rs35838082 M SD N
African American TT 13.08 1.21 9
CT 12.18 1.71 51
CC 12.34 1.33 115
Total 12.33 1.45 175
Caucasian CT 13.60 0.81 7
CC 13.28 1.25 536
Total 13.29 1.25 543
Total TT 13.08 1.21 9
CT 12.35 1.69 58
CC 13.12 1.32 651




Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2267163 M SD N
African American TT 11.77 1.92 13
TC 12.32 1.69 55
CC 12.37 1.23 104
Total 12.31 1.45 172
Caucasian TT 13.39 1.08 120
TC 13.32 1.29 211
CC 13.28 1.22 194
Total 13.32 1.22 525
Total TT 13.23 1.27 133
TC 13.11 1.44 266
CC 12.96 1.30 298
Total 13.07 1.35 697
TCN2_rs1801198 M SD N
African American GG 12.02 1.90 15
CG 12.30 1.65 63
CC 12.39 1.23 97
Total 12.33 1.45 175
Caucasian GG 13.36 1.09 130
CG 13.28 1.32 236
CC 13.26 1.26 176
Total 13.29 1.25 542
Total GG 13.22 1.26 145
CG 13.07 1.45 299
CC 12.95 1.31 273
Total 13.06 1.36 717
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820021 M SD N
African American AT 12.32 1.56 6
TT 12.33 1.44 173
Total 12.33 1.44 179
Caucasian AA 13.50 1.33 14
AT 13.40 1.32 87
TT 13.28 1.22 434
Total 13.31 1.24 535
Total AA 13.50 1.33 14
AT 13.33 1.35 93
TT 13.01 1.35 607
Total 13.06 1.36 714
TCN2_rs9621049 M SD N
African American TT 12.38 0.90 6
CT 12.23 1.27 44
CC 12.36 1.52 128
Total 12.32 1.44 178
Caucasian TT 13.14 1.81 14
CT 13.58 1.12 92
CC 13.25 1.26 431
Total 13.30 1.26 537
Total TT 12.91 1.61 20
CT 13.14 1.32 136
CC 13.04 1.37 559
Total 13.06 1.37 715
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820886 M SD N
African American GG 12.12 1.00 4
GT 12.25 1.29 43
TT 12.33 1.51 129
Total 12.31 1.44 176
Caucasian GG 13.38 0.83 12
GT 13.59 1.25 93
TT 13.23 1.24 433
Total 13.30 1.24 538
Total GG 13.07 1.01 16
GT 13.16 1.41 136
TT 13.02 1.36 562
Total 13.05 1.36 714
TCN2_rs4820887 M SD N
African American AA 11.10 0.00 2
GA 12.33 1.08 23
GG 12.33 1.51 149
Total 12.32 1.45 174
Caucasian AA 13.67 1.28 9
GA 13.57 1.23 78
GG 13.23 1.24 446
Total 13.29 1.25 533
Total AA 13.20 1.55 11
GA 13.29 1.30 101
GG 13.00 1.37 595
Total 13.05 1.36 707
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820888 M SD N
African American GG 12.71 1.12 37
AG 12.15 1.57 83
AA 12.30 1.40 57
Total 12.32 1.44 177
Caucasian GG 13.02 1.30 123
AG 13.32 1.27 222
AA 13.44 1.17 191
Total 13.29 1.25 536
Total GG 12.95 1.26 160
AG 13.00 1.46 305
AA 13.18 1.31 248
Total 13.05 1.37 713
TCN2_rs2301955 M SD N
African American TT 12.81 1.17 15
CT 12.30 1.27 67
CC 12.26 1.60 94
Total 12.32 1.45 176
Caucasian TT 13.04 1.30 117
CT 13.30 1.28 215
CC 13.43 1.16 212
Total 13.29 1.24 544
Total TT 13.01 1.28 132
CT 13.06 1.34 282
CC 13.07 1.42 306
Total 13.06 1.36 720
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2301958 M SD N
African American CC 12.71 1.03 9
CG 12.29 1.29 55
GG 12.30 1.54 114
Total 12.32 1.44 178
Caucasian CC 13.02 1.64 31
CG 13.22 1.25 164
GG 13.37 1.20 351
Total 13.31 1.25 546
Total CC 12.95 1.52 40
CG 12.98 1.32 219
GG 13.11 1.37 465
Total 13.06 1.36 724
TCN2_rs1131603 M SD N
African American
Caucasian
TC 14.20 . 1
TT 12.32 1.42 181
Total 12.33 1.43 182
CC 13.60 0.57 2
TC 13.36 1.14 47
TT 13.29 1.26 507
Total 13.29 1.25 556
Total CC 13.60 0.57 2
TC 13.38 1.14 48
TT 13.03 1.37 688
Total 13.06 1.36 738
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820889 M SD N
African American AA 13.14 0.58 5
GA 12.05 2.13 30
GG 12.34 1.27 141
Total 12.31 1.44 176
Caucasian AA 13.40 0.14 2
GA 13.52 1.01 22
GG 13.30 1.26 522
Total 13.31 1.25 546
Total AA 13.21 0.49 7
GA 12.67 1.88 52
GG 13.09 1.32 663
Total 13.06 1.37 722
TCN2_rs2072194 M SD N
African American GG 10.30 1.83 4
GA 12.36 1.29 43
AA 12.32 1.45 123
Total 12.28 1.44 170
Caucasian GG 13.40 1.09 110
GA 13.28 1.32 224
AA 13.22 1.25 193
Total 13.29 1.25 527
Total GG 13.29 1.25 114
GA 13.14 1.36 267
AA 12.87 1.40 316
Total 13.04 1.37 697
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs173665 M SD N
African American TT 12.53 0.84 7
CT 12.08 1.82 31
CC 12.35 1.38 136
Total 12.31 1.45 174
Caucasian TT 13.51 0.80 10
CT 13.16 1.22 77
CC 13.33 1.26 442
Total 13.30 1.24 529
Total TT 13.11 0.93 17
CT 12.85 1.49 108
CC 13.10 1.35 578
Total 13.06 1.37 703
CD320_rs250510 M SD N
African American TT 14.17 1.03 3
CT 11.96 1.53 21
CC 12.34 1.43 144
Total 12.32 1.46 168
Caucasian TT 13.30 . 1
CT 13.38 1.14 5
CC 13.29 1.23 514
Total 13.29 1.23 520
Total TT 13.95 0.94 4
CT 12.23 1.55 26
CC 13.08 1.34 658
Total 13.05 1.35 688
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2232787 M SD N
African American AA 12.50 . 1
AG 13.70 0.42 2
GG 12.32 1.46 173
Total 12.34 1.45 176
Caucasian AA 12.80 . 1
GG 13.29 1.24 521
Total 13.29 1.24 522
Total AA 12.65 0.21 2
AG 13.70 0.42 2
GG 13.05 1.36 694
Total 13.05 1.36 698
CD320_rs2227288 M SD N
African American CC 12.13 0.86 10
GC 12.00 1.82 47
GG 12.47 1.29 118
Total 12.32 1.44 175
Caucasian CC 13.01 1.49 11
GC 13.49 1.15 94
GG 13.28 1.26 407
Total 13.31 1.25 512
Total CC 12.59 1.28 21
GC 12.99 1.57 141
GG 13.10 1.31 525
Total 13.06 1.37 687
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2336573 M SD N
African American TT 12.25 1.36 21
TC 12.45 1.41 68
CC 12.25 1.52 84
Total 12.33 1.46 173
Caucasian TT 13.73 1.71 9
TC 13.54 1.33 35
CC 13.29 1.22 486
Total 13.31 1.24 530
Total TT 12.70 1.60 30
TC 12.82 1.47 103
CC 13.13 1.32 570
Total 13.07 1.36 703
CD320_rs2232779 M SD N
African American TT 12.55 0.49 2
CT 12.31 1.10 18
CC 12.33 1.48 160
Total 12.33 1.43 180
Caucasian TT 12.84 0.51 5
CT 13.00 0.28 2
CC 13.32 1.25 547
Total 13.31 1.25 554
Total TT 12.76 0.49 7
CT 12.37 1.06 20
CC 13.09 1.37 707
Total 13.07 1.36 734
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2927707 M SD N
African American CC 12.27 1.24 16
CT 12.19 1.82 47
TT 12.38 1.32 108
Total 12.32 1.46 171
Caucasian CC 13.30 1.09 56
CT 13.27 1.19 195
TT 13.33 1.31 271
Total 13.31 1.24 522
Total CC 13.07 1.20 72
CT 13.06 1.40 242
TT 13.06 1.38 379
Total 13.06 1.37 693
CD320_rs3760680 M SD N
African American TT 12.32 1.36 29
CT 12.37 1.35 69
CC 12.26 1.50 71
Total 12.32 1.41 169
Caucasian TT 13.26 1.37 79
CT 13.37 1.27 205
CC 13.30 1.15 234
Total 13.32 1.23 518
Total TT 13.01 1.42 108
CT 13.12 1.36 274
CC 13.06 1.31 305
Total 13.07 1.35 687
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Table 19 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs8100119 M SD N
African American CC 12.17 1.39 23
CT 12.32 1.40 59
TT 12.36 1.47 96
Total 12.32 1.43 178
Caucasian CC 12.82 2.65 5
CT 13.46 1.24 35
TT 13.28 1.23 498
Total 13.29 1.25 538
Total CC 12.29 1.64 28
CT 12.74 1.44 94
TT 13.14 1.32 594




Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs16988828 M SD N
African American GG 93.00 7.70 4
GA 90.51 5.29 35
AA 89.91 6.71 131
Total 90.11 6.45 170
Caucasian GG 96.40 4.97 10
GA 93.37 5.01 81
AA 94.29 5.28 427
Total 94.18 5.24 518
Total GG 95.43 5.77 14
GA 92.51 5.24 116
AA 93.26 5.94 558
Total 93.18 5.83 688
TCN2_rs7289549 M SD N
African American CC 92.83 5.80 18
CG 89.30 6.72 60
GG 90.25 6.23 97
Total 90.19 6.41 175
Caucasian CC 92.55 5.15 11
CG 94.27 5.23 86
GG 94.14 5.23 431
Total 94.13 5.23 528
Total CC 92.72 5.47 29
CG 92.23 6.36 146
GG 93.43 5.63 528
Total 93.15 5.80 703
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs7286107 M SD N
African American CC 93.82 6.62 11
CT 89.83 6.51 54
TT 90.19 6.31 109
Total 90.31 6.42 174
Caucasian CC 96.33 5.51 3
CT 99.00 . 1
TT 94.13 5.22 528
Total 94.15 5.22 532
Total CC 94.36 6.28 14
CT 90.00 6.57 55
TT 93.45 5.61 637
Total 93.20 5.77 706
TCN2_rs9606756 M SD N
African American GG 90.67 7.86 9
GA 90.18 6.38 44
AA 90.16 6.28 122
Total 90.19 6.35 175
Caucasian GG 93.65 4.11 26
GA 93.38 5.22 80
AA 94.41 5.29 423
Total 94.22 5.23 529
Total GG 92.89 5.36 35
GA 92.24 5.84 124
AA 93.46 5.80 545
Total 93.22 5.79 704
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs740234 M SD N
African American CC 90.33 7.51 3
TC 90.24 6.24 29
TT 90.17 6.51 143
Total 90.19 6.44 175
Caucasian CC 96.15 3.58 34
TC 93.93 5.22 148
TT 94.12 5.34 350
Total 94.20 5.23 532
Total CC 95.68 4.18 37
TC 93.33 5.55 177
TT 92.98 5.97 493
Total 93.21 5.81 707
TCN2_rs35915865 M SD N
African American CC 90.00 . 1
CT 85.00 2.83 2
TT 90.35 6.47 173
Total 90.29 6.45 176
Caucasian CC 93.25 5.62 4
CT 93.37 3.98 19
TT 94.23 5.27 511
Total 94.19 5.23 534
Total CC 92.60 5.08 5
CT 92.57 4.58 21
TT 93.25 5.84 684
Total 93.22 5.80 710
 285 
Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs11703570 M SD N
African American AA 88.83 5.06 12
AT 90.57 5.07 46
TT 90.32 7.10 114
Total 90.28 6.47 172
Caucasian AA 95.23 4.79 40
AT 93.74 5.25 141
TT 94.20 5.26 346
Total 94.16 5.22 527
Total AA 93.75 5.52 52
AT 92.96 5.37 187
TT 93.24 6.00 460
Total 93.20 5.80 699
TCN2_rs35838082 M SD N
African American TT 94.00 3.74 9
CT 90.33 6.36 51
CC 89.84 6.56 114
Total 90.20 6.42 174
Caucasian CT 95.57 3.26 7
CC 94.12 5.21 529
Total 94.14 5.19 536
Total TT 94.00 3.74 9
CT 90.97 6.29 58
CC 93.37 5.71 643
Total 93.18 5.77 710
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2267163 M SD N
African American TT 86.08 6.36 12
TC 90.84 6.87 55
CC 90.10 6.10 104
Total 90.05 6.44 171
Caucasian TT 94.18 5.21 119
TC 93.74 5.39 209
CC 94.42 4.72 191
Total 94.09 5.11 519
Total TT 93.44 5.79 131
TC 93.14 5.84 264
CC 92.89 5.63 295
Total 93.09 5.74 690
TCN2_rs1801198 M SD N
African American GG 86.21 7.28 14
CG 91.44 6.37 63
CC 89.70 6.16 97
Total 90.05 6.44 174
Caucasian GG 94.31 5.61 129
CG 93.97 5.28 233
CC 94.48 4.84 173
Total 94.22 5.22 535
Total GG 93.52 6.25 143
CG 93.44 5.62 296
CC 92.76 5.81 270
Total 93.20 5.82 709
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820021 M SD N
African American AT 87.33 9.24 6
TT 90.26 6.35 172
Total 90.16 6.46 178
Caucasian AA 93.71 5.51 14
AT 94.16 6.09 86
TT 94.19 4.96 428
Total 94.17 5.16 528
Total AA 93.71 5.51 14
AT 93.72 6.49 92
TT 93.06 5.68 600
Total 93.16 5.78 706
TCN2_rs9621049 M SD N
African American TT 89.33 4.46 6
CT 90.30 7.93 44
CC 90.07 5.96 127
Total 90.10 6.43 177
Caucasian TT 95.07 4.63 14
CT 93.98 5.19 91
CC 94.21 5.23 425
Total 94.20 5.20 530
Total TT 93.35 5.21 20
CT 92.78 6.42 135
CC 93.26 5.68 552
Total 93.17 5.81 707
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820886 M SD N
African American GG 91.25 4.72 4
GT 89.95 7.95 43
TT 90.03 5.94 128
Total 90.04 6.44 175
Caucasian GG 93.17 5.25 12
GT 94.27 4.87 92
TT 94.18 5.27 427
Total 94.18 5.20 531
Total GG 92.69 5.04 16
GT 92.90 6.32 135
TT 93.23 5.70 555
Total 93.15 5.81 706
TCN2_rs4820887 M SD N
African American AA 89.00 12.73 2
GA 91.96 7.68 23
GG 89.96 6.21 148
Total 90.21 6.48 173
Caucasian AA 93.11 4.20 9
GA 93.62 5.19 78
GG 94.27 5.23 439
Total 94.16 5.21 526
Total AA 92.36 5.75 11
GA 93.24 5.85 101
GG 93.19 5.80 587
Total 93.18 5.80 699
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820888 M SD N
African American GG 88.46 5.80 37
AG 90.82 6.31 82
AA 90.09 6.95 57
Total 90.09 6.45 176
Caucasian GG 94.60 4.91 121
AG 93.88 5.10 219
AA 94.32 5.43 189
Total 94.20 5.18 529
Total GG 93.16 5.74 158
AG 93.05 5.62 301
AA 93.34 6.07 246
Total 93.17 5.80 705
TCN2_rs2301955 M SD N
African American TT 89.07 4.76 15
CT 90.54 5.41 67
CC 90.17 7.34 93
Total 90.22 6.45 175
Caucasian TT 95.02 4.94 115
CT 93.84 5.24 212
CC 94.16 5.25 210
Total 94.22 5.19 537
Total TT 94.33 5.26 130
CT 93.05 5.46 279
CC 92.93 6.24 303
Total 93.23 5.78 712
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2301958 M SD N
African American CC 88.44 5.59 9
CG 89.96 4.83 55
GG 90.50 7.08 113
Total 90.23 6.38 177
Caucasian CC 94.67 4.57 30
CG 93.79 5.51 161
GG 94.39 5.17 348
Total 94.23 5.24 539
Total CC 93.23 5.44 39
CG 92.81 5.59 216
GG 93.44 5.93 461
Total 93.24 5.80 716
TCN2_rs1131603 M SD N
African American TC 94.00 . 1
TT 90.20 6.46 180
Total 90.22 6.45 181
Caucasian CC 102.50 2.12 2
TC 94.55 5.06 47
TT 94.17 5.21 500
Total 94.24 5.21 549
Total CC 102.50 2.12 2
TC 94.54 5.01 48
TT 93.12 5.83 680
Total 93.24 5.80 730
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820889 M SD N
African American AA 85.80 8.44 5
GA 90.48 7.56 29
GG 90.09 6.12 141
Total 90.03 6.44 175
Caucasian AA 94.50 6.36 2
GA 94.09 4.29 22
GG 94.23 5.23 515
Total 94.22 5.19 539
Total AA 88.29 8.50 7
GA 92.04 6.55 51
GG 93.34 5.69 656
Total 93.19 5.81 714
TCN2_rs2072194 M SD N
African American GG 88.00 6.48 4
GA 89.60 6.24 42
AA 90.22 6.52 123
Total 90.01 6.43 169
Caucasian GG 94.27 5.37 109
GA 93.95 5.24 220
AA 94.48 5.08 191
Total 94.21 5.20 520
Total GG 94.04 5.50 113
GA 93.25 5.63 262
AA 92.81 6.05 314
Total 93.18 5.81 689
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs173665 M SD N
African American TT 90.29 2.21 7
CT 89.94 7.77 31
CC 90.24 6.29 135
Total 90.19 6.44 173
Caucasian TT 95.80 5.85 10
CT 94.40 4.43 77
CC 94.08 5.35 435
Total 94.16 5.23 522
Total TT 93.53 5.37 17
CT 93.12 5.92 108
CC 93.17 5.82 570
Total 93.17 5.81 695
CD320_rs250510 M SD N
African American TT 87.00 9.64 3
CT 90.67 5.35 21
CC 90.15 6.59 143
Total 90.16 6.48 167
Caucasian TT 97.00 . 1
CT 95.20 5.36 5
CC 94.16 5.21 507
Total 94.17 5.21 513
Total TT 89.50 9.33 4
CT 91.54 5.55 26
CC 93.28 5.79 650
Total 93.19 5.81 680
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2232787 M SD N
African American AA 80.00 . 1
AG 88.00 9.90 2
GG 90.44 6.42 172
Total 90.35 6.46 175
Caucasian AA 101.00 . 1
GG 94.15 5.21 514
Total 94.16 5.21 515
Total AA 90.50 14.85 2
AG 88.00 9.90 2
GG 93.22 5.76 686
Total 93.19 5.79 690
CD320_rs2227288 M SD N
African American CC 89.10 4.28 10
GC 91.72 6.69 46
GG 89.78 6.31 118
Total 90.25 6.35 174
Caucasian CC 92.50 4.90 10
GC 94.13 5.25 94
GG 94.28 5.17 402
Total 94.22 5.17 506
Total CC 90.80 4.81 20
GC 93.34 5.85 140
GG 93.26 5.76 520
Total 93.20 5.76 680
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2336573 M SD N
African American TT 89.52 4.57 21
TC 89.53 6.44 68
CC 91.30 6.69 83
Total 90.38 6.40 172
Caucasian TT 95.56 8.22 9
TC 94.20 6.18 35
CC 94.14 5.10 479
Total 94.17 5.23 523
Total TT 91.33 6.40 30
TC 91.12 6.70 103
CC 93.72 5.45 562
Total 93.23 5.77 695
CD320_rs2232779 M SD N
African American TT 93.00 2.83 2
CT 89.78 6.16 18
CC 90.32 6.50 159
Total 90.30 6.43 179
Caucasian TT 97.80 3.70 5
CT 98.50 3.54 2
CC 94.16 5.21 540
Total 94.21 5.21 547
Total TT 96.43 3.99 7
CT 90.65 6.47 20
CC 93.29 5.76 699
Total 93.25 5.78 726
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Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2927707 M SD N
African American CC 90.06 7.33 16
CT 89.91 6.58 47
TT 90.55 6.34 107
Total 90.33 6.47 170
Caucasian CC 94.48 4.29 56
CT 93.92 5.28 194
TT 94.17 5.30 266
Total 94.11 5.18 516
Total CC 93.50 5.39 72
CT 93.14 5.76 241
TT 93.13 5.84 373
Total 93.17 5.76 686
CD320_rs3760680 M SD N
African American TT 90.03 6.10 29
CT 89.57 6.06 68
CC 90.86 6.99 71
Total 90.20 6.47 168
Caucasian TT 93.90 5.59 77
CT 94.17 5.17 202
CC 94.02 5.22 232
Total 94.06 5.24 511
Total TT 92.84 5.96 106
CT 93.01 5.75 270
CC 93.28 5.83 303
Total 93.10 5.81 679
 296 
Table 20 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs8100119 M SD N
African American CC 87.91 5.74 23
CT 90.32 6.07 59
TT 90.78 6.83 95
Total 90.25 6.48 177
Caucasian CC 93.20 9.78 5
CT 94.14 6.35 35
TT 94.21 5.08 491
Total 94.20 5.21 531
Total CC 88.86 6.73 28
CT 91.74 6.41 94
TT 93.65 5.54 586




Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs16988828 M SD N
African American GG 484.60 126.53 5
GA 579.40 239.84 35
AA 555.97 270.99 123
Total 558.81 260.84 163
Caucasian GG 306.38 100.81 8
GA 437.71 242.41 83
AA 468.33 224.95 427
Total 460.92 227.27 518
Total GG 374.92 139.32 13
GA 479.74 249.25 118
AA 487.93 238.58 550
Total 484.35 239.22 681
TCN2_rs7289549 M SD N
African American CC 620.33 284.44 18
CG 534.57 244.33 58
GG 557.00 261.93 90
Total 556.03 258.03 166
Caucasian CC 381.91 171.09 11
CG 489.36 234.80 86
GG 458.51 226.39 429
Total 461.95 227.01 526
Total CC 529.90 270.99 29
CG 507.57 238.87 144
GG 475.59 235.64 519
Total 484.52 238.05 692
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs7286107 M SD N
African American CC 555.73 183.24 11
CT 554.02 283.46 54
TT 556.63 255.21 100
Total 555.72 259.48 165
Caucasian CC 485.00 378.37 3
CT 701.00 . 1
TT 463.58 225.44 524
Total 464.15 226.03 528
Total CC 540.57 220.82 14
CT 556.69 281.52 55
TT 478.49 232.77 624
Total 485.95 237.46 693
TCN2_rs9606756 M SD N
African American GG 561.88 255.22 8
GA 554.90 266.91 40
AA 560.92 263.38 118
Total 559.52 262.29 166
Caucasian GG 460.25 174.68 24
GA 464.98 237.81 82
AA 460.47 223.90 419
Total 461.17 223.78 525
Total GG 485.66 198.36 32
GA 494.46 250.24 122
AA 482.55 236.58 537
Total 484.79 237.17 691
 299 
Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs740234 M SD N
African American CC 543.67 389.96 3
TC 533.78 256.15 27
TT 562.95 260.07 136
Total 557.86 260.08 166
Caucasian CC 474.71 269.94 31
TC 463.35 217.17 153
TT 458.97 224.78 344
Total 461.16 225.05 528
Total CC 480.79 275.42 34
TC 473.91 224.09 180
TT 488.43 239.67 480
Total 484.29 237.33 694
TCN2_rs35915865 M SD N
African American CC 525.00 . 1
CT 484.50 37.48 2
TT 562.90 264.81 165
Total 561.74 262.59 168
Caucasian CC 331.75 199.99 4
CT 387.78 168.02 18
TT 465.94 227.71 509
Total 462.28 226.19 531
Total CC 370.40 193.56 5
CT 397.45 161.92 20
TT 489.67 240.77 674
Total 486.18 239.07 699
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs11703570 M SD N
African American AA 609.38 243.72 13
AT 497.04 204.63 45
TT 566.47 269.92 106
Total 550.82 252.67 164
Caucasian AA 473.15 242.48 39
AT 440.14 224.87 142
TT 469.44 222.83 342
Total 461.76 224.83 523
Total AA 507.21 247.65 52
AT 453.83 220.98 187
TT 492.40 238.11 448
Total 483.02 234.69 687
TCN2_rs35838082 M SD N
African American TT 494.78 199.66 9
CT 576.69 286.86 48
CC 554.89 254.04 108
Total 557.95 260.70 165
Caucasian CT 455.83 101.33 6
CC 463.30 226.43 526
Total 463.21 225.37 532
Total TT 494.78 199.66 9
CT 563.26 274.61 54
CC 478.90 233.71 634
Total 485.64 237.46 697
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2267163 M SD N
African American TT 484.42 263.59 12
TC 524.19 256.74 47
CC 579.78 262.13 104
Total 556.73 261.07 163
Caucasian TT 462.66 222.67 117
TC 453.32 219.07 211
CC 471.80 237.27 189
Total 462.19 226.40 517
Total TT 464.68 225.71 129
TC 466.23 227.52 258
CC 510.13 251.32 293
Total 484.85 238.42 680
TCN2_rs1801198 M SD N
African American GG 468.00 259.22 13
CG 530.34 245.31 56
CC 584.21 268.51 96
Total 556.77 261.09 165
Caucasian GG 462.60 222.09 125
CG 450.63 225.47 235
CC 468.70 226.64 172
Total 459.28 224.78 532
Total GG 463.11 224.79 138
CG 465.97 231.14 291
CC 510.08 248.25 268
Total 482.36 237.34 697
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820021 M SD N
African American AT 417.17 130.62 6
TT 561.85 260.90 163
Total 556.71 258.58 169
Caucasian AA 399.43 163.02 14
AT 424.10 163.23 92
TT 472.14 237.89 418
Total 461.76 225.52 524
Total AA 399.43 163.02 14
AT 423.67 160.86 98
TT 497.31 247.64 581
Total 484.92 237.35 693
TCN2_rs9621049 M SD N
African American TT 546.29 325.18 7
CT 617.10 273.01 42
CC 536.39 249.37 119
Total 556.98 259.33 168
Caucasian TT 520.29 258.95 14
CT 441.10 203.09 93
CC 462.59 230.68 419
Total 460.33 226.77 526
Total TT 528.95 274.71 21
CT 495.85 240.44 135
CC 478.91 236.70 538
Total 483.72 238.49 694
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820886 M SD N
African American GG 614.50 423.22 4
GT 612.05 271.73 43
TT 536.56 248.99 120
Total 557.86 259.86 167
Caucasian GG 570.42 257.14 12
GT 440.13 201.08 95
TT 460.21 231.33 420
Total 459.10 227.12 527
Total GG 581.44 291.03 16
GT 493.70 238.25 138
TT 477.18 237.27 540
Total 482.87 238.98 694
TCN2_rs4820887 M SD N
African American AA 654.67 540.11 3
GA 604.24 290.92 21
GG 552.49 250.85 140
Total 560.99 260.94 164
Caucasian AA 532.33 223.98 9
GA 447.39 206.04 77
GG 459.70 229.37 437
Total 459.13 225.85 523
Total AA 562.92 304.28 12
GA 481.00 234.30 98
GG 482.21 237.90 577
Total 483.45 238.49 687
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820888 M SD N
African American GG 539.57 266.12 35
AG 522.48 219.77 79
AA 622.68 300.67 53
Total 557.86 259.86 167
Caucasian GG 448.88 245.76 116
AG 457.21 217.68 223
AA 473.66 227.02 186
Total 461.20 227.20 525
Total GG 469.90 252.65 151
AG 474.28 219.75 302
AA 506.70 252.31 239
Total 484.52 238.92 692
TCN2_rs2301955 M SD N
African American TT 572.00 266.71 16
CT 525.84 228.89 64
CC 590.85 285.81 86
Total 563.97 263.63 166
Caucasian TT 458.68 230.73 107
CT 463.38 229.29 220
CC 464.62 222.78 206
Total 462.92 226.67 533
Total TT 473.42 237.63 123
CT 477.45 230.29 284
CC 501.80 249.29 292
Total 486.91 239.67 699
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2301958 M SD N
African American CC 613.40 282.57 10
CG 503.04 213.01 53
GG 583.82 275.02 105
Total 560.10 259.02 168
Caucasian CC 477.79 256.12 28
CG 448.36 228.39 164
GG 466.01 221.28 343
Total 461.22 225.12 535
Total CC 513.47 266.37 38
CG 461.71 225.48 217
GG 493.62 239.91 448
Total 484.85 237.26 703
TCN2_rs1131603 M SD N
African American TC 268.00 . 1
TT 564.16 260.02 171
Total 562.44 260.24 172
Caucasian CC 645.50 275.06 2
TC 465.38 209.65 48
TT 460.34 226.55 494
Total 461.47 225.10 544
Total CC 645.50 275.06 2
TC 461.35 209.36 49
TT 487.04 239.75 665
Total 485.72 237.79 716
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820889 M SD N
African American AA 513.25 182.90 4
GA 474.39 234.16 28
GG 581.38 266.69 135
Total 561.81 261.91 167
Caucasian AA 364.00 59.40 2
GA 468.18 293.26 22
GG 461.67 222.28 509
Total 461.58 224.98 533
Total AA 463.50 163.45 6
GA 471.66 259.00 50
GG 486.77 237.14 644
Total 485.49 238.00 700
TCN2_rs2072194 M SD N
African American GG 604.67 119.06 3
GA 534.31 260.46 39
AA 566.49 266.05 121
Total 559.49 262.20 163
Caucasian GG 457.84 225.35 109
GA 460.29 213.15 222
AA 463.80 236.92 184
Total 461.03 224.04 515
Total GG 461.78 224.13 112
GA 471.35 221.88 261
AA 504.54 253.50 305
Total 484.70 237.35 678
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs173665 M SD N
African American TT 569.50 261.49 6
CT 597.00 350.38 27
CC 555.38 243.27 133
Total 562.66 262.67 166
Caucasian TT 466.25 260.76 8
CT 490.08 220.57 76
CC 451.87 225.55 435
Total 457.69 225.32 519
Total TT 510.50 256.37 14
CT 518.11 263.25 103
CC 476.11 233.75 568
Total 483.13 238.99 685
CD320_rs250510 M SD N
African American TT 357.00 83.61 3
CT 606.38 231.30 21
CC 558.32 262.26 136
Total 560.85 257.45 160
Caucasian TT 199.00 . 1
CT 508.17 208.90 6
CC 458.51 224.14 503
Total 458.58 223.91 510
Total TT 317.50 104.41 4
CT 584.56 226.45 27
CC 479.75 236.12 639
Total 483.00 236.23 670
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2232787 M SD N
African American AA 567.00 . 1
AG 368.00 65.05 2
GG 568.59 265.04 165
Total 566.19 263.60 168
Caucasian AA 243.00 . 1
GG 461.57 226.32 511
Total 461.14 226.31 512
Total AA 405.00 229.10 2
AG 368.00 65.05 2
GG 487.69 240.59 676
Total 487.10 240.19 680
CD320_rs2227288 M SD N
African American CC 423.60 110.39 10
GC 561.29 232.97 41
GG 582.24 281.93 114
Total 567.42 264.76 165
Caucasian CC 387.50 253.56 12
GC 441.90 193.61 93
GG 469.21 233.66 398
Total 462.21 227.38 503
Total CC 403.91 198.08 22
GC 478.43 212.84 134
GG 494.38 249.42 512
Total 488.20 241.27 668
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2336573 M SD N
African American TT 616.71 261.70 21
TC 602.05 292.60 65
CC 520.58 227.57 78
Total 565.18 261.38 164
Caucasian TT 480.78 199.96 9
TC 512.63 229.28 32
CC 456.96 225.97 479
Total 460.80 225.77 520
Total TT 575.93 249.55 30
TC 572.55 275.39 97
CC 465.87 227.07 557
Total 485.83 238.80 684
CD320_rs2232779 M SD N
African American TT 647.50 267.99 2
CT 617.80 300.16 15
CC 554.80 255.06 153
Total 561.45 258.47 170
Caucasian TT 421.00 170.37 5
CT 442.50 282.14 2
CC 460.82 225.53 535
Total 460.38 224.90 542
Total TT 485.71 208.65 7
CT 597.18 295.30 17
CC 481.72 235.49 688
Total 484.51 237.12 712
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2927707 M SD N
African American CC 450.93 224.32 15
CT 600.09 265.55 44
TT 560.71 260.22 103
Total 561.24 260.11 162
Caucasian CC 468.53 212.15 53
CT 458.31 222.49 192
TT 462.90 234.77 269
Total 461.76 227.59 514
Total CC 464.65 213.31 68
CT 484.75 237.06 236
TT 489.98 245.67 372
Total 485.60 239.39 676
CD320_rs3760680 M SD N
African American TT 578.36 273.01 28
CT 593.21 282.72 66
CC 515.81 236.59 69
Total 557.90 263.29 163
Caucasian TT 484.87 264.93 75
CT 460.71 230.92 206
CC 458.11 207.42 230
Total 463.09 225.88 511
Total TT 510.28 269.07 103
CT 492.86 250.50 272
CC 471.43 215.47 299
Total 486.02 238.75 674
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Table 21 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs8100119 M SD N
African American CC 555.38 255.89 21
CT 596.02 291.37 59
TT 541.30 243.85 88
Total 562.27 262.57 168
Caucasian CC 508.75 71.25 4
CT 516.09 252.72 33
TT 457.58 224.64 491
Total 461.63 225.93 528
Total CC 547.92 235.59 25
CT 567.35 279.38 92
TT 470.31 229.42 579




Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs16988828 M SD N
African American GG 8.80 1.64 5
GA 10.91 4.15 34
AA 11.04 4.18 117
Total 10.94 4.12 156
Caucasian GG 10.10 2.51 8
GA 10.98 3.76 81
AA 10.37 3.73 415
Total 10.46 3.72 504
Total GG 9.60 2.24 13
GA 10.96 3.86 115
AA 10.52 3.84 532
Total 10.58 3.82 660
TCN2_rs7289549 M SD N
African American CC 10.27 3.52 18
CG 11.49 3.86 54
GG 10.82 4.38 87
Total 10.99 4.11 159
Caucasian CC 10.95 4.12 11
CG 9.84 2.92 85
GG 10.63 3.85 416
Total 10.50 3.72 512
Total CC 10.53 3.70 29
CG 10.48 3.40 139
GG 10.66 3.94 503
Total 10.62 3.82 671
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs7286107 M SD N
African American CC 9.00 2.46 11
CT 11.30 3.86 52
TT 11.05 4.37 95
Total 10.99 4.12 158
Caucasian CC 9.13 1.91 3
CT 10.90 . 1
TT 10.47 3.72 510
Total 10.46 3.71 514
Total CC 9.03 2.28 14
CT 11.29 3.82 53
TT 10.56 3.83 605
Total 10.59 3.81 672
TCN2_rs9606756 M SD N
African American GG 13.05 7.12 8
GA 10.35 3.52 38
AA 10.99 4.06 113
Total 10.94 4.14 159
Caucasian GG 11.05 2.57 24
GA 10.59 3.89 80
AA 10.41 3.73 407
Total 10.47 3.70 511
Total GG 11.55 4.14 32
GA 10.52 3.76 118
AA 10.54 3.81 520
Total 10.58 3.82 670
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs740234 M SD N
African American CC 5.80 0.57 2
TC 11.10 4.03 25
TT 11.01 4.15 132
Total 10.96 4.14 159
Caucasian CC 10.63 4.34 30
TC 10.26 3.73 146
TT 10.58 3.64 338
Total 10.49 3.70 514
Total CC 10.33 4.37 32
TC 10.39 3.77 171
TT 10.70 3.79 470
Total 10.60 3.81 673
TCN2_rs11703570 M SD N
African American AA 11.38 3.17 13
AT 10.58 4.08 44
TT 11.10 4.32 100
Total 10.98 4.15 157
Caucasian AA 11.32 3.54 38
AT 10.98 4.21 139
TT 10.20 3.49 332
Total 10.50 3.72 509
Total AA 11.34 3.42 51
AT 10.89 4.17 183
TT 10.41 3.71 432
Total 10.61 3.83 666
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs35915865 M SD N
African American CC 10.40 . 1
CT 14.90 . 1
TT 10.91 4.15 159
Total 10.93 4.13 161
Caucasian CC 11.53 4.00 4
CT 10.07 3.69 18
TT 10.52 3.72 495
Total 10.51 3.72 517
Total CC 11.30 3.50 5
CT 10.33 3.76 19
TT 10.61 3.83 654
Total 10.61 3.82 678
TCN2_rs35838082 M SD N
African American TT 8.48 3.24 9
CT 10.93 3.56 48
CC 11.16 4.42 101
Total 10.94 4.14 158
Caucasian CT 9.70 1.51 6
CC 10.52 3.75 512
Total 10.51 3.73 518
Total TT 8.48 3.24 9
CT 10.80 3.40 54
CC 10.62 3.87 613
Total 10.61 3.83 676
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2267163 M SD N
African American TT 11.50 3.87 9
TC 11.52 4.62 47
CC 10.72 3.96 100
Total 11.01 4.16 156
Caucasian TT 9.87 3.03 114
TC 10.38 3.77 208
CC 11.00 3.97 181
Total 10.49 3.71 503
Total TT 9.99 3.11 123
TC 10.59 3.96 255
CC 10.90 3.96 281
Total 10.61 3.82 659
TCN2_rs4820021 M SD N
African American AT 11.52 4.10 6
TT 10.95 4.12 156
Total 10.97 4.11 162
Caucasian AA 10.38 3.49 13
AT 9.97 3.53 92
TT 10.57 3.66 405
Total 10.46 3.63 510
Total AA 10.38 3.49 13
AT 10.06 3.57 98
TT 10.68 3.79 561
Total 10.58 3.76 672
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs1801198 M SD N
African American GG 12.63 5.11 10
CG 10.92 4.15 55
CC 10.88 4.05 93
Total 11.00 4.15 158
Caucasian GG 9.90 3.05 121
CG 10.40 3.81 230
CC 10.95 3.88 167
Total 10.46 3.68 518
Total GG 10.11 3.31 131
CG 10.50 3.87 285
CC 10.92 3.93 260
Total 10.59 3.80 676
TCN2_rs9621049 M SD N
African American TT 13.77 6.70 7
CT 10.08 3.85 40
CC 11.11 3.97 114
Total 10.97 4.12 161
Caucasian TT 11.81 2.94 14
CT 10.78 3.84 90
CC 10.36 3.69 408
Total 10.48 3.71 512
Total TT 12.47 4.47 21
CT 10.56 3.84 130
CC 10.53 3.77 522
Total 10.59 3.81 673
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820886 M SD N
African American GG 14.88 8.73 4
GT 10.26 3.89 41
TT 11.13 3.95 115
Total 11.00 4.12 160
Caucasian GG 11.68 3.04 12
GT 10.90 3.89 92
TT 10.36 3.70 409
Total 10.49 3.72 513
Total GG 12.48 4.90 16
GT 10.70 3.89 133
TT 10.53 3.76 524
Total 10.61 3.82 673
TCN2_rs4820888 M SD N
African American GG 11.30 4.58 35
AG 10.78 3.88 73
AA 11.11 4.19 52
Total 11.00 4.12 160
Caucasian GG 11.02 4.04 115
AG 10.37 3.78 213
AA 10.33 3.43 183
Total 10.50 3.72 511
Total GG 11.09 4.16 150
AG 10.47 3.80 286
AA 10.50 3.62 235
Total 10.62 3.83 671
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820887 M SD N
African American AA 17.03 8.94 3
GA 9.09 3.18 20
GG 11.13 3.97 134
Total 10.99 4.11 157
Caucasian AA 11.54 3.92 9
GA 10.96 3.97 76
GG 10.38 3.67 424
Total 10.48 3.72 509
Total AA 12.92 5.65 12
GA 10.57 3.88 96
GG 10.56 3.76 558
Total 10.60 3.82 666
TCN2_rs2301955 M SD N
African American TT 10.71 3.91 16
CT 10.63 3.95 62
CC 11.28 4.37 81
Total 10.97 4.15 159
Caucasian TT 11.24 4.13 106
CT 10.27 3.75 211
CC 10.32 3.38 202
Total 10.49 3.70 519
Total TT 11.17 4.09 122
CT 10.35 3.79 273
CC 10.59 3.71 283
Total 10.60 3.82 678
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2301958 M SD N
African American CC 10.33 3.23 10
CG 10.97 3.99 52
GG 10.89 4.13 99
Total 10.88 4.02 161
Caucasian CC 11.21 3.34 28
CG 11.01 4.12 160
GG 10.18 3.45 333
Total 10.49 3.68 521
Total CC 10.98 3.29 38
CG 11.00 4.08 212
GG 10.34 3.63 432
Total 10.58 3.77 682
TCN2_rs4820889 M SD N
African American AA 11.93 7.52 4
GA 11.70 4.50 25
GG 10.86 3.93 131
Total 11.02 4.11 160
Caucasian AA 7.50 2.55 2
GA 10.22 3.21 21
GG 10.50 3.71 496
Total 10.48 3.68 519
Total AA 10.45 6.36 6
GA 11.03 3.99 46
GG 10.57 3.75 627
Total 10.60 3.79 679
 321 
Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs1131603 M SD N
African American TC 12.30 . 1
TT 10.94 4.09 164
Total 10.95 4.08 165
Caucasian CC 8.45 1.20 2
TC 11.38 4.61 48
TT 10.43 3.60 480
Total 10.51 3.71 530
Total CC 8.45 1.20 2
TC 11.39 4.56 49
TT 10.56 3.74 644
Total 10.61 3.80 695
TCN2_rs2072194 M SD N
African American GG 14.43 4.29 3
GA 10.89 3.46 36
AA 10.89 4.32 117
Total 10.96 4.14 156
Caucasian GG 10.15 3.21 106
GA 10.32 3.64 215
AA 10.82 4.09 180
Total 10.47 3.73 501
Total GG 10.27 3.30 109
GA 10.41 3.62 251
AA 10.85 4.18 297
Total 10.58 3.83 657
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs173665 M SD N
African American TT 9.87 2.50 6
CT 11.19 4.57 25
CC 11.01 4.09 128
Total 11.00 4.11 159
Caucasian TT 11.75 4.32 8
CT 10.50 4.31 73
CC 10.47 3.61 424
Total 10.49 3.72 505
Total TT 10.94 3.66 14
CT 10.68 4.36 98
CC 10.59 3.73 552
Total 10.61 3.82 664
CD320_rs2232787 M SD N
African American AA 13.80 . 1
AG 9.35 3.32 2
GG 10.96 4.14 158
Total 10.95 4.12 161
Caucasian AA 13.40 . 1
GG 10.47 3.72 497
Total 10.48 3.72 498
Total AA 13.60 0.28 2
AG 9.35 3.32 2
GG 10.59 3.83 655
Total 10.59 3.82 659
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs250510 M SD N
African American TT 17.20 5.81 3
CT 9.99 2.89 21
CC 10.95 4.18 129
Total 10.94 4.14 153
Caucasian TT 13.80 . 1
CT 8.87 2.35 6
CC 10.44 3.72 489
Total 10.43 3.70 496
Total TT 16.35 5.04 4
CT 9.74 2.78 27
CC 10.55 3.82 618
Total 10.55 3.82 649
CD320_rs2227288 M SD N
African American CC 11.02 3.13 10
GC 11.54 4.44 39
GG 10.64 4.07 109
Total 10.89 4.11 158
Caucasian CC 11.70 4.04 12
GC 10.27 3.45 92
GG 10.52 3.79 387
Total 10.51 3.74 491
Total CC 11.39 3.58 22
GC 10.65 3.80 131
GG 10.55 3.85 496
Total 10.60 3.83 649
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2336573 M SD N
African American TT 10.20 3.54 20
TC 10.82 4.20 62
CC 11.35 4.23 75
Total 10.99 4.13 157
Caucasian TT 10.68 3.79 9
TC 11.05 3.03 31
CC 10.39 3.72 466
Total 10.43 3.68 506
Total TT 10.34 3.56 29
TC 10.90 3.84 93
CC 10.52 3.81 541
Total 10.57 3.80 663
CD320_rs2927707 M SD N
African American CC 12.37 4.67 15
CT 11.17 4.78 42
TT 10.76 3.73 98
Total 11.03 4.13 155
Caucasian CC 10.64 3.76 51
CT 10.40 3.57 188
TT 10.57 3.84 262
Total 10.51 3.73 501
Total CC 11.04 4.02 66
CT 10.54 3.82 230
TT 10.62 3.80 360
Total 10.63 3.83 656
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Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2232779 M SD N
African American TT 10.90 2.12 2
CT 10.24 2.71 14
CC 11.02 4.22 147
Total 10.95 4.09 163
Caucasian TT 11.20 3.05 5
CT 11.30 2.97 2
CC 10.46 3.68 521
Total 10.47 3.67 528
Total TT 11.11 2.64 7
CT 10.38 2.66 16
CC 10.58 3.81 668
Total 10.58 3.77 691
CD320_rs3760680 M SD N
African American TT 10.21 3.82 27
CT 10.47 4.19 62
CC 11.72 4.16 67
Total 10.96 4.14 156
Caucasian TT 11.26 4.95 75
CT 10.29 3.15 198
CC 10.33 3.67 224
Total 10.46 3.71 497
Total TT 10.98 4.68 102
CT 10.33 3.42 260
CC 10.65 3.83 291
Total 10.58 3.82 653
 326 
Table 22 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs8100119 M SD N
African American CC 10.91 3.70 21
CT 10.55 3.95 55
TT 11.20 4.30 85
Total 10.94 4.10 161
Caucasian CC 12.08 4.86 4
CT 11.23 3.33 32
TT 10.44 3.75 478
Total 10.50 3.74 514
Total CC 11.10 3.81 25
CT 10.80 3.73 87
TT 10.55 3.85 563




Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs16988828 M SD N
African American
GG 180.40 105.05 5
GA 211.37 128.10 35
AA 197.64 117.83 116
Total 200.17 119.29 156
Caucasian GG 248.38 124.04 8
GA 275.65 156.66 80
AA 246.89 136.24 411
Total 251.53 139.65 499
Total GG 222.23 117.64 13
GA 256.09 150.94 115
AA 236.05 133.87 527
Total 239.29 136.76 655
TCN2_rs7289549 M SD N
African American CC 178.11 80.15 18
CG 186.89 89.11 54
GG 214.38 139.49 87
Total 200.94 119.05 159
Caucasian CC 302.27 176.86 11
CG 241.29 159.25 83
GG 253.25 135.81 413
Total 252.36 140.79 507
Total CC 225.21 137.23 29
CG 219.85 138.19 137
GG 246.49 137.12 500
Total 240.08 137.59 666
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Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs7286107 M SD N
African American CC 182.55 78.81 11
CT 188.67 93.00 52
TT 209.81 135.30 95
Total 200.96 119.53 158
Caucasian CC 229.00 19.52 3
CT 232.00 . 1
TT 249.97 139.72 505
Total 249.81 139.18 509
Total CC 192.50 72.30 14
CT 189.49 92.29 53
TT 243.61 139.69 600
Total 238.24 136.30 667
TCN2_rs9606756 M SD N
African American GG 197.38 110.07 8
GA 193.58 123.51 38
AA 203.67 120.48 113
Total 200.94 120.07 159
Caucasian GG 228.96 78.96 24
GA 236.43 117.66 80
AA 255.34 147.00 402
Total 251.09 140.29 506
Total GG 221.06 86.92 32
GA 222.63 120.73 118
AA 244.00 143.11 515
Total 239.10 137.32 665
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Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs740234 M SD N
African American CC 101.50 23.33 2
TC 246.64 164.84 25
TT 193.79 107.34 132
Total 200.94 119.09 159
Caucasian CC 266.00 147.75 30
TC 243.63 134.00 145
TT 253.16 142.28 334
Total 251.20 140.14 509
Total CC 255.72 148.58 32
TC 244.08 138.42 170
TT 236.34 135.87 466
Total 239.24 137.02 668
TCN2_rs35915865 M SD N
African American CC 204.00 . 1
CT 401.00 . 1
TT 198.53 118.44 159
Total 199.82 118.78 161
Caucasian CC 325.50 232.75 4
CT 326.22 164.41 18
TT 248.14 138.48 490
Total 251.49 140.78 512
Total CC 301.20 208.76 5
CT 330.16 160.70 19
TT 235.98 135.45 649
Total 239.13 137.53 673
 330 
Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs11703570 M SD N
African American AA 222.46 140.88 13
AT 208.57 152.66 44
TT 198.10 103.63 100
Total 203.05 121.74 157
Caucasian AA 242.82 136.85 38
AT 258.52 134.93 138
TT 247.60 140.09 328
Total 250.23 138.28 504
Total AA 237.63 136.76 51
AT 246.45 140.63 182
TT 236.03 134.01 428
Total 239.02 135.94 661
TCN2_rs35838082 M SD N
African American TT 170.00 37.20 9
CT 189.35 102.30 48
CC 208.79 131.31 101
Total 200.68 119.67 158
Caucasian CT 373.00 231.24 6
CC 250.10 138.62 507
Total 251.54 140.31 513
Total TT 170.00 37.20 9
CT 209.76 133.11 54
CC 243.24 138.19 608
Total 239.56 137.36 671
 331 
Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2267163 M SD N
African American TT 202.56 119.31 9
TC 217.85 108.44 46
CC 192.81 126.00 101
Total 200.76 120.50 156
Caucasian TT 263.14 159.04 112
TC 245.82 139.28 206
CC 251.36 129.63 180
Total 251.72 140.52 498
Total TT 258.64 156.85 121
TC 240.71 134.42 252
CC 230.32 131.17 281
Total 239.56 137.65 654
TCN2_rs1801198 M SD N
African American GG 207.60 113.61 10
CG 207.62 106.37 55
CC 199.57 131.97 93
Total 202.88 121.87 158
Caucasian GG 257.73 155.72 119
CG 246.82 137.09 228
CC 249.57 132.17 166
Total 250.24 139.89 513
Total GG 253.84 153.11 129
CG 239.20 132.42 283
CC 231.61 134.01 259
Total 239.09 137.25 671
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Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820021 M SD N
African American AT 245.83 133.08 6
TT 200.23 120.18 156
Total 201.92 120.54 162
Caucasian AA 254.46 100.31 13
AT 249.01 149.36 90
TT 252.89 139.69 402
Total 252.24 140.38 505
Total AA 254.46 100.31 13
AT 248.81 147.76 96
TT 238.17 136.48 558
Total 240.02 137.45 667
TCN2_rs9621049 M SD N
African American TT 160.43 60.93 7
CT 203.90 130.03 40
CC 203.95 120.64 114
Total 202.04 120.91 161
Caucasian TT 271.38 90.48 13
CT 248.44 120.76 90
CC 251.57 145.93 404
Total 251.52 140.47 507
Total TT 232.55 96.39 20
CT 234.74 124.89 130
CC 241.09 142.02 518
Total 239.60 137.56 668
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Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820886 M SD N
African American GG 152.50 44.81 4
GT 203.07 128.43 41
TT 203.48 120.78 115
Total 202.10 121.28 160
Caucasian GG 260.92 74.03 12
GT 252.22 122.26 91
TT 250.36 146.10 405
Total 250.94 140.66 508
Total GG 233.81 82.29 16
GT 236.95 125.80 132
TT 239.99 142.12 520
Total 239.24 137.77 668
TCN2_rs4820887 M SD N
African American AA 185.00 27.73 3
GA 190.65 132.14 20
GG 203.00 122.93 134
Total 201.08 122.65 157
Caucasian AA 251.78 78.94 9
GA 246.49 121.19 76
GG 252.36 144.73 419
Total 251.46 140.36 504
Total AA 235.08 74.73 12
GA 234.85 124.93 96
GG 240.40 141.25 553
Total 239.49 137.95 661
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Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820888 M SD N
African American GG 219.46 147.54 35
AG 209.18 128.71 73
AA 180.48 84.88 52
Total 202.10 121.28 160
Caucasian GG 262.19 143.47 115
AG 247.00 138.36 210
AA 251.90 142.16 181
Total 252.21 140.74 506
Total GG 252.22 145.06 150
AG 237.24 136.72 283
AA 235.96 134.73 233
Total 240.17 137.90 666
TCN2_rs2301955 M SD N
African American TT 231.94 194.23 16
CT 202.92 120.61 62
CC 195.42 104.05 81
Total 202.02 121.62 159
Caucasian TT 261.31 143.84 106
CT 240.71 129.08 208
CC 259.97 152.17 200
Total 252.45 141.54 514
Total TT 257.46 150.76 122
CT 232.03 127.96 270
CC 241.36 142.86 281
Total 240.54 138.68 673
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Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2301958 M SD N
African American CC 179.80 149.64 10
CG 211.23 139.11 52
GG 197.85 108.26 99
Total 201.05 121.14 161
Caucasian CC 255.86 151.94 28
CG 256.08 139.48 158
GG 250.11 141.53 330
Total 252.25 141.23 516
Total CC 235.84 153.12 38
CG 244.98 140.40 210
GG 238.05 136.27 429
Total 240.07 138.37 677
TCN2_rs1131603 M SD N
African American TC 131.00 . 1
TT 202.27 120.50 164
Total 201.84 120.26 165
Caucasian CC 162.00 18.38 2
TC 238.02 124.02 48
TT 253.35 141.56 475
Total 251.60 139.84 525
Total CC 162.00 18.38 2
TC 235.84 123.67 49
TT 240.24 138.19 639
Total 239.70 136.99 690
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Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820889 M SD N
African American AA 164.00 77.90 4
GA 213.80 100.31 25
GG 202.34 126.73 131
Total 203.18 121.74 160
Caucasian AA 191.50 21.92 2
GA 295.43 163.56 21
GG 249.34 139.59 491
Total 250.99 140.55 514
Total AA 173.17 62.76 6
GA 251.07 137.65 46
GG 239.44 138.22 622
Total 239.64 137.74 674
TCN2_rs2072194 M SD N
African American GG 159.33 23.25 3
GA 215.64 130.69 36
AA 197.58 120.10 117
Total 201.01 121.45 156
Caucasian GG 262.49 161.43 104
GA 239.00 128.91 213
AA 254.87 132.73 179
Total 249.65 137.73 496
Total GG 259.60 160.08 107
GA 235.63 129.16 249
AA 232.22 130.73 296
Total 238.02 135.52 652
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Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs173665 M SD N
African American TT 182.67 90.88 6
CT 229.36 170.45 25
CC 196.76 108.92 128
Total 201.35 119.85 159
Caucasian TT 291.50 69.03 8
CT 249.11 143.52 73
CC 250.30 141.69 419
Total 250.78 141.01 500
Total TT 244.86 94.16 14
CT 244.07 150.18 98
CC 237.77 136.54 547
Total 238.86 137.75 659
CD320_rs250510 M SD N
African American TT 175.67 90.59 3
CT 155.50 35.84 20
CC 207.31 128.48 130
Total 199.92 120.81 153
Caucasian TT 234.00 . 1
CT 200.67 100.82 6
CC 251.82 142.59 484
Total 251.16 142.05 491
Total TT 190.25 79.51 4
CT 165.92 58.19 26
CC 242.40 140.80 614
Total 238.99 138.93 644
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Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2232787 M SD N
African American AA 133.00 . 1
AG 166.50 98.29 2
GG 199.71 119.80 158
Total 198.88 119.10 161
Caucasian AA 497.00 . 1
GG 251.34 141.37 492
Total 251.84 141.66 493
Total AA 315.00 257.39 2
AG 166.50 98.29 2
GG 238.79 138.14 650
Total 238.80 138.26 654
CD320_rs2227288 M SD N
African American CC 232.10 160.90 10
GC 218.66 105.04 38
GG 191.87 119.57 110
Total 200.86 119.19 158
Caucasian CC 230.50 103.92 12
GC 235.51 130.80 90
GG 252.52 142.77 384
Total 248.83 139.76 486
Total CC 231.23 129.44 22
GC 230.51 123.54 128
GG 239.02 140.12 494
Total 237.06 136.49 644
 339 
Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2336573 M SD N
African American TT 193.57 129.12 21
TC 196.29 121.07 62
CC 204.65 118.61 74
Total 199.87 120.30 157
Caucasian TT 245.44 90.14 9
TC 233.61 107.26 31
CC 252.40 143.65 461
Total 251.11 140.80 501
Total TT 209.13 119.68 30
TC 208.73 117.40 93
CC 245.79 141.32 535
Total 238.88 137.85 658
CD320_rs2232779 M SD N
African American TT 132.50 38.89 2
CT 200.00 172.49 14
CC 200.20 112.97 147
Total 199.35 118.13 163
Caucasian TT 368.40 232.81 5
CT 326.00 241.83 2
CC 251.44 139.44 516
Total 252.84 140.93 523
Total TT 301.00 222.79 7
CT 215.75 177.59 16
CC 240.08 135.62 663
Total 240.13 137.67 686
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Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2927707 M SD N
African American CC 211.93 100.98 15
CT 186.12 101.27 41
TT 205.04 130.91 99
Total 200.70 120.73 155
Caucasian CC 277.08 179.43 50
CT 254.82 149.22 187
TT 243.87 124.35 259
Total 251.35 140.41 496
Total CC 262.05 166.27 65
CT 242.46 144.06 228
TT 233.13 127.21 358
Total 239.29 137.60 651
CD320_rs3760680 M SD N
African American TT 193.32 134.51 28
CT 197.02 122.50 62
CC 213.52 118.48 66
Total 203.33 122.56 156
Caucasian TT 263.72 143.46 74
CT 249.48 145.11 198
CC 242.20 133.13 220
Total 248.37 139.52 492
Total TT 244.39 143.90 102
CT 236.97 141.61 260
CC 235.58 130.26 286
Total 237.52 136.91 648
 341 
Table 23 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs8100119 M SD N
African American CC 204.95 170.95 21
CT 175.02 77.00 56
TT 220.58 129.28 84
Total 202.70 121.65 161
Caucasian CC 232.75 58.20 4
CT 249.44 108.20 32
TT 250.86 142.45 473
Total 250.62 139.97 509
Total CC 209.40 157.75 25
CT 202.08 96.00 88
TT 246.29 140.85 557
Total 239.11 137.24 670
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Table 24
Geriatric Depression Scale Score
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs16988828 M SD N
African American GG 8.40 4.88 5
GA 6.54 4.77 39
AA 6.30 5.11 141
Total 6.41 5.02 185
Caucasian GG 2.60 2.72 10
GA 7.06 5.76 87
AA 6.59 5.60 454
Total 6.60 5.61 551
Total GG 4.53 4.42 15
GA 6.90 5.46 126
AA 6.52 5.48 595
Total 6.55 5.46 736
TCN2_rs7289549 M SD N
African American CC 6.79 5.57 19
CG 5.81 4.48 67
GG 6.84 5.24 103
Total 6.47 5.01 189
Caucasian CC 4.73 2.90 11
CG 6.22 5.22 92
GG 6.73 5.66 458
Total 6.61 5.55 561
Total CC 6.03 4.82 30
CG 6.04 4.91 159
GG 6.75 5.58 561
Total 6.57 5.42 750
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs7286107 M SD N
African American CC 8.17 5.44 12
CT 5.25 3.77 60
TT 7.03 5.34 117
Total 6.53 4.96 189
Caucasian CC 3.33 2.08 3
CT 16.00 . 1
TT 6.64 5.56 561
Total 6.64 5.56 565
Total CC 7.20 5.28 15
CT 5.43 3.99 61
TT 6.71 5.52 678
Total 6.62 5.42 754
TCN2_rs9606756 M SD N
African American GG 8.40 6.65 10
GA 6.83 5.46 48
AA 6.33 4.83 132
Total 6.56 5.09 190
Caucasian GG 8.43 6.01 28
GA 6.62 5.51 87
AA 6.48 5.50 447
Total 6.60 5.53 562
Total GG 8.42 6.09 38
GA 6.70 5.47 135
AA 6.44 5.35 579
Total 6.59 5.42 752
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs740234 M SD N
African American CC 5.50 5.26 4
TC 6.10 5.09 29
TT 6.55 5.02 157
Total 6.46 5.01 190
Caucasian CC 8.71 6.46 35
TC 6.64 5.60 159
TT 6.32 5.43 371
Total 6.56 5.57 565
Total CC 8.38 6.36 39
TC 6.55 5.52 188
TT 6.39 5.31 528
Total 6.54 5.43 755
TCN2_rs35915865 M SD N
African American CC 5.00 . 1
CT 1.50 2.12 2
TT 6.48 5.01 188
Total 6.42 5.00 191
Caucasian CC 8.25 6.18 4
CT 8.42 8.64 19
TT 6.49 5.41 544
Total 6.56 5.55 567
Total CC 7.60 5.55 5
CT 7.76 8.47 21
TT 6.48 5.30 732
Total 6.53 5.41 758
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs11703570 M SD N
African American AA 7.07 5.41 14
AT 6.42 5.12 50
TT 6.30 5.01 123
Total 6.39 5.04 187
Caucasian AA 6.73 5.63 45
AT 6.51 5.12 148
TT 6.54 5.71 367
Total 6.55 5.54 560
Total AA 6.81 5.54 59
AT 6.49 5.11 198
TT 6.48 5.54 490
Total 6.51 5.42 747
TCN2_rs35838082 M SD N
African American TT 6.33 5.12 9
CT 5.59 4.14 54
CC 6.83 5.35 126
Total 6.46 5.03 189
Caucasian CT 3.86 4.74 7
CC 6.67 5.56 562
Total 6.63 5.56 569
Total TT 6.33 5.12 9
CT 5.39 4.21 61
CC 6.70 5.52 688
Total 6.59 5.43 758
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2267163 M SD N
African American TT 6.07 5.06 14
TC 6.29 5.03 56
CC 6.62 5.03 116
Total 6.48 5.01 186
Caucasian TT 6.37 5.77 123
TC 6.26 5.60 225
CC 7.25 5.55 203
Total 6.65 5.63 551
Total TT 6.34 5.68 137
TC 6.27 5.48 281
CC 7.02 5.37 319
Total 6.61 5.48 737
TCN2_rs1801198 M SD N
African American GG 5.94 4.85 16
CG 6.11 5.05 65
CC 6.76 5.06 108
Total 6.47 5.03 189
Caucasian GG 6.33 5.68 133
CG 6.49 5.69 251
CC 6.98 5.25 183
Total 6.61 5.55 567
Total GG 6.29 5.58 149
CG 6.41 5.56 316
CC 6.90 5.18 291
Total 6.57 5.42 756
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820021 M SD N
African American AT 5.17 3.43 6
TT 6.47 5.03 187
Total 6.42 4.98 193
Caucasian AA 5.36 4.13 14
AT 6.17 5.88 92
TT 6.76 5.56 455
Total 6.63 5.58 561
Total AA 5.36 4.13 14
AT 6.11 5.75 98
TT 6.67 5.41 642
Total 6.58 5.43 754
TCN2_rs9621049 M SD N
African American TT 6.86 4.98 7
CT 6.25 5.04 51
CC 6.49 5.01 134
Total 6.44 4.99 192
Caucasian TT 4.86 3.01 14
CT 6.96 5.84 101
CC 6.57 5.57 448
Total 6.60 5.57 563
Total TT 5.52 3.78 21
CT 6.72 5.58 152
CC 6.55 5.44 582
Total 6.56 5.43 755
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820886 M SD N
African American GG 5.25 4.03 4
GT 6.12 5.02 50
TT 6.52 5.05 135
Total 6.39 5.01 189
Caucasian GG 5.50 3.42 12
GT 6.67 5.77 102
TT 6.70 5.59 450
Total 6.67 5.58 564
Total GG 5.44 3.44 16
GT 6.49 5.53 152
TT 6.66 5.47 585
Total 6.60 5.44 753
TCN2_rs4820887 M SD N
African American AA 5.25 3.86 4
GA 6.33 5.14 27
GG 6.55 5.01 157
Total 6.49 4.99 188
Caucasian AA 5.56 3.13 9
GA 6.89 5.83 85
GG 6.56 5.55 465
Total 6.59 5.56 559
Total AA 5.46 3.20 13
GA 6.76 5.65 112
GG 6.56 5.41 622
Total 6.57 5.42 747
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820888 M SD N
African American GG 6.24 5.06 38
AG 6.52 4.95 90
AA 6.31 5.09 62
Total 6.39 5.00 190
Caucasian GG 6.87 5.28 127
AG 6.83 5.89 235
AA 6.38 5.46 199
Total 6.68 5.60 561
Total GG 6.73 5.22 165
AG 6.75 5.64 325
AA 6.36 5.37 261
Total 6.61 5.45 751
TCN2_rs2301955 M SD N
African American TT 7.47 4.94 17
CT 6.55 5.09 71
CC 6.13 5.00 102
Total 6.41 5.02 190
Caucasian TT 7.01 5.36 120
CT 6.37 5.49 230
CC 6.46 5.72 220
Total 6.54 5.55 570
Total TT 7.07 5.30 137
CT 6.41 5.39 301
CC 6.35 5.49 322
Total 6.50 5.42 760
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2301958 M SD N
African American CC 8.91 4.70 11
CG 6.17 4.93 59
GG 6.37 5.03 121
Total 6.46 5.00 191
Caucasian CC 6.03 5.45 32
CG 6.78 5.22 172
GG 6.67 5.77 368
Total 6.67 5.58 572
Total CC 6.77 5.37 43
CG 6.63 5.15 231
GG 6.60 5.59 489
Total 6.62 5.44 763
TCN2_rs1131603 M SD N
African American TC 0.00 . 1
TT 6.54 5.00 195
Total 6.51 5.01 196
Caucasian CC 6.00 1.41 2
TC 6.57 5.80 49
TT 6.62 5.54 531
Total 6.62 5.55 582
Total CC 6.00 1.41 2
TC 6.44 5.81 50
TT 6.60 5.40 726
Total 6.59 5.42 778
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820889 M SD N
African American AA 4.20 3.56 5
GA 5.23 4.16 31
GG 6.73 5.19 154
Total 6.42 5.03 190
Caucasian AA 6.00 4.24 2
GA 7.43 8.19 23
GG 6.64 5.50 547
Total 6.67 5.61 572
Total AA 4.71 3.50 7
GA 6.17 6.23 54
GG 6.66 5.43 701
Total 6.61 5.47 762
TCN2_rs2072194 M SD N
African 
American
GG 10.25 9.78 4
GA 6.43 5.38 44
AA 6.26 4.74 136
Total 6.39 5.02 184
Caucasian GG 6.21 5.27 115
GA 6.63 5.83 238
AA 6.82 5.46 200
Total 6.61 5.58 553
Total GG 6.34 5.46 119
GA 6.60 5.75 282
AA 6.59 5.18 336
Total 6.55 5.44 737
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs173665 M SD N
African American TT 7.14 7.01 7
CT 5.48 3.27 33
CC 6.65 5.23 148
Total 6.46 5.01 188
Caucasian TT 7.20 5.03 10
CT 7.25 5.32 79
CC 6.50 5.65 466
Total 6.62 5.59 555
Total TT 7.18 5.71 17
CT 6.73 4.86 112
CC 6.53 5.55 614
Total 6.58 5.45 743
CD320_rs250510 M SD N
African American TT 10.67 7.57 3
CT 4.32 3.87 22
CC 6.52 4.91 157
Total 6.32 4.90 182
Caucasian TT 3.00 . 1
CT 4.00 3.03 6
CC 6.63 5.59 539
Total 6.59 5.57 546
Total TT 8.75 7.27 4
CT 4.25 3.66 28
CC 6.60 5.44 696
Total 6.52 5.41 728
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2232787 M SD N
African American AA 21.00 . 1
AG 5.67 1.53 3
GG 6.41 4.95 186
Total 6.47 5.01 190
Caucasian AA 3.00 . 1
GG 6.52 5.53 547
Total 6.51 5.53 548
Total AA 12.00 12.73 2
AG 5.67 1.53 3
GG 6.49 5.39 733
Total 6.50 5.40 738
CD320_rs2227288 M SD N
African American CC 9.38 5.80 13
GC 5.90 4.25 50
GG 6.46 5.06 125
Total 6.52 4.96 188
Caucasian CC 5.25 5.22 12
GC 7.09 6.13 98
GG 6.53 5.45 427
Total 6.61 5.58 537
Total CC 7.40 5.81 25
GC 6.69 5.58 148
GG 6.52 5.36 552
Total 6.58 5.42 725
 354 
Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2336573 M SD N
African American TT 7.05 6.11 21
TC 5.78 5.16 72
CC 6.71 4.40 94
Total 6.39 4.91 187
Caucasian TT 8.00 6.40 9
TC 6.03 6.13 35
CC 6.59 5.55 512
Total 6.58 5.59 556
Total TT 7.33 6.10 30
TC 5.86 5.47 107
CC 6.61 5.38 606
Total 6.53 5.43 743
CD320_rs2232779 M SD N
African American TT 15.00 1.41 2
CT 6.61 3.93 18
CC 6.46 5.08 174
Total 6.56 5.02 194
Caucasian TT 11.60 6.27 5
CT 8.50 7.78 2
CC 6.58 5.57 573
Total 6.63 5.59 580
Total TT 12.57 5.41 7
CT 6.80 4.16 20
CC 6.55 5.46 747
Total 6.61 5.45 774
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2927707 M SD N
African American CC 6.88 4.95 16
CT 5.61 4.57 51
TT 6.70 5.02 118
Total 6.42 4.90 185
Caucasian CC 6.60 4.46 57
CT 6.42 5.68 202
TT 6.55 5.52 288
Total 6.50 5.47 547
Total CC 6.66 4.54 73
CT 6.25 5.48 253
TT 6.59 5.37 406
Total 6.48 5.33 732
CD320_rs3760680 M SD N
African American TT 5.83 5.71 29
CT 6.35 5.19 75
CC 6.23 4.28 78
Total 6.21 4.89 182
Caucasian TT 5.77 4.68 81
CT 6.48 5.64 221
CC 6.89 5.79 242
Total 6.55 5.58 544
Total TT 5.78 4.94 110
CT 6.44 5.52 296
CC 6.73 5.47 320
Total 6.47 5.41 726
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Table 24 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs8100119 M SD N
African American CC 6.87 5.78 23
CT 6.51 4.97 65
TT 6.47 4.90 102
Total 6.53 5.01 190
Caucasian CC 5.60 6.19 5
CT 6.71 6.91 35
TT 6.65 5.53 524
Total 6.65 5.62 564
Total CC 6.64 5.76 28
CT 6.58 5.69 100
TT 6.62 5.43 626




Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs16988828 M SD N
African American GG 4.19 1.56 5
GA 8.80 4.54 31
AA 8.43 4.48 97
Total 8.35 4.48 133
Caucasian GG 9.23 4.72 8
GA 7.85 4.32 57
AA 8.49 4.40 258
Total 8.40 4.39 323
Total GG 7.29 4.51 13
GA 8.19 4.39 88
AA 8.47 4.42 355
Total 8.39 4.41 456
TCN2_rs7289549 M SD N
African American CC 8.15 5.46 18
CG 8.13 4.44 47
GG 8.91 4.45 71
Total 8.54 4.57 136
Caucasian CC 8.17 3.82 6
CG 8.11 4.68 54
GG 8.38 4.36 269
Total 8.33 4.39 329
Total CC 8.15 5.02 24
CG 8.12 4.54 101
GG 8.49 4.37 340
Total 8.39 4.44 465
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs7286107 M SD N
African American CC 8.23 5.72 10
CT 8.20 4.62 46
TT 8.62 4.42 80
Total 8.45 4.55 136
Caucasian CC 9.39 6.49 3
CT 18.78 . 1
TT 8.40 4.41 331
Total 8.44 4.45 335
Total CC 8.50 5.64 13
CT 8.43 4.82 47
TT 8.44 4.40 411
Total 8.44 4.47 471
TCN2_rs9606756 M SD N
African American GG 8.61 4.98 9
GA 7.93 3.90 28
AA 8.55 4.75 99
Total 8.42 4.58 136
Caucasian GG 7.81 4.15 15
GA 7.59 4.23 47
AA 8.59 4.48 271
Total 8.41 4.44 333
Total GG 8.11 4.39 24
GA 7.72 4.09 75
AA 8.58 4.55 370
Total 8.41 4.47 469
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs740234 M SD N
African American CC 8.81 6.20 4
TC 8.41 4.41 16
TT 8.56 4.55 117
Total 8.55 4.55 137
Caucasian CC 9.58 5.07 24
TC 8.77 4.44 87
TT 8.05 4.30 223
Total 8.35 4.41 334
Total CC 9.47 5.12 28
TC 8.72 4.42 103
TT 8.22 4.39 340
Total 8.41 4.44 471
TCN2_rs35915865 M SD N
African American CC 8.90 . 1
CT 16.25 . 1
TT 8.43 4.53 137
Total 8.49 4.55 139
Caucasian CC 5.79 3.38 3
CT 6.28 3.06 11
TT 8.45 4.43 321
Total 8.35 4.40 335
Total CC 6.57 3.17 4
CT 7.11 4.10 12
TT 8.44 4.46 458
Total 8.39 4.44 474
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs11703570 M SD N
African American AA 7.64 5.56 10
AT 9.21 4.35 37
TT 8.35 4.45 87
Total 8.53 4.50 134
Caucasian AA 7.81 4.40 33
AT 8.09 4.33 86
TT 8.58 4.49 212
Total 8.38 4.43 331
Total AA 7.77 4.63 43
AT 8.43 4.35 123
TT 8.51 4.47 299
Total 8.42 4.45 465
TCN2_rs35838082 M SD N
African American TT 8.30 6.07 9
CT 8.27 4.37 39
CC 8.45 4.36 87
Total 8.39 4.46 135
Caucasian CT 7.26 1.85 3
CC 8.40 4.43 331
Total 8.39 4.41 334
Total TT 8.30 6.07 9
CT 8.20 4.24 42
CC 8.41 4.41 418
Total 8.39 4.42 469
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2267163 M SD N
African American TT 9.43 5.13 10
TC 9.24 3.85 38
CC 7.96 4.66 86
Total 8.43 4.49 134
Caucasian TT 8.17 4.13 72
TC 8.46 4.47 119
CC 8.37 4.45 131
Total 8.36 4.38 322
Total TT 8.32 4.25 82
TC 8.65 4.33 157
CC 8.21 4.53 217
Total 8.38 4.41 456
TCN2_rs1801198 M SD N
African American GG 10.22 5.22 12
CG 9.10 3.93 41
CC 7.86 4.68 83
Total 8.44 4.55 136
Caucasian GG 8.33 4.37 80
CG 8.40 4.39 138
CC 8.29 4.55 119
Total 8.35 4.43 337
Total GG 8.58 4.50 92
CG 8.56 4.29 179
CC 8.11 4.60 202
Total 8.37 4.46 473
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820021 M SD N
African American AT 8.62 4.15 5
TT 8.49 4.56 134
Total 8.50 4.54 139
Caucasian AA 9.06 3.79 8
AT 8.60 4.19 49
TT 8.38 4.49 272
Total 8.43 4.43 329
Total AA 9.06 3.79 8
AT 8.60 4.15 54
TT 8.41 4.51 406
Total 8.45 4.45 468
TCN2_rs9621049 M SD N
African American TT 7.96 0.70 5
CT 7.12 4.06 34
CC 9.00 4.74 99
Total 8.50 4.55 138
Caucasian TT 8.97 6.14 8
CT 7.74 4.00 52
CC 8.38 4.41 271
Total 8.29 4.39 331
Total TT 8.58 4.74 13
CT 7.50 4.01 86
CC 8.54 4.51 370
Total 8.35 4.44 469
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820886 M SD N
African American GG 6.53 2.45 3
GT 6.93 3.54 34
TT 9.04 4.73 99
Total 8.45 4.50 136
Caucasian GG 9.77 5.08 7
GT 7.63 4.12 54
TT 8.49 4.47 273
Total 8.38 4.43 334
Total GG 8.80 4.58 10
GT 7.36 3.90 88
TT 8.64 4.54 372
Total 8.40 4.45 470
TCN2_rs4820887 M SD N
African American AA 7.86 0.90 3
GA 7.24 4.48 15
GG 8.72 4.61 117
Total 8.53 4.55 135
Caucasian AA 9.59 6.01 5
GA 8.00 4.45 42
GG 8.38 4.39 282
Total 8.35 4.41 329
Total AA 8.94 4.65 8
GA 7.80 4.43 57
GG 8.48 4.45 399
Total 8.41 4.45 464
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820888 M SD N
African American GG 8.35 4.07 26
AG 9.28 4.69 64
AA 7.59 4.53 47
Total 8.52 4.56 137
Caucasian GG 8.75 4.90 85
AG 8.20 4.27 131
AA 8.29 4.23 118
Total 8.37 4.42 334
Total GG 8.66 4.70 111
AG 8.55 4.43 195
AA 8.09 4.31 165
Total 8.42 4.45 471
TCN2_rs2301955 M SD N
African American TT 6.03 3.40 9
CT 9.01 4.73 55
CC 8.28 4.52 73
Total 8.43 4.57 137
Caucasian TT 8.66 4.70 87
CT 8.18 4.34 122
CC 8.32 4.19 130
Total 8.36 4.37 339
Total TT 8.41 4.64 96
CT 8.44 4.47 177
CC 8.31 4.30 203
Total 8.38 4.43 476
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2301958 M SD N
African American CC 5.61 1.96 5
CG 9.27 4.82 46
GG 8.34 4.57 87
Total 8.55 4.62 138
Caucasian CC 8.72 4.61 23
CG 8.13 4.56 101
GG 8.45 4.30 217
Total 8.37 4.39 341
Total CC 8.17 4.40 28
CG 8.49 4.66 147
GG 8.42 4.37 304
Total 8.42 4.45 479
TCN2_rs1131603 M SD N
African American TT 8.51 4.59 142
Total 8.51 4.59 142
Caucasian CC 6.84 3.47 2
TC 8.38 4.53 24
TT 8.34 4.42 320
Total 8.33 4.41 346
Total CC 6.84 3.47 2
TC 8.38 4.53 24
TT 8.39 4.47 462
Total 8.38 4.46 488
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820889 M SD N
African American AA 8.31 2.57 4
GA 9.36 4.58 20
GG 8.20 4.56 112
Total 8.38 4.51 136
Caucasian AA 3.36 . 1
GA 7.10 3.04 13
GG 8.44 4.45 328
Total 8.38 4.41 342
Total AA 7.32 3.14 5
GA 8.47 4.14 33
GG 8.38 4.48 440
Total 8.38 4.44 478
TCN2_rs2072194 M SD N
African American GG 7.91 5.27 4
GA 9.96 4.00 28
AA 7.96 4.47 102
Total 8.38 4.44 134
Caucasian GG 8.14 4.12 71
GA 8.61 4.41 132
AA 8.03 4.51 126
Total 8.28 4.38 329
Total GG 8.12 4.15 75
GA 8.84 4.36 160
AA 8.00 4.48 228
Total 8.31 4.40 463
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs173665 M SD N
African American TT 7.55 6.08 5
CT 8.04 4.36 21
CC 8.79 4.66 110
Total 8.63 4.64 136
Caucasian TT 9.31 4.64 7
CT 9.31 4.64 44
CC 8.24 4.40 274
Total 8.41 4.44 325
Total TT 8.57 5.10 12
CT 8.90 4.55 65
CC 8.40 4.48 384
Total 8.48 4.50 461
CD320_rs250510 M SD N
African American TT 9.74 4.77 3
CT 11.51 5.13 12
CC 8.01 4.29 115
Total 8.38 4.46 130
Caucasian TT 6.70 . 1
CT 7.16 2.69 4
CC 8.37 4.45 314
Total 8.34 4.42 319
Total TT 8.98 4.18 4
CT 10.43 4.95 16
CC 8.27 4.40 429
Total 8.35 4.43 449
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2232787 M SD N
African American AA 7.04 . 1
AG 10.86 4.49 2
GG 8.46 4.57 135
Total 8.49 4.54 138
Caucasian AA 6.44 . 1
GG 8.40 4.43 320
Total 8.39 4.42 321
Total AA 6.74 0.42 2
AG 10.86 4.49 2
GG 8.41 4.46 455
Total 8.42 4.45 459
CD320_rs2227288 M SD N
African American CC 7.00 3.05 10
GC 8.01 4.60 36
GG 8.91 4.70 90
Total 8.53 4.59 136
Caucasian CC 5.45 3.55 6
GC 9.77 4.93 59
GG 7.99 4.25 250
Total 8.27 4.43 315
Total CC 6.42 3.22 16
GC 9.10 4.86 95
GG 8.23 4.39 340
Total 8.35 4.48 451
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2336573 M SD N
African American TT 9.24 3.17 16
TC 7.99 4.37 52
CC 8.98 4.98 65
Total 8.62 4.56 133
Caucasian TT 8.07 3.57 8
TC 8.24 4.30 21
CC 8.36 4.46 293
Total 8.35 4.41 322
Total TT 8.85 3.28 24
TC 8.06 4.33 73
CC 8.47 4.55 358
Total 8.43 4.46 455
CD320_rs2232779 M SD N
African American TT 5.10 1.26 2
CT 6.15 3.14 12
CC 8.82 4.65 127
Total 8.54 4.58 141
Caucasian TT 6.52 2.47 5
CT 5.68 1.08 2
CC 8.37 4.38 338
Total 8.33 4.35 345
Total TT 6.11 2.20 7
CT 6.08 2.91 14
CC 8.50 4.46 465
Total 8.39 4.42 486
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2927707 M SD N
African American CC 10.96 5.37 13
CT 8.40 4.21 32
TT 8.34 4.53 88
Total 8.61 4.57 133
Caucasian CC 7.43 3.56 40
CT 8.77 4.54 107
TT 8.38 4.52 168
Total 8.39 4.42 315
Total CC 8.29 4.30 53
CT 8.69 4.45 139
TT 8.37 4.52 256
Total 8.46 4.46 448
CD320_rs3760680 M SD N
African American TT 9.51 4.64 21
CT 8.23 4.56 55
CC 8.44 4.70 55
Total 8.52 4.62 131
Caucasian TT 7.22 3.98 52
CT 8.87 4.69 121
CC 8.37 4.29 144
Total 8.38 4.42 317
Total TT 7.88 4.28 73
CT 8.67 4.65 176
CC 8.39 4.40 199
Total 8.42 4.48 448
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Table 25 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs8100119 M SD N
African American CC 8.67 3.46 15
CT 7.78 4.73 48
TT 8.76 4.78 75
Total 8.41 4.63 138
Caucasian CC 10.99 5.18 5
CT 7.65 3.56 23
TT 8.36 4.47 305
Total 8.35 4.43 333
Total CC 9.25 3.94 20
CT 7.74 4.36 71
TT 8.43 4.53 380




Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs16988828 M SD N
African American GG 28.75 5.85 4
GA 21.61 6.65 31
AA 23.61 6.05 127
Total 23.36 6.24 162
Caucasian GG 19.89 7.62 9
GA 22.08 4.86 80
AA 21.74 5.84 420
Total 21.76 5.73 509
Total GG 22.62 8.09 13
GA 21.95 5.40 111
AA 22.17 5.94 547
Total 22.14 5.89 671
TCN2_rs7289549 M SD N
African American CC 23.94 6.58 18
CG 22.98 6.14 57
GG 23.33 6.24 90
Total 23.28 6.21 165
Caucasian CC 16.20 7.98 10
CG 21.75 5.41 85
GG 21.91 5.64 423
Total 21.77 5.70 518
Total CC 21.18 7.92 28
CG 22.25 5.72 142
GG 22.16 5.77 513
Total 22.13 5.86 683
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs7286107 M SD N
African American CC 25.80 6.16 10
CT 22.94 5.91 52
TT 23.25 6.37 103
Total 23.31 6.21 165
Caucasian CC 18.33 2.52 3
CT 16.00 . 1
TT 21.72 5.72 518
Total 21.69 5.71 522
Total CC 24.08 6.34 13
CT 22.81 5.93 53
TT 21.97 5.85 621
Total 22.08 5.87 687
TCN2_rs9606756 M SD N
African American GG 18.63 2.67 8
GA 23.60 6.57 42
AA 23.53 6.17 116
Total 23.31 6.22 166
Caucasian GG 20.04 5.89 24
GA 21.65 5.66 79
AA 21.84 5.74 417
Total 21.73 5.74 520
Total GG 19.69 5.27 32
GA 22.32 6.04 121
AA 22.21 5.87 533
Total 22.11 5.89 686
 374 
Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs740234 M SD N
African American CC 23.75 4.11 4
TC 24.79 7.40 28
TT 22.96 5.96 134
Total 23.29 6.19 166
Caucasian CC 20.61 4.13 33
TC 22.06 5.43 146
TT 21.71 5.93 343
Total 21.74 5.69 522
Total CC 20.95 4.19 37
TC 22.50 5.85 174
TT 22.06 5.96 477
Total 22.11 5.85 688
TCN2_rs35915865 M SD N
African American CC 27.00 . 1
CT 24.00 2.83 2
TT 23.16 6.30 164
Total 23.20 6.26 167
Caucasian CC 24.75 4.57 4
CT 23.50 6.95 18
TT 21.68 5.64 502
Total 21.77 5.69 524
Total CC 25.20 4.09 5
CT 23.55 6.61 20
TT 22.05 5.84 666
Total 22.11 5.86 691
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs11703570 M SD N
African American AA 26.92 5.26 12
AT 22.21 6.55 42
TT 23.22 6.08 110
Total 23.23 6.22 164
Caucasian AA 21.26 5.66 39
AT 21.96 5.74 137
TT 21.72 5.72 341
Total 21.75 5.71 517
Total AA 22.59 6.02 51
AT 22.02 5.92 179
TT 22.08 5.84 451
Total 22.11 5.86 681
TCN2_rs35838082 M SD N
African American TT 24.22 6.69 9
CT 22.91 5.92 46
CC 23.26 6.27 110
Total 23.22 6.17 165
Caucasian CT 22.57 7.48 7
CC 21.68 5.70 518
Total 21.70 5.72 525
Total TT 24.22 6.69 9
CT 22.87 6.07 53
CC 21.96 5.83 628
Total 22.06 5.86 690
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2267163 M SD N
African American TT 22.14 7.26 14
TC 22.98 6.71 46
CC 23.55 5.88 103
Total 23.27 6.22 163
Caucasian TT 21.47 6.06 115
TC 22.38 5.43 209
CC 21.24 5.47 184
Total 21.76 5.61 508
Total TT 21.54 6.17 129
TC 22.49 5.67 255
CC 22.07 5.72 287
Total 22.13 5.79 671
TCN2_rs1801198 M SD N
African American GG 22.25 6.78 16
CG 24.02 6.82 55
CC 23.15 5.65 94
Total 23.35 6.16 165
Caucasian GG 21.48 6.23 124
CG 22.06 5.59 233
CC 21.47 5.47 167
Total 21.73 5.71 524
Total GG 21.57 6.27 140
CG 22.43 5.88 288
CC 22.07 5.58 261
Total 22.12 5.85 689
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820021 M SD N
African American AT 20.67 7.74 6
TT 23.39 6.10 162
Total 23.29 6.15 168
Caucasian AA 22.43 8.27 14
AT 22.50 6.00 88
TT 21.54 5.52 417
Total 21.73 5.69 519
Total AA 22.43 8.27 14
AT 22.38 6.09 94
TT 22.06 5.74 579
Total 22.11 5.84 687
TCN2_rs9621049 M SD N
African American TT 22.86 6.36 7
CT 23.55 5.21 44
CC 23.22 6.51 117
Total 23.29 6.15 168
Caucasian TT 21.42 5.33 12
CT 21.71 5.52 92
CC 21.70 5.72 417
Total 21.70 5.67 521
Total TT 21.95 5.60 19
CT 22.30 5.47 136
CC 22.04 5.93 534
Total 22.09 5.82 689
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820886 M SD N
African American GG 21.75 2.63 4
GT 23.49 5.39 43
TT 23.27 6.58 118
Total 23.29 6.21 165
Caucasian GG 21.70 5.70 10
GT 21.60 5.60 93
TT 21.74 5.73 419
Total 21.72 5.70 522
Total GG 21.71 4.91 14
GT 22.20 5.59 136
TT 22.08 5.96 537
Total 22.10 5.86 687
TCN2_rs4820887 M SD N
African American AA 19.00 4.58 3
GA 25.17 4.91 23
GG 23.08 6.39 139
Total 23.30 6.22 165
Caucasian AA 20.86 6.62 7
GA 21.68 5.77 77
GG 21.75 5.69 433
Total 21.73 5.70 517
Total AA 20.30 5.89 10
GA 22.48 5.75 100
GG 22.07 5.89 572
Total 22.11 5.86 682
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820888 M SD N
African American GG 23.35 5.73 34
AG 23.44 6.82 78
AA 23.02 5.58 54
Total 23.28 6.19 166
Caucasian GG 21.98 5.93 117
AG 21.77 5.47 216
AA 21.52 5.79 184
Total 21.73 5.68 517
Total GG 22.29 5.89 151
AG 22.21 5.89 294
AA 21.86 5.77 238
Total 22.11 5.84 683
TCN2_rs2301955 M SD N
African American TT 24.13 5.57 15
CT 23.75 6.37 60
CC 22.86 6.27 91
Total 23.30 6.23 166
Caucasian TT 21.49 5.32 111
CT 22.16 5.67 212
CC 21.47 5.89 204
Total 21.75 5.69 527
Total TT 21.80 5.40 126
CT 22.51 5.86 272
CC 21.90 6.04 295
Total 22.12 5.85 693
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2301958 M SD N
African American CC 25.22 5.38 9
CG 23.18 6.39 50
GG 23.08 6.22 108
Total 23.23 6.21 167
Caucasian CC 21.59 5.77 29
CG 22.08 5.70 159
GG 21.50 5.71 341
Total 21.68 5.70 529
Total CC 22.45 5.82 38
CG 22.34 5.87 209
GG 21.88 5.87 449
Total 22.05 5.86 696
TCN2_rs1131603 M SD N
African American TC 32.00 . 1
TT 23.15 6.16 169
Total 23.20 6.18 170
Caucasian CC 19.50 6.36 2
TC 22.66 5.64 44
TT 21.65 5.70 491
Total 21.72 5.69 537
Total CC 19.50 6.36 2
TC 22.87 5.75 45
TT 22.03 5.85 660
Total 22.08 5.84 707
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820889 M SD N
African American AA 23.60 4.39 5
GA 24.21 7.26 28
GG 23.07 6.04 133
Total 23.28 6.20 166
Caucasian AA 20.50 9.19 2
GA 23.82 6.28 22
GG 21.57 5.63 506
Total 21.66 5.67 530
Total AA 22.71 5.41 7
GA 24.04 6.79 50
GG 21.88 5.74 639
Total 22.04 5.84 696
TCN2_rs2072194 M SD N
African American GG 17.33 3.79 3
GA 22.79 7.07 38
AA 23.55 5.84 121
Total 23.25 6.15 162
Caucasian GG 21.38 6.23 106
GA 21.92 5.40 220
AA 21.67 5.78 184
Total 21.72 5.71 510
Total GG 21.27 6.20 109
GA 22.05 5.67 258
AA 22.41 5.87 305
Total 22.09 5.85 672
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs173665 M SD N
African American TT 25.00 9.47 6
CT 23.93 6.75 28
CC 22.98 5.98 132
Total 23.22 6.23 166
Caucasian TT 21.25 5.04 8
CT 21.96 5.34 72
CC 21.68 5.73 432
Total 21.71 5.65 512
Total TT 22.86 7.20 14
CT 22.51 5.80 100
CC 21.99 5.81 564
Total 22.08 5.83 678
CD320_rs250510 M SD N
African American TT 19.00 5.00 3
CT 25.14 5.11 22
CC 23.02 6.45 135
Total 23.24 6.30 160
Caucasian TT 18.00 . 1
CT 23.80 4.49 5
CC 21.80 5.64 500
Total 21.81 5.62 506
Total TT 18.75 4.11 4
CT 24.89 4.95 27
CC 22.06 5.83 635
Total 22.15 5.82 666
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2232787 M SD N
African American AG 26.00 5.66 2
GG 23.13 6.31 165
Total 23.16 6.29 167
Caucasian AA 22.00 . 1
GG 21.79 5.67 507
Total 21.79 5.67 508
Total AA 22.00 . 1
AG 26.00 5.66 2
GG 22.12 5.86 672
Total 22.13 5.85 675
CD320_rs2227288 M SD N
African American CC 23.83 6.95 12
GC 23.37 5.68 41
GG 22.63 6.32 111
Total 22.90 6.19 164
Caucasian CC 20.42 5.92 12
GC 21.75 5.62 91
GG 21.82 5.76 394
Total 21.77 5.73 497
Total CC 22.13 6.55 24
GC 22.25 5.67 132
GG 22.00 5.89 505
Total 22.05 5.86 661
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2336573 M SD N
African American TT 22.59 4.06 17
TC 22.47 6.34 62
CC 23.99 6.53 85
Total 23.27 6.26 164
Caucasian TT 21.44 7.26 9
TC 21.91 5.42 34
CC 21.77 5.65 472
Total 21.78 5.66 515
Total TT 22.19 5.27 26
TC 22.27 6.01 96
CC 22.11 5.84 557
Total 22.14 5.84 679
CD320_rs2232779 M SD N
African American TT 31.00 . 1
CT 25.00 5.90 15
CC 23.06 6.21 153
Total 23.28 6.21 169
Caucasian TT 24.80 3.96 5
CT 17.00 7.07 2
CC 21.73 5.71 529
Total 21.74 5.70 536
Total TT 25.83 4.36 6
CT 24.06 6.38 17
CC 22.03 5.85 682
Total 22.11 5.86 705
 385 
Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2927707 M SD N
African American CC 23.50 7.88 16
CT 23.43 6.37 47
TT 23.10 6.02 100
Total 23.23 6.28 163
Caucasian CC 21.11 4.54 54
CT 21.99 5.98 186
TT 21.84 5.78 266
Total 21.82 5.73 506
Total CC 21.66 5.51 70
CT 22.28 6.07 233
TT 22.18 5.86 366
Total 22.16 5.90 669
CD320_rs3760680 M SD N
African American TT 21.96 4.89 27
CT 22.92 6.00 64
CC 24.30 6.83 70
Total 23.36 6.24 161
Caucasian TT 21.68 6.46 74
CT 22.05 5.85 207
CC 21.55 5.44 222
Total 21.78 5.76 503
Total TT 21.75 6.06 101
CT 22.26 5.89 271
CC 22.21 5.91 292
Total 22.16 5.92 664
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Table 26 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs8100119 M SD N
African American CC 21.90 6.74 20
CT 23.96 6.27 54
TT 22.98 6.02 91
Total 23.17 6.19 165
Caucasian CC 19.40 9.91 5
CT 22.79 4.53 33
TT 21.77 5.72 481
Total 21.81 5.70 519
Total CC 21.40 7.31 25
CT 23.52 5.68 87
TT 21.96 5.78 572




Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs16988828 M SD N
African American GG 0.68 0.22 5
GA 0.61 0.26 34
AA 0.63 0.31 132
Total 0.62 0.29 171
Caucasian GG 0.77 0.37 10
GA 0.76 0.32 83
AA 0.81 0.35 430
Total 0.80 0.35 523
Total GG 0.74 0.32 15
GA 0.72 0.31 117
AA 0.77 0.35 562
Total 0.76 0.34 694
TCN2_rs7289549 M SD N
African American CC 0.54 0.22 19
CG 0.56 0.31 62
GG 0.67 0.28 93
Total 0.62 0.29 174
Caucasian CC 0.92 0.30 10
CG 0.83 0.34 86
GG 0.79 0.35 437
Total 0.80 0.35 533
Total CC 0.67 0.31 29
CG 0.71 0.35 148
GG 0.77 0.34 530
Total 0.75 0.34 707
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs7286107 M SD N
African American CC 0.55 0.26 10
CT 0.54 0.30 57
TT 0.67 0.28 105
Total 0.62 0.29 172
Caucasian CC 0.56 0.23 3
CT 0.33 . 1
TT 0.80 0.35 532
Total 0.80 0.35 536
Total CC 0.55 0.24 13
CT 0.54 0.30 58
TT 0.78 0.34 637
Total 0.76 0.34 708
TCN2_rs9606756 M SD N
African American GG 0.49 0.22 8
GA 0.67 0.34 43
AA 0.62 0.27 123
Total 0.62 0.29 174
Caucasian GG 0.72 0.37 26
GA 0.81 0.36 83
AA 0.80 0.34 422
Total 0.80 0.34 531
Total GG 0.66 0.35 34
GA 0.76 0.36 126
AA 0.76 0.33 545
Total 0.75 0.34 705
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs740234 M SD N
African American CC 0.70 0.33 4
TC 0.67 0.28 29
TT 0.61 0.30 140
Total 0.62 0.29 173
Caucasian CC 0.74 0.28 32
TC 0.83 0.37 153
TT 0.79 0.34 351
Total 0.80 0.35 536
Total CC 0.73 0.28 36
TC 0.80 0.36 182
TT 0.74 0.34 491
Total 0.75 0.34 709
TCN2_rs35915865 M SD N
African American CC 0.74 . 1
CT 0.70 0.12 2
TT 0.62 0.30 172
Total 0.62 0.29 175
Caucasian CC 0.81 0.29 4
CT 0.88 0.45 18
TT 0.80 0.34 516
Total 0.80 0.34 538
Total CC 0.80 0.25 5
CT 0.87 0.43 20
TT 0.75 0.34 688
Total 0.75 0.34 713
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs11703570 M SD N
African American AA 0.65 0.21 13
AT 0.61 0.27 45
TT 0.62 0.32 113
Total 0.62 0.30 171
Caucasian AA 0.76 0.34 43
AT 0.78 0.33 139
TT 0.81 0.35 348
Total 0.80 0.35 530
Total AA 0.73 0.31 56
AT 0.74 0.32 184
TT 0.77 0.35 461
Total 0.76 0.34 701
TCN2_rs35838082 M SD N
African American TT 0.61 0.23 9
CT 0.56 0.32 51
CC 0.65 0.29 113
Total 0.62 0.30 173
Caucasian CT 0.94 0.29 6
CC 0.80 0.35 532
Total 0.80 0.35 538
Total TT 0.61 0.23 9
CT 0.60 0.33 57
CC 0.77 0.34 645
Total 0.76 0.34 711
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2267163 M SD N
African American TT 0.67 0.22 13
TC 0.65 0.36 48
CC 0.60 0.27 109
Total 0.62 0.29 170
Caucasian TT 0.79 0.35 118
TC 0.82 0.37 209
CC 0.77 0.32 195
Total 0.80 0.35 522
Total TT 0.78 0.34 131
TC 0.79 0.37 257
CC 0.71 0.31 304
Total 0.75 0.34 692
TCN2_rs1801198 M SD N
African American GG 0.63 0.23 15
CG 0.67 0.34 57
CC 0.59 0.28 101
Total 0.62 0.29 173
Caucasian GG 0.80 0.35 128
CG 0.82 0.37 232
CC 0.76 0.31 178
Total 0.80 0.35 538
Total GG 0.78 0.35 143
CG 0.79 0.36 289
CC 0.70 0.31 279
Total 0.76 0.34 711
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820021 M SD N
African American AT 0.57 0.19 6
TT 0.62 0.30 170
Total 0.62 0.29 176
Caucasian AA 0.79 0.37 14
AT 0.83 0.36 90
TT 0.79 0.35 429
Total 0.80 0.35 533
Total AA 0.79 0.37 14
AT 0.81 0.36 96
TT 0.74 0.34 599
Total 0.75 0.34 709
TCN2_rs9621049 M SD N
African American TT 0.62 0.20 7
CT 0.66 0.34 46
CC 0.60 0.28 123
Total 0.62 0.29 176
Caucasian TT 0.78 0.34 14
CT 0.80 0.39 98
CC 0.80 0.34 421
Total 0.80 0.35 533
Total TT 0.73 0.31 21
CT 0.76 0.38 144
CC 0.75 0.33 544
Total 0.75 0.34 709
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820886 M SD N
African American GG 0.58 0.15 4
GT 0.67 0.34 46
TT 0.60 0.28 124
Total 0.62 0.29 174
Caucasian GG 0.80 0.36 12
GT 0.79 0.38 98
TT 0.80 0.34 424
Total 0.80 0.34 534
Total GG 0.75 0.33 16
GT 0.75 0.37 144
TT 0.76 0.33 548
Total 0.75 0.34 708
TCN2_rs4820887 M SD N
African American AA 0.56 0.13 3
GA 0.70 0.31 24
GG 0.61 0.29 145
Total 0.62 0.29 172
Caucasian AA 0.84 0.39 9
GA 0.79 0.39 81
GG 0.80 0.34 439
Total 0.80 0.35 529
Total AA 0.77 0.36 12
GA 0.77 0.37 105
GG 0.75 0.34 584
Total 0.76 0.34 701
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820888 M SD N
African American GG 0.66 0.27 36
AG 0.61 0.28 81
AA 0.60 0.32 58
Total 0.62 0.29 175
Caucasian GG 0.77 0.30 122
AG 0.80 0.36 220
AA 0.80 0.35 190
Total 0.79 0.34 532
Total GG 0.74 0.30 158
AG 0.75 0.35 301
AA 0.75 0.36 248
Total 0.75 0.34 707
TCN2_rs2301955 M SD N
African American TT 0.69 0.23 16
CT 0.62 0.29 64
CC 0.61 0.31 94
Total 0.62 0.30 174
Caucasian TT 0.76 0.31 114
CT 0.82 0.35 218
CC 0.80 0.36 208
Total 0.80 0.35 540
Total TT 0.75 0.30 130
CT 0.77 0.35 282
CC 0.74 0.36 302
Total 0.76 0.34 714
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs2301958 M SD N
African American CC 0.72 0.21 10
CG 0.59 0.26 52
GG 0.63 0.31 114
Total 0.62 0.29 176
Caucasian CC 0.72 0.32 32
CG 0.79 0.33 160
GG 0.81 0.36 349
Total 0.80 0.35 541
Total CC 0.72 0.30 42
CG 0.74 0.33 212
GG 0.77 0.36 463
Total 0.76 0.34 717
TCN2_rs1131603 M SD N
African American TC 0.85 . 1
TT 0.62 0.29 178
Total 0.62 0.29 179
Caucasian CC 0.73 0.20 2
TC 0.79 0.34 47
TT 0.80 0.35 501
Total 0.80 0.35 550
Total CC 0.73 0.20 2
TC 0.79 0.34 48
TT 0.75 0.34 679
Total 0.75 0.34 729
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
TCN2_rs4820889 M SD N
African American AA 0.64 0.25 5
GA 0.66 0.30 30
GG 0.61 0.30 139
Total 0.62 0.29 174
Caucasian AA 1.11 0.39 2
GA 0.86 0.41 22
GG 0.80 0.34 517
Total 0.80 0.35 541
Total AA 0.77 0.34 7
GA 0.75 0.36 52
GG 0.76 0.34 656
Total 0.76 0.34 715
TCN2_rs2072194 M SD N
African American GG 0.38 0.48 3
GA 0.65 0.33 38
AA 0.62 0.28 128
Total 0.62 0.30 169
Caucasian GG 0.79 0.34 110
GA 0.81 0.36 222
AA 0.79 0.34 192
Total 0.80 0.35 524
Total GG 0.78 0.35 113
GA 0.79 0.36 260
AA 0.72 0.33 320
Total 0.76 0.34 693
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs173665 M SD N
African American TT 0.56 0.21 6
CT 0.60 0.25 29
CC 0.63 0.31 138
Total 0.62 0.29 173
Caucasian TT 0.55 0.27 8
CT 0.78 0.33 77
CC 0.81 0.35 440
Total 0.80 0.35 525
Total TT 0.56 0.23 14
CT 0.73 0.32 106
CC 0.76 0.35 578
Total 0.75 0.34 698
CD320_rs250510 M SD N
African American TT 0.55 0.18 3
CT 0.70 0.31 21
CC 0.62 0.29 144
Total 0.63 0.29 168
Caucasian TT 0.47 . 1
CT 0.91 0.36 6
CC 0.80 0.35 509
Total 0.80 0.35 516
Total TT 0.53 0.16 4
CT 0.75 0.33 27
CC 0.76 0.34 653
Total 0.76 0.34 684
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2232787 M SD N
African American AA 0.06 . 1
AG 0.77 0.19 2
GG 0.62 0.29 172
Total 0.62 0.29 175
Caucasian AA 1.05 . 1
GG 0.80 0.35 518
Total 0.80 0.35 519
Total AA 0.56 0.70 2
AG 0.77 0.19 2
GG 0.75 0.34 690
Total 0.75 0.34 694
CD320_rs2227288 M SD N
African American CC 0.64 0.23 12
GC 0.70 0.31 42
GG 0.60 0.28 118
Total 0.63 0.29 172
Caucasian CC 0.94 0.41 11
GC 0.80 0.37 94
GG 0.80 0.34 403
Total 0.80 0.35 508
Total CC 0.78 0.36 23
GC 0.77 0.35 136
GG 0.75 0.34 521
Total 0.76 0.34 680
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2336573 M SD N
African American TT 0.68 0.36 20
TC 0.62 0.33 68
CC 0.62 0.23 83
Total 0.62 0.29 171
Caucasian TT 0.66 0.15 8
TC 0.83 0.26 32
CC 0.80 0.35 487
Total 0.80 0.35 527
Total TT 0.67 0.32 28
TC 0.68 0.33 100
CC 0.78 0.35 570
Total 0.76 0.34 698
CD320_rs2232779 M SD N
African American TT 0.59 0.04 2
CT 0.57 0.19 16
CC 0.63 0.30 159
Total 0.62 0.29 177
Caucasian TT 0.67 0.24 4
CT 1.28 0.32 2
CC 0.80 0.35 543
Total 0.80 0.35 549
Total TT 0.64 0.19 6
CT 0.65 0.30 18
CC 0.76 0.34 702
Total 0.76 0.34 726
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs2927707 M SD N
African American CC 0.63 0.25 14
CT 0.64 0.29 47
TT 0.61 0.30 109
Total 0.62 0.29 170
Caucasian CC 0.78 0.32 55
CT 0.81 0.37 191
TT 0.81 0.34 273
Total 0.80 0.35 519
Total CC 0.75 0.31 69
CT 0.77 0.36 238
TT 0.75 0.34 382
Total 0.76 0.34 689
CD320_rs3760680 M SD N
African American TT 0.63 0.35 28
CT 0.63 0.32 71
CC 0.62 0.23 70
Total 0.62 0.29 169
Caucasian TT 0.78 0.27 75
CT 0.83 0.38 209
CC 0.79 0.34 232
Total 0.80 0.35 516
Total TT 0.74 0.30 103
CT 0.78 0.38 280
CC 0.75 0.32 302
Total 0.76 0.34 685
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Table 27 Continued
Means, Standard Deviations, and Sample Sizes by Race and SNP
CD320_rs8100119 M SD N
African American CC 0.58 0.37 20
CT 0.65 0.30 61
TT 0.61 0.27 93
Total 0.62 0.29 174
Caucasian CC 0.68 0.24 5
CT 0.81 0.27 30
TT 0.80 0.35 499
Total 0.80 0.35 534
Total CC 0.60 0.34 25
CT 0.70 0.30 91
TT 0.77 0.35 592
Total 0.75 0.34 708
